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Abstract
Previously, it has been shown that islets are surrounded by a continuous basement 
membrane (BM) containing perlecan, a heparan sulfate proteoglycan (HSPG). Islets 
also express extraordinarily high levels of HS, which acts as an antioxidant and is 
critical for beta cell survival. Islet HS is lost following islet isolation. The onset of Type 
1 diabetes in the NOD mice correlated with the production of catalytic active 
heparanase, an HS-degrading endoglycosidase by the insulitis mononuclear cells 
(MNCs), accompanied by the loss of islet HS. This thesis entails a study to investigate 
the mechanisms contributing to the loss of HS during islet isolation and to assess the 
status of islet HS following transplantation. Additionally, the role of heparanase in the 
rejection of islet allografts is examined.
This project provided evidence that islets express various forms of HSPGs, e.g., type 
XVIII collagen, syndecan-1 and CD44, which possibly contribute to the extraordinarily 
high levels of intra-islet HS. Islets lose their BM and HS but retain the core proteins of 
HSPGs following isolation. In addition, we identified reactive oxygen species as the 
primary factor contributing to the loss of islet HS during the islet isolation process. 
Combined treatment with antioxidant butylated hydroxyanisole, BHA (120 mg/kg i.p) 
and N,N-dimethyIthiourea, DMTU (50 mM), as well as addition of 4,4’- 
diisothiocyanostilbene-2,2'-disulfonic acid, DIDS (200 pM), a chloride ion channel 
blocker which is anti-oxidative and anti-apoptotic, significantly increase intra-islet HS 
content by 2-2.7-fold, compared to non-treated islets following isolation. Islet BM and 
HS recover by 10 days after isotransplantation. In allografts, islet BM recovery is 
initiated early post-transplant. However, islet BM matrix proteins are later diverted to 
form enlarged peri-islet blood vessels that may facilitate leukocyte recruitment to the 
graft site during rejection. Likewise, islet HS shows signs of recovery in allografts early 
post-transplant. Subsequent loss of Islet HS correlates with the expression of high levels 
of heparanase by the infiltrating MNCs during the rejection process. Adoptive transfer 
of activated anti-H-2k heparanase knockout (B6.Hpse-KO) effector T cells delays the 
rejection of established islet allografts in immunoincompetent B6.Ragl-/- transplant 
recipients, compared to the transfer of activated wild-type C57BL/6 effector T cells. We 
propose that heparanase produced by the MNCs degrades the subendothelial BM HS 
and intra-graft HS, to facilitate their entry to the graft site. Heparanase could also 
degrade the newly restored peri-islet BM. In contrast, islets which lack their islet BM,
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would be expected to be highly susceptible to MNC invasion. Once islet cell invasion is 
achieved, the degradation of intra-islet HS by the local production of heparanase would 
contribute to beta cell death.
This study has identified a potential strategy for improving the quality of isolated islets 
for transplantation and alternative approaches for preventing islet transplant rejection. 
These important findings may help to establish clinical islet transplantation as a more 
routine therapy for patients with established Type 1 diabetes. Ultimately islet 
transplantation has the potential to prevent the development of serious secondary 
vascular complications of Type 1 diabetes, resulting from imperfect control of blood 
glucose levels by insulin therapy.
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CHAPTER 1 : Literature review
1.1 Historical Perspective of Islet Transplantation
The concept of islet transplantation as a cure for diabetes was explored a century ago 
when Oscar Minkowski discovered that the pancreas contained substances that 
controlled blood sugar levels, thereby linking it to diabetes. In 1892, he and his 
colleague, Joseph von Mering, showed that diabetes was reversed when autologous 
fragments of pancreas were transplanted subcutaneously in a pancreatectomised dog 
(Minkowski, 1892). The earliest clinical attempt at islet transplantation occurred a year 
later. On 20 December 1893, Dr Watson-William and his colleague Mr. Harsant 
transplanted three pieces of sheeps’ pancreas, “each the size of a Brazil nut”, 
subcutaneously into a 15-year-old boy with severe ketoacidosis. The patient showed 
temporary improvement in his clinical condition. Unfortunately, the xenograft was 
rapidly rejected and he died three days later (Williams, 1894). Nevertheless, this 
transient effect encouraged subsequent attempts, in both experimental and clinical 
settings, to advance the understanding of the technical and immunological aspects of 
islet transplantation.
In 1916, Frederick Charles Pybus reported the first clinical allogeneic islet 
transplantation, using fragments of cadaveric human pancreas. The patient was reported 
to exhibit a reduction in glycosuria before rapid rejection ensued (Pybus, 1924). Four 
years later, Frederick Banting, inspired by Moses Barron’s publication of the 
experimental ligation of pancreatic duct leading to the degeneration of acinar tissues, 
successfully extracted insulin from islets of Langerhans. This milestone discovery led to 
the introduction of exogenous insulin as the widespread treatment of diabetes (Banting 
et al., 1922, Bliss, 1982). In 1923, Frederick Banting, at the age of 32, together with 
John Macleod were awarded the Nobel Prize for their enormous contribution to the 
treatment of diabetes. Despite the encouraging results of insulin therapy in preventing 
the death from ketoacidosis, it was slowly realised that exogenous insulin treatment was 
not a cure for diabetes, as the patients succumbed to debilitating secondary vascular 
complications arising from diabetes (Bliss, 1982).
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Efforts in exploiting alternative treatment for diabetes led to a second wave of advances 
in islet transplantation. In the late 1960’s, Paul E. Lacy proposed the concept of using 
isolated islets instead of the fragmented pancreas in islet transplantation studies. 
Following Moskalewski’s finding in 1965 that mechanical and enzymatic dispersion of 
pancreas using bacterial collagenase derived from Clostridium histolyticum allowed 
complete separation of islets, Paul E. Lacy and his colleague, Dr. Kostianovsky 
introduced two modifications to the isolation technique to improve the recovery of 
isolated islets. They demonstrated that the intraductal injection of a balanced salt 
solution, followed by collagenase digestion of the pancreas greatly enhanced the islet 
yield. They further suggested that pure islets could be obtained from the surrounding 
digested acinar tissues by differential density elutriation on discontinuous sucrose 
gradients. However, these islets were functionally impaired, due to the hyperosmolar 
sucrose-induced cellular dehydration and islet exhaustion (Lacy and Kostianovsky, 
1967, Moskalewski, 1965). As a result, Ficoll, a high molecular weight synthetic 
polymer of sucrose was used to replace sucrose in the gradients (Lindall et al., 1969, 
Scharp et al., 1973).
With the dramatic improvement in islet isolation, transplantation studies in small 
animals became more feasible and provided a driving force for diabetes research. In 
1970, Younoszai and colleagues reported that the intraperitoneal transplantation of 
allogeneic islets in diabetic rats improved glycosuria but only transiently reversed 
hyperglycemia (Younoszai et al., 1970). Three years later, Rechard and Barker 
demonstrated that chemically-induced diabetes was successfully reversed in rats by 
transplanting a large number of islets (800-1200) intraperitonally (Reckard et al., 1973). 
Subsequent work by Kemp et al. (1973) identified that the intraportal embolisation of 
islets to the intrahepatic space was the most effective site for islet transplantation, as it 
required the lowest number of rodent islets (400-600) to completely reverse diabetes 
within 24 hours. The authors attributed the swift reversal of diabetes in the rodents to 
the excellent capacity for islet revascularisation at the hepatic site and to the availability 
of islet-specific nutrient factors. In addition, the hepatic portal system being the 
physiological route of insulin delivery to the liver, provided further support for the liver 
as an ideal site for islet engraftment (Kemp et al., 1973).
The techniques designed for islet isolation in rodents, however, were not applicable for 
the isolation of islets from larger animals, including humans due to the denser and more
fibrous nature of the pancreas in the non-rodent species. Research in islet 
transplantation in the early 1980’s focussed on improving islet isolation and purification 
from the pancreas of large animal species. The introduction of continuous perfusion of 
intraductal collagenase resulted in a high islet yield and allowed successful isolation of 
porcine, nonhuman-primate and human islets (Gray et al., 1986, Ricordi et al., 1986). In 
1986, a major advance in islet isolation was made by Dr. Camillo Ricordi, with the 
invention of the Ricordi Chamber, an automated pancreas dissociation chamber, which 
enabled the large-scale isolation and purification of human islets. Using this method, 
Lacy and collaborators showed that transplants of human islets were able to reverse 
diabetes in the clinic. However, insulin independence was only achieved in the short-
term as the graft was rejected due to the insufficient recipient immunosuppression 
(Gray et al., 1986, Ricordi et al., 1986, Scharp et al., 1990).
Encouraging studies were later reported by the Pittsburgh group in 1990. Long-term 
reversal of diabetes, with insulin independence for up to 5 years, was achieved after 
human islet allotransplantation with a steroid-free immunosuppressive regime including 
tacrolimus (Tzakis et al., 1990). Over the next 10 years, approximately 450 clinical islet 
transplants were performed in Type 1 diabetes (T1D) patients at various islet transplant 
centres in Milan, Miami, Edmonton, St Louis and Minneapolis. Nonetheless, the 
incidence of insulin-independence post-transplant was disappointingly low. Graft failure 
was attributed to allograft rejection and the recurrence of autoimmunity in type 1 
diabetes transplant recipients (Ricordi and Strom, 2004).
A landmark study by the Edmontol group in 2000 demonstrated that seven consecutive 
islet allotransplant recipients, treated with a steroid-free immunosuppressive protocol, 
remained insulin-free up to 1 year. Their unprecedented achievement in clinical islet 
transplantation prompted enthusiasm world-wide, with islet transplant centres adopting 
and further refining the transplant protocol (Shapiro et al., 2000). As a consequence, the 
outcomes and safety of islet transplantation have dramatically improved over the last 
decade. Greater than 50% insulin-independence at 5 years post-transplant was reported 
and is now on par with the transplant outcome of solitary pancreas transplants (Shapiro, 
2011). However, islet transplantation is still far from being a widespread treatment for 
T1D. The 3 major challenges that await to be overcome are: the shortage of donor 
human pancreases, the requirement for life-long immunosuppression and suboptimal
route of transplantation that contributes to early non-immunological loss of the donor 
islets.
1.2 Morphology of pancreatic islets
The pancreas is a glandular organ that contains two distinct parenchymal compartments: 
exocrine tissue and endocrine tissue (Slack, 1995). The exocrine tissue comprises the 
majority of the pancreas. It is made up of serous acinar cells that secrete digestive 
enzymes into the gut through the pancreatic duct (Pin et al., 2001). On the other hand, 
the endocrine tissues consists of the hormone-producing “islets of Langerhans”, which 
are named after Paul Langerhans who first noted the presence of “islands” (islets) amid 
a “sea” of acinar cells in 1869 (Ebling, 1980). The islets of Langerhans constitute 
approximately 1-2% of the total mass of that pancreas and range between 50-500 pm in 
diameter within different species (Konstantinova and Lammert, 2004).
Pancreatic islets resemble a micro-organ as they are populated by a variety of different 
cell types, namely the glucagon-secreting alpha (a)-cells, insulin-producing beta (ß)- 
cells, somatostatin-producing delta (ö)-cells and polypeptide-secreting (PP) cells (Fig. 
1.1) (Konstantinova and Lammert, 2004). The main function of the islets is to produce 
hormones that modulate the levels of glucose in the blood. Insulin is secreted by beta- 
cells in response to elevation of blood glucose levels. Its action is counteracted by 
glucagon which increases blood glucose levels by stimulating glycogenolysis in the 
liver (Greenbaum et al., 1991). Somatostatin inhibits the activity of both insulin and 
glucagon, whereas pancreatic polypeptide acts to self-modulate exocrine and endocrine 
secretions in response to increased food intake or to hypoglycemia (Cejvan et al., 2003, 
Rizza et al., 1982, Stanley et al., 2005). Apart from the hormone-secreting endocrine 
cells, non-endocrine cells such as neurons, macrophages, dendritic cells, fibroblasts, 
endothelial cells and pericytes (the contractile cells which wrap around the abluminal 
side of endothelium), also reside within the islets (Mattsson, 2005). The composite of 
intra-islet cells is required for islet integrity and to tightly regulate islet function.
The cytoarchitecture of the islets differs between species. In rodent islets, the beta cells 
are distributed within the central core and surrounded by a mantle of alpha, delta and PP 
cells (mouse islets, % beta cells=76%; % alpha cells=20%; % delta cells=6%). In 
contrast, human islets have a more random organisation with the beta cells being 
associated closely with intra-islet blood vessels, along with the alpha and delta cells
Figure 1.1 Morphology of pancreatic islets in situ
Islets consist of several cell types including glucagon-secreting a-cells (green), 
insulin-producing ß-cells (yellow), somatostatin-producing 5-cells (pink) and 
polypeptide-secreting PP cells (blue). Islets are highly vascularised with intra-islet 
capillaries (red/purple) to provide nutrients and oxygen as well as to rapidly sense 
fluctuations in blood glucose Each islet is surrounded by a continuous basement 
membrane (cross-hatched region). In rodent islets, ß cells constitute the central core 
whereas a, 5 and PP cells form the mantle region (at the islet periphery).
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(human islets, % beta cells=54%; % alpha cells=35%; % delta cells=T 1%) (Brissova et 
al., 2005, Cabrera et ah, 2006).
1.3 Islet vasculature and innervation
Pancreatic islets are highly vascularised. The islet capillary network is five times denser 
than the vasculature of the pancreatic exocrine (acinar) tissue (Henderson and Moss, 
1985). Large islets are normally supplied by 1-3 arterioles that branch into an intra-islet 
capillary network which subsequently drains into post-capillary venules at the islet 
periphery. The capillaries of small islets are connected to exocrine efferent venules, 
forming an insulo-acinar portal system. The islet cells are arranged such that every cell 
is no more than one cell away from arterial blood (Bonner-Weir and Orci, 1982).
The islet capillaries are relatively wide, with a diameter of approximately 5 pm. The 
endothelial cells that ensheath the blood capillaries form a very thin layer, about 10 nm 
in width (Olsson and Carlsson, 2006). Additionally, the islet capillaries are 10 times 
more fenestrated and display higher blood flow than the exocrine capillary network 
(Henderson and Moss, 1985). Together, these complex features of the islet vasculature 
provide support for the high metabolic activity of the islets via the efficient delivery of 
oxygen and nutrients, particularly to the islet beta cells. Likewise, the close proximity of 
islet cells to the vasculature allows for rapid sensing of fluctuations in blood glucose 
levels and the subsequent release of insulin or other hormones into the blood 
circulation.
Islet endothelial cells (ECs) express differential cell surface markers that distinguish 
them from the exocrine ECs. The common endothelial cell markers expressed by the 
islet ECs include PECAM-1 (CD31) and von Willebrand factor. Islet ECs also 
demonstrate uptake of acetylated low density liproprotein (ac-LDL) and cytokine- 
induced expression of endothelial cell leukocyte adhesion molecule-1 (ELAM-1) 
expression (Lou et al., 1999, Olsson and Carlsson, 2006). Brissova et al. also reported 
that the angiogenic factors, vascular endothelial growth factor-A (VEGF-A), 
Angiopoietin 1 (Angl) and ephrin-Al were expressed at higher levels in islet cells, 
relative to the exocrine and ductal cells. VEGF-A is consistently expressed by islets 
during and post-pancreatic development. These islet-derived angiogenic factors most 
likely regulate the complex branching and fenestration of the islet vasculature (Brissova 
et al., 2006).
VEGFR2, the receptor for VEGF-A has been detected within the islet microvasculature, 
as well as the exocrine and periductal capillary plexus. Within pancreatic islets, higher 
levels of Tie-2 receptors (receptor for Angl) are expressed on islet arterioles and 
venules than on intra-islet capillaries whereas Tie-1 receptor is localised in the islet 
microvasculature and exocrine tissues. In contrast, postcapillary venules, formed by the 
convergence of the intra-islet capillaries, displayed increased expression of the venous 
marker, EphB4 (ephrin receptor). The differential expression of these angiogenic factors 
and receptors between the exocrine and endocrine compartments as well as within 
pancreatic islets may account for the phenotypic and functionally distinct properties of 
the vascular beds in the endocrine and exocrine compartments (Brissova et al., 2006). In 
addition to the proangiogenic factors, islet ECs express angiostatin factors such as al- 
antitrypsin, endostatin and pigment-epithelial derived factor (PEGF). Both pro-
angiogenic and angiostatin factors are kept in equilibrium to maintain a low turnover 
rate in adult islet ECs (Lou et al., 1999, Olsson and Carlsson, 2006).
Islets are also richly innervated by the parasympathetic and sympathetic networks as 
well as the sensory nervous system that branches into the islets. The classical 
neurotransmitters such as acetylcholine, norepinephrine and several neuropeptides 
reside within nerve terminals that are in close contact with the islets. These neuronal 
signalling molecules are released upon stimulation to control hormonal secretion within 
the islets (Ahren et al., 2006, Cabrera-Vasquez et al., 2009). Together, the nervous and 
vascular network works cooperate to ensure tight control of islet endocrine function.
1.4 Effects of islet isolation on islet integrity
Prior to transplantation, islets are isolated via enzymatic digestion and mechanical 
dissociation of the pancreas. The enzymatic digestion process is of paramount 
importance for optimising islet yield and graft function. Pancreas digestion is achieved 
using the enzyme collagenase, derived from Clostridium histolyticum. Bacterial 
collagenase (a mixture of enzymes) is widely used as a tissue-dispersing enzyme to 
isolate different cell types from their surrounding connective tissue e.g., adipocytes 
from adipose tissue, myocytes from heart, osteoblasts from bone and islets from 
pancreas (Kin et al., 2007). The efficiency of human islet isolation depends on the 
relative concentration of collagenase class I (CCI) and collagenase class II (CCII), 
which target different collagen structures during pancreas digestion. Proteases are also
required for the digestion of other extracellular matrix proteins present at the islet- 
exocrine interface (Brandhorst et al., 2008). However, islets are exposed to multiple 
insults during the isolation process (Fig. 1.2).
1.4.1 Loss of islet vasculature and innervation during islet isolation
During islet isolation, the islets are stripped of their dense network of vasculature and 
complex innervation. As a result, the islets are rendered hypoxic and nutrient-deprived 
until their revascularisation after transplantation (see Section 1.5.1) (Morini et al., 2007, 
Persson-Sjögren et al., 2000). In the intervening period, intra-islet ischemia can lead to 
central necrosis, due to the death of cells within the islet core (Giuliani et al., 2005).
Previously, studies of the gene transcription profile in islets were often confounded by 
the need to firstly isolate the islets. Cultured rat islets showed upregulation of 
proangiogeneic factors such as VEGF and Ang-1 due to the hypoxic culture conditions 
(Gorden et al., 1997, Tillmar and Welsh, 2004, Vasir et al., 1998). Recently, laser 
capture microdissection (LCM) techniques have allowed a detailed analysis of the gene 
expression profile of islets in situ in the pancreas. A 5-fold increase in the expression of 
the genes relevant for vasculature development and angiogenesis was observed in 
freshly human isolated islets, relative to the islets in situ (Negi et al., 2012). Extensive 
characterisation of the transcript profile of various proangiogenic/anti-angiogenic 
factors that govern islet vascularisation in isolated islets is likely to be of enormous 
benefit for improving islet transplantation. Genetic engineering of proangiogenic/anti- 
angiogenenic factors in the isolated islets, could potentially enhance the 
revascularisation of islets after transplantation and thus improve islet function (see 
Section 1.5.1).
1.4.2 Loss of islet extracellular matrix (ECM) during islet isolation
As a consequence of islet isolation, the islets detach from the surrounding extracellular 
matrix, inducing anoikis, a phenomenon of cell death induced by loss of cell anchorage 
(Thomas et al., 2001, Thomas et al., 1999, Wang et al., 1999)
The importance of cell-matrix interactions in gene regulation, cytoskeletal organisation, 
cell differentiation and proliferation has long been established and underpins the 
importance of cell anchorage for normal cell health and function. The term “anoikis” 
(Greek: homelessness) was originally coined by Martin Schwartz and Steve Frisch, to
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Figure 1.2 Detrimental effects of islet isolation on islet integrity
The process of islet isolation impacts on the subsequent function and survival 
of the islets. Isolated islets lose their vasculature, innervation and the peri-islet 
ECM during the isolation process. Additionally, the expression of pro- 
inflammatory cytokines is induced in islets during the stress of the mechanical 
and enzymatic dissociation of the surrounding pancreas tissue.
describe epithelial cell death induced by the loss of cell anchorage and to provide an 
explanation for why ECM had previously been reported to act as a survival factor for 
endothelial cells (Frisch and Francis, 1994, Meredith et al., 1993). Several 
fundamental principles for anoikis were demonstrated in these early reports. First, the 
authors noted the importance of integrin-mediated signals for dictating cell 
death/survival. Secondly, the inhibition of anoikis by overexpression of the pro-survival 
molecule, Bcl-2, suggested that the permeabilisation of the mitochondrial membrane 
played an intrinsic role in eliciting cell death. Thirdly, different cell types showed 
varying degrees of susceptibility to anoikis (Frisch and Francis, 1994, Meredith et al., 
1993). Today, anoikis is used to describe apoptosis induced by the loss of cell-matrix or 
cell-cell anchorage, as well as defective cell-ECM signalling when cells adhere to the 
inappropriate ECM (Gilmore, 2000).
Over the years, extensive research efforts have been directed towards elucidating the 
molecular mechanisms underlying anoikis-mediated apoptosis. The main signalling 
molecules include the non-receptor kinases, focal adhesion kinase (FAK) and Integrin- 
Linked Kinase (ILK). Ligation of cell surface integrins phosphorylate FAK, which in 
turn, activates several signalling pathways such as the phosphatidylinositol-3-kinase 
(PI-3K) signaling pathway and the Mitogen Activated Protein Kinase (MAPK) 
pathways including Extracellular signal-Regulated Kinase (ERK) pathway, Jun-NH2- 
terminal Kinase (JNK) and p38 signalling (Aikawa et al., 2002, Saleem et al., 2009, 
Weber and Menko, 2003, Xia et al., 2004).
Central to the integrin-associated cell survival signalling pathway, is the subsequent 
activation of protein kinase B (PKB/AKT), the downstream effector of the PI-3K 
signalling pathway. In contrast to FAK, ILK bypasses the interaction with PI-3 kinase 
and interacts directly with AKT (Persad et al., 2001). PKB/AKT confers signals for cell 
growth, proliferation and survival. In addition, PKB/AKT signaling exerts an anti- 
apoptotic effect by inhibiting the pro-apoptotic protein, Bad, by activating caspase 9 and 
inducing NF-kB activity and the Forkhead family transcription factors (Cardone et al., 
1998, Datta et al., 1997, Kops and Burgering, 2000, Romashkova and Makarov, 1999). 
In contrast, the failure of integrin engagement upon cell membrane detachment releases 
the inhibitory effect of PKB/AKT on the pro-apoptotic signals. As a result, Bad is 
translocated into mitochondria, and leads to pore formation in the outer mitochondrial 
membrane. The subsequent release of cytochrome c and activation of executioner
caspases (the downstream caspases activated by a cascade of initiator caspases during 
apoptotic signalling), results in apoptosis (Datta et al., 1997, Khwaja, 1999, Tait and 
Green, 2010). It is noteworthy that differences in the composition of matrix proteins, 
tissues, integrins and cell types may lead to alternative signalling pathways that also 
culminate in anoikis-induced apoptosis (Gilmore, 2000, Grossmann, 2002).
Anoikis has been reported in a range of cell types including islets. The destruction of 
the islet microenvironment during the isolation process results in the loss of tropic 
support and survival factors from the surrounding ECM, which contribute to anoikis- 
induced apoptosis. The loss of integrin-mediated signalling during islet isolation 
correlated with decreased insulin content and function of beta cells as well as a rise in 
beta cell death (Wang and Rosenberg, 1999). Loss of the FAK activity and the 
differential expression of MAPK signalling pathway have also been reported. As 
expected, the prosurvival signal ERK was upregulated immediately after isolation and 
declined during in vitro culture. Conversely, expression of the proapoptotic signal p38 
was enhanced during islet culture (Rosenberg et al., 1999). In addition, caspase-6 was 
found to be upregulated in isolated islets (Thomas et al., 2001). In contrast, anoikis- 
induced apoptosis was attenuated in ECM-embedded islets resulting from incomplete 
pancreas digestion (“mantled” islets). Moreover, these mantled islets showed superior 
function in vivo (Ricordi et al., 1995, Thomas et al., 1999). Hence, it is envisaged that 
the preservation of the peri-islet ECM during islet isolation is of paramount importance 
in maintaining the survival and function of islet beta cells.
1.4.3 Induction of cytokines in isolated islets
Cytokines are low molecular weight proteins that are secreted by virtually all nucleated 
cells to mediate a series of cellular processes, e.g., embryonic development, cell 
proliferation, migration, angiogenesis, tissue remodelling, fibrosis, inflammation and 
immunity (Feldmann, 2008, Oppenheim, 2001). The advance of molecular biological 
approaches has allowed detailed characterisation of various cytokines and cytokine 
receptors (VÜ9ek and Feldmann, 2004). Several functional categories have arisen due to 
the redundant and pleiotropic nature of cytokines. The major functional subsets are 
cytokines that contribute to the differentiation and effector function of Thl helper T 
cells, namely Thl, Th2 and Thl7 cytokines. The Thl cytokines are IL-1, IL-2, IL-12, 
IL-18, IFN-y. Th2 cytokines include IL-4, IL-5, IL-18, IL-25, IL-33 whereas Thl7 
cytokines consist of IL-17, IL-23, IFN-y. Thl cytokines mainly drive cell-mediated
immune responses. In contrast, Th2 cytokines are key mediators for antibody-mediated 
immune responses. Recently, Thl7 cytokines have been shown to be involved in a 
series of pathological settings including autoimmunity and allograft rejection (Duerr et 
al., 2006, Itoh et al., 2010, Nakagiri et al., 2010, Wong et al., 2008, Yang et al., 2008). 
Additionally, cytokines can be further categorised into different functional units, such as 
pro-inflammatory cytokines (IL-la, IL-lß, TNF-a, IL-12, IL-18, IL-23) and anti-
inflammatory cytokines (IL-10, IL-13, TGF-ß, IL-22, IL-IRa, IFN-a and IFN-ß) 
(Dinarello, 2007).
By convention, cytokines bind to specific high affinity membrane receptors. The 
interaction between a cytokine and its receptor triggers a cascade of intracellular 
signalling pathways which include tyrosine phosphorylation of the receptor. Signal 
transduction via tyrosine kinases (Janus kinases (JAKs)) leads to activation of the 
transcription factor ST AT which modulates a variety of biological responses including 
cell growth, differentiation and cell death (Leonard and Lin, 2000).
Chemokines are small cytokines that range between 8 to 10 kDa in size. They are 
secreted proteins and are classified into 4 categories: C, CC, CXC and CX3C, based on 
the number of amino acids (X) separating the first two cysteine residues (C) in their 
primary amino acid sequence. There exist seven-transmembrane-spanning G-protein 
coupled chemokine receptors with distinct but overlapping chemokine and leukocyte 
specificity. The overlapping specificity allows chemokines to interact with multiple 
receptors and vice versa (Abdi et al., 2003, Nelson and Krensky, 2001).
Isolated islets are found to express a wide array of proinflammatory mediators, 
including the chemokine monocyte chemoattractant protein (MCP-1), and the cytokines 
interleukin-1 ß (IL-lß), tumour necrosis factor-a (TNF-a), IL-6 and IL-8, in response to 
oxidative, mechanical, osmotic and ischemic stress induced by the isolation process. In 
addition, microarray analysis of freshly isolated human islets revealed induction of islet- 
intrinsic NF-kB signalling, compared with native islets. In concert with this finding, 
electrophoretic mobility shift assay (EMSA) demonstrated NF-k B DNA binding 
activity in freshly isolated human islets, suggesting activation of NF-k B signalling 
pathways. The NF-kB pathway regulates the expression of a suite of genes involved in 
inflammation and apoptosis. Upregulation of NF-kB target genes, namely complement 
factor B (CFB), CXCL6, IL-8 and vascular cell adhesion molecule-1 (VCAM-1) were
observed in freshly isolated human islets. Despite evidence showing expression of 
inflammatory mediators by islet beta cells, resident intra-islet macrophages, endothelial 
cells and pancreatic ductal cells, may in part, contribute to this intra-islet cytokine 
production (Azzi et al., 2010, Bottino et al., 2004, Hanley et al., 2006, Johansson et al., 
2003, Piemonti et al., 2002).
The induction of pro-inflammatory mediators during islet isolation augments the 
inflammatory islet milieu via the generation of free radicals (see Section 1.5.2), 
induction of apoptosis and chemotaxis that can negatively impact on islet graft survival 
and function.
1.5.0 Factors contributing to early graft loss
A large number of islets (up to 11 000 islet equivalents/kg body weight) is required to 
restore glucose homeostasis in human transplant recipients, far surpassing the 10-20% 
of total islet volume allegedly needed to maintain normoglycemia (Carlsson, 2011, 
Correa-Giannella and Raposo do Amaral, 2009, Shapiro, 2011). This implies that a 
large number of transplanted islets are functionally impaired or lost after transplantation. 
In fact, studies of acute C-peptide release and quantitative positron emission 
tomography scan of labelled islet cells have indicated that approximately 60% to 80% 
of the transplanted islet mass is lost within the immediate post-transplant period (Eich et 
al., 2007, Eriksson et al., 2009, Harlan et al., 2009, Shapiro, 2011). This loss in donor 
islets is attributed to early islet cell death as a consequence of isolation-induced injury 
(Fig. 1.3).
1.5.1 Sub-optimal revascularisation and reinnervation after islet transplantation
The loss of islet vasculature during the islet isolation procedure exposes the islets to a 
hypoxic environment immediately after transplantation. Prior to revascularisation, the 
engrafted islets rely solely on the inefficient diffusion of nutrients and oxygen from 
blood vessels in the surrounding tissues (Davalli et al., 1996). This situation is in stark 
contrast to organ transplants where blood flow and organ perfusion are rapidly restored 
upon vascular anastomosis of donor arterial and venous vessels to the transplant 
recipient’s blood vessels. The complete revascularisation of rodent islet isografts at 
transplant sites such as the subrenal capsule or intrahepatic (via the intraportal vein) 
requires 7-14 days (Andersson et al., 1989, Menger et al., 1989, Morini et al., 2007). 
Studies have demonstrated the participation of donor- and recipient- derived endothelial
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Figure 1.3 Factors contributing to early graft failure
During the immediate post-transplant period, islets are continuously exposed to a 
hostile microenvironment. Major factors that contribute to early graft failure include 
ischaemia due to the slow process of neo-vascularisation, hypoxia-induced generation 
of free radicals and non-specific inflammation arising from isolation-induced cell 
injury, surgical trauma and prolonged hypoxia.
cells in the revascularisation process (Brissova et al., 2004, Carlsson et al., 2002, 
Nyqvist et al., 2005, Vajkoczy et al., 1995).
Importantly, the newly formed intra-graft blood vessels have been found to have less 
fenestration, decreased vascular density and blood flow. Mattson et al. provided 
quantitative data demonstrating decreased vascular density in C57BL/6 mouse islet 
isografts at 1 month post-transplant, irrespective of the transplant sites (subrenal capsule, 
spleen and intrahepatic vein), compared with the native islets in the pancreas (Mattsson 
et al., 2002). The suboptimal islet vasculature resulted in a lower oxygen tension in the 
islet transplants. Carlsson et al reported that the mean oxygen tension in transplanted 
syngeneic rat islets was 14-19 mmHg at 1 day post-transplant compared to that of native 
pancreatic islets, 31-37 mmHg. The oxygen tension decreased further (9-15 mmHg) in 
the syngeneic islet transplants after 1 month post-transplantation. In addition, the 
authors found that diabetic transplant recipient mice which received insufficient number 
of islets, displayed a lower oxygen tension of 6-8 mmHg (Carlsson et al., 1998). Like 
decreased vascular density, the lower oxygen tension in islet transplants was found to be 
unrelated to the implantation sites (subrenal capsule, spleen and liver). Decreased 
insulin secretion in diabetic recipients was also attributed to the chronic hyperglycemia 
and more pronounced hypoxia (Carlsson et al., 2001). In parallel, islet transplants 
displayed a lower tissue pH, suggesting that the islet transplants adopted anaerobic 
metabolism under prolonged hypoxia (Carlsson et al., 2003).
Brissova et al. observed that VEGF-A represents a key regulator of the revascularisation 
of islet transplants. Transplants of RIP-Cre VEGFn/fl islets that displayed reduced 
VEGF-A levels in the beta cells exhibited a lower vascular density when compared to 
wild-type islet transplants. Notably, the vasculature was mainly found at the islet 
periphery, suggesting that VEGF may be important for recruiting endothelial cells (ECs) 
for the revascularisation of the donor islets (Brissova et al., 2006).
The lag in revascularisation, sub-optimal blood supply and inadequate oxygen delivery 
are likely to negatively impact on islet graft function and survival. Various studies 
demonstrated that increasing the expression of proangiogenic factors in mouse islets via 
the delivery of genes encoding VEGF, hepatocyte growth factor (HGF) and fibroblast 
growth factor (FGF) or by incorporating collagen-immobilised VEGF into encapsulated 
islets, enhanced graft survival and function (Olerud et al., 2008, Panakanti and Mahato,
2009, Sigrist et al., 2003, Zhang et al., 2004). Zhang et al. used an adenoviral vector to 
transfect murine islets with human VEGF cDNA prior to marginal mass islet 
transplantation in immunoincompetent diabetic recipient mice. Recipient mice 
demonstrated immediate reversal of hyperglycemia, superior glycaemic control and 
rapid establishment of intra-graft microvasculature (Zhang et al., 2004). Likewise, 
inhibiting the angiostatin factor, thrombospondin-1 (TSP-1) by transfecting islets with 
TSP-1 siRNA resulted in improved islet engraftment and vascularisation of the 
transplants (Olerud et al., 2008).
1.5.2 Hypoxia-induced generation of free radicals
During the peri-transplant period, avascular donor islets are subjected to oxidative stress. 
Thereafter, suboptimal islet graft revascularisation and the resultant decreased partial 
oxygen pressure create a sustained hypoxic environment at the graft site. Prolonged 
hypoxia leads to the generation of free radicals that are detrimental to islet graft survival.
Free radicals including reactive oxygen species (ROS) and reactive nitrogen species 
(RNS), are amongst potent inflammatory mediators that contributes to islet beta cell 
death. Free radicals are chemically reactive species that contain one or more unpaired 
electrons. As a consequence, they seek electron donation from other molecules, which 
leads to electron transfer cascade by alternating between reduction and oxidation state. 
Whilst redox reactions are essential for ATP production in the mitochondria (Valko et 
al., 2007), high levels of free radicals can be deleterious to cell survival. During 
inflammation, high levels of ROS/RNS are generated by macrophages, dendritic cells 
and endothelial cells upon cytokine exposure (Steiner et al., 1997, Wiegand et al., 1993).
Islet beta cells and ductal cells are also sources for the production of the RNS nitric 
oxide (NO) production. Increased NO levels have been detected in isolated islets 
(Corbett et al., 1992, Pavlovic et al., 1999). Compared with other cells, islets produce 
low levels of antioxidant enzymes such as glutathione peroxidase, catalase, thioredoxin 
and superoxide dismutase (SOD). As a consequence, islets are highly susceptible to 
oxidative stress. Increased levels of NO can potentially impair glucose-stimulated 
insulin secretion and insulin biosynthesis by inhibiting aconitase, the Krebs cycle- 
associated enzyme involved in metabolic regulation in the mitochondria (Welsh et al., 
1991). Excess free radicals act on cellular lipids, proteins and nucleic acids, resulting in
increased capillary permeability, cell membrane disruption, nucleic acid disintegration, 
and ultimately cell death (Barshes et al., 2005)
In view of the exquisite sensitivity of islets to oxidative damage, antioxidants included 
during isolation or administered in the peri-transplant period, have been tested for their 
capacity to improve marginal mass islet transplants. Antioxidants including vitamins 
(tocopherol, ascorbic acid), metabolites (glutamine, bilirubin) and enzyme mimetics 
(SOD mimetics) have been shown to improve insulin secretion in response to a glucose 
challenge and overall graft survival (Avila et al., 2005, Bottino et al., 2002, Brown et al., 
2005, Tajiri and Grill, 1999).
The intraductal administration of L-glutamine, a precursor to glutathione (GSH) that 
possesses anti-oxidative properties improves the yield of isolated mouse islets. 
Recipient mice transplanted with L-glutamine-treated islets also responded better to an 
in vivo glucose challenge (Avila et al., 2005). Similarly, addition of the antioxidant 
SOD mimetics, AEOL10113 and AEOL10150, to the collagenase solution during 
isolation and culture increased the total human islet cell mass and improved the 
marginal mass islet transplants in diabetic NOD-SCID or Rag 1 recipient mice (Bottino 
et al., 2002). These findings were attributed to the antioxidant activity of the mimetics.
Bilirubin is a natural product of haeme catabolism and possesses anti-inflammatory, 
anti-oxidant and cytoprotective properties. The administration of bilirubin to syngeneic 
transplant recipient rats improved graft survival and glycaemic control in intraportal 
islet transplantation. The treatment also enhanced the function of marginal mass islet 
isografts. Decreased serum levels of ICAM-1, MCP-1, ICAM-1, IL-lß and TNF-a, 
together with diminished Kupffer cell infiltration and improved glucose tolerance were 
also observed (Zhu et al., 2010). Reduction of free radicals was also achieved by 
manipulating the expression of Haem-oxygenase-1 (HO-1). HO-1 is a ubiquitous heat 
shock protein induced by stress-related stimulants such as oxidative stress, 
inflammatory cytokines, hemolysis, heavy metals and endotoxin. HO-1 is 
cytoprotective because of its ability to scavenge free radicals and prevent cytokine- 
induced apoptosis. Protoporphyrins such as Cobalt-protoporphyrin (CoPP) and Ferrous- 
protoporphyrin (FePP) can upregulate HO-1 expression. Induction of HO-1 using CoPP 
and FePP protected islets from cytokine-mediated apoptosis, improved marginal mass
islet transplantation and prolonged allograft survival (Pileggi et al., 2001, Pileggi et al., 
2005)
1.5.3 Non-specific inflammation
Isolation-induced cell injury, surgical trauma and prolonged hypoxia can lead to non-
specific inflammation early after islet transplantation, which can damage donor islet 
tissue. Isolated islets express an array of proinflammatory mediators, including MCP-1, 
IL-lß, TNF-a, IL-6, IL-8, CFB, CXCL6 and VCAM-1 due to the oxidative, mechanical, 
osmotic and ischemic stress induced by the isolation process (Azzi et al., 2010, Hanley 
et al., 2006, Johansson et al., 2003, Piemonti et al., 2002). The production of 
proinflammatory cytokines can be further amplified locally by resident macrophages 
and neutrophils at the transplant site (Barshes et al., 2005).
The intra-graft expression of pro-inflammatory mediators promotes the recruitment of 
inflammatory leuckoytes during the host’s adaptive immune response against donor 
islet alloantigens. The upregulated chemokines set up a chemotactic gradient to guide 
leukocytes into the graft site and enhance antigen presentation. In addition, pro- 
inflammatory cytokines trigger a wide array of proinflammatory signalling pathways 
that are detrimental to islet graft function and survival. Islet susceptibility to cytokine- 
mediated damage is well documented in the context of the pathogenesis of type 1 
diabetes. IL-lß is a major inflammatory mediator in pancreatic islet injury. IL-lß 
expression was shown to decrease the levels of glucose-stimulated insulin biosynthesis 
and secretion by down-regulating mRNA expression for glucose transporter 2 (GLUT2) 
and glucokinase, the enzyme that phosphorylates glucose in islet beta cells (Park et al., 
1999). When expressed at high doses, IL-lß leads to a cascade of cellular signalling that 
activates NF-kB, the transcription factor that modulates the expression of inflammatory 
genes, including IL-1, IL-6 and TNF-a as well as adhesion molecules (intercellular 
adhesion molecule 1 (ICAM-1), VCAM-1 and ELAM-1), inducible nitric oxide 
synthase (iNOS) and prostaglandin E2 (PGE2) (Barshes et al., 2005).
Various approaches have been used to suppress the non-specific inflammatory response 
in the immediate post-transplant period. Combined treatment using anti-1L-lß, anti- 
TNF-a and anti-IFN-y enhanced the function of marginal mass islet transplants in 
diabetic C57BL/6 mice, resulting in better insulin secretion in response to 
intraperitoneal glucose challenge (Satoh et al., 2007). a 1-antitrypsin (hAAT) is a serine
protease inhibitor which inhibits the enzymatic activity of a wide range of inflammatory 
proteases such as neutrophil elastase, cathepsin G, proteinase 3, thrombin, trypsin and 
Chymotrypsin. hAAT treatment of chemically-induced diabetic recipient mice improved 
islet allograft survival and function. The cellular infiltrate, NO production, cytokine and 
MIP-1 levels were reduced, insulin secretion was enhanced and intra-graft MHC class II 
expression was decreased (Lewis et al., 2005). However, while prolonged allograft 
survival was observed in allogeneic spontaneous diabetic NOD mice, repeated 
administration of hAAT was found to be toxic, possibly due to the hypersensitivity of 
the autoimmune hosts (Pileggi et al., 2008).
1.6 The immune response to islet allografts
Despite initial engraftment, attrition of the transplanted islet mass occurs due to 
alloimmunity, autoimmunity and the toxicity of immunosuppressive drugs.
1.6.1 Historical overview by allograft immunity
Transplantation immunology was a fundamental field of study long before the 
development of islet transplantation. By transplanting tumours in inbred mouse-strains 
derived from brother-sister mating in 1910’s, Clarence Little elucidated the genetic 
basis of transplantation immunology. He observed that a tumour derived from a parental 
strain was accepted in FI progeny but was rejected in F2 progeny of a rate much lower 
than the Mendelian law of inheritance would predict (Little, 1914). He concluded that 
transplant immunity is governed by multiple loci, which were later called the “major 
histocompatibility” (MHC) loci (Auchincloss and Winn, 2004).
Peter Medawar was assigned the task of investigating the rejection of skin homografts 
(allografts) due to the demand for treating bum injuries during World War II. He and 
Thomas Gibson presented a comprehensive report entitled “The Fate of Skin 
Homografts in Man” based on studies on serial biopsies on a single bum victim. They 
proposed that homograft rejection was mediated by active immunisation and that the 
rejection of a second graft was accelerated “second set rejection” (Gibson and 
Medawar, 1943). Medawar went on to conduct experiments using a rabbit skin graft 
model, confirming the finding that allograft rejection is an acquired immune response. 
However, he mistakenly concluded at the time that transplant rejection is due to a 
humoral (antibody-mediated) response (Medawar, 1944, Medawar, 1945).
A decade later, the concept of the cellular basis of transplantation immunity developed 
from several important findings. In 1949, Burnet and Fenner argued against the role of a 
systemic response in graft rejection since no antibodies were detected during graft 
rejection (Burnet and Fenner, 1949). A separate study performed by Mitchison showed 
that the passive transfer of lymphoid cells but not peritoneal exudate or serum from 
immunised mice conferred induced the rejection of tumour allografts in non-susceptible 
mice (Mitchison, 1954). Subsequent studies with rabbit skin allografts by Billingham, 
Brent and Medawar lent further support to the cellular basis of transplantation 
immunity. To avoid confusion with the term “passive transfer” which was 
conventionally used for performed antibodies, they introduced the term “adoptive 
transfer” to describe the transfer of cells which conferred immunity in the secondary 
hosts. Billingham et al. noted that skin allografts were rejected in secondary hosts which 
received adoptive transfer of regional lymph nodes from actively immunised mice (mice 
that have previously rejected their allografts) (Billingham et al., 1954). Collectively, 
these findings established “cellular” immunology as the bases for transplant rejection.
Inspired by Little’s work documented in a book chapter entitled “ The Genetics of 
Tumour Transplantation”, George Snell embarked studies on mouse genetics that led 
him to the ground-breaking discovery of MHC loci and was awarded the prestigious 
Nobel Prize for this breakthrough. Today, the MHC is known as the set of cell surface 
molecules that regulates the generation of immune responses, including transplant 
rejection (Klein, 2001).
1.6.2 The Major histocompatibility complex (MHC)
Snell’s work identified several “histocompatibility (H) genes” that were involved in the 
rejection of tumour transplants. The H genes were found to be closely associated within 
a single chromosome. Today, the region associated with the H genes that controls 
immune response is termed “Major Histocompatibility Complex (MHC). In mice, MHC 
was referred to as Histocompatibility-2 (H-2) to reconcile Snell’s findings with those 
made independently by Gorer, who discovered that antigen II was responsible for 
tumour transplant growth or rejection. Similarly, the human MHC is called human 
leukocyte antigen “HLA” (Klein, 2001).
The MHC resides within chromosome 17 in mice and in the short arm of chromosome 6 
in humans. The MHC is made up of multiple loci which encode three different gene
products, namely class I, II and III. MHC class I and II molecules are cell surface 
antigens which present foreign peptides to immune cells, and class III molecules are 
components of the complement system (C2, C4 and factor B) or the cytokine TNF-a 
(Fig. 1.4). MHC genes are polymorphic loci characterised by high degrees of allelic 
variation within each locus (Ayala Garcia et al., 2012, Melvold, 2001).
1.6.2.1 MHC class I
MHC class I consists of three loci, H-2-K, -D and -L in mice or HLA-A, -B and -C loci 
in humans (Melvold, 2001). Class I loci encode a large glycosylated a-chain of 45 kDa 
that is associated noncovalently with the non-polymorphic 12 kDa ß-microglobulin 
chain encoded in in chromosome 2 and 15 in mice and human, respectively, to form the 
heterodimeric MHC class I molecules. The a-chain folds into 3 domains, a l, a2 and 
a3. The a3 domain and ß-microglobulin are positioned at the bottom of the complex, 
with the a3 extending into the transmembrane region, al and a2 fold together to form a 
long cleft that provides the peptide-binding site. The polymorphisms of the a chains 
allow the generation of a variety of cleft surfaces to cater for different antigen/peptide 
binding (Fig. 1.5) (Jones, 1997, Pease et al., 1991).
1.6.2.2 MHC class II
Class II loci consist of H-2-A, -E in mice and HLA-DP, -DQ, -DR in humans (Melvold, 
2001). Class II molecules consist of two membrane-spanning glycoprotein chains, a- 
(34 kDa) and ß- (29 kDa) chains, each comprises 2 domains (al:a2 and ßl:ß2). The a2 
and ß2 domains are located at the base in proximity to the cell membrane bottom and 
possess transmembrane-spanning regions whereas al and ßl form the highly variable 
peptide-binding groove of the MHC class II molecule (Fig. 1.5) (Jones, 1997).
1.6.2.3 Polymorphism and polygeny of MHC loci
Since the MHC loci are closely linked, the set of allelles from each member of the tight 
cluster of MHC genes are inherited together as a unit called the MHC haplotype. Each 
individual will have 2 haplotypes representing the alleles from the chromosome pair 
each derived from each parents. Inbred laboratory mice bear 2 pairs of the same 
haplotypes that are prototypic (e.g., H-2b, H-2k, H-2d) across different mouse strains. 
For instance, C57BL/6 mice carry the H-2b haplotype that consists of MHC genes H- 
2Kb, -Db and -Abb, -Aab, -Ebb that encode MHC class I and II, respectively (Melvold, 
2001). In humans, each individual can express 6 different types of MHC class I
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Figure 1.4 The genetic organisation of human and mouse MHC loci
The human MHC (HLA) is located in chromosome 6 and mouse MHC (H-2) is on 
chromosome 17. The MHC loci harbour three individual gene clusters, which 
encode class I, II and III molecules, respectively. In mice, MHC class I gene 
cluster is split into two regions, with H-2D and H-2L (on the far right of the figure) 
and H-2K (on the far left of the figure). MHC class I and II molecules are cell 
surface antigens that present foreign peptides to immune cells, and class III 
molecules are components of the complement system.
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Figure 1.5 The structure of MHC class I and class 11 molecules
The MHC class I molecule is a heterodimer consisting of u-chains (u l, u2 and u3) 
bound covalently to ß2-microglobulin. al and a2 chains form the 
immunoglobulin-like peptide-binding domain positioned above the a3 and ß2- 
microglobulin domains. The a3 chain has a transmembrane region with a 
cytoplasmic tail, (b) The MHC class II molecule has two membrane-spannning 
chains, each comprising 2 domains (al:a2 and ßl:ß2). al and ßl form a highly 
variable peptide-binding groove while a2 and ß2 each contain a transmembrane 
region and a cytoplasmic tail (Klein and Sato 2000).
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molecules and 8 different MHC class II molecules. MHC has highly polymorphic loci 
due to the high levels of allelic variation within a single MHC locus. The polygeny and 
polymorphism of MHC loci thus confer great diversity in the capacity for MHC 
molecules to recognise different forms of antigens and peptides. This serves as an 
evolutionary advantage by preserving stringent immunosurveillance of pathogens 
(Ayala Garcia et al., 2012, Melvold, 2001).
By convention, MHC class I molecules are expressed by all nucleated cells whereas 
MHC class II molecules can only be found on antigen presenting cells such as dendritic 
cells, macrophages, B lymphocytes, monocytes, activated T cells, endothelial cells and 
thymic epithelial cells (Ayala Garcia et al., 2012, Klein and Sato, 2000). MHC class I 
and II present peptides to CD8+ and CD4+ T cells, respectively. The presentation of 
peptide antigens by MHC to T cells constitutes a primary step in the generation of an 
adaptive immune response.
1.6.2.4 Antigen processing by MHC class I molecules
MHC class I molecules present intracellular peptides from altered or viral-infected cells. 
In the context of MHC class I antigen processing, the catabolism of endogenous 
proteases by proteasomes and proteolytic enzymes, results in the generation of short 
peptides. These peptides are actively delivered to the lumen of endoplasmic reticulum 
(ER) via a specialised heterodimeric adenosine triphosphate (ATP)-dependent 
transporter associated with antigen processing (TAP). In the ER, the MHC class I alpha- 
chain binds to calnexin until the beta-2 microglobulin domain is loaded to form the 
complete MHC class I heterodimer. Molecular chaperones such as Erp57, calreticulin 
and the TAP-binding protein, tapasin interact with the MHC class I heterodimer to 
generate the peptide-loading complex. A single short peptide is lodged into the peptide-
binding groove of the MHC I complex. The fully assembled peptide-bound MHC is 
released from the chaperone-bound complex and exported to the cell surface through 
the Golgi cistemae (Fig. 1.6) (Cresswell, 2005, Klein and Sato, 2000).
1.6.2.5 Antigen processing by MHC class II molecules
MHC class II presents extracellular antigens. In contrast to MHC class I, antigen 
processing for MHC class II molecules requires a specialised type II transmembrane 
chaperone protein, the invariant chain (Ii). Ii acts as a surrogate peptide that fits into the 
peptide-binding region of MHC class II to stabilise the protein and prevent premature
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peptide binding. Ii is released from the MHC class II molecules through a series of 
proteolytic cleavage mediated by cathepsins. Cathepsin S cleaves the cytoplasmic tail of 
the Ii in an acidified vesicle, leaving a short peptide of Ii (CLIP) that bound to the 
peptide-binding groove. A nonpolymophic MHC class II heterodimer with a catalyst- 
chaperone function then interacts with the CLIP-bound MHC class II molecule to 
release CLIP in exchange for peptide, before it is exported to the cell surface (Fig. 1.6) 
(Jensen, 2007, Klein and Sato, 2000).
1.6.3 Lymphocytes
Following James Gowans’ finding, that lymphocytes recirculated between blood and 
lymph by traversing through postcapillary venules (Gowans, 1959), Medawar showed 
that small lymphocytes were immunologically competent (Medawar, 1958). 
Accumulating data from Medawar and Gowans demonstrated that the small 
lymphocytes underwent growth and mitosis upon antigen stimulation, which fits in with 
Burnet’s clonal selection theory, which proposed that antigen-specific lymphocytes are 
able to undergo proliferative clonal expansion upon antigen encounter. (Billingham et 
ah, 1956, Gowans et al., 1962).
It later became clear that lymphocytes derived from the thymus (T lymphocytes) were 
responsible for graft rejection. This cell type is different to the bone marrow-residing 
lymphocytes (B lymphocytes), the principal cell type responsible for humoral immune 
response. B cells produce antibodies against antigen and can serve as antigen presenting 
cells to T lymphocytes. In contrast, T cells play a key role in cellular immune response. 
Elegant studies by Miller et al. showed that the removal of thymus impaired the ability 
of the recipient mice to reject allogeneic skin grafts. However, thymectomised mice that 
were subsequently grafted with thymus tissue were able to reject the skin allografts 
(Miller, 1962).
Early experiments by Harvey Cantor and Ed Boyse identified two major T lymphocyte 
subsets with helper and cytotoxic effector functions. They identified that helper T cells 
express the cell surface marker Ly-1+ and that cytotoxic T cells express Ly-2+3+ 
(Cantor and Boyse, 1975). Today, these two major subsets are known as helper CD4+ T 
cells and cytotoxic CD8+ T cells, respectively. CD4+ T cells aid the activation and 
growth of CD8+ T cells, stimulate B cells to produce antibody, help antibody isotype 
switching and induce the activation and migration of macrophages, eosinophils,
basophils and other lymphocytes via the production of cytokines and chemokines (Zhu 
and Paul, 2008). Conversely, cytotoxic CD8^ T cells kill virus-infected cells by 
releasing granzyme B, perforin and granulysins from intracellular granules (Barry and 
Bleackley, 2002)
1.6.3.1 In vitro cytotoxicity assay
The function of T lymphocytes was unveiled by a series of in vitro studies. 
Lymphocytes retrieved from dogs that had rejected their kidney allografts were shown 
to be cytotoxic to donor kidney cells in vitro (Govaerts, 1960). Rosenau and Moon 
observed that pre-sensitised lymphocytes clustered around their allogeneic target cells 
in culture, followed by progressive cytopathic changes and extensive lysis of the target 
cells. The authors further suggested that close contact between sensitised lymphocytes 
and their target cells was essential for the cytolytic effect (Rosenau and Moon, 1961). A 
quantitative assay for in vitro cytotoxicity, named cell-mediated lympholysis (CML) 
assay, was later developed. Brunner et al. pre-labelled target cells with radioactive 
chromium (51Cr) before mixing them with sensitised splenocytes. In vitro cytotoxicity 
indicating the lysis of allogeneic target cells by sensitised lymphoid cells was measured 
by the release of MCr (Brunner et al., 1968). This classical cell-mediated lympholysis 
(CML) assay, then served as an in vitro model for assessing the killing capacity of 
effector cells in transplant immunity.
1.6.3.2 Mixed lymphocyte reaction (MLR)
Another invaluable tool used to study lymphocytes was the mixed lymphocyte culture 
(MLC) assay. In 1963, a group of investigators coined the term “mixed lymphocyte 
reaction (MLR)” to describe the enlargement of cells in culture when lymphocytes 
derived from two genetically distinct individuals were mixed in vitro. They noted that 
the cells were capable of synthesising DNA and underwent mitoses. The authors further 
proposed that the MLR may be related to allograft rejection (Bain et al., 1964). Bach et 
al. demonstrated that most related individuals displayed minimal MLR reactivity. The 
authors further proposed that the MLC assay could be used as a valid in vitro assay to 
evaluate graft compatibility. These authors later developed the one-way MLR, in which 
the reactivity of the recipients, was assessed by inhibiting the activation of the donor 
cells via mitomycin-C treatment or X-ray irradiation of the donor cells prior to MLC 
(Bach and Voynow, 1966).
1.6.3.3 Signal 1 - T cell receptor (CD3):MHC
T cells interact with MHC molecules on antigen presenting cells (APCs) via their T cell 
receptor (TCR). The TCR:MHC interaction constitutes signal 1 for alloreactive T cell 
activation. This interaction forms a bridge between T cells and APCs upon T cell 
priming. The heterodimeric TCR consists of two membrane-spanning glycoprotein 
chains, alpha and beta chains. Each chain contains a variable and a constant region 
domain. The variable domains of both chains form 3 complementary-determining 
regions (CDRs), CDR1, CDR2 and CDR3 that associate with peptide-bound MHC 
molecules. The less variable CDR1 and CDR2 interacts primarily with the conversed 
region of the MHC molecules whereas the highly variable CDR3 loop binds the most 
variable part of the peptide and hence determine the specificity of TCR:peptide:MHC 
interaction (Fig. 1.7) (Klein and Sato, 2000). TCR expression and signalling is 
modulated by CD3, a complex of four invariant signalling protein (two epsilon, one 
delta and one gamma chains) and a zeta-chain accessory molecule that interact with 
alpha:beta heterodimer. Each CD3 chain contains an immunoreceptor tyrosine-based 
activation motifs (IT AMS) except the epsilon chain that has 3 IT AMS in their 
cytoplasmic tails. These ITAMS serve as the critical sites for TCR signalling upon 
MHC ligation.
1.6.3.4 Signal 2 -  The costimulatory signal
Snell first noted that donor lymphocytes serve as the major donor antigens that migrate 
to regional lymph nodes and induce an immune response (Snell, 1957). The term 
“passenger leukocytes” was later coined by Elkin and Guttman. In their studies of the 
graft-versus-host reaction (GVHR), Elkin et al transplanted parental donor rat kidneys 
into FI hybrid recipients, in which the transplanted kidneys were expected to survive. 
However, an inflammatory response was observed after parental strain spleen cells were 
introduced under the capsule of the transplanted kidneys. The authors proposed that the 
GVHR was brought about by the donor passenger cells and further postulated that they 
could be an important factor in organ allograft rejection (Elkins and Guttmann, 1968). 
An immediate question arising from the “passenger leukocyte concept” was how do 
passenger leukocytes activate the allogeneic response?
The idea that donor leukocytes were simply a mere source of antigen recognition was 
quickly refuted by experimental observations. Firstly, Simonsen noted that a local 
GVHR occured when adult lymphoid cells were introduced into genetically unrelated
MHC
Figure 1.7 Signal 1: T-cell receptor and MHC
T cells interact with MHC molecules (on APCs) via T-cell receptor (TCR). The 
TCR is a heterodimer that consists of two transmembrane glycoprotein chains, a 
and ß chains. Each chain consist of a variable and constant domain. TCR 
expression and signalling is modulated by CD3, which consists of four invariant 
signalling peptide protein (two epsilon, one delta and one gamma chain) and a 
zeta-chain accessory molecule (Stauss et al., 2007).
chicken embryos that were unable to reject the grafted cells due to the immaturity of 
their immune system (Simonsen, 1962). Subsequent studies by Lafferty et al. 
demonstrated the species specificity of the GVHR. These authors elegantly showed that 
xenogeneic pigeon spleen cells failed to initiate a GVHR in developing chicken 
embryos (Lafferty and Jones, 1969). These findings argued against the notion that 
foreign antigen alone were sufficient to trigger transplantation immunity (Medawar, 
1944).
Secondly, despite the generation of a strong immune response against MHC 
alloantigens during graft rejection, MHC alloantigens were essentially weak 
immunogens when presented to the immune system as a soluble antigen. In fact, 
alloantigens stimulate T cell activation only when they are presented by metabolically 
active cells (Batchelor et al., 1978). This transplantation paradox, advocated against the 
notion that the interaction of MHC alloantigen with T cell receptor directly stimulates T 
cell activation.
Collectively, these findings culminated in the development of Lafferty/Cunningham two 
signal model that led to a paradigm shift in transplantation immunology (Lafferty and 
Cunningham, 1975). Influenced by the Bretscher-Crohn’s proposition that two signals 
were essential for self/nonself discrimination in lymphocytes (Bretscher and Cohn, 
1970), Lafferty amended this concept and highlighted the role of a stimulator cell in the 
presentation of antigens to T cells. He reasoned that the antigen presentation provides 
signal one for the activation of T cells. In addition to antigen recognition, a second 
signal, the non-antigen specific inductive stimulus (co-stimulator activity) derived from 
stimulator cells, was also required to elicit an alloimmune response. Conversely, the 
presence of signal one without co-stimulation was considered a null event. In addition, 
co-stimulation was found to be a functional property of APCs, i.e. predominantly 
hematopoietic lymphoid cells. According to this model, MHC acts as a “control” 
structure which, upon ligation of T cell receptor, triggers co-stimulatory activity 
(Lafferty et al., 1983).
The stimulator cells needed to be metabolically active to express co-stimulatory activity 
as cells treated with UV irradiation were not able to activate T cells. Taken together, the 
Lafferty/Cunningham’s two signal theory provided a valid explanation for the important 
role of donor passenger leukocytes, fulfilling the criteria of providing both alloantigen
(signal 1) and costimulation (signal 2) for the activation of alloreactive T cells. By 
contrast, graft parenchymal tissue per se, despite their expression of MHC alloantigens, 
was unable to induce alloreactivity due to the lack of co-stimulatory function. Thus, the 
major source of immunogenicity is derived from graft-derived APC or passenger 
leukocytes and not alloantigen expressed by tissue parenchymal cells (Bowen et al., 
1980, Bowen and Lafferty, 1980, Lafferty et al., 1976, Lafferty et al., 1983, Nicolls et 
al., 2001).
1.6.3.5 Co-stimulatory signalling
Today, it is well accepted that interaction between T cell receptor (TCR) and MHC 
alone is insufficient to fully activate T cells. A second signal provided by costimulatory 
molecules on APCs is essential for T cell activation. It is now evident that a range of 
costimulatory molecules are expressed by APCs, including the B7 molecules (CD86 
and CD80) and members of the TNF receptor family including CD40 and 0X40 ligand 
(Fig. 1.8). These costimulatory molecules interact with their respective counter-
receptors on the surface of T cells, namely CD28, CD40 ligand (CD 154) and 0X40. 
The role of costimulatory molecules in modulating islet allograft rejection was 
emphasised when allogeneic islets from transgenic mice over-expressing CD80 were 
acutely rejected in the absence of islet donor-derived APCs (Coulombe et al., 1996). 
Signalling through the CD28.B7 (CD86 and CD80) axis lowers the threshold for T cell 
activation, increases production of interleukin-2 (IL-2), promotes T cell proliferation 
and confers resistance to T cell apoptosis (Le Moine et al., 2002, Wood and Goto, 2012). 
Interactions between CD 154 (CD40L): CD40 and OX40:OX40L activate the 
transcription factor, nuclear factor k  B (NF-kB) in both T cells and APCs. NF-kB 
activation, in turn, upregulates a range of proinflammatory genes such as chemokines, 
cytokines and costimulatory molecules. This signalling cascade initiates a positive 
feedback loop that contributes to T cell expansion. Additionally, interactions between 
ICAM-l(T-cells) and LFA-3 (APCs) as well as LFA-1 (T cells) and ICAM-1 (APCs) 
provide ancillary signals alongside costimulation to aid T cell activation. During the 
later stages of an immune response, T cells express CD 152 (CTLA-4), an inhibitory 
molecule, which shares close homology to CD28 and has a higher binding affinity to 
CD80 and CD86. CTLA-4 expression provides a negative feedback loop in fine-tuning 
and dampening immune responses (Wood and Goto, 2012). In view of the critical role 
of the co-stimulatory molecules in regulating T cell reactivity, modulation of co-
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Figure 1.8 Signal 2: Co-stimulatory molecules
Interactions between MHC alloantigens and the corresponding T-cell receptors 
provide signal 1 for T cell activation. In addition, a second signal is provided by 
binding of costimulatory molecules on APCs to their receptors/ligands on T cells. 
The costimulatory molecules include T cells include CD28, CD40L and 0X40 on T 
cells, CD80/86, CD40 and OX40L on APCs, respectively. Other interactions such as 
LFA-1 and ICAM-1 signalling acts to optimise cell-cell interactions. Both signal 1 
and 2 are required for T cell activation (Wood and Goto 2012).
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stimulatory activity was recognised as a promising strategy for preventing allograft 
rejection (see Section 1.8.4).
1.6.4 Antigen presentation
The intense immune response generated against allogeneic islet transplants is a result of 
alloantigen recognition by recipient T cells. As discussed in Section 1.6.2, the MHC 
class I and class II molecules represent the strongest alloantigens. Since approximately 
1-10% of the T cell repertoire is able to respond to a single alloantigen, a frequency 
which is about 10 to 100 fold higher than the frequency of T cells reactive against 
nominal or auto-antigens, MHC disparity between an islet donor and transplant 
recipient represents a formidable barrier to graft acceptance (Ricordi and Strom, 2004, 
Sherman and Chattopadhyay, 1993).
In a conventional immune response that conforms to MHC restriction, T cells are 
activated upon antigen presentation by recipient APCs. Transplantation immunology 
features a unique immunological situation, whereby the priming of alloreactive T cells 
can be mediated by both donor and recipient APCs via two distinct pathways, namely 
direct allorecognition and indirect allorecognition (Le Moine et al., 2002).
Direct allorecognition by T cells occurs when donor alloantigen is presented by donor- 
type APCs. In this setting, recipient T cells are able to recognise the peptide-bound 
allogeneic MHC. These peptides can be derived from endogenous donor proteins and 
MHC peptides of donor or recipient origin. Theoretically, the antigenic epitopes 
recognised by the direct pathway could included the donor allogeneic MHC (alloMHC) 
with or without processed donor MHC peptides (Sayegh et al., 1994). While most 
allorecognition involves peptide-bound MHC, there is evidence suggesting that a small 
subset of T cells could recognise empty alloMHC, i.e., in the absence of bound peptides 
(Elliott and Eisen, 1990, Ohlen et al, 1990)
Direct allorecognition leads to the activation of recipient CD4+ or CD8+ T cells by 
interacting with donor-type MHC class II and class I, respectively. Conversely, indirect 
pathways require recipient APCs to process and present the alloantigen in the context of 
recipient type MHC class II to the alloreactive T cells. Due to the requirement of 
antigen processing, indirect pathway primarily activates recipient CD4+ T cells.
1.6.4.1 Direct allorecognition
Direct allorecognition driven by donor APCs is the primary antigen presentation 
pathway in islet allograft rejection (Fig. 1.9). Lafferty’s concept of passenger leukocytes 
(see Section 1.6.3.4) predicted that the depletion of donor leukocytes should promote 
allograft survival. Lafferty demonstrated that the pretreatmnet of thyroid tissue by 
culturing in an oxygen-rich gas phase led to the long term survival of thyroid allografts 
due to the removal of donor-type passenger leukocytes (APCs). Lafferty seubsequently 
applied this concept to an islet allograft setting (Lafferty et al., 1976). Indeed, they 
successfully demonstrated that pretreatment of allogeneic islets in 95% O2 and 5% CO2 
for 7 days prior to transplantation resulted in the indefinite survival of islet allografts in 
non-immunosuppressed recipient mice (Bowen et al., 1980, Bowen and Lafferty, 1980). 
Oxygen treatment reduced the immunogenicity of the donor tissue by selectively 
removing donor APCs while retaining the antigenicity of the tissue. Thus, precultured 
islets were still vulnerable to rejection following donor-specific active immunisation of 
the recipients. Simeonovic et al. showed that acute rejection was elicited in the cultured 
islet allografts when recipient mice were challenged with lxlO5 donor APCs at the time 
of transplantation (Simeonovic et al., 1980).
1.6.4.2 Indirect allorecognition
While it is generally accepted that direct allorecognition is the principal pathway in 
mediating islet allograft rejection, it is possible that indirect allorecognition can play a 
supplementary role. Makhlouf et al. showed that MHC class Il-deficient islet allografts 
were rejected more rapidly than islet allografts transplanted to MHC class Il-deficient 
recipient mice. This study revealed that islet allografts were rejected at a faster tempo 
with the help of CD4+ T cells activated via the indirect pathway, than with CD8+ T cells 
alone (Makhlouf et al., 2003). However, the fact that islet allografts were spontaneously 
rejected in MHC class Il-deficient recipients and that donor APC-depleted allografts 
survived indefinitely (Bowen et al., 1980, Bowen and Lafferty, 1980, Makhlouf et al., 
2003), excluded an essential contribution of the indirect presentation of alloantigen- 
peptide to the rejection of islet allografts.
1.6.5 T cell repertoire in islet allograft rejection
The relative contribution of direct and indirect allorecognition dictates the types of 
effector cells that mediate allograft rejection. In addition, the choice of donor-recipient
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Figure 1.9 Direct allorecognition
Direct allorecognition is the primary antigen presentation pathway in islet allograft 
rejection. Donor APCs provide signal 1, via T cell receptor-donor MHC alloantigen 
engagement, and the costimulatory signal 2 via the interactions between B7 and CD28 
on the cell surface of the donor APC and T cell, respectively. Recipeint alloreactive (A) 
CD8+ and (B) CD4+ T cells are activated by donor APCs that present alloantigens in 
the context of donor MHC class I and II, respectively.
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mouse strain combinations, the types of graft tissues, MHC class I and II expression on 
the graft tissues and the source of vascular endothelium have a significant impact on 
islet allograft immunity (Gill, 1998, Makhlouf et al., 2003, Simeonovic et ah, 1996). 
The predominant direct alloantigen presentation pathway can activate both alloreactive 
CD4+ and CD8+ T cells, via TCR interaction with donor MHC class II and I, 
respectively. Once activated, the alloreactive T cells are able to directly engage MHC 
alloantigens on graft tissues to induce damage. However, since islet parenchymal tissue 
displays only MHC class I alloantigens, CD8+ T cells are the major effector cells in the 
rejection of islet allografts. Consistent with this, long term graft survival was observed 
in Streptozotocin-treated recipient mice depleted of CD8+ T cells via anti-CD8 mAb 
treatment and in MHC class I-deficient islet allografts (Markmann et ah, 1992, Osorio 
et ah, 1993, Simeonovic et ah, 1996). On the contrary, anti-CD4 monotherapy only 
transiently restored normoglycaemia in recipient mice carrying islet allografts 
(Simeonovic et ah, 1996). Furthermore, islet allografts did not show prolonged survival 
in MHC class II-deficient recipients, suggesting that CD4+ T Cells are not the principal 
effector cells in mediating the rejection response (Nicolls et ah, 2001).
Despite the dominant role of CD8+ T cells in islet allograft rejection, CD4+ T cells are 
also found to participate in the rejection response. Islet allografts were rejected more 
efficiently in the presence of both CD8+ and CD4+T cells, compared with the omission 
of either T cells (Markmann et ah, 1992, Nicolls et ah, 2001, Simeonovic et ah, 1996). 
CD4+ T cells are likely to contribute to islet graft damage by facilitating the activation 
of CD8+ T cells or by secreting soluble inflammatory mediators including cytokines and 
free radicals that are toxic to the islets (Gill, 1998). Interestingly, Simeonovic et ah 
showed de novo induction of MHC class II expression on damaged islet grafts. The 
expression of MHC class II alloantigens in the later stages of rejection suggested that 
CD4+ T cells may act as secondary effectors by amplifying the local inflammatory 
milieu and thus exacerbating islet graft destruction (Simeonovic et ah, 1996).
1.7 Effector mechanisms in islet allograft rejection
CD8+ T cells are the principal effectors in islet allograft rejection (see Section 1.6.5). 
Early studies focussed on elucidating the molecular effector mechanisms that underpin 
the rejection response. In 1989, Sutton et ah demonstrated that when a mixture of 
isogeneic and allogeneic islet tissue were transplanted under the same kidney capsule of 
recipient rats, only the allogeneic component of the islet transplants was damaged. The
exquisite specificity of the graft-destructive immune response supported the idea that 
islet damage was most likely mediated via contact-dependent cytotoxicity, instead of a 
relatively non-specific cytokine-induced graft mechanism of destruction (Sutton et al., 
1989). In agreement with this idea, beta2-microglobulin-deficient islets, which lack cell 
surface expression of MHC class I, survived indefinitely in immunocompetent 
allogeneic recipient mice (Markmann et al., 1992). The two major contact-dependent 
mechanisms of cytolysis employed by CD8+ T cells are perforin/granzyme B- and 
Fas/Fas ligand (FasL)-mediated (Diamond and Gill, 2000). The TCR-MHC class I 
interaction between activated CD8+ T cells and the target islet cells stimulates vectorial 
release of cytotoxic granules containing perforin and granzymes. Perforin permeabilises 
the target cell membrane, causing osmostic lysis of the target cells and entry of 
granzyme B into the cytoplasm, which in turn, triggers apoptosis via the direct 
activation of the executioner caspases. Alternatively, granzyme B can bind to the Bcl-2 
interacting domain (BID) and promote the assembly of the Bcl-2 homologous 
antagonist BAK/BAX oligomers on the mitochondria outer membrane, causing 
membrane permeabilisation. Cytochrome C released from the mitochondria then forms 
the apoptosome containing the initiator caspase-9. Activation of caspase-9 triggers the 
activation of a cascade of effector caspases that leads to DNA fragmentation (Hui et al., 
2004, Rocha et al., 2003).
In the case of the Fas/FasL signalling-mediated cell death pathway, upregulation of 
FasL (CD95L) on the cell surface of activated CD8+ T cells binds to the TNF 
superfamily molecule, Fas (CD95) expressed on the target cells. Fas undergoes 
multimerisation upon ligation with FasL, which leads to the assembly of death-inducing 
signalling complexes (DISC). FADD, the adaptor protein is then recruited to DISC and 
interacts with the initiator caspase-8, promoting the activation of cascade of caspases 
and cell death (Li and Yuan, 2008, Sleater et al., 2007). Sleater et al. reported that 
established Fas-deficient islet allografts were rejected when in vitro activated anti-donor 
CD8+ T cells were transferred into fully MHC-mismatched immunoincompetent host 
mice. Similarly, islet allografts were rejected in the allogeneic immunoincompetent 
recipient mice following the adoptive transfer of in vitro stimulated perforin-deficient 
anti-donor CD8+ effectors. Nevertheless, prolonged survival of Fas-deficient islets was 
observed after the transfer of perforin-deficient CD8+ effectors. Taken together, these 
findings suggested that CD8+ T cells execute graft rejection using either perforin or 
Fas/FasL signalling pathways (Sleater et al., 2007).
In addition to cytolytic pathways, activated CD8+ T cells, as well as other immune cells 
such as activated CD4+ T cells, NK cells and NKT cells produce high levels of 
proinflammatory cytokines including IFN-y. IFN-y can upregulate MHC molecules and 
promote antigen presentation by APCs. IFN-y can further amplify inflammatory 
responses by stimulating non-specific effector cells such as macrophages and NK cells. 
The important role for IFN-y in islet allograft rejection was depicted in studies by 
Diamond et al. While abrogation of either Fas or perforin-mediated cytolytic pathways 
did not prevent CD8+ T cell-mediated islet graft rejection, islet allografts showed 
improved survival when in vitro primed IFN-y-deficient CD8+ T cells were adoptively 
transferred as donor-specific effectors to immunoincompetent hosts. IFN-y-deficient 
islet allografts in IFN-y-deficient immunocompetent recipient mice, however, did not 
show prolonged survival in the presence of a full complement of immune cells, namely 
CD4 , CD8+ T cells, B cells and NKT cells (Diamond and Gill, 2000).
Taken together, these findings suggest that contact-dependent cytolytic pathways are 
mainly mediated by perforin and Fas/FasL signalling and competence of either pathway 
alone is sufficient to elicit islet graft rejection. IFN-y may also play a critical role by 
upregulating the expression of MHC class I and Fas on the susceptible islet tissue 
(Diamond and Gill, 2000). However, other compensatory mechanisms of immune cells 
can contribute to islet graft rejection when CD8+ T cell-mediated effector mechanisms 
fail (Fig. 1.10).
The role of T cell-specific NF-k B in islet allograft rejection has recently been examined. 
Islet allograft survival was markedly prolonged in recipient mice overexpressing the 
super-repressor form of the NF-k B inhibitor, IxBaAN-Tg that selectively inhibits NF- 
kB. Allograft survival in this mouse model was associated with a dramatic decline in 
intra-graft populations of CD4+ and CD8+ T cells. Albeit with a lower level of T cell 
infiltration, reduced NF-k B activation did not appear to affect T cell priming or 
differentiation. The transplant recipient mice did not develop donor-specific tolerance as 
the secondary donor skin transplant was rapidly rejected. Mechanistically, the TCR- 
MHC interaction normally leads to the assembly of the adaptosome complex made up 
of CARMA-1, Bel-10, and Malt-1, which results in the phosphorylation and 
degradation of Ik Bol  This releases NF-kB dimers which translocate into the nucleus to 
activate the expression of a range of inflammatory genes that facilitate T cell function
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Figure 1.10 Leukocyte recruitment and effector mechanisms involved in the 
rejection of islet allografts
Leukocyte recruitment to a graft site is a multi-step process: leukocytes adhere to the 
apical surface of inflamed endothelial cells, traverse the vascular endothelium and 
navigate to the islet tissue allografts. Leukocyte migration, activation and proliferation 
are assisted by the upregulation of chemokines and the induction of cytokine 
secretion. Multiple effector mechanisms are employed to damage the islet tissue. 
These include perforin/granzyme cytotoxicity, Fas/FasL signalling leading to 
apoptosis, secretion of inflammatory cytokines and the generation of reactive oxygen 
species (ROS).
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and survival as well as augment the graft-specific rejection response. Similarly, 
engagement of other receptors including tol-like receptors (TLRs) and tumour necrosis 
factor receptors (TNFRs) can also trigger NF-kB activation via different adaptors such 
as TNFR-associated family members (TRAF, TRADD) or the myeloid differentiation 
primary response gene 88 (MyD88) (Porras et al., 2012). NF-k B activation turns on the 
expression of gene for inducible nitric oxide synthase (iNOS), which in turn, gives rise 
to the elevated production of NO. The local production of free radicals by inflammatory 
cells in the rejecting graft niche exert deleterious effects on transplanted islets because 
islet tissue intrinsically expresses a low level of antioxidant enzymes (Rabinovitch and 
Suarez-Pinzon, 1998).
1.8 Immunotherapy
In view of the multiple mechanisms that can contribute to the destruction of islet 
allografts, extensive studies have been dedicated to identify approaches for improving 
islet graft survival and function. Various strategies have been employed to primarily 
target different stages of graft destruction, e.g., activation of the innate immune 
response (non-immune mediated inflammation), antigen presentation and initiation of 
the adaptive immune response, i.e., autoimmunity and alloimmunity.
1.8.1 Strategies for targeting the non-immune mediated destruction of islet 
transplants
Non-immune mediated inflammatory occurs during the early post-transplant period, 
results in primary non-function of islet transplants and necessitates a massive number of 
donor islets for re-establishment of normoglycaemia in the host. In addition, it sets the 
stage for the subsequent adaptive immune response against the transplanted islets. 
Efforts have been made to prevent non-specific inflammation by using various 
compounds, which are anti-inflammatory (e.g., hAAT (see Section 1.5.3), anti-oxidative 
(e.g., glutamine, bilirubin, SOD mimetics, vitamins (see Section 1.5.2) and anti- 
apoptotic (e.g., CoPP and FePP (see Section 1.5.2).
1.8.2 Modification of donor islet tissue
Early studies showed that allogeneic islet tissue cultured in 95% O2 and 5% CO2 for 7 
days prior to transplantation exhibited indefinite islet allograft survival (Bowen et al., 
1980, Bowen and Lafferty, 1980). The effectiveness of high oxygen pretreatment was 
attributed to the removal of donor APCs (passenger leukocytes), the main source of
immimogenicity of islet allograft rejection (Simeonovic et al., 1980). The efficacy of in 
vitro culture of donor islets has been reported in various mouse strains and across a 
different histocompatibility barriers, including outbred recipient mice receiving short-
term immunosuppression with cyclosporine (Simeonovic et al., 1986). However, this 
approach is not feasible for clinical islet transplantation due to toxicity to islets imposed 
by the high oxygen culture. A variety of pretreatment techniques designed to modulate 
tissue immunogenicity by depleting donor APCs have also been shown to prolong the 
survival of islet allografts in rodents. These include UV irradiation (Lau et al., 1984), 
low-temperature culture (Lacy et al., 1979), incorporation of anti-la or anti-dendritic 
cell antibodies in culture (Faustman et al., 1981, Faustman et al., 1984), and low pH 
media (La Rosa, 1988). Collectively, these studies suggested that allograft acceptance 
could be achieved by pretreatment of the grafts to remove the stimulating donor APCs.
1.8.3 Anti-CD3 monoclonal antibodies
CD3 is a component of the TCR complex and is responsible for the intracellular 
signalling required to achieve optimal T cell activation and function. CD3-specific 
monoclonal antibody (anti-CD3 mAb) treatment interferes with immune response by 
transiently depleting T cells and/or by blocking T cell activation by modulating 
TCR:CD3 signalling pathway upon antigen exposure. Anti-CD3 mAb treatment has 
successfully reversed acute renal allograft rejection (Woodle et al., 1999). Significantly, 
anti-CD3 mAb treatment has restored normoglycaemia in NOD mice when treatment 
commenced after the onset of autoimmune type 1 diabetes (Chatenoud et al., 1994).
1.8.4 Co-stimulatory blockade 
(a) CTLA4-Ig and LEA29Y
Co-stimulatory blockade represents a promising immunomodulatory strategy as it has 
been shown that TCR-MHC interaction in the absence of costimulatory signals leads to 
T cell anergy and donor-specific tolerance (Molano et al., 2001). Blockade of the 
CD28-B7 costimulatory pathway using CTLA4-Ig monotherapy, a genetically 
engineered fusion protein of human CTLA4 and IgGl Fc was shown to transiently 
prolong islet allograft survival in nonhuman primates. Peripheral lymphocytes retrieved 
from the transplant recipients exhibited donor-specific hyporesponsiveness when 
cultured in vitro with donor-type splenocytes, but not with third party splenocytes 
(Levisetti et al., 1997). CTLA4-Ig interferes with CD28-B7 interaction by binding to 
the cognate stimulatory molecules, CD80 and CD86. While CTLA4Ig monotherapy
showed short-term graft protection, combined treatment of CTLA4-Ig with other 
immunomodulatory agents resulted in long-term graft survival. Emamaullee et al. 
demonstrated that combinatorial treatment with the caspase inhibitor (EP1013) and 
CTLA4-Ig significantly reduced the islet cell mass required to reverse hyperglycaemia 
in allogeneic transplant recipient mice. A lower frequency of alloreactive IFN-y- 
secreting T cells and a higher level of intra-graft FoxP3+ regulatory T cells (Tregs) 
were also observed (Emamaullee et al., 2010). LEA29Y (Belatacept) is a second- 
generation CTLA4-Ig. It has a higher affinity for B7 molecules, due to a mutation in 2 
amino acid residues in the binding region for B7 molecules and hence acts as a more 
potent immunosuppressant. Adams et al. demonstrated that rhesus monkeys receiving 
LEA29Y treatment with rapamycin and daclizumab (anti-IL-2R mAb) showed 
substantial prolongation of islet allograft survival, relative to their control counterparts 
treated with only rapamycin and daclizumab (Adams et al., 2002).
(b) Anti-CD154 and anti-CD40 monoclonal antibodies
Monotherapy targeting the CD40-CD154 axis is by far the most efficacious single 
treatment in preventing transplant rejection in preclinical animal models. Humanised 
anti-CD 154 mAb (hu5c8) monotherapy resulted in long-term survival of islet allografts 
in baboons (Kenyon et al., 1999). In addition, Molano et al. showed that the 
administration of a hamster anti-murine CD 154 mAb (MR1) significantly prolonged the 
survival of both syngeneic and allogeneic islets in diabetic NOD mice. This 
extraordinary data strongly suggested that anti-CD 154 mAb protected against both 
allograft rejection and the recurrence of autoimmune disease (Molano et al., 2001). 
However, there has been speculations anti-CD 154 mAb treatment can also exert graft 
protection by inducing a signalling event that promotes T cell death or by marking 
activated T cells for complement-mediated cell lysis. Despite its potential role in 
dampening immune rejection, clinical trials using anti-CD 154 mAb have failed due to 
the increased incidence of fatal thromboembolic complications. An alternative strategy 
is to target the CD40 molecule. Treatment of a chimeric anti-CD40 mAb (Chi220), in 
combination with LEA29Y dramatically prolonged islet allograft survival in nonhuman 
primates (Adams et al., 2005).
(c) Anti-OX40 monoclonoal antibodies
Like CD 154, 0X40 is a costimulatory molecule from the TNF receptor family. It is 
expressed by activated but not naive T cells. OX40-OX40L signalling has been shown
to enhance cytokine production and to increase T cell proliferation and survival (Watts, 
2005). Chen and co-workers reported long-term islet allograft survival in CD 154 
knockout recipient mice treated with anti-OX40 mAb. The authors further suggested 
that Treg-mediated donor-specific tolerance has induced, since nephrectomised 
recipient mice tolerated second islet allografts from the same donor strain but rejected 
third party islet allografts (Chen et al., 2008).
(d) Anti-LFA-1 monoclonal antibodies
Islet rejection is a complex immune response orchestrated by multiple signalling 
pathways and immune mediators. It is therefore conceivable that optimal therapy is 
likely to require combinatorial treatment to target the different immunological 
signalling pathways. Recently, lymphocyte function-associated antigen (LFA-1) has 
emerged as a potential target in modulating adaptive immune response. LFA-1 is a cell 
surface ß2 integrin heterodimer made up of CDlla and CD 18 subunits. LFA-1 
participates in leukocyte trafficking by interacting with ICAM-1. Further studies have 
revealed additional functions in immunological synapses, regulating T cell activation 
and costimulatory signalling (Nicolls and Gill, 2006). LFA-1 is increasingly expressed 
on memory T cells. Hence, targeting LFA-1 provides a means to eliminate the memory 
T cell population, which has lower requirements for activation and costimulatory 
signalling. Immunosuppressive regimes consisting of anti-LFA-1 mAb (TS-1/22) in 
combination with basiliximab (anti-IL-2Ra Ab) and sirolimus or belatacept (CTLA4-Ig) 
dramatically delayed islet allograft rejection in nonhuman primates. In particular, rhesus 
macques treated with TS-1/22 and belatacept failed to develop donor-specific antibodies. 
The authors concluded that anti-LFA-lmAb potentially targets costimulation blockade- 
resistant T cells such as donor-specific memory T cells as well as primary alloreactive T 
cells (Badell et al., 2010). Furthermore, the chronic administration of efalizumab (a 
humanised anti-CDlla mAb which blocks the interaction between the CDlla subunit 
of LFA-1 and ICAM-1), with sirolimus and in the absence/presence of mycophenolate 
mofetil (MMF, an inhibitor of T/B cell growth by blockade of purine synthesis) resulted 
in the expansion of the peripheral Treg population (Posselt et al., 2010). However, 
efalizumab was subsequently withdrawn from the market due to the incidence of 
progressive multifocal leukoencephalopathy (PML) in psoriasis patients (Shapiro, 2011). 
In a separate study, co-administration of anti-OX40L mAb, anti-CD 122 mAb (to 
deplete memory CD8+ T cells), anti-CD 154 mAb and anti-LFA-1 mAb showed
enhanced secondary allograft survival and marked reduction of memory T cells (Xia et 
al., 2010).
1.9 Immunotolerance
Islet graft acceptance by the induction of immunological tolerance and without 
compromising the ability to mount other immune responses, remains the “holy grail” of 
islet transplantation. Billingham, Brent and Medawar first explored the concept of 
establishing bone marrow chimaeras to achieve donor-specific tolerance in 1953. They 
successfully induced indefinite donor-specific tolerance to skin allografts by 
transplanting donor-derived bone marrow cells into newborn recipient mice (Billingham 
et al., 1953). Similar concepts have been applied to islet transplantation. Short-term 
immunosuppression is required during the early post-transplant phase until the 
establishment of mixed chimaerism in the recipient mice. The strategy of mixed 
chimaerism allows donor-specific tolerance to be induced whilst preserving recipient 
immune responsiveness to other foreign antigens. Compelling data showing long-term 
survival of allografts has been reported in small animal models. Luo et al. demonstrated 
robust donor-specific tolerance to fully MHC-mismatched islet allografts in recipient 
mice which received nonmyeloblative conditioning with short-term administration of 
rapamycin and lymphocyte-depleting antibodies together with the transfusion of donor 
bone marrow cells (Luo et al., 2005). Studies using large animal models and human 
islet transplants have failed to recapitulate the success of donor-specific mixed 
chimaeism in small animals. Clinical studies using allogeneic islets and the infusion of 
donor CD34+ hematopoietic stem cells with minimal immunosuppression failed to 
achieve long-term graft survival and function (Mineo et al., 2008). Mixed chimaerism 
for human islet transplantation, however, remains problematic due to several issues. The 
preprarative treatments are aggressive and require the use of pan-T-cell Abs, irradiation 
and cytotoxic drugs. Furthermore, robust mixed chimaerism is difficult to achieve in 
fully MHC-mismatched allografts due to the large MHC disparity. The depletion of 
donor-specific recipient alloreactive T cells may further exacerbate the recurrence of 
autoimmune disease in islet transplants and give rise to unintended graft-versus-host 
disease (Ricordi and Strom, 2004).
Today, extensive efforts are focussed on generating donor-specific CD4+CD25+ Tregs 
to induce donor-specific tolerance. Various treatments targeting different immune 
signalling have shown to induce the marked expansion of Tregs. Vergani et al. showed
that co-treatment of ATG and CTLA4-Ig markedly expanded the Treg population, while 
depleting effector T cells (Vergani et al., 2006). In addition, treatment of rapamycin 
with the agonist IL-2- and antagonist IL-15-related cytolytic fusion proteins has 
promoted allograft survival by preserving Treg population, limiting the early expansion 
of activated T cells, enhancing the apoptotic clearance of T cells and by amplifying the 
depletion of activated T cells via antibody-dependent mechanisms (Zheng et al., 2003).
1.10 Immunotherapy in clinical islet transplantation 
Combined Treatment of Daclizumab, Sirolimus and Tacrolimus
The use of a glucocorticoid-free immunosuppressive regimen, with rapamycin 
(sirolimus), daclizumab (anti-IL-2R mAb) and low-dose FK506 (tacrolimus) was the 
hallmark feature for the early success of the Edmonton protocol for clinical human islet 
transplantation. 100% insulin independence was achieved at one-year post-transplant in 
seven consecutive type 1 diabetes patients prone to severe hypoglycaemia (Shapiro et 
al., 2000). Daclizumab was used at the initial phase of transplantation to induce 
immunosuppression while rapamycin and low-dose tacrolimus were administered life-
long as maintenance of immunosuppression. Rapamycin (sirolimus) is the mTOR 
inhibitor that blocks the translation of mRNAs encoding cell cycle mediators, and thus 
prevents cells from entering G1 to S phase of the cell cycle. The calcineurin inhibitor, 
FK506 (tacrolimus) inhibits the production of growth-promoting cytokines, including 
interleukin-2 (IL-2) whereas daclizumab is an anti-CD25 mAb directed against the 
alpha subunit of IL-2 receptor (Noguchi et al., 2006, Ricordi and Strom, 2004). The 
combination of rapamycin and FK506 treatment has been shown to delay rejection in 
both rodent and clinical renal and pancreas allografts (McAlister et al., 2000). 
Furthermore, co-administration of rapamycin and tacrolimus significantly prolonged 
syngeneic islet graft survival in non-obese diabetic (NOD) mice, suggesting its 
protective role against recurrence of autoimmune diseases (Shapiro et al., 2002).
Despite the initial success of islet engraftment and function, the Edmonton protocol did 
not promote long-term graft protection. As a consequence, the insulin independence and 
donor islet cell mass were dramatically reduced by 5 years post-transplant. 
Paradoxically, in the long term FK506 and calcineurin inhibitors led to beta cell toxicity, 
insulin resistance and direct nephrotoxicity. Nir. et al. also reported that combined 
rapamycin/FK506 potentially impaired engraftment and islet regeneration (Chatenoud, 
2008, Nir et al., 2007). Thus, the current immunosuppressive regime incorporates initial
immunosuppressive induction therapy by transiently depleting T-cells using anti- 
CD3mAb, hOKT3yl (Ala-Ala), alemtuzumab (Campath-1, anti-CD52 mAb that targets 
the highly glycosylated surface protein expressed by mature T and B lymphocytes, 
monocytes, NK cells and macrophages) and polyclonal anti-Thymocyte globulin (ATG). 
Different pathways of the cell-mediated immune response are targeted for the 
maintenance phase of immunosuppression, such as TCR:CD3 signalling, costimulation 
and leukocyte trafficking, while reducing the use of the diabetogenic calcineurin 
inhibitors. Treatments are generally available in the forms of depleting/non-depleting 
monoclonal antibodies (mAbs) and receptor-Ig fusion proteins (Chhabra and Brayman, 
2011, Merani and Shapiro, 2006). Each therapeutic agent has a considerably long serum 
half-live to improve drug efficacy in vivo (ElBakri et al., 2010, Linsley, 1994).
The immune response to islet transplants encompasses alloimmunity (donor-specific 
alloreactive T cells) and autoimmunity (islet-specific autoreactive T cells). Donor- 
specific memory T cells may also contribute to the infllamtory response if the transplant 
recipients were previously exposed to donor-type antigens from blood transfusions, 
previous islet transfusions or pregnancies prior to transplantation (Xia et al., 2010). 
Despite the seemingly insurmountable challenges, the quality of transplanted islets and 
transplant outcome awaits major improvement in order for islet transplantation to be 
made more readily available for the treatment of established T1D.
1.11 Microenvironment of pancreatic islets
The complex machinery for blood glucose regulation is operated by a basis dynamic 
interplay between hormonal, neural and vascular factors. Within islets, beta cells, along 
with other endocrine cell types work together to regulate blood glucose levels. The 
close coordination among different cell types requires intricate cell-cell interaction for 
autocrine and paracrine signalling within islets. In addition, the islet microenvironment 
provides an additional layer of regulation for the maintenance and metabolic function of 
pancreatic islets.
1.11.1 Extracellular matrix
The extracellular matrix (ECM), consisting of a mixture of polysaccharides and proteins, 
constitutes the immediate peri-islet environment. The ECM is made up of two 
biochemically and morphological distinct entities, namely the interstitial matrix and 
basement membrane (BM) which form separate but adjacent structure in the
microenvironment (Laurila and Leivo, 1993). Interstitial matrices are found in the 
intercellular space. Basement membranes are specialised thin sheets of ECM that lie in 
contact with adjacent cells. BMs are found at sub-epithelial or sub-endothelial levels, 
usually surrounding groups of cells (Timpl and Brown, 1996). The BMs are composed 
of four major matrix proteins: collagen, laminin, nidogen and perlecan. Collagen forms 
the lattice-like scaffold that interacts with the laminin polymer. These two major 
frameworks are interconnected by nidogen and perlecan. Each tissue has a unique BM 
consisting of combination of matrix protein components, determined by the BM’s 
functionality and homeostatic requirement (Erickson and Couchman, 2000). In general, 
BMs function as a scaffold for underlying cells, provide tensile strength due to collagen, 
serve as molecular sieves due to the properties of perlecan, facilitate cell attachment via 
laminin and act as a storage depot for various bio-active factors such as chemokines, 
cytokines, growth factors and proteases. The interaction between BMs and various cell 
surface receptors is also critical for regulating a myriad of cellular responses including 
cell morphogenesis, gene expression, cell migration, proliferation, differentiation and 
apoptosis (Kragl and Lammert, 2010, LeBleu et al., 2007, Sorokin, 2010).
In addition, various gap junctions, voltage-gated channels and transporters facilitate 
intercellular signalling within islets. The maintenance of cell-cell and cell-matrix 
interaction is essential for normal islet function.
1.11.2 Basement membrane of pancreatic islets
Early descriptions of a BM around islets were incomplete due largely to the limited 
availability of reagents. Van Deijnen et al. reported a species-specific difference in the 
continuity of peri-islet BMs. Pig islets were reported to lack a peri-islet BM, canine islet 
were characterised by a continuous BM and rat as well as human islets were described 
as having a discontinuous BM (Deijnen et al., 1992). However, Jiang et al. reported a 
discontinuous peri-islet capsule with the absence of laminin in human, canine and 
hamster islets (Jiang et al., 2002a). These studies led to the idea that islets were devoid 
of a conventional BM for separating the pancreatic exocrine and endocrine tissues.
Studies by Pavin et al. identified thin and continuous staining for laminin around islets, 
suggesting the presence of a peri-islet BM. This staining was lost in islets with 
destructive insulitis, associated with the onset of autoimmune diabetes in NOD mice 
(Pavin et al., 2003). Recently, compelling evidence provided by Irving-Rodgers et al.
48
reinforced the notion that a conventional BM exists around islets in mouse pancreas 
(Fig. 1.11). The authors identified laminin chains a2, ß l, y 1, nidogen 1 and 2, collagen 
type IV al and a2, and perlecan. The presence of continuous peri-islet staining for 
perlecan and in the intra-islet capillaries had not been reported previously. The authors 
further suggested that the equivocal findings from previous studies were most likely due 
to the limited range of reagents for staining and incomplete analyses (Irving-Rodgers et 
al., 2008).
1.11.3 Function of individual matrix proteins within islets
(a) Collagen Type IV
Collagen type IV is one of the major components in the BMs that is able to self- 
assemble to form a covalently-stabilised network polymer. Type IV collagen network is 
critical for the stabilisation and assembly of the BMs. Collagen type IV consists of a 
combination of three a-chains selected from 6 different a-chains, al(IV)- a6(IV). The 
three a-chains intertwine to form a triple-helical protomer. Type IV collagen has been 
shown to facilitate insulin secretion. Type IV collagen interacts with integrins such as 
a lß l, a2ßl, alOßl and a l lß l  (Kragl and Lammert, 2010, Sorokin, 2010). Kaido et al. 
have shown that alßl  helps cultured beta cells attach to type IV collagen, migrate and 
secrete insulin in vitro (Kaido et al., 2004). It is also possible that type IV collagen 
binds to non-integrin receptors such as the discoidin domain, which has been found in 
islet cells. Discoidin domain receptors regulate cell adhesion, migration, differentiation 
and proliferation (Alves et al., 1995).
(b) Laminin
Laminin, a heterotrimeric glycoprotein is another key BM matrix protein that forms a 
network that interacts with the collagen framework. Laminin consists of three laminin 
chains, e.g., alpha (a), beta (ß) and gamma (y) chains, with five, three and three 
subtypes, respectively. The heterotrimeric laminins have three short arms that bind to 
other laminin molecules to assemble into a sheet of network, and one long arm that 
interacts with cell membranes (Kragl and Lammert, 2010, Sorokin, 2010). Laminin can 
interact with major integrins (alßl,  a2ßl, a3ßl, a6ßl, a7ßl and a9ßl) and non-integrin 
receptors such as dystroglycan protein complex, the Lutheran blood group glycoprotein 
and laminin receptor-1 (Kikkawa and Miner, 2005, Miner and Yurchenco, 2004). In 
islets, it has been suggested that laminin-411 (a4, ßl, yl) and laminin-511 (a5, ßl, yl) 
are involved in beta cell proliferation and insulin transcription (Nikolova et al., 2006).
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(c) Nidogen
Nidogen is an elongated globular glycoprotein that exists in two isoforms, nidogen-1 
and nidogen-2. Nidogens act to connect other BM matrix proteins such as collagen type 
IV, laminin and perlecan. At present, the precise role of nidogen in islet physiology 
remains unknown (Kragl and Lammert, 2010).
(d) Perlecan
Perlecan is a BM heparan sulfate (HS) proteoglycan (HSPG) and consists of a core 
protein, with five distinct domains, to which several HS glycosaminoglycans (GAGs) 
(see Section 1.12) are attached (Vlodavsky and Friedmann, 2001). Perlecan, localised in 
the BM physically impedes cell migration and invasion as well as provides binding sites 
for leukocytes during inflammation (Hulett et al., 1999, Parish, 2006, Parish et al., 
2001). In addition, perlecan in the glomerular BM serves as a filtration barrier to 
charged molecules due to its highly-negatively charged HS. The negatively charged HS 
GAGs also allows perlecan to bind to a variety of molecules such as VEGFs, HGFs and 
FGFs. Perlecan therefore acts as a growth factor reservoir and protects these molecules 
from proteolytic degradation (Hacker et al., 2005, Iozzo, 1998).
1.11.4 The role of basement membrane in inflammation
The complex architecture of BMs provides a barrier function against cell infiltration, 
particularly in the context of inflammation. Transmigration of the BMs constitutes a 
critical step during leukocyte migration to inflamed tissues. Elucidation of the 
molecular mechanisms for leukocyte migration from the vasculature into underlying 
tissues was made feasible by intravital microscopy that captures real-time leukocyte 
movement and a series of in vitro and in vivo studies dissecting the roles of various key 
molecules (Halin et al., 2005).
Leukocyte recruitment to the inflamed site entails a sequential multi-step process 
including leukocyte rolling on the apical side of inflamed endothelial monolayers 
mediated by selectins, chemokine-induced activation of leukocytes to up-regulate 
integrins that facilitate leukocyte arrest, followed by intravascular crawling. Leukocytes 
then move between ECs at the endothelial intercellular junction (paracellular migration) 
or across the ECs (transcellular migration) before they face the barrier of the 
subendothelial BM and the associated pericyte sheath (Ley et al., 2007, Sorokin, 2010).
Evidence from electron microscopy studies suggests that the transmigration of the 
endothelial BM is the rate-limiting step during leukocyte recruitment. Studies in T cell 
extravasation has demonstrated that whereas the migration of T cells through the 
endothelium took approximately 9-10 mins, the subsequent penetration of the sub- 
endothelial BM required a much longer time, as shown as by the cuff of cells retained at 
the outer vessel surface for up to 30 mins (Bartholomaus et ah, 2009). A battery of 
proteases is employed to solubilise the various BM matrix components, such as MMPs 
(Lukes et ah, 1999, Page-McCaw et ah, 2007), ADAM (Seals and Courtneidge, 2003), 
sulfatases (Uchimura et ah, 2006), neutrophil elastase (Watanabe et ah, 1990), 
cathepsins (Obermajer et ah, 2008), heparanase (see Section 1.13) (Bartlett et ah, 1995, 
Parish et ah, 2001, Vlodavsky et ah, 2002). The action of the proteases release the 
bioactive molecules from the BMs to amplify the inflammatory milieu (Ley et ah, 2007, 
Sorokin, 2010).
1.12 Heparan Sulfate
Heparan sulfate (HS) is a linear glycosaminoglycan (GAG) consisting of repeating 
disacharrides of glucosamine and uronic acid linked by a 1-4 glycosidic bond (Fig. 
1.12). Several HS GAGs (5-70kDa) are found covalently attached to a core protein via a 
serine residue to form a heparan sulfate proteoglycan (HSPG) (20-470kDa) (Vreys and 
David, 2007).
The uronic acid can exist in both glucuronic (GlcA) or epimer iduronic (IdoA) acid. 
Both forms of uronic acid can be 2-O-sulfated (GlcA(2S) or Ido(2S)). In addition, the 
glucosamine can be N-sulfated (GlcNS) or N-acetylated (GlcNAc) at the C2 residue, as 
well as 6-O-sulfated (GlcNS(6S) or GlcNAc(6S)). The GlcNS and GlcNS(6S) can also 
be 3-O-sulfated (GlcNS(3S) or GlcNS(3, 6S)) (Rabenstein, 2002). Taken together, the 
various sulfation groups along the chain and the epimerisation of the uronic acid give 
rise to the extraordinary structural and functional diversity of HS.
1.12.1 Biosynthesis of HS
The biosynthesis of HS consists of 3 major steps: chain initiation, elongation and 
modification. HS synthesis requires the presence of a core protein, to which a 
tetrasaccharide linker protein with the sequence (xylose-galactose-galactose-uronic 
acid) is attached via a serine residue located on the core protein. HS is then assembled 
by the addition of repeating disaccharide units of N-acetylglycosamine (GlcNAc) and
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glucuronic aicd (GlcA). Chain modification by N-deacetylation-N-sulfation, 
epimerisation of GlcA to iduronic acid, 2-O-sulfation, 3-O-sulfation and 6-O-sulfation 
leads to the generation of heterogenous mature HS polysaccharides (Fig. 1.13) (Hacker 
et ah, 2005, Vreys and David, 2007).
1.12.2 Types ofHSPGs
HSPGs are ubiquitously expressed on cell surfaces, in basement membranes and 
extracellular matrices. The five classes of “full-time” HSPGs that express HS chains are: 
syndecans, glypicans, perlecan, type XVIII collagen and agrin. Several HSPGs express 
HS chains under specific circumstances, and hence are called “part-time” HSPGs, 
namely CD44, betaglycan and testican. HSPG is a structurally diverse molecule, which 
in part, is due to the remarkable structural heterogeneity of HS chains (Fig. 1.14). The 
different position of sulfation groups, for instance, N-deacetylation-N-sulfation, 2-O- 
Sulfation and 6-O-Sulfation along the HS chains and epimerization of glucuronic acid 
residues to iduronic residues confer great structural and functional diversity of HSPGs. 
As a result, HS binds to a wide array of bioactive molecules such as cytokines, 
chemokines, growth factors, lipases, proteases and cell-adhesion molecules through 
specific binding motifs (Parish, 2006).
(a) Syndecans
Syndecans are transmembrane HSPGs that are conventionally expressed at the cell 
surface. There are four types of syndecans identified to date, syndecans 1 -4. Syndecans 
are made up of an N-terminal signal peptide, an extracellular domain that interacts with 
HS, a transmembrane domain and a C-terminal cytoplasmic domain. Syndecans have 
been reported to participate in a range of biological settings such as development, 
wound repair and neoplastic transformation, which is due partly to its multifaceted HS 
side chains (Velleman and Caini, 2005). The highly conserved cytoplasmic domain of 
syndecans plays a major functional role in intracellular signalling transduction and 
organisation of cytoskeletal proteins that results in changes in cell shape, cell adhesion, 
spreading and migration (Lambaerts et al., 2009, Zimmermann and David, 1999).
(b) Glypicans
There are six HSPG members of the glypican family, glypicans 1-6. The cell surface 
glypicans contain a glycosyl phosphatidyl inositol (GPI) moiety that is anchored to the 
outer leaflet of the lipid bilayer. Glypicans consist of an N-terminal signal sequence, an
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Figure 1.13 Biosynthesis of HS
The biosynthesis of HS consists of 3 major steps: chain initiation, elongation and 
modification. HS is bound to the core protein via a serine residue located on the 
core protein. Chain elongation (via addition of repeating disaccharide units, N- 
acetylglycosamine (GlcNac) and glucuronic acid (GlcA)) occurs following the 
assembly of a tetrasaccharide linker protein (xylose-galactose-galactose-GlcA) and 
an GlcNac. The nascent polysacharride undergoes chain modification by N- 
deacetylation-N-sulfation, epimerisation of GlcA to iduronic acid, 2-O-sulfation, 3- 
O-sulfation and 6-O-sulfation (Vreys and David, 2007).
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Figure 1.14 Molecular structure of HSPGs
(A) There are five classes of “full-time” HSPGs that express HS chains, e.g., 
syndecans, glypicans, perlecan, agrin and type XVIII collagen (Iozzo, 2001).
(B) CD44 is a “part-time HSPG” that expresses HS under specific 
circumstances. The CD44 isoform containing the V3 exon is able to bind to HS 
(Rops et al., 2004).
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extracellular globular domain with HS binding site and a C-terminal GPI anchor. 
Glypicans have been studied particularly in relation to their role in development. The 
expression of glypicans varies at different developmental stages in a tissue-specific 
manner (Velleman and Caini, 2005). For example, glypican-3 induces apoptosis 
through an HS-independent pathway, possibly by acting as a negative regulator to 
insulin-like growth factor-2 (IGF-2) signalling that promotes cell growth. Mutation of 
glypican-3 is linked to pre- and post-natal overgrowth and dysmorphisms due to the 
failure to induce apoptosis during development (Gonzalez et al., 1998). Due to its 
regulatory role in the local availability of growth factors, glypicans are active 
participants in the progression of various cancers such as pancreatic cancer, 
hepatocellular carcinomas and colorectal tumours (Kleeff et al., 1998, Wang et al., 
2010, Yuan et al., 2008).
(c) Perlecan
Perlecan is a HSPG localised in the basement membrane (BM) (see Section 1.11.3 (d)). 
The core protein of perlecan consists of five distinct domains. HS binds to domain I, 
which gives perlecan a “pearls on a string” molecular configuration (Velleman and 
Caini, 2005). Perlecan has been shown to act as a physical barrier to migrating cells and 
to serve as a storage depot for a plethora of bioactive molecules such as cytokines, 
chemokines, growth factors, Upases, proteases, cell-adhesion molecules (Hulett et al., 
1999, Parish, 2006, Parish et al., 2001).
(d) Collagen type XVIII
The HSPG collagen type XVIII is usually found in BMs and ECM and consists of a 
core protein with eight potential GAG glycosylation sites. The HS of type XVIII 
collagen interacts with the adhesion leukocyte receptor, L-selectin, during leukocyte 
migration to peripheral lymph nodes. Type XVIII collagen has angiostatin activity that 
counters the pro-angiogenic properties of perlecan, syndecans and glypicans. The 
angiostatic nature of type XVIII collagen provides a negative feedback loop to regulate 
angiogenesis. It has been proposed that the cleavage of type XVIII collagen by the 
cysteine protease, cathepsin L releases the angiostatic fragment, endostatin, to inhibit 
VEGF- and FGF-mediated angiogenesis and endothelial cell proliferation.
(e) Agrin
Agrin represents another BM HSPG that can be localised in BMs and ECM. It has been 
reported that agrin plays a role in postsynaptic differentiation at the neuromuscular 
junction (Bezakova and Ruegg, 2003). Agrin is also a major HSPG constituent of the 
glomerular BM, where, like perlecan, is most likely acts as a filtration barrier (Groffen 
et al., 1998).
(f) CD44
The CD44 protein family consists of multiple isoforms generated via alternative 
splicing, a process in which multiple proteins are encoded by a single gene via different 
combinations of exons. The majority of CD44 isoforms are not HSPGs. Only a distinct 
sub-group that expresses the HS-binding exon V3 are able to bind to HS (Tuhkanen et 
al., 1997). CD44 is a part-time HSPG that expresses HS under specific circumstances. 
Resting leukocytes generally do not express the HSPG CD44. However the expression 
of the HSPG is induced upon leukocyte activation, hence CD44 HSPG is termed “part- 
time HSPG” (Jackson, 1997, Jones et al., 2000).
The induction of cell surface HSPGs is crucial for the migration of leukocytes by 
serving as adhesion molecules. In addition, they also help set up chemokine gradient 
and interact with growth factors such as FGF-2,facilitating the development of the 
inflammatory milieu (Goodison et al., 1999, Ponta et al., 2003).
1.12.3 Function of HS
Due to the structural heterogeneity of HS and its promiscuous binding properties, HS is 
involved in a range of molecular events such as embryological development, normal 
physiology, inflammation and the progression of certain cancers.
1.12.4 The role of HS in normal cell physiology
Under physiological conditions, HS in the ECM and BMs contributes to the scaffold 
stability and tissue architecture. At the extracellular level, negatively charged HS 
preferentially interacts with positively charged sodium ions. This ionic interaction 
attracts water molecules. As a consequence, HS is highly hydrated and provides space-
filling and molecular sieving properties within the ECM or BMs (Parish, 2006, Reid, 
2011). Additionally, the elongated HS chains in the ECM and BMs serve as a 
formidable barrier against cell invasion (Parish et al., 2001).
The ECM harbours trophic factors that modulate cellular function and integrity 
(Meredith et al., 1993). In this context, HS serves as a reservoir for a wide array of 
chemokines, cytokines, cell adhesion molecules, growth factors, proteases and lipases, 
as well as protects the bioactive molecules from proteolytic degradation in the ECM 
(Parish, 2006). The ability of HS to interact with a variety of growth factors such as 
vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet- 
derived growth factor (PDGF), colony-stimulating factors (GM-CSF), FGF and 
transforming growth factor-beta (TGF-ß) that function to promote angiogenesis, cell 
proliferation, differentiation and cell death provide an explanation for the diverse role of 
HS in normal physiology (Ali et al., 2003).
Interaction with HS modulates the activities of the bound molecules. For instance, HS 
acts as a co-receptor for fibroblast growth factor (FGF) signalling by forming a ternary 
complex between HS, FGF and FGF receptors (FGFRs). This complex greatly lowers 
the concentration of FGF to initiate signalling transduction and prolongs the duration of 
response (Bishop et al., 2007, Rapraeger et al., 1991, Yayon et al., 1991).
HS also contributes to the homeostatic control of the coagulation pathway. Upon 
vascular injury, vascular constriction occurs to limit blood flow to the injured site. This 
is followed by platelet activation, plug formation and activation of the coagulation 
cascade to form a fibrin clot at the site of injury. HS negatively regulates coagulation by 
activating the protease inhibitor anti-thrombin. HS binds to anti-thrombin with high 
affinity to form a HS-anti-thrombin complex. The interaction between HS and anti-
thrombin III leads to a conformational change that enhances substrate binding and 
hence, accelerates the inhibition of thrombin and other clotting enzymes (Liu and 
Pedersen, 2007, Stringer and Gallagher, 1997).
1.12.5 The role of HS in inflammation
In inflammatory situations, the transmigration of leukocytes across the subendothelial 
BM constitutes a rate-limiting step for leukocyte recruitment. The action of heparanase, 
proteases and proinflammatory cytokines released by the leukocytes disturbs the 
architecture and the integrity of the BM including HS (Sorokin, 2010). Additionally, 
bioactive fragments are released from the aberrantly regulated BMs to augment the 
inflammatory milieu (Adair-Kirk and Senior, 2008). The structural diverse HS interacts
with multiple molecules and serves as versatile ligands. Therefore, HS is an important 
regulator which imparts inflammation at a number of levels.
Following tissue injury, resident macrophages and mast cells secrete proinflammatory 
cytokines such as TNF-a and IL-1 to activate nearby endothelial cells (Ali et al., 2003). 
HS potentially exerts a pro-inflammatory role at the luminal surface of the endothelium. 
Endothelial cell HS interacts with L-selectin expressed on lymphocytes to stabilise 
lymphocyte rolling and enhance lymphocyte adhesion to the endothelium. Consistent 
with this role, mice selectively lacking the endothelial expression of the gene Ndstl, 
which encodes the enzyme, N-deacetylase/N-sulfotransferase that attaches N-sulfate 
groups to HS, produced less sulfated HS and demonstrated impaired neutrophil 
infiltration to inflammatory sites (Wang et al., 2005). Despite the presence of an 
alternative sulfated, sialylated and fucosylated mucinous ligand for L-selectin, namely 
6-sulpho sialyl Lewis X, the study by Wng et al. (2005) suggested that endothelial HS 
may act as the dominant ligand for L-selectin during acute inflammation (Parish, 2006).
Apart from its role in mediating lymphocyte adhesion, HS aids in chemokine 
presentation. HS interacts with essentially all chemokines. The interaction between HS 
and chemokines facilitates chemokine oligomerisation to enhance chemokine activity 
(Hoogewerf et al., 1997, Proudfoot et al., 2003). After the initial selectin-mediated 
rolling, leukocytes bind to chemokines along the endothelium, a process which induces 
integrin expression on the leukocytes and promotes more stable leukocyte adhesion. 
These chemokines are unlikely to be in soluble form as that could be removed by shear 
blood flow at the luminal side of endothelium. Indeed, the chemokines are bound to HS 
expressed on endothelial cells (Ali et al., 2002). The endothelial HS immobilises 
chemokines such as CXC-chemokine ligand 8 (CXCL8) produced by tissue-resident 
macrophages to facilitate the binding of chemokine receptors on the leukocytes. 
Additionally, HS enables the bound chemokine to be transported across the endothelial 
barrier, a process known as “transcytosis” (Middleton et al., 1997, Middleton et al., 
2002). HS therefore helps to shape the distribution of chemokines along the migration 
path. As a result, leukocytes are guided by chemokine gradients established by HS- 
bound chemokines and soluble chemokines to enable their navigation to depots of 
foreign antigen, resulting in inflammatory foci (Celie et al., 2009).
Following transmigration across the endothelium, leukocytes need to traverse the 
subendothelial BM barrier before they can migrate to sites of inflammation. A series of 
proteases (including heparanase) are deployed to solubilise the BM matrix proteins, 
allowing leukocyte passage (Sorokin, 2010). HS-bound fragments liberated (mediated 
by the HS-degrading heparanase) during this process also play an important role in 
modulating the inflammatory response by influencing tissue remodelling and 
angiogenesis (Parish, 2006).
1.13 Heparanase
“Heparinase” was originally isolated from a transplantable mouse mastocytoma (mast 
cell tumour) as a heparin-degrading enzyme. The enzyme was described as an 
endoglucuronidase that cleaves heparin macromolecules at non-random glycosidic 
linkages to generate fragments similar to commercial heparin (Ogren and Lindahl, 
1975). The term “heparanase” was later coined by Nakajima et al. to distinguish the 
mammalian HS-degrading endoglucuronidase from heparinase and heparitinase, an 
elimination enzyme produced by Flavobacteriwn heparinum, that cleaves heparin at 
different sites to heparanase (Nakajima et al., 1984).
Efforts to purify heparanase were largely impeded by the lack of a reliable assay to 
monitor the degradation of HS/heparin as well as by the low abundance and instability 
of the enzyme. It took almost 15 years from its discovery to isolate and clone the 
heparanase gene. The cloning of a single human gene encoding heparanase from human 
placenta, platelets and a hepatoma, the production of a putative precursor and the 
expression of active recombinant heparanase protein were reported by several groups in 
1999 (Hulett et al., 1999, Kussie et al., 1999, Toyoshima and Nakajima, 1999, 
Vlodavsky et al., 1999). Subsequent studies demonstrated that an identical or highly 
homologous heparanase cDNA sequence was present in normal and malignant cells 
from different species (Bernard et al., 2001, Bitan et al., 2002, Endo et al., 2001, Ginath 
et al., 2001, Kizaki et al., 2001, Koliopanos et al., 2001, Marchetti and Nicolson, 2001). 
Only one cDNA sequence encoding catalytically active heparanase was identified, 
suggesting that the expression of the mammalian heparanase enzyme is unique. In 
addition, heparanase was found to be the predominant enzyme that degrades HS (Hulett 
et al., 1999, Toyoshima and Nakajima, 1999). Thus unlike other matrix degradative 
enzymes that possess high levels of redundancy and broad substrate specificity,
heparanase became a promising drug target for inhibiting HS degradation-mediated 
disease pathologies.
1.13.1 Structure of heparanase
Today, heparanase is known as an endo-ß-D-glucoronidase that cleaves HS at specific 
intra-chain sites, yielding HS fragments of 5-7kDa (10-20 sugar residues) (Gingis- 
Velitski et al., 2007, Vlodavsky and Friedmann, 2001). The heparanase gene is located 
on human chromosome 4q22 and is generated by alternative splicing to yield a 
precursor pre-proheparanase of 543 amino acids. The pre-propheparanase possesses an 
N-terminal signal peptide that directs protein translocation to endoplasmic reticulum 
(ER) and ensures protein secretion (Shafat et ah, 2006). The cleavage of a signal peptide 
within the ER generates the inactive precursor with a molecular weight of 
approximately 65 kDa. Pro-heparanase undergoes proteolytic cleavage of a 6 kDa 
linkage region, mediated by a lysosomal cysteine protease, cathepsin L, to form a 
heterodimer consisting of a 50 kDa subunit associated non-covalently with a 8 kDa 
subunit (Fig. 1.15) (Abboud-Jarrous et ah, 2008, Fairbanks et ah, 1999, Levy-Adam et 
ah, 2003). The catalytically active heparanase exhibits maximal HS-degrading activity 
at pH 5.4 -  6.8 and loses its enzymatic function outside this range (Gilat et ah, 1995, 
Vlodavsky et ah, 1999).
1.13.2 Role of heparanase in tumour growth, angiogenesis, metastasis and cell 
invasion
Initial studies focussed on the important role of heparanase for degrading HS in ECMs 
or subendothelial BMs, a vital step for tumour metastasis and cell invasion. The 
prometastatic role of heparanase was demonstrated using experimental models of cancer, 
e.g., B16 melanoma and T-cell lymphoma (Nakajima et ah, 1983, Vlodavsky et ah, 
1983). Similar to other matrix-degrading enzymes such as the matrix metalloproteases, 
heparanase possesses pro-angiogenic activity that is essential for the establishment of 
the vascular network required for tumour growth and metastasis. Elkin et ah showed by 
immunohistochemistry, that heparanase in a human colon adenocarcinoma was 
differentially localised in endothelial cells at different stages of development. 
Heparanase was mainly localised in sprouting capillaries and small blood vessels but 
not the endothelium of mature quiescent vessels. The authors further demonstrated the 
involvement of heparanase in angiogenesis is in part, due to the release of the pro- 
angiogenic factor, basic fibroblast growh factor (bGFG) from HS. Addition of
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Figure 1.15 Molecular structure of heparanase
Heparanase is synthesised as pre-proheparanase (68 kDa) with a N- 
terminal signal peptide that directs protein translocation to endoplasmic 
reticulum (ER) and ensures protein secretion. The cleavage of the signal 
peptide (s.p.) in the ER yields proheparanase (65 kDa). Proheparanase 
then undergoes proteolytic cleavage by cathepsin L to generate the active 
heterodimer consisting of 50 kDa non-covalently linked to an 8 kDa 
subunit (Vreys and David, 2007).
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recombinant heparanase to subendothelial ECM preincubated with the radioactively 
labelled 125I-bFGF enhanced the release of sulfate-labelled HS and the ECM-bound l25I- 
bFGF. The released bFGF was found to stimulate the proliferation of 3T3 fibroblasts 
and bovine aortic endothelial cells (Elkin et al., 2001).
Using a Matrigel plug assay, Elkin et al. reported an in vivo angiogenic response to 
Matrigel embedded with heparanase-transfected Eb lymphoma cells prior to 
subcutaneous injection into BALB/c mice. The angiogenic response was characterised 
by the formation of a capillary network and increased haemoglobin levels in the 
matrigel plug with heparanase-transfected Eb cells, compared to the mock-transfected 
controls (Elkin et al., 2001).
A significant increase in heparanase expression was implicated in various cancers 
including haematological malignancies, sarcomas and carcinomas (e.g., bladder, breast, 
cervical, colorectal, endometrial, gastric, head and neck, lung, pancreatic and renal 
carcinomas). Elevated local levels of heparanase were associated with reduced post-
operative survival and increased tumour growth and vascularity (Davidson et al., 2007, 
Doweck et al., 2006, Ilan et al., 2006, Kelly et al., 2003, Vlodavsky et al., 2007).
Overall, the degradation of HS in ECMs by heparanase was found to aid tumour cell 
metastasis and invasion by releasing the HS-bound bioactive molecules that modulate 
cell growth, differentiation, migration, angiogenesis and coagulation in the tumour 
microenvironment.
1.13.3 Role of heparanase in inflammation
The functional impact of heparanase in cell migration is equally be relevant for 
inflammation in the context of health and diseases, e.g., in embryonic development, 
tissue remodelling and various pathological conditions such as delayed type 
hypersensitivity, experimental autoimmune encephalomyelitis (EAE), glomerular 
diseases, inflammatory bowel diseases, rheumatoid arthritis, atherosclerosis, 
autoimmune T1D (Bartlett et al., 1995, Hershkoviz et al., 1995, Nakajima et al., 1984, 
Parish, 2006, Parish et al., 2001, Patel et al., 2007, Vlodavsky and Friedmann, 2001, 
Vlodavsky et al., 1983, Ziolkowski et al., 2012). The breakdown of ECMs and 
subendothelial BMs is central to the extravasation of leukocytes during inflammation. 
The degradation of BM matrix protein alters the architecture of the BM and releases
regulatory molecules such as cytokines, chemokines, growth factors, tissue remodelling 
factors, coagulation factors, cell adhesion molecules, lipoproteins, lipases, proteases, 
angiogenic and anti-angiogeneic factors. The liberation of these bioactive factors via 
heparanase-mediated HS degradation modulates various aspects of the inflammatory 
response (Vlodavsky and Friedmann, 2001).
Activated immune cells serve as the primary source of heparanase during inflammation. 
These include T cells, B cells, macrophages, dendritic cells, neutrophils, platelets, 
monocytes and Langerhans cells (in the skin) (Bartlett et al., 1995, Freeman and Parish, 
1997, Marchetti et al., 2000, Matzner et al., 1985, Naparstek et al., 1984, Sewell et al., 
1989, Vlodavsky et al., 1992, Vreys and David, 2007). Studies in delayed type 
hypersensitivity further highlighted endothelial cells as equally important producer of 
heparanase needed for the breakdown of the subendothelial BM and vascular leakage 
(Edovitsky et al., 2006). Additionally, placental trophoblasts, skin keratinocytes, 
astrocytes, smooth muscle cells and colonic epithelium were also found to express 
heparanase (Bartlett et al., 1995, Freeman and Parish, 1997, Marchetti et al., 2000, 
Matzner et al., 1985, Naparstek et al., 1984, Sewell et al., 1989, Vlodavsky et al., 1992, 
Vreys and David, 2007).
1.13.4 Non-enzymatic functions of heparanase
Apart from its enzymatic activity, heparanase also has non-enzymatic functions. Gilat et 
al. noted that heparanase bound to HS under physiological pH (pH 1.2-1 A) promoted 
the adhesion of human CD4+ T cells independent of HS-degrading activity. The authors 
suggested that heparanase may function either as a matrix-degrading enzyme (pH 5.4- 
6.8) or exhibit its T cell adhesive properties (pH 7.2-7.4) depending on the pH of the 
microenvironment (Gilat et al., 1995). Transfection of non-adherent mouse Eb 
lymphoma cells with a chimeric heparanase transgene conferred the ability for the cells 
to adhere to ECM components and endothelial cells. Cell adhesion was also noted in Eb 
cells transfected with point-mutated, non-active heparanase, suggesting that heparanase 
functions as a cell adhesion molecule independent of its enzymatic activity. The authors 
proposed that heparanase-mediated cell adhesion is integrin-dependent and facilitates 
subsequent intracellular signalling through tyrosine phosphorylation and reorganisation 
of the cytoskeletal molecule, paxillin (Goldshmidt et al., 2003).
Sotnikov et al further showed that the expression of non-enzymatic heparanase induced 
T cell adhesion and facilitated T cell arrest, thereby preventing the T cells from rolling 
under shear flow conditions. This interaction was primarily via o^ßiintegrin-vascular 
cell adhesion molecule-1 (VCAM-1). Moreover, heparanase-bound T cells promoted 
additional interactions between ECM fibronectin and ßl-integrin (T cells) as well as 
hyaluronic acid (ECM) and CD44 (T cells), via the activation of the protein kinase C 
(PKC) pathway and the intracellular signalling of phosphotidylinositol-3-Kinase (PI3K) 
and extracellular signal-regulated kinase (ERK). T cell adhesion was abolished in the 
presence of wortmannin, GF109203X and PD98059 that suppress the activity of PI3K, 
PKC and ERK signalling. Furthermore, the non-enzymatic heparanase improved T cell 
chemotaxis in the presence of SDF-la (a proadhesive chemokine). (Sotnikov et al., 
2004).
1.13.5 Heparanase regulation
In view of the pathological consequences of heparanase activity, it is clear that stringent 
regulation of heparanase expression is necessary to prevent undesired outcomes. Indeed, 
heparanase expression is limited to a subset of cell types which include placental 
trophoblasts, keratinocytes and circulating blood borne cells (e.g. monocytes, 
neutrophils, mast cells, T cells and platelets) under normal conditions (Edovitsky et al., 
2006, Nadir et al., 2006, Vlodavsky et al., 1992, Vreys and David, 2007). In addition to 
the restricted expression of heparanase in certain cell types, its post-translational 
activation (see Section 1.13.1), cellular localisation (see Section 1.13.6) and regulated 
secretion (see Section 1.13.7) add additional layers of regulation for heparanase activity.
1.13.6 Subcellular localisation of heparanase
Heparanase is detected predominantly within endocytic vesicles such as endosomes and 
lysosomes (Cohen et al., 2005, Goldshmidt et al., 2002, Nadav et al., 2002). The latent 
form of heparanase (proheparanase) is delivered to the Golgi for vesicular packaging 
and extracellular secretion. Upon secretion, proheparanase rapidly interacts with cell 
surface HSPGs and the resulting heparanase/HSPG complex undergoes endocytosis 
(Shafat et al., 2006). The activation of heparanase takes place intracellularly within the 
acidic lysosomal compartment in the presence of cathepsin L. This route of heparanase 
trafficking and activation facilitates the normal intracellular turnover of HS GAGs. 
Alternatively, heparanase uptake can also be mediated by mannose-6-phosphate 
receptors (MPRs) and the low density lipoprotein (LPL)-related receptors at the cell
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surface (Vreys et al., 2005). Under normal conditions, the pool of activated heparanase 
mainly resides within lysosomes in a stable condition. The subcellular localisation of 
the active heparanase and rapid uptake of heparanase upon binding to cell membrane 
HSPGs provide a means for limiting the enzyme’s bioavailability and accumulation in 
the extracellular space, preventing potentially deleterious, inadvertent HS degradation 
(Gingis-Velitski et al., 2004, Zetser et al., 2004).
1.13.7 Regulated secretion of heparanase
Upon stimulation, the intracellular pool of active heparanase can be secreted to exert its 
enzymatic HS-degrading function extracellularly. Shafat et al. reported that there was a 
marked increase in active heparanase in the culture medium following treatment of 
heparanase gene-transfected breast carcinoma (MDA-468, MDA-435), colon carcinoma 
(HT29) and human embryonic kidney (HEK293) cell lines with the stimulus, phorbol 
12-myrisate 13-acetate (PMA). The authors further demonstrated the induced secretion 
of heparanase by physiological stimuli such as nucleotides (APD, ATP and adenosine) 
in HEK293, MDA-435 and MDA-231 cell lines. For MDA-435 and -231 cells, 
heparanase secretion was mainly detected in the presence of adenosine whereas 
HEK293 cells preferentially responded to ADP and ATP (Shafat et al., 2006). In 
addition, two separate studies showed the stimulated secretion of endothelial heparanase 
in response to tumour necrosis factor-a (TNF- a), interleukin-lß (1L-Iß), interferon-y 
(IFN-y) and fatty acids (Chen et al., 2004, Edovitsky et al., 2006). Taken together, these 
studies suggest that the stimulus for heparanase secretion varies among different cell 
types and biological settings.
1.13.8 Transcriptional regulation of heparanase expression
The finding that heparanase expression is induced in various tumour cells, immune cells 
and inflamed tissues suggested that post-transcriptional regulatory mechanisms could 
operate during pathological conditions. Several transcription factors were documented 
to play a role in modulating heparanase expression. Studies by Jiang et al. identified 
several binding sites for transcription factors, namely three Sp-1 sites and four Ets- 
relevant elements (ERE) in the GC-rich heparanase promoter region. The Sp-1 promoter 
site was essential for increased heparanase expression in endothelial cells in response to 
fatty acids and in thyroid tumour cells (Chen et al., 2004, Jiang et al., 2002b). 
Transcription factors, Etsl and Ets2 were shown to upregulate heparanase expression in 
metastatic breast tumour models. Mutations in Ets binding sites significantly abrogated
the Ets-induced transcriptional activity of the heparanase promoter in MDA-231 breast 
tumour cells (Lu et al., 2003). In addition, two interferon-stimulated response elements 
(ISREs) consensus sequences (binding sites for the transcription factors activated by 
IFN-y) that could potentially serve as targets for IFN-y-induced heparanase expression 
were identified in the promoter region of heparanase gene (Edovitsky et ah, 2006).
Heparanase expression is also subjected to epigenetic regulation. Shteper et ah showed 
that hypomethylation of the heparanase promoter was associated with increased 
heparanase expression in various cancer cell lines (Shteper et ah, 2003). Likewise, 
induction of heparanase gene expression due to hypomethylation and binding of the 
transcription factor, early growth response-1 (EGR1), was reported for human prostate 
cancer and bladder cancer (Ogishima et ah, 2005a, Ogishima et ah, 2005b).
Conversely, heparanase expression is negatively regulated by the tumour suppressor 
gene, p53. Loss of p53 activity is associated with 40-50% human cancers and represents 
the most common genetic alteration found in human tumours (Nasser, 2008). Chromatin 
immunoprecipitation (ChIP) assays have demonstrated that p53 binds to the heparanase 
promoter region. This tumour suppressor exerts an inhibitory effect on heparanase 
expression. Transfection of p53 in human osteosarcoma SaoS-2 cells resulted in 
reduced heparanase promoter activity, measured by a luciferase assay. In contrast, 
transfection of mutant p53 variants led to increased heparanase expression (Baraz et ah, 
2006).
1.13.9 Heparanase inhibition
The capacity for heparanase to facilitate the migration of cancer cells and leukocytes via 
the degradation of BM and ECM HS, have led to the generation of heparanase inhibitors 
particularly as anti-cancer drug, but potentially also as anti-inflammatory agents.
(a) Suramin
Suramin is one of the first heparanase inhibitors that exhibited promising anti- 
tumourigenic effects. Suramin is a polysulphonated napthylurea that was originally used 
as an anti-parasitic drug to treat early stages of sleeping sickness caused by 
trypanosomes. Nakajima et ah reported that suramin was an effective dose-dependent 
inhibitor of heparanase activity in melanoma (Nakajima et ah, 1991). Subsequent
studies showed that suramin inhibited tumour growth, metastasis and angiogenesis in 
different cancer models (Bhargava et al., 2007, Marchetti et al., 2003).
(b) Heparin and chemically modified heparins
Heparin is a highly sulfated form of heparan sulfate. It is widely known for its 
medicinal application as an anti-coagulant and anti-thrombotic drug. Studies have 
shown that the administration of heparin improved the survival of cancer patients (Klerk 
et al., 2005, Rickies, 2006). Heparin inhibits the heparanase activity by competing with 
HS as an alternative substrate. Acting in this way, heparin treatment has inhibited 
experimental metastasis, invasion and angiogenesis (Bar-Ner et al., 1987, Irimura et al., 
1986, Parish et al., 1987, Vlodavsky and Friedmann, 2001). However, its in vivo use as 
an anti-cancer therapeutic is limited by its anti-coagulant property. As a consequence, 
chemically modified heparins and sulfated oligosacharrides were developed as 
alternative heparanase inhibitors for in vivo use. Chemical modifications such as glycol-
splitting via periodate oxidation creates a flexible joint along the heparin chain. These 
glycol-split heparins lack anti-colagulant activity and prevent heparanase activity by 
acting as a non-cleavable substrate. Changes in the sulfation status of the chemically 
modified heparins may also increase the binding affinity of the molecules to heparanase 
and enhance their inhibitory effect (Casu and Naggi, 2003, Naggi et al., 2005).
(c) PI-88
Phosphomannopentaose sulfate, PI-88 is a potent heparanase inhibitor with some anti-
coagulant activity. Experimental studies demonstrated the efficacy of PI-88 in inhibiting 
tumour growth of invasive rat adenocarcinoma cells, reducing metastasis to the draining 
lymph nodes and tumour vascularity (Parish et al., 1999). PI-88 also inhibits the activity 
of heparin binding proteins such as FGF-1, FGF-2, VEGF-2 and interleukin-8 (Ferro et 
al., 2004). It was evaluated in Phase 2 clinical trial as a monotherapy or combined 
therapy for metastatic melanoma, non-small cell lung cancer, prostate cancer and 
multiple myeloma (McKenzie, 2007). Recently, it has also been reported that PI-88 has 
progressed to Phase 3 clinical trial for virus-related hepatocellular carcinoma 
(http://www.progen-pharma.com/userfiles/files/news/pi- 
88%20phase%20iii%20update.pdf).
(d) Neutralising antibodies
The development of antibodies against the active site of heparanase was made feasible 
by the cloning of human heparanase. Zetser et al. produced an antibody that was raised 
against the 50 kDa subunit of heparanase (antibody #733) and preferentially recognised 
active heparanase rather than latent 65 kDa proheparanase. In vitro studies revealed a 
partial inhibition of heparanase activity in heparanse-transfected HEK 293 cells using 
this antibody (Zetser et al., 2004). Myler et al. described an anti-heparanase antibody, 
which significantly reduced neointima hyperplasia in the in vivo rat carotid balloon 
injury model. The efficacy of the anti-heparanase treatment was attributed to its ability 
to inhibit heparanase activity and to partially suppress bFGF release (Myler et al., 2006). 
The in vivo administration of a polyclonal anti-heparanase antibody was also shown to 
reduce urinary protein excretion and the incidence of proteinuria in passive Heymann 
nephritis (PHN) (Levidiotis et al., 2004).
1.14 Cathepsin L
The cathepsin family consists of a wide range of lysosomal proteases that function in 
the biosynthesis, maturation, function and terminal degradation of proteins via 
proteolytic cleavage. The term “cathepsin” (of Greek origin, meaning to digest or to boil 
down) was first described in gastric juices in the 1920s. Cathepsins are also called 
papain-like proteases as they closely resemble papain, the major protease of papaya. 
Cathepsins are classified according to their structure and catalytic type such as serine 
(cathepsins A and G), aspartic (cathepsins D and E) and cysteine (cathepsins B, C, F, H, 
K, L, O, S, W, V and Z) cathepsins. In general, cathepsins are commonly found in 
lysosomes and endosomes and mediate a series of peptide cleavages to maintain normal 
cell physiology. More recently, cathepsins have been shown to contribute to a variety of 
pathological processes such as cancer metastasis, cell invasion and inflammation.
1.14.1 Structure and activation of cathepsin L
Cathepsin L is ubiquitously expressed across different tissues. It is synthesised as an 
inactive preprocathepsin L. This precursor is transported through the Golgi apparatus 
where it undergoes glycosylation and phosphorylation of terminal mannose residues. 
Whilst in the Golgi, prepro-cathepsin L is also processed to procathepsin L with a 
molecular weight of 37-39 kDa (Probst et al., 2006, Reiser et al., 2010). The immature 
procathepsin L subsequently undergoes autocatalytic processing to mature cathepsin L
in the acidic environment within lysosomes, forming a single chain of 30 kDa or a 
heterodimer with molecular weight of 25 kDa and 5 kDa (Ishidoh et al., 1998).
1.14.2 Function of cathepsin L
Cathepsin L is primarily localised intracellularly in lysosomes. It is also expressed 
within nuclei and is secreted extracellularly. This differential localisation suggests 
multiple functions exist for cathepsin L (Brix et al., 2008). Indeed, cathepsin L together 
with other members of the cathepsin family are involved in MHC class II antigen 
processing by degrading the associated invariant chain (Ii) in cortical thymic epithelial 
cells. Ii is an important chaperone molecule that ensures the proper folding of MHC 
class II molecules. Ii functions as a surrogate peptide that binds to the MHC peptide-
binding groove to prevent premature peptide loading onto the MHC class II molecules. 
In addition, Ii facilitates the transport of newly synthesised MHC class II molecules to 
endosomes and lysosomes. Upon arrival in endocytic compartments, Ii undergoes a 
series of proteolytic cleavages to form CLIP (class Il-associated Ii protein). CLIP is 
then removed to allow the loading of non-self or self peptides. Cathepsin L also 
participates in the later stages of Ii degradation in thymic cortical epithelial cells (cTEC). 
Mice deficient in cathepsin L expression displayed substantial reduction in CD4+ T cells 
in both the thymus and periphery, due to the impairment of thymic CD4" T cell 
selection resulting from a defective Ii degradation pathway (Nakagawa et al., 1998).
In addition, cathepsin L participates in adipogenesis and glucose tolerance. Fibronectin 
is a critical matrix protein that negatively regulates pre-adipocyte differentiation by 
reducing lipogenic gene expression by interfering with the cytoskeletal and 
morphological changes required for the expression of the lipogenic genes. Cathepsin L 
is released into the extracellular milieu and promotes adipogenesis by degrading 
fibronectin. Cathepsin L also mediates the processing of insulin receptor (IR) and 
insulin-like growth factor-1 receptor (IGF-1R) in lysosomes and endosomes. Inhibition 
of cathepsin L revealed the accumulation of intact IR and IFG-1R ß-subunits and 
upregulation of glucose transporter 4 (GLUT4). As a consequence, glucose uptake is 
increased in cathepsin L knockout mice fed a high-fat diet (Yang et al., 2007). 
Cathepsin L knockout mice also display severe dysregulation of hair growth, 
exemplifying the diverse functions of this protease.
1.14.3 The pathological role of cathepsin L
Cathepsin L is also involved in diseases such as tumor metastasis and invasion, 
autoimmune myasthenia gravis, rheumatoid arthritis, Sjogren’s syndrome and 
autoimmune type 1 diabetes. Elevated expression of cathepsin L has been detected in 
kidney, testis, colon and lung tumours (Chauhan et al., 1991). In the context of 
autoimmune T1D, autoreactive CD8+ T cells have been found to express high levels of 
cathepsin L, which is required to activate dipeptidyl peptidase I (DPPI), a granule 
protease that processes the proenzyme form of the serine proteases (granzymes) of 
cytotoxic CD8+ T cells (Yamada et al., 2010). In addition, cathepsin L-deficient NOD 
mice has a lower incidence of T1D, which is associated with a reduction in CD4+ T 
cells and an increase in regulatory T cells, suggesting that cathepsin L may be involved 
in the homeostasis of CD4T T cell compartment for the development of the 
autoimmune disease (Maehr et al., 2005).
1.15 Scope of this thesis
Islet transplantation is a promising treatment for individuals with established type 1 
diabetes. Enormous progress has been made since the introduction of the Edmonton 
protocol, the clinical islet transplant protocol for preventing islet transplant rejection. 
However, islet transplantation is still far from being a standard treatment, due to the 
limited supply of donor organs and the dependence of heavy immunosuppression to 
maintain graft survival and function.
Recently, a novel finding by Ziolkowski et al. has highlighted a critical role for 
intracellular HS in the survival of islet beta cells. This vital component is lost during the 
islet isolation process. In vitro treatment of isolated beta cells with HS mimetics 
significantly increased their survival and exerted a protective effect on the beta cells 
against reactive oxygen species (ROS)-mediated damage. Additionally, the authors 
established a pivotal role for heparanase in the onset of type 1 diabetes (T1D) in 
NOD/Lt mice. Autoimmune destruction of islets in NOD/Lt mice was associated with 
the up-regulation of heparanase expression by insulitis mononuclear cells (MNCs) and 
the loss of intra-islet HS. Alcian blue histochemistry that selectively stains HS, showed 
disruption of intra-islet HS with destructive insulits and well-preserved HS in intact 
islets without insulitis in the NOD/Lt mice. Heparanase transcripts were significantly 
elevated in isolated islets from prediabetic and onset diabetic NOD/Lt mice. The high
levels of heparanase mRNA expression correlated with increased levels of transcript 
expression for CD45, a common leukocyte marker. Moreover, immunohistochemical 
analyses revealed that heparanase was localised in the insulitis MNCs. Collectively, the 
studies indicated that insulitis MNCs produce catalytically active heparanase to 
breakdown the islet BM HS, thereby permitting leukocyte invasion. Thereafter, the 
local production of active heparanase targets the intracellular HS in beta cells, essential 
for their survival. The progressive loss of islet HS eventually leads to beta cell death 
and the onset of T1D. Consistent with this notion, in vivo treatment with the heparanase 
inhibitor PI-88 significantly preserved intra-islet HS and reduced the incidence of T1D 
in the NOD/Lt mice by 50%. Together, these findings led to a new paradigm for the 
development of T1D, with leukocyte-derived heparanase mediating the loss of islet BM 
and beta cell HS, resulting in beta cell death (Ziolkowski et al., 2012).
Based on these findings, this project tested the hypothesis that heparanase plays a novel 
effector function in the rejection of islet allografts in mice. Hence, this project set out to 
assess the status of BM and islet HS after islet isolation and transplantation and to 
evaluate the role of islet HS as a target for heparanase-mediated damage during the 
rejection of islet allografts. It was postulated that these studies could potentially identify 
novel approaches for improving the quality of isolated islets for transplantation and for 
preventing the rejection of islet allografts.
The aims of the studies were
(i) To assess the integrity of the islet basement membrane following islet isolation and 
transplantation
(ii) To identify the HSPG core proteins responsible for the exceptionally high HS 
content of islets in situ in the pancreas
(iii) To compare the status of HSPG core proteins and HS in islets in situ in the 
pancreas, after islet isolation and after transplantation
(iv) To determine whether HS replacement can restore the normal HS content of 
isolated islets or whether HS loss during islet isolation can be preserved
(v) To investigate the role of heparanase in islet allograft rejection and thus identify 
whether islet HS represents a target for immune destruction, and
(vi) To determine whether novel HS mimetics/heparanase inhibitors or anti-heparanase 
antibodies can protect islet allografts from rejection.
CHAPTER 2 : Materials and Methods
2.0 Animals
C57BL/6, Ragl knockout C57BL/6 (B6.Ragl-/-), Heparanase knockout C57BL/6 (B6. 
Hpse-KO) and Cathepsin L knockout C57BL/6 (B6.Ctsl-KO) mice were obtained from 
the Australian Phenomics Facility (APF), the John Curtin School of Medical Research, 
the Australian National University (ANU). CBA mice were purchased from Monash 
University, Melbourne via the APF. Mr. Peter Hamilton, Diabetes/Transplantation 
Immunobiology Laboratory, and animal technicians from APF were responsible for the 
maintenance of the mice. All procedures and experiments performed with mice were 
approved by the Australian National University, Animal Ethics Committee.
2.1 Moue strains
2.1.1 C57BL/6
C57BL/6 (H-2b) male mice were used for islet isotransplantation studies. C57BL/6 mice 
were also made diabetic by administration of intravenous (i.v) alloxan (45 mg/kg i.v) 
and served as hosts (H-2k—► H-2b) for studies of islet allograft function (see Section 
2.5). Kidney tissue harvested from C57BL/6 mice was analysed by quantitative real-
time RT-PCR (See Section 2.7) for contaminating background mRNA in islets graft 
samples. Lymph nodes and spleens from C57BL/6 mice were used as responder cell 
populations in allogeneic mixed lymphocyte reactions (MLRs) (see Section 2.14). 
C57BL/6 mice also served as donor mice for in vitro islet studies of heparan sulfate 
(HS) loss, replacement and preservation (see Section 2.12-2.13).
2.1.2 CBA
CBA (H-2k) male mice were used for islet isotransplantation studies and served as hosts 
(H-2b —► H-2k) and donors (H-2k—► H-2b) for allogeneic islet transplantation. Spleens 
harvested from CBA mice were used as stimulator cells for allogeneic MLRs (see 
Section 2.14).
2.1.3 Ragl KO (C57BL/6.129S7-Ragl,mlMom/J)
B6.Ragl-/- mice were rendered diabetic by administration of i.v alloxan (50 mg/kg). 
B6.Ragl-/- mice, which were diabetic for > 3 weeks were used as recipient mice for 
islet allografts. These graft-bearing transplant recipient mice received adoptively 
transferred in vitro activated effector T cells derived from allogeneic MLRs (see Section 
2.14).
2.1.4 B6.Heparanase (Hpse) KO
Heparanase KO (B6.Hpse-KO) mice were obtained from Jin Ping Li (Dept of Medical 
Biochemistry and Microbiology, Molecular Geriatrics, University of Uppsala, Sweden). 
B6.Hpse-KO mice were generated by selectively deleting the minimal promoter region 
and exon 1 using targeted gene disruption in the embryonic stem (ES) cells as described 
(Zcharia et al., 2009) and backcrossed for more than 10 generations with C57BL/6J 
mice to produce homozygous B6.Hpse-KO mice on a C57BL/6J background.
B6.Hpse-KO mice were used as recipient mice for allogeneic islet transplantation. 
Alloxan-induced diabetic B6.Hpse-KO mice (alloxan, 45 mg/kg i.v) were used for islet 
allograft studies (see Section 2.5.3). Lymph nodes and spleens derived from B6.Hpse- 
KO mice were also used as responder T cell populations in allogeneic MLRs (see 
Section 2.14). B6.Hpse-KO mice also served as donor mice for in vitro islet studies of 
heparan sulfate (HS) loss and preservation (see Section 2.12-2.13).
2.1.5 B6.Cathepsin L (Ctsl) KO
Cathepsin L KO (B6.Ctsl-KO) mice were obtained from Dr. J. Villadangos (Walter and 
Eliza Hall Institute). The B6.Ctsl-KO was generated at AstraZeneca Pharmaceuticals 
(Cheshire, UK) by deleting part of exon 2 to the start of exon 4 using gene targeting in 
ES cells as described (Potts et al., 2004) and backcrossed to C57BL/6 mice to produce 
the B6.Ctsl-KO mousetrain on a C57BL/6 background.
B6.Ctsl-KO mice were used as recipient mice for allogeneic islet transplantation. 
Pancreatic islets isolated from B6.Ctsl-KO mice served as a negative control sample for 
Western blotting analysis of Cathepsin L protein (Section 2.11). B6.Ctsl-KO mice also 
served as donor mice for the studies of the loss of islet heparan sulfate (HS) during islet 
isolation.
2.2 Alloxan Injection
C57BL/6, Bö.Ragl-/- and B6.Hpse-KO mice were made diabetic by administration of 
alloxan. Alloxan is a cytotoxic glucose analogue, which selectively destroys islet beta 
cells in the pancreas. It preferentially accumulates in the beta cells via the GLUT2 
glucose transporter. Alloxan generates reactive oxygen species (ROS) in the presence of 
intracellular thiols. Alloxan and its reduction product, dialuric acid establish a redox 
cycle to form highly reactive hydroxyl radicals, which in turn, leads to the rapid 
destruction of islet beta cells. Alloxan treatment has been shown to induce diabetes in 
animals but not in humans (Lenzen, 2008).
Mice were starved for 17-20 hours prior to alloxan treatment via intravenous injection 
to minimise the interference of glucose that could compete with alloxan for beta cell 
uptake. Alloxan monohydrate (Cat. No.: A7413, Sigma-Aldrich, St. Louis, MO, USA) 
was reconstituted in normal saline at 4.5-5 mg/ml on the day of injection. Mice were 
placed under a heat lamp (75 watts, Cat No. N616/T2K, Luxo, Elmsford, NY, USA) for 
4 mins to promote vasodilation before the i.v administration of alloxan at 45-50 mg/kg. 
The mice were then refed at 1 hour after alloxan treatment. The blood glucose levels of 
the alloxan-treated mice were measured twice a week to monitor diabetes induction. 
Diabetes was defined as blood glucose > 20 mmol/L on 2 consecutive occasions.
2.3 Islet Isolation
For the isolation of islets from the pancreas, donor mice were anaesthetised by 
intraperitoneal injection of 0.4 ml Avertin (See Appendix 1). The abdominal region 
was sterilised using 80% ethanol before an incision was made in the skin over the lower 
ventral region. The underlying muscle layer was revealed. A new incision was made in 
the muscle below the sternum and at each side of the rib cage. The liver was exposed 
and everted over the thorax region and secured with a sterilised gauze pre-soaked in 
wash medium A (see Appendix 2), to expose the upper peritoneal area. With the aid of a 
dissecting microscope (Model SDZ-P, Kyowa Optical, Tokyo, Japan), the distal part of 
common bile duct at the duodenal entry was clamped with a pair of artery forceps. A cut 
was made at the proximal part of the common bile duct close to the liver to allow 
cannulation of the common bile duct with collagenase P solution (Roche, Mannheim, 
Germany) (2.5 mg/ml, Appendix 2) using a 30.5 gauge needle (Beckton Dickinson & 
Co, Franklin Lakes, NJ, USA) bent at 45° and attached to a 3ml syringe (Terumo 
Medical Corporation, Somerset, NJ, USA). The collagenase P solution was slowly
injected into the pancreas. The pancreas was then removed and transferred to a 
siliconised glass vial containng with 2 ml of collagenase P solution (2.5 mg/ml) and 
incubated for 15 mins at 37°C. The glass vial was shaken and vortexed briefly. The 
digested pancreas was washed twice in wash medium A for 5 mins, followed by a wash 
medium B (see Appendix 2) for 3 mins. The digested tissue was resuspended in wash 
medium A and transferred to a glass petri dish (100 mm). The islets were hand-picked 
using the dissecting microscope and a drawn-out pasteur pipette connected to a piece of 
thin rubber tubing attached to a 5ml syringe (Simeonovic et ah, 1998) (Fig. 2.1).
2.4 Islet Transplantation
The number of islets used for transplantation to recipient mice was determined by the 
experimental analysis to be performed. 250 islets were transplanted for 
immunohistochemical and histological studies. For studies of islet allograft function, 
400 islets/transplant were used. 450 islets were transplanted for grafts to be analysed by 
quantitative real-time RT-PCR. For Western blotting studies, 500 islets per transplant 
were required.
Islets were counted and placed into a Linbro®/Titertek® 96 U-shaped well plate (Cat 
No.: 76-242-05, ICN Biomedicals, Inc. Aurora, Ohio, USA) in groups of 50-100 
islets/well. The islets were allowed to settle to the bottom of the well (for 
approximately 15 mins) and excess medium was carefully removed using a finely 
drawn-put siliconised Pasteur pipette (Irving-Rodgers et ah, 2012, Simeonovic et ah, 
1996, Simeonovic et ah, 1998).
2.4.1 Embedding islets in blood clots for transplantation
Isolated islets were embedded in blood clots to facilitate transplantation. 5 pi tail vein 
blood was withdrawn from normglycaemic mice of the recipient strain using a 5 pi 
microcapillary (Drummond Scientific Co., Broomall, PA, USA). The blood was 
transferred to individual wells containing 50-100 islets. The islets were resuspended in 
the blood and a clot was allowed to form at room temperature (for approximately 10 
mins) (Fig. 2.1) (Irving-Rodgers et ah, 2012, Simeonovic et ah, 1996, Simeonovic et ah, 
1998).
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Figure 2.1 Islet isolation and islet transplantation
Islets are isolated from donor mouse pancreas by collagenase digestion of the 
pancreas to separate the islets from the surrounding pancreatic acinar tissues 
followed by hand-picking of islets. The isolated islets are embedded in blood 
clots of the recipient mouse strain. The blood clots containing the isolated 
islets are transplanted under the kidney capsule of the recipient mice.
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2.4.2 Transplantation of islets under the kidney capsule of recipient mice
Recipient mice were anaesthetised by intraperitoneal injection of Avertin (0.012 ml/g 
body weight) (see Appendix 1). The left flank was shaved and swabbed with 80% 
ethanol. An incision was made in the skin and muscle layer above the left kidney using 
a pair of sterilised curved scissors to expose the peritoneal cavity. The left kidney was 
exposed, elevated and secured with a cotton bud pre-soaked in 20 mM HEPES-buffered 
Hanks Balanced Salt solution (HBSS, see Appendix 1). The exposed kidney was 
constantly rehydrated with 20 mM HEPES-buffered HBSS. With the aid of a dissecting 
microscope (SZ Series 255623, Olympus, Tokyo, Japan), the kidney capsule at the far 
right pole of the kidney was gently lifted up using a fine forceps (L.R Instruments, VIC, 
Australia). A small incision in the capsule was made using a 23 gauge needle (Terumo 
Medical Corporation, Somerset, NJ, USA). A probe consisting of a sealed and blunted 
metal 27G Luer-Lock needle attached to a disposable 1ml syringe, was used to expose 
the space between the kidney capsule and kidney parenchyma for placement of the islet 
containing blood clot. Each blood clot was then inserted into the subcapsular space 
using sterile fine forceps and an autoclaved, plugged 10 pi glass microcapillary. Each 
blood clot was positioned at a separate site under the kidney capsule to allow optimal 
engraftment. The grafted kidney was then returned to the peritoneal cavity and the 
incision sites in the skin and muscle layers were closed using wound clips (Beckton 
Dickinson & Co, Franklin Lakes, NJ, USA). The transplanted recipient mice were 
placed under an incandescent lamp (60 watts) until the mice recovered from 
anaesthesia. The day of transplantation was defined as day 0 (Irving-Rodgers et al., 
2012, Simeonovic et al., 1996, Simeonovic et al., 1998) (Fig. 2.1).
2.5 In vivo treatment of mice carrying islet allografts 
2.5.1 Treatment with heparin-derived heparanase inhibitors
Alloxan-diabetic C57BL/6 (H-2b) transplant recipient mice carrying CBA (H-2k) islet 
allografts were treated with the heparanase inhibitors prepared by Dr. C. Freeman (Dept 
of Immunology, JCSMR). Periodate-treated low molecular weight heparin 382 or 
periodate-treated 12 kDa heparin 206 (see Appendix 18), were administered at 80 
mg/kg/day i.p from the day of transplantation (day 0) (see Appendix 3). Blood glucose 
levels were monitored daily for signs of rejection. Recipient mice were sacrificed when 
2 consecutive blood glucose were registered > 20 mmol/L. Grafts were harvested and 
divided into 3 segments. 2 segments were fixed in 10% neutral buffered formalin and 1
segment was snap-frozen in liquid nitrogen or liquid Forane® 134a refrigerant (Alkema 
Inc, King of Prussia, PA, USA).
Triple daily doses of the heparanase inhibitors 382 or 206 were administered at 40 
mg/kg/dose i.p at 6-8 hours intervals (see Appendix 3). Blood glucose levels were 
measured daily. Recipients were sacrificed and grafts were retrieved for fixation in 
formalin or freezing (see Section 2.6).
2.5.2 Treatment with polyclonal rabbit anti-heparanase serum
Diabetic C57BL/6 (H-2b) allograft recipient mice were treated with rabbit anti- 
heparanase serum prepared by Dr. C. Freeman (Dept of Immunology, JCSMR) (250 pi, 
10 mg Ig/ml) at days 0, 3, 6 and 9 post-transplant i.p. Blood glucose readings were 
taken daily to monitor rejection. Recipient mice were sacrificed when hyperglycaemia 
was established and grafts were harvested as for Section 2.6.
2.5.3 Treatment with rapamycin ± anti-heparanase serum
Alloxan diabetic C57BL/6 (H-2b) and B6.Hpse-KO (H-2b) mice carrying CBA (H-2k) 
islets allografts were treated with rapamycin (Selleck Chemicals, Houston, USA) in 1% 
carboxymethylcellulose-Tween80 (see Appendix 4) at 0.3mg/kg/day i.p (Fabian et al., 
1993) from days 1-7 post-transplant. Control alloxan diabetic C57BL/6 (H-2b) 
allotransplant recipient mice were treated with diluent (1% carboxymethylcellulose- 
Tween 80) from days 1-7 post-transplant. Blood glucose levels were monitored daily for 
signs of rejection. Recipient mice which showed re-establishment of diabetes were 
sacrificed and grafts were retrieved as for Section 2.6.
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Additional C57BL/6 (H-2 ) recipient mice received rapamycin at 0.3 mg/kg/day i.p 
from days 1-7 post-transplant, followed by anti-heparanase serum (250 pi, 10 
mg/ml/dose) i.p at days 12, 15, 18 and 21 post-transplant. Control C57BL/6 (H-2b) 
recipient mice were treated with rapamycin as above followed by saline (250 pi) i.p at 
days 12, 15, 18 and 21 post-transplant. Blood glucose was measured daily for signs of 
rejection. Recipient mice were sacrificed and grafts were harvested as for Section 2.6.
2.6 Harvest of isolated islets and islet transplants
2.6.1 Preparation of tissue and transplants for histochemistry and 
immunohistochemistry
Transplant recipient mice were sacrificed via cervical dislocation. The graft-bearing 
kidney was excised and rinsed in 20 mM HEPES-buffered Hanks Balanced Salt 
solution. The part of kidney that containing each graft was sliced into segments using a 
surgical scalpel blade (No. 11, ref num: 0203, Swann-Morton, Sheffield, England) and 
fixed in 10% neutral buffered formalin for at least two days prior to processing for 
histological examination (Paraffin embedding and sectioning were performed by Ms. 
Anne Prins, Histology Unit, JCSMR). Paraffin sections were used for the 
immunohistochemical localisation of heparan sulfate proteoglycans (type XVIII 
collagen, syndecan-1 and CD44), heparan sulfate (HS), heparanase (Hpse) and 
cathepsin L (CtsL). Paraffin sections were also used for Alcian blue histochemical 
detection of HS. Sections stained by H&E were used for histological assessment of 
tissue and graft morphology.
2.6.1.1 Histological analyses of islet transplants
Formalin-fixed C57BL/6 islet isografts and CBA islet allografts from C57BL/6, 
B6.Hpse-KO and B6.Ctsl-KO recipient mice were serially sectioned at 8 pm intervals. 
Four sections at > 15 section intervals were stained with Haematoxylin and Eosin 
(H&E). The H&E-stained sections were photographed using a light microscope 
(Olympus 1X17) connected to digital camera (Olympus DP70). The images were 
analysed for total graft area and total area of intact islet tissue (in mm ) using NIH 
Image J, version 1.46r software. 3-6 grafts were analysed/group (4 sections/graft). Data 
was expressed as mean ± standard deviation. Statistical analyses were performed using 
GraphPad InStat, version 3.10.
2.6.2 Embedding islets in agar
Isolated islets were fixed in 10% neutral buffered formalin in a 1.5ml microfuge tube 
(SARSTEDT, Nümbrecht, Germany). The fixed islets were then embedded in 3% 
agarose (Cat. No.: 0140-01, Bacto Laboratories, NSW, Australia) to facilitate handling 
during processing. 3% agarose was melted in boiling water and set aside to cool 
slightly. Formalin was removed without disturbing the islet pellet at the bottom of the 
1.5ml microtube. Islets were then resuspended in approximately 0.75-1.0ml of liquid 
agarose and centrifuged for 1-2 mins using a Microfuge E benchtop microcentrifuge
(Beckman Coulter, Brea, CA, USA) to allow the islets to pellet in the agar at the bottom 
of the tube. Agarose-containing islets, were cooled to set overnight at 4°C. The agarose- 
embedded islets was sliced using a scalpel blade (no. 22, ref no.: 0208, Swann-Morton, 
Sheffield, England). The agar plug containing the islets was carefully removed by 
rimming the tube with a 23G needle (Terumo, VIC, Australia) and transferred to a fresh 
vial containing 10% neutral buffered formalin.
2.6.3 Freezing tissue for immunohistochemistry
(a) Isolated islets
Isolated islets were transferred to a 1.5ml microfuge tube. The islets were left to settle 
for approximately 15 mins before the residual wash medium was removed. The bottom 
of the microfuge tube containing the islets were frozen in liquid Forane® 134a 
refrigerant (Alkema Inc, King of Prussia, PA, USA) or liquid nitrogen for 2-3 mins and 
stored at -70°C prior to blocking in embedding medium, TissueTek® Optimum cutting 
temperature (O.C.T) compound (Sakura Finetek, Torrance, CA, USA). Cryo-sectioning 
was performed by Ms. Debra Brown, Diabetes/Transplantation Immunobiology 
Laboratory, JCSMR). Frozen sections were used for immunofluorescence staining for 
basement membrane matrix proteins (type IV collagen, EHS laminin, laminin-a2, 
perlecan and nidogen-2) and platelet endothelial cell adhesion molecule-1 (PECAM-1).
(b) Islet transplants
For islet transplants, the kidney carrying the graft was sliced into segments using a 
surgical scalpel blade (no. 11, ref no.: 0203, Swann-Morton, Sheffield, England). 
Excess kidney parenchyma was removed from below the graft in each segment before 
the segments were frozen in liquid Forane® 134a refrigerant (Alkema Inc, King of 
Prussia, PA, USA) or liquid nitrogen for 2-3 mins. The frozen segments were stored in 
2.5ml plastic tubes (Cat. No.: SCP3316UU, Bacto Labs, NSW, Australia) at -70°C prior 
to blocking and cryo-sectioning as for Section 2.6.3 (a).
2.6.4 Freezing tissue for real-time RT-PCR analyses 
(a) Isolated islets
Isolated islets were transferred to a 1.5 ml microfuge tube. The islets were left to settle 
for approximately 15 mins before the residual wash medium was removed. The bottom 
of the microfuge tube containing the islets was frozen in liquid nitrogen for 5 mins and 
stored at-70°C until RNA extraction.
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(b) Islet transplants
For islet transplants, a small segment of the grafted kidney was sliced and fixed in 10% 
neutral buffered formalin. For the remainder of graft, the kidney capsule together with 
the graft was stripped from the kidney, placed on aluminium foil (Confoil Containers, 
Bayswater, VIC, Australia) and frozen immediately in liquid nitrogen (within 5 mins of 
recipient death). The frozen graft was stored at -70°C until RNA extraction.
(c) Control mouse kidney tissue
Non-grafted kidney segments were placed on aluminium foil, frozen in liquid nitrogen 
for 5 mins and stored -70°C until RNA extraction as above.
2.7 Real-time Reverse Transcriptase Polymerase Chain Reaction (real-time RT- 
PCR)
Total RNA was extracted from frozen tissue samples, and quantified. The mRNA was 
reverse transcribed to cDNA prior to PCR. Taqman quantitative real-time RT-PCR was 
used to determine the expression of Hpse, cathepsin L and CD45R in mRNA extracted 
from isolated islets, islet isografts, allografts and control mouse kidney tissue. The 
expression of the house keeping gene, ubiquitin-conjugating enzyme E2D 1 (Ube2dl) 
was used as the endogenous reference for normalising samples for comparison 
(Hamalainen et al., 2001). Two-step RT-PCR was performed where reverse 
transcription and PCR were carried out as separate steps. Following reverse 
transcription, a probe consists of a reporter dye at the 5’end and a quencher dye at the 
3’end of the probe binds to the target sequence of the cDNA. The intact probe has 
suppressed fluorescence due to the presence of the quencher dye. During the elongation 
phase of PCR, the 5’ to 3’ DNA polymerase cleaves the probes and displaces it off the 
target strand. The cleavage of the probe separates the reporter dye from the quencher 
dye, which leads to enhanced fluorescence signal by the reporter dye (Fig. 2.2).
2.7.1 RNA Extraction from isolated islets, islet transplants and mouse kidney tissue
Wheaton Potter-Elvehjem Safe-Grind® homogenising tubes (ref no.: 358029, Wheaton 
Science Products, NJ, USA) were pretreated with 10% hydrogen peroxide (H2O2) (Cat 
No.: HA 154, Chem-Supply, Pty. Ltd. Gillman, SA, Australia). Frozen islets were 
triturated in 500 pi guanidine isothiocyanate (GIT) lysis buffer (see Appendix 5) in pre-
treated homogenising tube, using a 1 ml Gilson pipette. Frozen mouse kidney tissue
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Figure 2.2 Real-time reverse transcription polymerase chain reaction (real 
time RT-PCR)
Two-step RT-PCR comprises separate steps for reverse transcription and PCR. 
Following reverse transcription, a probe consisting of a reporter dye at the 
5’end and a quencher dye at the 3’end of the probe binds to the target sequence 
of the cDNA. The reporter dye emission is quenched when the probe is intact. 
During each extension cycle (polymerisation), the 5’ to 3’ DNA polymerase 
cleaves the reporter dye from the probe., generating fluorescence. The 
fluorescence signal correlates with the levels of amplification of the cDNA.
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and islet transplants were homogenised in 500 pi GIT lysis buffer using an electric 
Braun homogeniser (Braun, Melsungen AG, Germany) for 1 min. The lysate was 
tipped into a 10 ml polypropylene conical tube (SARSTEDT, Nümbrecht, Germany) 
and kept on ice. The homogenising tube was washed twice in 1ml GIT buffer and the 
wash was transferred to the tissue lysate. Each sample was underlaid with 5.7M 
caesium chloride (CsCl) solution (see Appendix 5) in a 13x51 mm polyallomer 
centrifuge tube (Beckman Instruments Inc., CA, USA) and supplemented with 
additional GIT lysis buffer. The RNA was separated from DNA and proteins in the 
CsCl gradient by centrifugation at 120 000 x g for 21 hours at 20°C in a L7 
Ultracentrifuge (Beckman Coulter, Brea, CA, USA) using a SW55 Ti rotor. After 
centrifugation, the GIT lysis buffer, cell proteins and debris in the top layer were 
removed. The residual CsCl was tipped off and the tube containing a pellet of RNA was 
air-dried. The RNA pellet was resuspended in diethylpyrocarbonate (DEPC)-treated 
water (see Appendix 5). 3M sodium acetate (see Appendix 5) and absolute ethanol 
(Merck, Darmstadt, Germany) were added to the tube to precipitate RNA from the 
aqueous solution. The ethanol-precipitated RNA solution was gently mixed and stored 
at -70°C until RNA quantification was performed.
2.7.2 RNA Quantification
The extracted RNA samples were centrifuged at 16 000 x g for 30 mins at 4°C using a 
microcentrifuge (Model 5417R, Eppendoft, Hamburg, Germany). The supernatant was 
decanted without disturbing the RNA pellet and the tube was inverted to air dry. Excess 
ethanol was removed and the RNA was resuspended in 10-20 pi DEPC-treated water. 
The purity and concentration of RNA was assessed using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). The ratio of absorbance 
at 260 nm/absorbance at 280 nm indicates pure RNA samples for value of 1.8-2.2.
2.7.3 Reverse Transcription
2 pg total RNA was reverse transcribed in a 20 pi reaction mix to a final concentration 
of 100 ng/pl. 2 pg of total RNA were made up to a final volume of 7.5 pi with the 
addition of DEPC-treated water. 5.5 pi of the reaction mixture containing 5 pi of oligo 
dTi2-i8 (Amersham Health Pty Limited, NSW, Australia) and 0.5 pi dNTPs (dATP, 
dGTP, dCTP and dTTP) (Cat. No.: U1240, Promega, Madison, WI, USA) were added 
to the RNA solution. The samples were heated to 65°C for 5 mins, incubated for 2 mins 
on ice, followed by pulse centrifugation using a microcentrifuge. Samples were
supplemented with RT mix consisting of 4x first strand buffer, 0.1M DTT, RNasin 
(Promega Ambion, Madison, WI, USA) and Superscript III RNase Reverse 
Transcriptase (Invitrogen, Carlsbad, CA, USA). Samples were gently mixed and 
incubated at 50°C for 60 mins. The samples were transferred to a 70°C water bath for 
15 mins and then stored at -20°C until PCR was performed.
2.7.4 Real-time PCR
cDNA samples were diluted 1:4 with DEPC-treated water. 8 pi of PCR mixture 
containing 5 pi TaqMan Universal Master Mix (Ref No.: 4304437, Applied Biosystems, 
Foster City, CA, USA) (See Appendix 5), 0.25-1 pi of FAM-labelled TaqMan® MGB 
probe (TaqMan Gene Expression Assays, Applied Biosystems, Foster City, CA, USA) 
(see Appendix 5) and MilliQ water was transferred to each well of an ABI Prism™ 384- 
well clear optical reaction plate (Ref No.: 4309849, Applied Biosystems, Foster City, 
CA, USA). 2 pi of cDNAs were added to each well, 4 wells/sample (quadruplicate) 
while non-template control (NTC) wells were loaded with 2 pi of MilliQ water. The 
plate was covered with ABI PrismIM optical adhesive cover (Ref No.: 4311971, 
Applied Biosystems, Foster City, CA, USA) and the PCR was performed using a 
ABI7900HT real-time PCR machine with 7900HT Sequence Detection System, Version 
2.2.2 2004 software program (Applied Biosystems, Foster City, CA, USA).
2.7.5 Data Analysis
Real-time RT PCR data was analysed using the comparative Ct  method (Popp et al., 
2007). Cy is the threshold cycle number at which the fluorescence signal generated 
within a reaction crosses the baseline. The level of expression of the targeted gene 
(PCR product) is inversely proportional to the Cj value.
The Cj value of the gene of interest was subtracted from the mean Ct  value of the 
endogenous reference gene (normaliser), i.e Ube2dl, to give the corrected Ct  or ACt . 
The ACt  value of controls (i.e donor isolated islets) was then subtracted from the ACt  
value of the gene of interest to yield AACt  value. The fold difference in the expression 
of the gene of interest in an islet transplant with respect to the donor islets was 
calculated using the formula 2'AACr (Online Applied Biosystems Tutorials, Manual: 
Real-Time PCR Systems: Applied Biosystems 7900HT Fast Real-time PCR System and 
7300/7500/7500 Fast Real-Time PCR Systems,
http://tools.invitrogen.com/content/sfs/manuals/cms_042681 .pdf).
88
2.8 Histology
2.8.1 Haematoxylin and Eosin (H&E) Staining
Sections of mouse pancreata, isolated islets and islet transplants were stained with 
haematoxylin and eosin (H&E) for general morphology including the identification of 
islet and mononuclear cells. H&E sections were used for the selection of adjacent 
unstained slides for immunohistochemistry. The sections were first stained with the 
basic dye haematoxylin for 3 mins, washed well in running tap water and then stained 
with the acidic dye eosin for 2 mins. The slides were then transferred to a staining boat 
filled with absolute ethanol to wash off residual stain. The slides were dipped in xylene 
before coverslipping.
2.8.2 Alcian Blue Histochemistry
Alcian blue histochemistry was used to examine the expression of HS. Formalin-fixed 
paraffin sections were deparaffmised in xylene, rehydrated in graded ethanols and 
washed in running tap water for 5 mins. The sections were treated with 1M acetate 
buffer containing 0.65M MgCl2 (see Appendix 6) at pH 5.8 for 10 mins and transferred 
to alcian blue working solution (0.01% Acian blue 8GZ in 1M acetate buffer pH 5.8 
containing 0.65M MgCl2) (see Appendix 6) for 40 mins. The sections were washed in 
deionised water (dH20), counterstained with 0.01% Safranin O for 5 mins, dipped in 
dH20, dehydrated in graded ethanols and then mounted using DePex mounting media 
(VWR International Ltd., Lutterworth, Leicestershire, UK).
2.8.3 Immunohistochemistry
(a) Heparan sulfate proteoglycan -  Collagen type XVIII
Formalin-fixed paraffin embedded sections were deparaffmised in xylene, rehydrated in 
graded ethanols and washed in running tap water for 5 mins. Endogenous peroxidise 
activity was blocked by incubating sections with 3% hydrogen peroxide (H20 2) (see 
Appendix) for 10 mins. The sections were washed in PBS for 2 x 2 mins and each 
section was incubated with 0.05% pronase (Calbiochem®, EMD Millipore, Darmstadt, 
Germany) (see Appendix 7) for 10 mins at 37°C for antigen retrieval. Sections were 
washed in PBS for 2 x 2 mins and then incubated with M.O.M Ig Blocking Reagent 
(M.O.M Immunodetection Kit, Vector Laboratories Inc., Burlingame, CA, USA) (see 
Appendix 8) at room temperature to minimise binding of the primary mouse mAb. 
Following washing in PBS ( 2 x 2  mins) followed by dH20, the sections were treated
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with Animal Free Blocker (Vector Laboratories Inc., Burlingame, CA, USA) for 5 mins 
to further reduce background staining. The Animal Free Blocker was then gently tipped 
off. The sections were incubated with anti-collagen type XVIII (mouse collagen type 
XVIII mAb, Cat No.: COL18A1 (1837-46), sc-32720, Santa Cruz Biotechnology Inc, 
CA, USA) or isotype control (BD Pharmingen™ purified mouse IgG2bic, Cat No.: 
557351, BD Biosciences, San Jose, CA, USA) (see Appendix 8) for 30 mins and then 
washed in PBS. The sections were incubated with secondary antibody (horseradish 
peroxide (HRP)-conjugated polyclonal rabbit anti-mouse Ig, Cat No.: P0161, DAKO, 
Carpinteria, CA, USA) (see Appendix 8) for 30 mins and then washed in PBS. The 
chromogen, 3-amino-9-ethylcarbazole (AEC) (Sigma-Aldrich, St. Louis, MO, USA) 
(see Appendix 7) was applied to each section for colour development due to the 
formation of chromogenic precipitate. The sections were washed in dFUO, 
counterstained in Gill’s Flaematoxylin for 35 secs, washed in dFUO, dipped into 
ammonium water (2 dips at 2 secs/dip; (see Appendix 7), and washed in dFUO. Sections 
were dehydrated in graded alcohols and cover-slipped using DAKO Glycergel 
mounting medium (DAKO, Carpinteria, CA, USA).
(b) Heparan sulfate proteoglycans -Syndecan-1 and CD44
Formalin-fixed paraffin embedded sections were dewaxed in xylene, rehydrated in 
graded alcohols and washed in running tap water for 2 mins. Endogenous peroxidise 
activity was blocked by incubating sections in 3% H2O2 for 10 mins. Sections were 
washed twice in PBS ( 2 x 2  mins) and water. Antigen retrieval was performed by 
heating sections in 10 mM citrate buffer (pH 6.0) in a microwave (900 watts, Model No. 
NN-s548WA, Panasonic, Kadoma, Osaka, Japan) for 2 mins on high power, followed 
by 12 mins ( 2 x 6  mins) on low power. Sections were set aside to cool for 
approximately 30 mins and washed in PBS. The sections were then incubated in 
Animal Free Blocker (Vector Laboratories Inc., Burlingame, CA, USA) for 10 mins. 
Animal Free Blocker was tipped off the slides, the primary rat anti-mouse CD138 
(syndecan-1, Cat No.: 553712, BD Biosciences, San Jose, CA, USA) or rat anti-mouse 
CD44 (Cat No. : 553130, BD Biosciences, San Jose, CA, USA ) (see Appendix 9) or 
isotype control, rat IgG2ax (BD PharmingenrM, Cat No.: 555841/559073, BD 
Biosciences, San Jose, CA, USA) or rat IgG2bK, (Cat No. : 555845, BD Biosciences, 
San Jose, CA, USA) (see Appendix 9), respectively, were applied to the sections for 1 
hr. The sections were washed in PBS and incubated with the secondary HRP-conjugated 
polyclonal rabbit anti-rat Ig (Cat No.: P0450, DAKO, Carpinteria, CA, USA) for 30
mins. The sections were washed in PBS and incubated in AEC (Appendix 7) for 30 
mins. The sections were washed in dhhO, counterstained in Gill’s Haematoxylin for 35 
secs, washed in dfGO. The sections were then dipped into ammounium water (see 
Appendix 7) for 2 dips at 2 secs/dip and washed in dPGO prior to coverslipping using 
DAKO Glycergel mounting medium (DAKO, Carpinteria, CA, USA).
(c) Heparanase
Endogenous peroxidase activity was blocked in deparaffinised sections using 3% H2O2 
(see Section 2.8.3(a)). For antigen retrieval, sections were heated in 10 mM citrate 
buffer (pH 6.0) as in Section 2.8.3(b). The sections were allowed to cool to room 
temperature and washed as in Section 2.8.3(b). Non-specific binding of mouse Ig was 
blocked using M.O.M Ig Blocking Reagent as in Section 2.8.3(a). Sections were washed 
in PBS and incubated in M.O.M diluent containing protein concentrate (see Appendix 
10) for 3 mins, followed by incubation with primary mouse anti-human heparanase 
HP 130 mAb (InSight, Rehovot, Israel) or the corresponding isotype control, mouse 
IgGl k , (Cat No.: 14-4714, eBioscience, San Diego, CA, USA) (see Appendix 10) for 
30 mins. Sections were then washed in PBS and incubated in M.O.M biotinylated anti-
mouse IgG reagent (see Appendix 10) for 10 mins. Sections were washed in PBS and 
then incubated with VECTASTAIN ABC Reagent (M.O.M Immunodetection Kit, 
Vector Laboratories Inc., Burlingame, CA, USA ) (See Appendix 10) for 5 mins and 
washed in PBS. The sections were incubated with AEC chromogen as for section 
2.8.3(a) for 30 mins, washed in dH20, counterstained in Mayer’s Haematoxylin for 45 
secs, treated with ammonium water (see Section 2.8.3(a)) (2 secs/dip) (see Appendix 7) 
and washed in dH20. Sections were dehydrated and coverslipped using DAKO 
Glycergel mounting medium (DAKO, Carpinteria, CA, USA).
(d) Cathepsin L
Sections were deparaffinised, rehydrated and washed in running tap water as for Section 
2.8.3(a). Endogenous peroxidise activity was blocked using 3% H2O2 as for Section 
2.8.3(a). Sections were washed twice in PBS and water. Antigen retrieval was 
performed by heating sections in 10 mM citrate buffer (pH 6.0) in a microwave as in 
Section 2.8.3(b). Sections were set aside to cool, washed in PBS, and then incubated in 
Animal Free Blocker (Vector Laboratories Inc., Burlingame, CA, USA) for 10 mins. 
Animal Free Blocker was tipped off the slides and the sections were incubated with 
primary rat anti-human/mouse cathepsin L mAb (Cat No.: MAB9521, R&D Systems,
Minneapolis, MN, USA) (see Appendix 11) or isotype control rat IgG2aK (Cat No. : 
555841, BD Biosciences, San Jose, CA, USA ) (see Appendix 11) for 1 hr. Sections 
were washed in PBS and treated with secondary HRP-conjugated polyclonal rabbit anti-
rat Ig (Cat No. : P0450, DAKO, Carpinteria, CA, USA) for 30 mins as for Section 
2.8.3(b). Sections were washed in PBS and incubated in the chromogenic substrate, 
AEC for 30 mins. Sections were washed in dH20  and counterstained in Gill’s 
Haematoxylin for 35 secs. Excess Gill’s Haematoxylin were removed by dipping slides 
into dH20. Sections were dipped into ammounium water as for Section 2.8.3(a) and 
washed in dH20  prior to coverslipping using DAKO Glycergel mounting medium 
(DAKO, Carpinteria, CA, USA).
(e) Macrophages, F4/80
Cryosections (see Section 2.6.3(b)) were mounted on microscope slides pre-coated with 
gelatine. The slides were fixed in ice-cold acetone for 10 mins, air dried for 1 hour and 
stored at 4°C overnight. Mouse spleens were used as positive control. On the following 
day, the sections were incubated in 5% diluent buffer (see Appendix 11) for 10 mins to 
block non-specific binding of the secondary antibody. The diluents buffer was tipped 
off and the sections were treated with rat-anti mouse monoclonal antibodies (culture 
supernatant, 1/4) against macrophages (F4/80) for 1 hour. The sections were then 
washed in PBS and treated with HRP-conjugated rabbit anti-rat secondary antibody (Cat 
No. : P0450, DAKO, Carpinteria, CA, USA) prepared in 25% diluent buffer (see 
Appendix 11). The sections were washed in PBS and incubated in the chromogenic 
substrate, AEC for 30 mins, washed in dH20, counterstained in Mayer’s Haematoxylin 
for 2 mins and treated with running tap water for 2 mins. Sections were dehydrated and 
coverslipped using DAKO Glycergel mounting medium (DAKO, Carpinteria, CA, 
USA).
2.8.4 Morphometry analysis
(a) Measurement of area with positive staining
Stained sections were photographed using a light microscope (Olympus 1X17) 
connected to a digital camera (Olympus DP70). Images were analysed for percentage of 
area with positive staining using Image J, version 1.46r software. Alcian blue or 
AEC+ve staining components were separated from the counter staining using Colour 
Deconvolution plugin. The intensity threshold (grey value of 0-255) was set to define 
positive staining (based on the staining of islets in situ in the pancreas). The area of
interest was firstly outlined to measure the total area and then the area of positive 
staining (equal to or above the intensity threshold) was measured and expressed as 
%+ve stained area.
(b) Measurement of staining intensity
Stained sections were photographed as for Section 2.8.4(a). Image J, version 1.46r 
software with Colour Deconvolution plugin was used to quantify the intensity of Alcian 
blue, type XVIII collagen, syndecan-1, CD44, heparanase and cathepsin L staining. 
Alcian blue or AEC+ve staining components were separated from the counter staining 
using colour deconvolution plugin. The mean intensity was calculated as mean optical 
density (OD) was calculated and expressed as arbitrary units (A.U), by converting the 
mean pixel value of area of interest to optical density, using the calculation logio 
(255/mean pixel value) (Ziolkowski et al., 2012).
2.9 Immunofluorescence Staining
Immunofluorescence staining for basement membrane (BM) matrix proteins, collagen 
type IV, EHS laminin, laminin-a2, perlecan and nidogen-2 and platelet endothelial cell 
adhesion molecule (PECAM-1) was performed by Dr. Helen Irving-Rodgers and Dr 
Ray Rodgers (Research Centre for Reproductive Health, Discipline of Obstetrics and 
Gynaecology, Robinson Institute, The University of Adelaide, Australia). Cryosections 
were prepared using a CM 1800 Leica cryostat (Adeal, Altona North, VIC, Australia), 
and mounted on Superfrost glass slides (HD Scientific Supplies, Glengala, VIC, 
Australia). Slides were stored at -20°C until immunofluorescence staining was 
performed. Unfixed sections were dried under vacuum for 5 mins, fixed in formalin or 
100% ethanol. Sections were then washed in hypertonic PBS (10 mmol/1 
sodium/potassium phosphate with 0.274 mol/1 NaCl and 5 mmol/1 KC1 at pH 7.2) for 3 
x 5 mins. Sections were blocked using 10% v/v normal donkey serum (Sigma-Aldrich, 
St. Louis, MO, USA) prepared in antibody diluent containing 0.55 mol/1 sodium 
chloride and 10 mmol/1 sodium phosphate (pH 7.1) for 20 mins at room temperature. 
Sections were incubated with primary antibody (see Appendix 12) overnight at room 
temperature, followed by secondary antibody (see Appendix 12) incubation for 1-2 hrs. 
Sections were treated with 1 OOpM 4,6-diamidino-2-phenylindole dihydrochloride 
(DAPI) (Molecular Probes, Eugene, OR, USA) for nuclei detection prior to 
coverslipping. Sections were examined and imaged using an Olympus BX50 
microscope with an epifluorescence attachment and a Spot RT digital camera
(Diagnostic Instruments, Sterling Heights, MI, USA). For light microscopy, sections 
were stained with haematoxylin and eosin for general morphology.
2.10 Detection of basement membrane matrix proteins/HSPGs by flow cytometry
2.10.1 Cell Preparation
(a) PFHR-9 cell line
The PFHR-9 cell line, derived from a mouse embryonal carcinoma was used as positive 
control for the localisation of intracellular basement membrane (BM) matrix proteins. 
The PFHR-9 cell line (see Appendix 13) was cultured in T-75 flask (Nunc, Roskilde, 
Denmark) at 37°C 5% CO2, in air (Forma Scientific Water Jacketed Incubator, Thermo 
Electron Corporation, Marietta, Ohio, USA). Cells were harvested at 80% confluence 
using 0.05% EDTA (Cat No.: 10093.5V, BDH Chemicals, VIC, Australia) and 
transferred to a 96 well U-bottom cell culture plate (Cellstar, Greiner Bio-one, 
Wemmel, Belgium), at 2xl05cells/well for cell surface and intracellular staining of 
matrix proteins.
(b) Primary islet beta cells
Isolated islets were transferred to a 15 ml centrifuge tube. 5 ml of chelation buffer (see 
Appendix 13) was added to the islets at room temperature for 5 mins. The islets were 
then centrifuged at 134 x g for 5 mins. The supernatant was removed. The islets were 
resuspended in 2 ml of dispersion buffer (see Appendix 13) for 2 mins at room 
temperature. The islets were resuspended and left at room temperature for a further 5 
mins. Approximately 1ml of the upper layer containing dissociated islet cells was 
transferred to a pre-cooled 5ml round bottom tube (Cat No. 352054, BD Falcon, San 
Jose, CA, USA) on ice. 1 ml fresh dispersion buffer was added to the remaining islets 
and cell harvest procedures were repeated 3 times. The tube containing the cell 
suspension was topped up to 5ml with chelation buffer and spun down for 5 mins at 134 
x g. The viable cell count was performed using a haemocytometer and trypan blue (see 
Appendix 13) exclusion method. Islet beta cells were transferred to a 96 well U-bottom 
cell culture plate (Cellstar, Greiner Bio-one, Wemmel, Belgium), at 3-4x104 cells/well 
for cell surface and intracellular staining of matrix proteins.
2.10.2 Trypan blue exclusion
Trypan blue is a vital dye that selectively stains dead cells or tissues blue. 10 pi cell 
suspension was added to 190 pi 0.2% trypan blue solution and mixed well. 10 pi of cell
mixture was loaded on to a haemacytometer and examined under a light microscope for 
cell enumeration. The total number of viable cells (non-blue) cells, x, were counted 
from the four grids of each comer. Cell density (cells/ml) was calculated as 
Cell density (cells/ml) = (x/4) x trypan blue dilution factor x 104
2.10.3 Cell surface and intracellular fluorescence staining of PFHR-9 and islet cells
Cell suspensions in culture plate wells (see Section 2.10.1) were supplemented with up 
to 200pl of FACS wash buffer (see Appendix 13) and centrifuged for 3 mins at 300 x g. 
The supernatant was removed by flicking, the plate was blotted with paper towel, and 
vortexed briefly to resuspend the cell pellet. The cells were treated with Fc block (Cat. 
No.: 553142, BD Pharmingen, San Jose, CA, USA) (1:100) for 10 mins on ice. The 
cells were washed with FACS wash buffer and centrifuged for 3 mins. The supernatant 
was flicked off, the plate was blotted and vortexed briefly at 300 x g. Cells were then 
incubated with primary antibody (see Appendix 13) or relevant isotype control Ig for 30 
mins on ice in the dark. Cells were washed with FACS wash buffer and centrifuged for 
3 mins and resuspended as above. Cells were then treated with secondary antibody for 
25 mins on ice, washed with FACS wash buffer and centrifuged for 3 mins as above.
For intracellular staining, the cells were fixed and permeabilised using CytoFix/perm 
solution (Cat No. : 554714, BD Cytofix/Perm kit, BD Biosciences, San Jose, CA, 
USA). The cells were washed in BD wash buffer and centrifuged for 3 mins at 300 x g. 
The supernatant was flicked off, the plate was blotted with paper towel and vortexed 
brief. Thereafter, the cells were blocked with Fc block, treated with primary antibodies 
or isotype control Ig and secondary antibody as above, except that BD wash buffer was 
used instead of FACS wash buffer for the washing steps.
For flow cytometry analysis of cell surface and intracellular staining, the cells were 
resuspended in 100 pi PBS and transferred to individual FACS tubes (Fisher Biotech). 
Samples were run on BD LSR1 flow cytometer and analysed using BD CellQuest™ 
Pro, Version 6.0 software.
2.11 Western blotting 
2.11.1 Sample Preparation 
(a) Isolated Islets
Islets were isolated from donor mouse pancreata. For heparanase Western blotting, the 
wash medium (see Appendix 14) was supplemented with protease inhibitors, i.e.,
Complete Protease Inhibitor Cocktail Tablets (Roche, Mannheim, Germany) and 
cathepsin L inhibitor E-64 (Sigma-Aldrich,St. Louis, MO, USA) to prevent activation of 
proheparanase during sample preparation. The conventional wash medium (adjusted to 
pH 8) was used for islets for Western blotting for Cathepsin L protein detection. Islets 
were picked into a glass petri dish on ice to further minimise enzymatic activity. The 
isolated islets were then transferred to a fresh 1.5 ml microfuge tube (SARSTEDT, 
Nümbrecht, Germany) on ice. Medium was removed and 50 pi lysis buffer (see 
Appendix 14) was added before the sample was frozen in dry ice and stored at -70°C 
(Ziolkowski et al., 2012).
(b) Islet Transplants
Recipient mice were sacrificed via cervical dislocation. An incision was made parallel 
to the initial incision site to expose the peritoneal cavity. The peritoneal cavity was 
flooded with 20 mM HEPES-buffered HBSS containing Complete Protease Inhibitor 
Cocktail Tablet (Roche, Mannheim, Germany) with or without cathepsin L inhibitor E- 
64 (Sigma-Aldrich, St. Louis, MO, USA) (see Appendix 14). The graft-bearing kidney 
was excised and the kidney capsule, together with the attached graft, was stripped from 
the kidney. The graft with attached kidney capsule was transferred to 50-80 pi lysis 
buffer (see Appendix 14), frozen in dry ice and stored at -70°C.
(c) Purified Human Platelet Heparanase (Hpse)
Heparanase purified from human platelets (Freeman and Parish, 1998) was kindly 
provided by Dr. Craig Freeman, Cancer Vascular Biology Group, Dept of Immunology, 
the John Curtin School of Medical Research (JCSMR).
(d) Proheparanase
Recombinant proheparanase (65 kDa) was produced in human embryonic kidney (HEK) 
293 cells (Zetser et al., 2003) and was kindly provided by Prof. Israel Vlodavsky, 
Rappaport Faculty of Medicine, Technion, Haifa, Israel.
2.11.2 Protein Extraction 
(a) Heparanase
Frozen samples of isolated islets and islet transplants were repeatedly thawed on ice and 
frozen on dry ice for 3 times. Samples were then centrifuged at 1 700 x g using a 
microcentrifuge (Model 5417R, Eppendoft, Hamburg, Germany) at 4°C for 5 mins. The
supernatant was harvested and the total protein concentration was determined 
colometrically using the Bradford Assay (see Section 2.11.3).
(b) Cathepsin L
Frozen samples of isolated islets and islet transplants in RIPA lysis buffer (see 
Appendix 14) was thawed on ice for 1 min and spun down for 10 mins at 1 700 x g 
using a microcentrifuge (Model 5417R, Eppendoft, Hamburg, Germany). The 
supernatant was harvested and the total protein concentration was determined as Section
2.11.2 (a).
2.11.3 Bradford Assay
The serial dilution of the standard and test samples (1:100-1:102 400) was prepared in 
duplicate in a Linbro® 96 flat-bottom well plate (Cat No. : 76-032-05, MP Biomedicals, 
Inc. Solon, Ohio, USA) plate. 20 pi commercial dye reagent, Bio-Rad Protein Dye 
Reagent Concentrate (Bio-Rad, Hercules, CA, USA), was added to each well and mixed 
well with the sample by trituration. The plate was left at room temperature for 30 mins 
before colour development was measured using a ThermoMax™ microplate reader 
(Molecular Devices, Sunnyvale, CA, USA), with wavelength set at 570nm.
2.11.4 Semipurification of heparanase protein
For detection of heparanase protein, 300 pg of total protein was added to 30 pi of 
Concanavalin A-Sepharose (ConA) beads (Pharmacia) suspended in 0.5M NaCl (Cat 
No. : 465, UNIVAR, Auburn, NSW, Australia) and incubated on a rotation wheel 
overnight at 4°C. The samples were spun at 1900 x g in a microcentrifuge (Model 
5417R, Eppendoft, Hamburg, Germany) at 4°C. The supernatant was removed. The 
pellet was washed in 0.5 M NaCl, centrifuged at 1500 x g for 5 mins and the 
supernatant was discarded.
2.11.5 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Reducing sodium dodecyl sulfate (SDS) sample buffer (see Appendix 14) was added to 
the sample in a 1:1 ratio (for ConA-bound sample, 30 pi sample and 30 pi sample 
buffer; for unbound sample, volume was determined based on the total protein loaded). 
Sample was then boiled for 5 mins. ConA bound or unbound samples were pellected at 
1500 x g for 1 min. Each sample was loaded on an individual lane of a SDS-PAGE gel 
(4-20% gradient LongLife, 1mm mini gel, NuSep, NSW, Australia) in Tris-HEPES
SDS running buffer (Cat No. : BG-163, NuSep, NSW, Australia) (see Appendix 14). An 
aliquot of commercial marker proteins of known molecular weight (Cat No. : 161-0374, 
Precision Plus ProteinIM Dual Colour Standards, Bio-Rad, Hercules, CA, USA) was 
loaded on a separate lane to identify the protein of interest, based on molecular weight. 
The gel was run with a constant voltage of 80 volts for approximately 1.5 hrs until the 
dye front reached the end of the gel. The resolved proteins in the SDS-PAGE gel were 
then transferred to a nitrocellulose membrane (Cat No. : RPN203G, Amersham 
Hybond-C Super, GE Healthcare, Little Chalfont, Buckinghamshire, UK) by 
electroblotting. An electroblotting stack containing the gel and membrane, sandwiched 
between blotting paper and fibre pad, was prepared in transfer buffer (see Appendix 14) 
pre-cooled to 4°C. The stack was clamped and slid into the BioRad blotting apparatus 
(Cat No. : 170-3930, Mini Tran-blot Eletrophoretic Transfer Cell Kit, Bio-Rad, 
Hercules, CA, USA). An electric current of 80 volts was applied to the apparatus for 1 
hr. Following the transfer of protein, the membrane was blocked with 5% (w/v) skim 
milk (see Appendix 14) in PBS overnight for heparanase Western blotting and at least 2 
hours for cathepsin L Western blotting to prevent non-specific binding of Ig.
2.11.6 Detection of protein of interest
The nitrocellulose membrane was incubated with primary mouse anti-human 
heparanase 1 HP130mAb (InSight, Rehovot, Israel), affinity-purified rabbit anti-
recombinant human proheparanase polyclonal Ab 1453 (provided by I. Vlodavsky, 
Rappaport Faculty of Medicine, Technion, Haifa, Israel), goat anti-mouse cathepsin L 
mAb (Cat No. : AF1515, R&D Systems, Minneapolis, MN, USA) or the corresponding 
isotype control mouse IgGlx, (Cat No. : 14-4714, eBioscience, San Diego, CA, USA), 
rabbit IgG (Cat No. : 0111-01, Southern Biotech, Birmingham, AL, USA) and normal 
goat IgG (Cat No. : AB-108-C, R&D Systems, Minneapolis, MN, USA) (see Appendix 
14) diluted in 3% (w/v) BSA in PBS (see Appendix) (hpse Western blotting: 2 hours; 
cathepsin L Western blotting: overnight). The membrane was washed 3 times in ice- 
cold 0.05% PBST (see Appendix 14) on a rocker for 20 mins wash at 4°C. The 
membrane was then probed for 1 hr with HRP-conjugated polyclonal rabbit anti-mouse 
Ig (Cat No. : P0161), HRP-conjugated polyclonal swine anti-rabbit Ig (Cat No. : P0217, 
DAKO, Carpinteria, CA, USA), HRP-conjugated affinity purified donkey anti-goat IgG 
(Cat No. : AB304P, Merck Millipore, Darmstadt, Germany) (see Appendix 14) prepared 
in 3% (w/v) BSA in PBS. The membrane was then washed 3 times in cold 0.05% PBST 
as above. Immunoreactive proteins were detected by applying ECLIM Western blotting
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Detection Reagent (Cat No. : RPN2106, Amersham GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) to the nitrocellulose membrane and imaged using the 
Chemiluminescence and Fluorescence Imaging System (Fuji Photo Film Co., Ltd., 
Minato, Tokyo, Japan) (Ziolkowski et al., 2012).
2.11.7 Densitometry Analysis
Protein levels were quantified by assessing the staining intensity of the bands of 
interest. The band intensity of catalytically active and inactive heparanase or cathepsin 
L protein of day 7 islet isografts and allografts was normalised using the intensity of an 
irrelevant band on the gel.
2.12 HS replacement- In vitro culture with FITC-conjugated HS mimetics
2.12.1 Examination using confocal microscopy
Islets were isolated from C57BL/6 (H-2b) donor mice (see Section 2.3) and plated into a 
hydrophobic 6-well culture plate (Greiner Labortecknik, Frickenhausen, Germany) 
containing 50 pg/ml of FITC-conjugated HS mimetic (provided by Dr. Craig Freeman, 
Cancer Vascular Biology Group, Dept of Immunology, the JCSMR) (see Appendix 19) 
or 0.4pM Calcein AM (Cat No. : C3100MP, Invitrogen, Carlsbad, CA, USA) in 2 ml of 
islet culture medium (See Appendix, 100islets/well. Islets were incubated overnight in 
5% CO2 / 95% air at 37°C (Forma Scientific Water Jacketed Incubator, Thermo 
Electron Corporation, Marietta, Ohio, USA). After culture for 24 hrs, the islets were 
washed twice in PBS and resuspended in 100 pi of PBS. Approximately 50-100 islets 
(in 5 pi) were mounted onto a 22 x 32 mm coverslip (HD Scientific Supplies Pty Ltd, 
NSW, Australia). A glass “well” slide was laid gently over the coverslip. Intracellular 
uptake of FITC-conjugated HS mimetic was examined using a LEICA confocal 
microscope (LEICA TCS SP5, Leica Microsystems CMS GmbH, Mannheim, 
Germany).
2.12.2 Quantitative analysis
Single colour fluorescent images (FITC positive images) were converted to greyscale 
(8-bit) image. The intensity threshold (grey value of 0-255) was set to define the 
positive staining with FITC. Individual islets and the associated FITC+ve islet area were 
quantified for calculation of % FITC+ve area of islets.
2.12.3 Assessment of beta cell uptake of FITC-conjugated HS mimetics
Uptake of HS mimetics by islet cells was assessed quantitatively using flow cytometry. 
Islets cultured with FITC-HS mimetics at 50 pg/ml (provided by Dr. Craig Freeman, 
Cancer Vascular Biology Group, Dept of Immunology, the JCSMR) overnight were 
transferred to a 5 ml polystyrene round-bottom tube (BD Biosciences, Franklin Lakes, 
NJ, USA) and centrifuged at 134 x g for 3 mins. The culture medium was removed and 
the islets were resuspended in 2ml of chelation buffer (See Appendix 15) for 5 mins at 
room temperature. The supernatant was removed and the islets were resuspended in 1 ml 
dispersion buffer (See Appendix 15) for 2 mins at room temperature. The islets were 
then resuspended and incubated for a further 5 mins at room temperature. 
Approximately 0.5ml of the upper layer containing single cells was transferred to a pre-
cooled FACS tube on ice. The process of dispersion was repeated 2x as previously 
described (see Section 2.10.1(b)). The dispersion was terminated by dilution with 
chelation buffer and centrifugation. The supernatant was removed and the cell pellet 
was resuspended in 100 pi PBS and transferred to a FACS tube. Samples were run on 
BD LSR1 flow cytometer and analysed using BD CellQuest™ Pro, Version 6.0 
software.
2.13 HS preservation
2.13.1 In vitro treatment with chemical free radical scavengers
Groups of 5 C57BL/6 (H-2b) donor mice were pretreated with butylated hydroxyanisole 
(BHA) (Cat No. :B 1253, Sigma-Aldrich, St. Louis, MO, USA) 120 mg/kg i.p at 1 hr 
prior to pancreas digestion. Islets were isolated as for Section 2.3 with the exception 
that the collagenase solution and wash medium A was supplemented with 50 mM 
dimethylthiourea (DMTU) (Sigma-Aldrich, Cat No.: D188700). Islets from 5 donor 
mice were pooled and fixed in 10% neutral buffered formalin for Alcian Blue 
histochemistry (see Section 2.8.2) and analysed as for Section 2.8.4
2.13.2 Islet Viability Assay
Islets were isolated as above. The freshly isolated islets were placed into a 96 U-shaped 
well plate (Cat No. : 76-242-05, Linbro®/Titertek®, ICN Biomedicals, Inc. Aurora, 
Ohio, USA) (50 islets/well) and isolation medium was removed. The viability of islets 
of the control and antioxidant-treated islets were assessed by using Calcein 
Acetoxymethyl (Calcein AM)/ Propidium iodide (PI). Calcein AM is a membrane
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permeable non-flurorescent dye that stains live cells. The intracellular esterase activity 
results in the fluorescent property of Calcein AM upon entry into cells (Decherchi et al., 
1997). Conversely, PI is a fluorescent intercalating dye, which specifically stains dead 
cells. PI is unable to enter viable cells due to its membrane impermeant property. PI 
intercalates into nucleic acids of the dead cells (with compromised cell membrane) 
which leads to increased fluorescence (Krishan, 1975). 20 pi propidium iodide (PI) (Cat 
No. :51-6621 IE, BD Pharmingen, San Jose, CA, USA) at 50 pg/ml were added to each 
well immediately followed by 20 pi of 0.4 pM Calcein AM (Cat No. : C3100MP, 
Invitrogen, Carlsbad, CA, USA). The islet cells were incubated in 5% CO2 / air at 37°C 
for 15 mins (Forma Scientific Water Jacketed Incubator, Thermo Electron Corporation, 
Marietta, Ohio, USA). The stained islets were washed twice with 100 pi PBS, 
resuspended in 100 pi PBS and 5 pi of the islet suspension was transferred onto a 22 x 
40 mm coverslip (Menzel-Glaser, Braunschweig, Germany). Cells were examined and 
imaged using a LEICA confocal microscope (LEICA TCS SP5, Leica Microsystems 
CMS GmbH, Mannheim, Germany).
2.13.3 Data Analysis
Islet viability was assessed by quantifying the propidium iodide (PI) positive area using 
N1H Image J, version 1.46r software. Single colour fluorescent images (PI positive 
images) were converted to greyscale (8-bit) image. The intensity threshold (grey value 
of 0-255) was set to define the positive staining with PI. The total area of individual 
islets and the associated Pl+ve islet area were measured for the calculation of % Pl+ve 
islet area.
2.13.4 In vitro treatment with 4,4’-diisothiocyanostilbene-2,2f-disulfonic acid, DIDS
Islets were isolated as Section 2.3 with the exception that the collagenase P solution and 
medium A was supplemented with 200 pM of DIDS (Cat. No.: sc 203919, Santa Cruz 
Biotechnology Inc, CA, USA). Islets from 5 donor mice were pooled and fixed in 10% 
neutral buffered formalin for Alcian Blue histochemistry (see Section 2.8.2) and 
analysed as for Section 2.8.4.
2.13.5 Islet culture for 4 days
Islets were isolated as for Section 2.3. Half of the isolated islets were pooled and fixed 
in 10% neutral buffered saline. The remaining islets were transferred to 6 well plates 
(100 islets/ well) and cultured in culture medium for 4 days in 5% CO2 / 95% air at
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37°C (Forma Scientific Water Jacketed Incubator, Thermo Electron Corporation, 
Marietta, Ohio, USA). The cultured islets were pooled and fixed in 10% neutral 
buffered formalin for Alcian Blue histochemistry (see Section 2.8.2) and analysed as for 
Section 2.8.4.
2.14 Allogeneic mixed lymphocyte reaction (MLR)
2.14.1 Cell Preparation
Lymph nodes and spleens were harvested from C57BL/6 (H-2 ) and B6.Hpse-KO (H-
l . u
2 ) mice. Spleens were retrieved from CBA (H-2 ) mice. Each sample was placed in a 
15 ml polypropylene conical tube (BD Biosciences, Franklin Lakes, NJ, USA) 
containing 10 ml mixed lymphocyte culture (MLC) medium (see Appendix 17). The 
lymphoid tissue was mashed using a 1ml syringe plunger (Cat. No.: 302100, BD 
Biosciences, Franklin Lakes, NJ, USA) through a 70 pm nylon mesh cell strainer (BD 
Biosciences Discovery Lab ware, Bedford, MA, USA). The resultant cell suspension 
was centrifuged at 209 x g using a bench centrifuge (Heraeus Megafuge 1 .OR, Kendro 
Laboratory Products, Asheville, NC, USA) for 5 mins at 4°C. The supernatant was 
discarded and the cell pellet was resuspended in 3-5 ml of red blood cell lysis buffer 
(see Appendix 17). Red cell lysis was terminated by dilution of the suspension with 
MLC medium and centrifugation at 209 x g for 3 mins at 18°C. Cell suspensions of 
lymph nodes and spleen from the same donor mouse strain were pooled for cell 
counting.
CBA (H-2k) stimulator cells were adjusted to 2.5 x 106 cells/ml in a total volume of 30 
ml in a T-75 flask (Nunc, Roskilde, Denmark). The cell suspension was then irradiated 
at 250 rad using an X-ray biological irradiator (Model: X-RAD 320, Precision X-Ray, 
Connecticut, USA).
2.14.2 Carboxyfluorescein succinimidyl ester (CFSE) labelling of responder T cells
2 x 108 wild-type and Hpse-KO C57BL/6 (H-2b) splenocytes/lymph node cells were 
labelled with CFSE (Cat. No.: Cl 157, Molecular Probes, Carlsbad, CA, USA) to assess 
the proliferation of the responder T population at days 1, 3 and 5 after culture with 
irradiated CBA (H-2k) stimulator splenocytes (Parish et al., 2009).
o
2x 10 responder cells were resuspended in 1 ml MLC medium and transferred to a fresh 
non-wetted 15ml polypropylene conical tube (BD Biosciences, Franklin Lakes, NJ,
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USA). The tube was laid horizontally before 110 jl l I PBS and 0.3 p i  of the 20 mM stock 
of CFSE (final concentration 5.4 pM) were added to the top end of the tube, without 
being allowed to mix with the cell suspension at the bottom of the tube. The tube was 
capped, inverted and vortexed to mix the cell suspension with the CFSE solution. The 
labelled cell suspension was incubated for 5 mins at room temperature. The labelled 
cells were washed 3 times with 10 ml MLC medium and centrifuged at 300 x g for 5 
mins (Quah et al., 2007). Viable cells were counted using Trypan blue exclusion (see 
Section 2.10.2).
2.14.3 Cell Plating
Both responder and stimulator cells were adjusted to 5 x 106 cells/ml. Responder and 
stimulator cells were mixed at 1:1 ratio in a T-75 flask (Nunc, Roskilde, Denmark). 
Control responder cells were prepared by adding the same volume of MLC medium 
instead of stimulator cells. Recombinant murine IL-2 (PeproTech, Rocky Hill, NJ, 
USA) was added to the cell mixture and responder controls at 1 ng/ml. The cell 
suspension was plated into a 96 well U-bottom cell culture plate (Cellstar, Greiner Bio- 
one, Wemmel, Belgium), 5 x 105 responders: 5 x 105 stimulators/ 200pl/ well). The cell 
cultures were incubated in a humidified incubator, with gas phase of 10% CO2 at 37°C 
(Forma Series II Water Jacketed C 02 Incubator, Thermo Electron Corporation, Marietta, 
Ohio, USA).
2.14.4 Flow Cytometry
The lymphocyte cultures were examined for proliferation and activation status at days 1, 
3 and 5 days by flow cytometry. The cells were stained with anti-CD4, anti-CD8, anti- 
H-2Kb (MHC-class I of the responder), anti-CD44, anti-B220 and Hoechst 33258 vital 
dye for 20 mins. The cells were washed 2 x with FACS buffer (see Appendix 13) before 
resuspended in 70 pi of PBS. The samples were run on BD Fortessa flow cytometer 
(BD, Franklin Lakes, New Jersey, USA) and analysed using FlowJo Version 8.8.7 
software (TreeStar Inc., Ashland, OR, USA). The total cell population was gated using 
forward scatter and side scatter to exclude debris, followed by Hoechst-negative and H- 
2K positive cells for live responder cell population. This population was then gated on 
CD4+ and CD8+ cells for responder-type CD4+ and CD8+ T cell populations, 
respectively (Fig. 2.3).
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Figure 2.3 Gating strategy for responder CD4+ and CD8+ T cells
(A) The total cell population was gated using forward scatter (FSC) and side 
scatter (SSC) to exclude debri. (B) Live cells were gated on Hoechst negative 
cell and H-2Kb positive cell population to identify the responder cell 
population (C57BL/6 or B6.Hpse-KO). (C) The cells were then gated on CD4+ 
and CD8+ T cell populations.
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2.14.5 Cytotoxic T Lymphocyte (CTL) Assay using CFSE Labelling
The cytotoxic function of responder T cells was assayed in 5 day-culture mixed 
lymphocyte reactions (MLRs). Splenocytes from stimulator CBA (H-2k) and responder 
C57BL/6 (H-2b) mouse strains were prepared as target populations as for Section 
2.14.1. Red blood cells were removed as for Section 2.14.1. CBA target cell 
suspensions were labelled with 5000 nM CFSE (see Appendix 17) and C57BL/6 targets 
were labelled with 300 nM CFSE (see Appendix 17). Labelled targets were resuspended 
at 1 x 106 cells/ml and mixed at 1:1 ratio.
Wild-type C57BL/6 and B6.Hpse-KO effector cells from day 5 MLRs were harvested, 
resuspended at 10 x 106 cells/ml, 5 x 106 cells/ml and 1 x 106 cells/ml and mixed with 
CFSE-labelled CBA stimulator-+C57BL/6 responder-type target cells at 10:1, 5:1 and 
1:1 ratios, respectively. The cell mixtures were cultured overnight for 12-20 hrs. The 
cells were then stained wth anti-CD8, Hoechst 33258 and anti-Lamp-1 for FACS 
analysis using a BD LSR1 flow cytometer and FlowJo Version 8.8.7 software 
(TreeStar). Flow-Count fluorospheres (Cat. No.: 7547053, Beckman Coulter, Brea, CA, 
USA) were added (5000 beads/cell sample) prior to staining to determine cell numbers.
2.14.6 Adoptive transfer
5 days in vitro stimulated wild-type C57BL/6 or B6.Hpse-KO effector T Cells were 
adjusted to lx 108 CD8+ effector T cells, reconstituted in 200 pi PBS and adoptively 
transferred to B6.Ragl-/- carrying established CBA islet allografts (at least 42 days 
post-transplant) i.v. The blood glucose levels of the adoptive transferred transplant 
mice were measured 3 x/week to monitor the kinetics of the induced rejection. Allograft 
rejection was defined as blood glucose > 20 mmol/L on 2 consecutive occasions. 
Recipient mice were sacrificed and grafts were harvested as for Section 2.6 and analyses 
as described in Section 2.6.1.1
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CHAPTER 3 : Molecular status of islet basement 
membranes after islet isolation and transplantation
3.0 Introduction
Several metabolically active endocrine cell populations, namely alpha (a), beta (ß), 
delta (8) and poly-peptide (PP) cells reside within the islets of Langerhans. These 
heterogeneous islet cell populations require cooperative cell-cell communication and 
intricate extracellular signals to meet their high metabolic demand for regulating blood 
glucose metabolism and homeostasis. The importance of the islet-extracellular matrix 
(ECM) interaction has long been established. The disintegration of islet-associated 
ECM and loss of ECM-associated trophic factors during islet isolation, a prerequisite 
for islet transplantation, led to matrix detachment-induced apoptosis (anoikis) via the 
enhanced activity of pro-apoptotic p38 and c-jun N-terminal kinase (JNK) pathways 
relative to pro-survival extracellular signal-related protein kinase (ERK) 1/2 signalling 
(Rosenberg et al., 1999, Wang and Rosenberg, 1999). In contrast, mantled islets, which 
retained the peri-islet ECM post-isolation showed superior function in vivo (Ricordi et 
al., 1995, Thomas et al., 1999)
Early studies of the islet ECM together with the tendency to use the terms ECM and 
BM interchangeably led to conflicting reports about the existence of a peri-islet 
basement membrane (BM). Limitations of the available reagents for staining and 
incomplete analyses suggested that the peri-islet boundary consisted of a capsule 
composed of reticulin fibre or basic matrix proteins (collagens and laminins). Jiang et al. 
were unable to detect the laminin chains -al, -ßl, -yl, -a2, -a5 and -y2 at the periphery 
of islets, leading to the conclusion that islets were not surrounded by a BM (Jiang et al., 
2002). In contrast, Van Deijnen et al. performed a comparative study between islets of 
different species. Using immunohistochemistry for type IV collagen and laminin, the 
authors proposed that a peri-islet BM existed and was species-specific. Porcine islets 
were essentially devoid of a peri-islet BM. Conversely, canine islets were totally 
enclosed by a BM while human and rat islets displayed discontinuous peri-islet BMs 
with evidence of direct exocrine-endocrine contact (Deijnen et al., 1992). Recent 
findings by Irving-Rodgers et al. have confirmed the existence of a continuous BM
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around islets in the mouse pancreas. Laminin chains-a2, -pi, -yl, nidogen-1 and -2, type 
IV collagen -al and -a2 and perlecan were localised at the periphery of non-diabetic 
NOD/Lt mouse islets in situ, constituting a continuous peri-islet BM (lrving-Rodgers et 
al., 2008).
The islet BM is immensely important for the integrity of islet cells. The seminal finding 
that perlecan was present in the islet BM supported the role of the islet BM as a physical 
barrier against invading cells. The large core protein of perlecan (400-470 kDa), 
together with several linear HS chains (5-70 kDa) represents a formidable barrier to 
tumour metastasis and the recruitment of extravasating leukocytes to the sites of 
inflammation (lrving-Rodgers et al., 2008, Parish, 2006, Parish et al., 2001). 
Compelling evidence provided by lrving-Rodgers et al. (2008) has shown that the islet 
BM is compromised during the onset of destructive autoimmune insulitis and leads to 
the development of type 1 diabetes in NOD mice.
Additionally, studies by Virtanen et al. demonstrated a double peri-vascular BM in 
human islets, consisting of laminin-511/521 (-a5ßlyl/a5ß2yl) (Virtanen et al., 2008). It 
was reasoned that the intra-islet vascular endothelial BMs in both rodent and human 
islets would provide local support and important tropic factors to islet cells located more 
distally from the peri-islet BM (Nikolova et al., 2006, Virtanen et al., 2008).
Despite previous studies reporting the loss of islet-associated ECM after isolation, a 
detailed analysis of the complete panel of the BM matrix proteins post-isolation had not 
been reported. In collaboration with Prof. Ray Rodgers and Dr. Helen lrving-Rodgers 
from the University of Adelaide, we investigate the status of BM matrix proteins 
(laminins, collagen type IV, nidogen and perlecan) in isolated islets and islets 
maintained in culture. We further examine the properties of the islet BM following islet 
iso- and allo-transplantation in the absence and presence of a graft rejection immune 
response, respectively. In this chapter, we seek (i) to investigate the potential for BM 
recovery in islets in vitro and following transplantation, (ii) to identify a potential 
mechanism for BM recovery after islet transplantation and (iii) to assess the impact of 
BM remodelling on islet engraftment and allograft rejection.
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3.1 Results
3.1.1 Experimental model for pancreatic islet transplantation
A mouse model of islet transplantation was used to examine the status of the islet BM 
and intra-islet HS (see Chapter 4) in isolated islets and islet transplants, as well as the 
role of heparanase (see Chapter 6) in the rejection of islet allografts. Isogeneic islet 
transplantation was done between donor and recipient mice of the same mouse strain 
(i.e., C57BL/6 (H-2b) -> C57BL/6 (H-2b) and CBA (H-2k) -> CBA (H-2k) mice), i.e., 
genetically identical donors and recipients. Conversely, allogeneic islet transplantation 
was performed between donor and recipient mouse strains which were histoincomptible 
for MHC and on-MHC loci (i.e., CBA (H-2k) C57BL/6 (H-2b) and C57BL/6 (H-2b)
-> CBA (H-2k) mice. The islet isografts served as intact controls for islet allografts 
susceptible to immunological rejection.
3.1.2 Histological appearance of islet isografts and allografts
Islets were isolated from donor pancreata and transplanted under the kidney capsule of 
the recipient mice. The recipient mice were sacrificed at days 3, 5, 7 and 10 post-
transplant to study the kinetics of islet allograft rejection. Histologically, C57BL/6 islet 
isografts remained intact at the graft site. Since islets were embedded in a blood clot to 
facilitate transplantation (Chapter 2, Section 2.4.1), initially the islets were found to be 
scattered beneath the kidney capsule, interspersed with clotted blood as shown in day 3 
isografts (Fig. 3.1C). By 5 days post-transplant, the clotted blood was no longer present 
at the graft site and the contents of the graft contracted, positioning the islets adjacent to 
each other. For this reason, the % area of the graft site occupied by islet tissue was low 
at day 3 (13.4+4.1%, Fig. 3.2) and increased 5.1-6.4-fold for isografts at 5-10 days post-
transplant (Day 5 isografts, % islet+ve graft area=68.2±12.1%; Day 7 isografts, % 
islet+ve graft area=85.2±2.4%; Day 10 isografts, % islet+ve graft area=76.1+6.7%, Fig. 
3.2). Isografts at 5-10 days post-transplant were characterised by intact and well- 
vascularised islet tissue at the graft site (Fig. 3.1 E, G, I).
In contrast, allografts of CBA islets in C57BL/6 recipient mice displayed a different 
histological appearance as the rejection response progressed. Residual blood clots were 
observed surrounding the islet tissue at 3 days post-transplant (Day 3 allografts, % 
islet+ve graft area=35.4±7.7%) (Fig. 3.ID, 3.2). By day 5, mononuclear cell infiltration 
at the graft site and damage to the periphery of the islet tissue was evident (Day 5 
allografts, % islet+ve graft area=22.3±4.9%) (Fig. 3.IF, 3.2). Day 7 allografts exhibited
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Figure 3.1 Histology of C57BL/6 islets in situ, isolated C57BL/6 islets, 
C57BL/6 islet isografts and CBA islet allografts in C57BL/6 recipient mice
The histological appearance of C57BL/6 islets in situ, isolated C57BL/6 islets, 
C57BL/6 islet isografts and CBA islet allografts in C57BL/6 recipient mice. The 
C57BL/6 native islet is surrounded by acinar tissue in the pancreas (A). In 
contrast to islets in situ, isolated C57BL/6 islets showed some minor disruption 
at their periphery (B). A day 3 isograft shows an intact islet embedded in a 
blood clot at the graft site (C). Isografts at 5-10 days post-transplant contained 
well-vascularised, intact islets (E, G, I). In allografts, intact islets within residual 
blood clots were observed at 3 days post-transplant (D). By 5 days, islet 
allografts were characterised by the accumulation of peri-islet MNCs and 
mainly intact islet tissue (F). At 7 days, islet allografts showed the presence of 
damaged islet tissue and an intense MNC infiltrate (H). By 10 days post-
transplant, islet allografts contained only islet remnants amongst the cell 
infiltrate (J). (A-J) Haematoxylin and eosin. I, islets; A, pancreatic acinar tissue; 
K, kidney parenchyma; B, residual blood clots; *, graft revascularisation; DI, 
damaged islets; MNCs, mononuclear cells. Scale bar=100pM.
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more intense MNC infiltration into the damaged islet tissue accompanied by a 
substantial loss of islet cell mass (Day 7 allografts, % islet+ve graft area=19.1±2.8%) 
(Fig. 3.1H, 3.2). By 10 days post-transplant, only remnant islet tissue and reduced levels 
of MNCs were visible at the graft site (Day 10 allografts, % islet+ve graft 
area=9.1±3.3%) (Fig. 3.1J, 3.2).
3.1.3 Localisation of BM matrix proteins in islets in situ, freshly isolated islets, 
cultured islets and islets isolated under various conditions
Immunofluorescence staining for BM matrix proteins identified continuous staining for 
collagen type IV (Fig. 3.3B, 3.5A), EHS laminin (Fig. 3.5C), nidogen-2 (Fig. 3.5D) and 
perlecan (Fig. 3.3A, 3.6A) at the islet periphery and associated with intra-islet 
capillaries of islets in normal CBA mouse pancreas. This finding reinforced the notion 
that a continuous peri-islet BM is present in murine islets, as previously demonstrated 
for insulitis-free islets in NOD/Lt mice (Irving-Rodgers et al., 2008). Co-localisation 
between the endothelial cell marker, PEC AM-1 and perlecan (Fig. 3.6C) also identified 
a sub-vascular BM associated with peri-islet blood vessels and intra-islet capillaries, 
comprising collagen type IV (Fig. 3.3B, 3.5A), EHS laminin (Fig. 3.5C), nidogen-2 
(Fig. 3.5D) and perlecan (Fig. 3.3A, 3.6A). In contrast, immunofluorescence staining 
for laminin-a2 (Fig. 3.3B, 3.5B) was mainly localised around the islets and showed only 
weak localisation in intra-islet capillaries. The strong localisation of laminin-a2 (Fig. 
3.3B, 3.5B) found in the exocrine pancreas tissue, supported the previous report by 
Miner et al (2004) that laminin-a2 is the dominant laminin chain in pancreatic acinar 
BMs. Anti-EHS laminin which is generated against Engelbreth-Holm-Swarm tumour 
BM, stains laminin-al, -ßl and -yl (Forsberg et al., 1994). The colocalisation of EHS 
laminin in islets is therefore indicated the presence of laminin-al, -ßl and -yl in the 
peri-islet BM and in the subendothelial BM of intra-islet capillaries (Ferletta and 
Ekblom, 1999, Jiang et al., 2002).
Isolated CBA islets lacked peri-islet staining for perlecan (Fig. 3.3C, 3.6D), type IV 
collagen (Fig. 3.3D, 3.5E), EHS laminin (Fig. 3.5G) and nidogen-2 (Fig. 3.5H), and 
showed extensive disruption of laminin-a2 (Fig. 3.5F), indicating disintegration of the 
peri-islet BM. In contrast, residual PECAM-l+ve endothelial cells and intra-islet BMs, 
identified by staining for perlecan (Fig. 3.3C, 3.6D ), collagen type IV (Fig. 3.3D, 
3.5E), EHS laminin (Fig. 3.5G) and nidogen-2 (Fig. 3.5H), indicated the presence of 
residual intra-islet capillaries and sub-endothelial BM in isolated islets. In contrast to a
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Figure 3.3 Immunofluorescence microscopy localising perlecan, collagen 
type IV, laminin-a2 and PECAM-1 in mouse pancreas, freshly isolated 
islets and 4-day cultured islets
Perlecan (green fluorescence) (A), collagen type IV (green fluorescence) (B) 
and laminin-a2 (red fluorescence) (B) staining was detected in the islet BM (see 
arrows) around CBA islets in situ in the pancreas and in BMs of pancreatic 
acinar tissue. Colocalisation of perlecan and PECAM-1 (red fluorescence) 
identified some subendothelial BM at the islet periphery and associated with 
intra-islet capillaries in islets in situ (A). Collagen type IV but not laminin-a2 
was seen in the subendothelial BM in intra-islet capillaries (B). The peri-islet 
BM was lost after isolation and did not recover after culture for 4 days, as seen 
by the almost complete lack of perlecan (C, E), collagen type IV (D, F) and 
laminin-a2 (D, F) staining at the periphery of islets. Patches of intra-islet 
staining for perlecan, collagen type IV, laminin-a2 and PECAM-1 represents 
residual subendothelial BM and remaining intra-islet vascular endothelial cells 
(VECs) was observed (C-F). Nuclei were counterstained with DAPI (blue 
fluorescence). Arrows indicate peri-islet BM. Scale bars=25pm.
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previous report of the reconstitution of the islet BM after culture (Wang et al., 1999), 
our study did not show recovery of the islet BM after culture for 4 days (Fig. 3.3E, F), 
with the staining pattern resembling freshly isolated islets. However, the residual intra-
islet staining for perlecan (Fig. 3.3E) and type IV collagen (Fig. 3.IF) showed a more 
diffuse staining pattern, which associated with PEC AM-1 staining (Fig. 3.3E) in the 
cultured islets, suggesting that the PEC AM-1 positive vascular endothelial cells were 
secreting matrix proteins.
Heparanase, an endoglycosidase that degrades heparan sulfate (HS), has been reported 
to be expressed at low levels in islets in situ in the pancreas (Ziolkowski et al., 2012). 
Since staining for the heparan sulfate proteoglycan (HSPG) perlecan was lost from the 
islet boundary during islet isolation (Fig. 3.3E, 3.6D), we investigated whether 
heparanse contributed to the observed loss of the islet BM in vitro. Two approaches 
were used to examine this issue: (i) inhibition of Cathepsin L, a cysteine protease that is 
responsible for converting inactive proheparanase to active heparanase, and (ii) 
heparanase gene disruption in heparanase knockout (KO) mice. Neither approach led to 
the preservation of the islet BM during the islet isolation procedure (Fig. 3.4C, E). In 
addition, reducing the exposure of the islets to collagenase from 15 mins to 7.5 mins 
(Fig. 3.4D) also did not prevent the loss of the islet BM in vitro, despite incomplete 
dissociation of the islets from the surrounding pancreatic acinar tissue.
3.1.4 Recovery of the islet BM and intra-islet vasculature BM following islet 
isotransplantation
Recovery of the islet BMs were observed after islet isotransplantation. Discontinuous 
staining for collagen type IV (Fig. 3.51), laminin-a2 (Fig. 3.5J), EHS laminin (Fig. 
3.5K), nidogen-2 (Fig. 3.5L) and perlecan (Fig. 3.6G) was found at the periphery of 
islets at the early time point of 3 days post-transplant. In contrast, almost continuous 
peri-islet staining for collagen type IV (Fig. 3.5M), EHS laminin (Fig. 3.50), nidogen-2 
(Fig. 3.5P) and perlecan (Fig. 3.6J) was found in islet isografts by day 5. The 
remodelling of the islet BM was accompanied by a slower recovery of laminin-a2 (Fig. 
3.5J, N, R), diffuse staining for collagen type IV (Fig. 3.5M), EHS laminin (Fig. 3.50), 
nidogen-2 (Fig. 3.5P) and perlecan (Fig. 3.6J) at the graft site. By 7 days post-
isotransplantation, staining for collagen type IV (Fig. 3.5Q), EHS laminin (Fig. 3.5S), 
nidogen-2 (Fig. 3.5T) and perlecan (Fig. 3.6M) were also localised within the islets, and 
appeared to be invaginated from the islet periphery. Staining for collagen type IV (Fig.
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Figure 3.4 Immunofluorescence staining of collagen type IV in mouse 
pancreas and islets isolated under various conditions
Staining for collagen type IV (green fluorescence) was observed at the 
periphery of CBA islets in situ, associated with intra-islet capillaries and also 
in the BMs of pancreatic acinar tissues (A). Peri-islet staining for collagen 
type IV was absent in islets isolated by (B) the conventional isolation method 
(15 min digestion with collagenase), (C) modified method including protease 
inhibitors to block cathepsin L activity during the isolation procedure, (D) 
with a shorter collagenase digestion time of 7.5 min instead of 15 min and (E) 
islets isolated from B6.Hpse-KO mice. Scale bars=25pm.
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Figure 3.5 Localisation of collagen type IV, laminin-a2, EHS laminin and 
nidogen>2 in mouse pancreas, isolated islets and islet isografts by 
immunofluorescence microscopy
Collagen type IV (A), laminin-a2 (B), EHS laminin (C) and nidogen-2 (D) were 
localised in CBA islet BMs in situ and in the subendothelial BMs of intra-islet 
capillaries (except for laminin-a2 (B)). Isolated CBA islets were depleted of 
their peri-islet BM as no peri-islet staining for collagen type IV (E), laminin-a2 
(F), EHS laminin (G) or nidogen-2 (H) was detected. Remnants of 
subendothelial BMs were observed in isolated iselets by intra-islet staining for 
collagen type IV, EHS laminin and nidogen-2 (E-H). Discontinuous peri-islet 
staining for collagen type IV (I), laminin-a2 (J), EHS laminin (K) and nidogen-2 
(L) appeared at day 3 post-isotransplantation. Day 5 isografts demonstrated 
continuous peri-islet BM staining for collagen type IV (M), EHS laminin (O) 
and nidogen-2 (P) but not laminin-a2 (N). By 7 days post-isotransplantation, 
staining for collagen type IV (Q), EHS laminin (S) and nidogen-2 (T) 
demonstrated invagination of BM matrix proteins into the engrafted islets (see 
asterisks). Staining for collagen type IV (U), laminin-a2 (V), EHS laminin (W) 
and nidogen-2 (X) at day 10 post-isotransplantation resembled the peri-islet BM 
staining in islets in situ, indicating that islet BM recovery was complete. Nuclei 
were counterstained with DAPI (blue fluorescence). Asterisks indicate 
invagination of BM matrix proteins into islets. Scale bars=25pm.
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Figure 3.6 Immunofluorescence staining of perlecan and PECAM-1 in 
mouse pancreas, isolated islets and islet isografts
PECAM-1 staining of VECs identified intra-islet and peri-islet capillaries in 
CBA islets in situ (B) and perlecan staining localised the peri-islet BM and 
intra-islet or peri-islet subendothelial BMs (A). Expression for PECAM-1 in 
isolated islets was punctate, indicating that the intra-islet vasculature had been 
disrupted due to the isolation process (E). Discontinuous peri-islet staining for 
perlecan (G) and PECAM-l+ve VECs (H) was detected in grafted islets at 3 
days post-transplant. Isografts at 5 days post-transplant exhibited continuous 
peri-islet staining for PECAM-l+ve VECs (K), which co-localised with 
perlecan expression (L). By day 7, staining for PECAM-l+ve VECs was 
disrupted at the islet periphery and was also observed at intra-islet sites, 
identifying intra-islet capillaries (N). In contrast, perlecan staining remained 
continuous at the islet periphery (M) and co-localised with intra-islet PECAM-1 
staining indicating that the intra-islet staining identified subendothelial BM (O). 
By day 10, expression of PECAM-l+ve VECs was detected only in intra-islet 
and peri-islet capillaries (Q) whereas continuous perlecan expression was 
localised in the peri-islet BM as well as in the subendothelial BM of intra-islet 
capillaries (P).Nuclei were counterstained with DAPI (blue fluorescence). 
Arrows and asterisks indicate invagination of BM matrix proteins into islets. 
Scale bars=25pm.
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3.5U), laminin-a2 (Fig. 3.5V), EHS laminin (Fig. 3.5W), nidogen-2 (Fig. 3.5X) and 
perlecan (Fig. 3.6P) in day 10 isografts resembled the BM staining in native islets in the 
pancreas.
The deposition of BM matrix proteins in islet isografts was accompanied by incomplete 
peri-islet staining for PECAM-1 (Fig. 3.6H), a marker for vascular endothelial cells 
(VECs) by 3 days post-transplant. This finding suggested that VECs had migrated to the 
islet periphery. Additionally, intra-islet staining for perlecan that was associated with 
PECAM-1 staining defined the residual intra-islet subendothelial BM of donor origin. 
Surprisingly, day 5 isografts exhibited continuous peri-islet staining for PECAM-1 (Fig. 
3.6K), which co-localised with BM staining for perlecan (Fig. 3.6L). The co-
localisation between PECAM-1 and perlecan staining at the islet periphery suggested 
that the BM matrix proteins may have been derived from the VECs. Day 7 isografts 
showed co-invagination of PECAM-1 (Fig. 3.6N) and BM perlecan (Fig. 3.6M) into 
islets, suggesting the formation of the subendothelial BM of intra-islet capillaries. 
Although the peri-islet staining for PECAM-1 became disrupted by day 7, continuous 
peri-islet perlecan staining was retained. By 10 days post-isotransplantation, the 
perlecan (Fig. 3.6P) and PECAM-1 (Fig. 3.6Q) staining resembled the localisation of 
BM proteins in native islets, indicating that the recovery of the islet BMs was complete. 
Taken together, these findings suggested that VECs may contribute to the recovery of 
the peri-islet BM. While VECs are capable of secreting BM matrix proteins, migrating 
or regressing VECs can leave behind the BM matrix proteins that they deposit 
(Nikolova et al., 2006, Nikolova et al., 2007).
3.1.5 Islet beta cells do not produce BM matrix proteins
To further investigate the source of islet BM matrix proteins, we examined the 
intracellular expression of the BM matrix proteins, e.g., EHS laminin, type IV collagen, 
perlecan, nidogen-2 in isolated CBA islet beta cells using flow cytometry. Compared to 
matrix-producing PFHR-9 cells, which demonstrated high expression of EHS laminin 
(mean GMFR=29.1±4.0, Fig. 3.7A, I), type IV collagen (mean GMFR=7.5±0.9, Fig. 
3.7C, I), perlecan (mean GMFR=6.9±0.6, Fig. 3.7G, I) and weak staining for nidogen-2 
(mean GMFR=1.7±0.4, Fig. 3.7E, I). BM matrix proteins were not detected in islet beta 
cells (mean GMFR-l, Fig. 3.7B, D, F, H, I). These data are consistent with a previous 
study showing that islet beta cells are unable to produce BM matrix proteins (Nikolova 
et al., 2006).
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Figure 3.7 Isolated islet beta cells do not produce BM matrix proteins
Flow cytometric analysis for intracellular expression of BM matrix proteins in 
control PFHR-9 cells and isolated islet beta cells revealed that PFHR-9 cells 
expressed EHS laminin (mean GMFR=29.1±4.0) (A, I), collagen type IV (mean 
GMFR=7.5±0.9) (C, I), nidogen-2 (mean GMFR=1.7±0.4) (E, I) and perlecan 
(mean GMFR=6.9±0.6) (G, I). In contrast, little or no expression of intracellular 
BM matrix proteins were observed in islet beta cells (mean GMFR-l) (B, D, F, 
H, I). The solid line in A-H represents the staining with primary rabbit anti-
mouse EHS laminin, collagen type IV, nidogen and perlecan and the dotted line 
shows the background staining with isotype control rabbit IgG. .The data in (I) 
is shown as mean GMFRiSEM for EHS laminin, collagen type IV, nidogen-2 
and perlecan staining in PFHR-9 cells and isolated islet beta cells. n=4-5 
independent experiments. *p=0.0079 ;**p=0.0286, compared to control PFHR- 
9 cells.
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3.1.6 The status of islet BM following islet allotransplantation
Similar to the BM staining in the corresponding C57BL/6 islet isografts, day 3 CBA 
islets transplanted into C57BL/6 recipient mice showed discontinuous staining for 
perlecan (Fig. 3.8E) and PECAM-1 (Fig. 3.8F) at the periphery of engrafted islets. By 
5-7 days after allotransplantation, vessel-like structures appeared exclusively in the 
allografts and co-stained with perlecan (Fig. 3.8K, N, T) and PECAM-1 (Fig. 3.8L, O, 
U) at the periphery of islets. The presence of mononuclear cells (MNCs) within the 
lumen of the vessels at day 5 (Fig. 3.8K, N) and day 7 (Fig. 3.8T) suggested the 
formation of large blood vessels. In addition, diffuse staining for perlecan was evident 
in the graft stroma for both iso- and allografts (Fig. 3.8H, K). The intra-graft deposition 
of collagen type IV and EHS laminin was also observed (Fig. 3.5M, O).
In contrast to perlecan staining, the intensity of PECAM-1 staining (Fig. 3.8L, O) 
diminished by 5 days post-allotransplantation, correlating with the presence of intra-
graft MNCs. Compared to the C57BL/6 islet isografts in which intra-islet vasculature 
was normally seen by 7 days post-transplant, the formation of intra-islet blood vessels 
was not observed in the allografts (Fig. 3.8T).
Taken together, these findings suggest that recovery of the islet BM is initiated during 
the early post-transplant period in islet allografts but the formation of intra-islet 
capillaries did not occur. Instead, enlarged blood vessels were formed around the islets 
in the rejecting allografts. Despite early evidence for the assembly of the islet BM, it is 
unclear from this allograft model whether a complete recovery of the islet BM was 
established before islet destruction occured. Nevertheless, the deposition of the BM 
matrix proteins throughout the graft stroma of the islet allografts is suggestive of an 
ECM-like barrier to the invading MNCs.
To further investigate the relative kinetics of the recovery of the islet BM and MNC 
invasion due to allograft rejection, islet allografts were analysed from the reverse mouse 
strain combination, where C57BL/6 islets transplanted to CBA recipient mice are 
rejected at a slower tempo. By day 7 post-transplant, allogeneic islets at the graft site 
appeared to be intact, with only peri-islet MNC infiltration (Fig. 3.9E). By 5-7 days, 
continuous peri-islet staining for perlecan (Fig, 3.9B, F) and PECAM-1 (Fig. 3.9 C,G) 
was evident, suggesting the recovery of the peri-islet BM was in progress. Like CBA
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Figure 3.8 Localisation of perlecan, EHS laminin and PECAM-1 in islet 
isografts and islet allografts by fluorescence microscopy
C57BL/6 islet isografts showed histological evidence of intact islets at 3-7 days 
post-transplant (A, G, P). In contrast, CBA islet tissue in allografts of C57BL/6 
recipient mice was progressively damaged over time with peri-islet 
accumulation of mononuclear cells (MNCs) observed at 5 days post-transplant 
(J, M) and intense infiltration of islets by MNCs evident in day 7 allografts (S). 
Similar to day 3 isografts (B), discontinuous perlecan staining was observed 
around the periphery of islets in day 3 allografts (E). Islet isografts at days 5-7 
post-transplant continued to show recovery of the peri-islet BM as indicated by 
prominent peri-islet staining for perlecan (H, Q) and PECAM-1 (I, R). The peri- 
islet and intra-islet staining for perlecan in islet allografts at day 5 (K) resembled 
corresponding islet isografts (H), with the exception of prominent perlecan+ve 
vessel-like structures at the islet periphery in islet allografts (K, see arrows). In 
5-7 day allografts, the vessel-like structure co-localised with PECAM-1 staining 
and contained MNCs, suggesting the formation of enlarged peri-islet blood 
vessels (L, O, U). Complete peri-islet staining for perlecan was not observed by 
7 days when intra-islet MNC infiltration was established (T). Arrows indicate 
enlarged peri-islet blood vessels. Open arrows indicate the peri-islet BM. 
Nuclei were counterstained with DAPI (blue fluorescence). (A, D, G, J, M, P, S) 
Haematoxylin and eosin. Scale bars=25pm.
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Figure 3.9 Immunofluorescence staining of perlecan and PECAM-1 in 
C57BL/6 (donor) islet allografts to CBA (recipient) mice
C57BL/6 islet allografts in CBA recipient mice showed islet tissue remaining at 
5-7 days post-transplant (A, E), indicating a slower rejection response. 
Continuous peri-islet staining for perlecan (B, F) was accompanied by peri-islet 
localisation of PECAM-1 (C, G), suggesting that recovery of the islet BM was 
progressing. The islets also showed vascular BM surrounding an expanded 
lumen but intra-islet vasculature was absent (B-D, F-H). Diffuse staining for 
perlecan was seen in days 5-7 islet allografts (B, F). Arrows indicate enlarged 
peri-islet blood vessels Nuclei were counterstained with DAPI (blue 
fluorescence). (A, E) Haematoxylin and eosin. Scale bars=25pm.
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islet allografts in C57BL/6 mice, enlarged peri-islet blood vessels were observed, but 
intra-islet capillaries were absent (Fig. 3.9B, F). In addition, high levels of perlecan 
staining were localised within the graft site stroma by 5-7 days post-transplant, 
accompanied by intense mononuclear cell infiltration (Fig. 3.9B, F). Collectively, our 
data suggest that assembly of the islet BM in this allograft model was complete before 
the onset of intra-islet MNC invasion and islet destruction due to the allograft rejection 
response. However, the formation of the MNC-containing peri-islet blood vessels and 
the absence of the intra-islet blood vessels appeared to be consistent features of the 
rejecting islet allografts at 5-7 days post-transplant.
3.2 Discussion
This study has confirmed that a conventional BM is present around the periphery of 
islets in situ in the pancreas of normal mouse strains as previously reported for insulitis- 
free NOD/Lt mouse islets (Ziolkowski et al., 2012). The islet BM consists of type IV 
collagen, laminin a l, -ß 1, -yl, -a2, perlecan and nidogen-2 (Fig. 3.5). Our finding that 
islets lose their BM during the islet isolation process is consistent with previous reports 
(Rosenberg et al., 1999, Thomas et al., 1999, Wang and Rosenberg, 1999, Wang et al., 
1999). Using antibodies against different BM matrix components and 
immunofluorescence staining, our study specifically identifies loss of the BM matrix 
proteins type IV collagen, laminin components of 111 and -a2, perlecan and nidogen-2 
from the periphery of islets after isolation (Fig. 3.3, 3.5). The loss of the peri-islet BM is 
most likely due to the collagenase-mediated enzymatic digestion of the pancreas and the 
associated mechanical shear force (Abdelli et al., 2004, Rosenberg et al., 1999). It is 
noteworthy that a similar panel of matrix proteins were also found to present in the BMs 
of pancreatic acini, suggesting that the peri-islet BMs are damaged indirectly due to 
bystander effects resulting from the digestion of the acinar tissue. In addition, the 
elevation of degradative enzymes such as matrix metalloproteases (MMPs) as reported 
previously (Barro et al., 1998) and heparanase (see Chapter 5) as well as the generation 
of reactive oxygen species (Rosenberg et al., 1999) during the isolation of islets could 
also contribute to the non-specific loss of the islet BM (Barro et al., 1998, Rees et al., 
2010).
Currently, pancreas digestion requires the use of collagenase derived from Clostridium 
histolyticum. The efficiency of the islet isolation procedure depends on the relative
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concentration of collagenase class I (CCI) and collagenase class II (CCII), which target 
different collagen structures in the pancreas during digestion. The presence of proteases 
is important in initiating digestion of other extracellular matrix proteins present at the 
islet-exocrine interface (Brandhorst et al., 2008). However, crude collagenase 
preparations are highly variable from batch-to-batch in terms of the relative composition 
of collagenase and proteases (Kin et al., 2007). In view of this, various purified enzyme 
blends containing different proportions of CCI, CCII and proteases such as thermolysin 
or neutral protease have been developed commercially (Balamurugan et al., 2012). The 
enzymatic digestion of the donor pancreas is of paramount importance in determining 
the yield of the islets and islet graft function. Based on the findings from our study, we 
suggest that a detailed comparison of the various isoforms of collagens and laminins in 
the BMs of islets and acini may help to identify enzyme combinations that could 
selectively dissociate the pancreatic acinar tissue, thereby sparing the islet BMs. 
Preservation of the islet BMs could substantially improve beta cell survival by 
preventing anoikis, cell death induced by matrix detachment (Thomas et al., 2001, 
Thomas et al., 1999, Wang and Rosenberg, 1999). Alternatively, knowledge of the 
critical components of the islet BM may help to identify an “artificial” BM that could be 
used to coat islets before transplantation, re-establishing beta cell-matrix interactions 
and minimising beta cell loss.
Basement membranes, by convention, act as a barrier against cell invasion (Irving- 
Rodgers et al., 2008, Sorokin, 2010). A recent study by Irving-Rodgers et al. (2008) has 
demonstrated that destructive insulitis and Type 1 diabetes in NOD/Lt mice correlated 
with breakdown of the peri-islet BM, rendering the islet beta cells susceptible to cell- 
mediated damage. Similarly, the loss of the islet BM during isolation indicated that this 
intrinsic defence mechanism of islets is ablated before transplantation. In addition, the 
release of bioactive molecules such as cytokines, chemokines, growth factors and 
proteases (Adair-Kirk and Senior, 2008, Sorokin, 2010, Vaday et al., 2001) from the 
matrix proteins may exacerbate islet tissue injury and the recruitment of inflammatory 
cells after transplantation. In contrast to a previous report by Wang et al. (1999), our 
study did not find recovery of the islet BM after culture (Fig. 3.4). This contradictory 
finding could be due to the different detection method used for identifying the islet BM. 
Reticulin staining used by Wang et al. (1999) recognises type III collagen, fibronectin 
and non-collagenous reticulin in the fibrous connective tissues and is not specific for 
BM matrix proteins (Unsworth et al., 1982). Hence, the islet BM detected previously in
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cultured islets was more likely to be a fibrous capsule around islets, and not a fully 
assembled peri-islet BM.
Our findings demosntrated that inhibition of heparanase activity by addition of 
cathepsin L inhibitor during islet isolation and the use of heparanase-knockout islets did 
not prevent loss of the islet BM (Fig. 3.4). Heparanase, a heparan sulfate-degrading 
enzyme, has been reported to degrade the HS of perlecan (Reiland et al., 2004), which is 
one of the major matrix proteins identified in the islet BM. However, our study 
indicated that heparanase is not the major factor contributing to the loss of islet BM 
perlecan during islet isolation. Likewise, reducing the collagenase digestion time did not 
inhibit the breakdown of the islet BM during isolation (Fig. 3.4). Future experiments 
could examine the status of islet BM at different stages of the islet isolation process 
(Chapter 2, Section 2.3), e.g., after pancreas inflation, incubation at 37°C and 
mechanical breakdown of pancreas tissue to identify the step at which breakdown of the 
islet BM damage is initiated.
Our study identified remnant PECAM positive endothelial cells and residual BM of 
intra-islet capillaries in isolated mouse islets (Fig. 3.3, 3.6). This finding is consistent 
with previous reports suggesting that residual donor-derived endothelial cells could 
contribute to the revascularisation of engrafted islets after transplantation (Brissova et 
al., 2004, Nyqvist et al., 2005). Also consistent with the previous studies, we found that 
the remaining endothelial cells were essentially lost following in vitro culture (Fig. 3.3). 
Other studies have shown that donor islet endothelial cells can contribute up to 40% of 
the vasculature of islet grafts after the transplantation of freshly isolated islets. This 
finding suggests that freshly isolated islets may offer an advantage over cultured islets 
for transplantation by providing a better preserved intra-islet endothelial cell mass to aid 
islet revascularisation post-transplant (Brissova et al., 2004, Nyqvist et al., 2005, 
Nyqvist et al., 2011).
We found that the islet BM is restored following iso-transplantation (Fig. 3.5). Signs of 
BM remodelling were evident as early as day 3 post-transplant and characterised by 
discontinuous peri-islet staining for collagen type IV, components of EHS laminin 111, 
nidogen-2 and perlecan. Continuous deposition of BM matrix proteins at the islet 
periphery was generally established by 5 days post-transplant, with the exception of 
laminin-a2 that showed a slower recovery. The BM repair process also restored the
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intra-islet BMs as illustrated by the invagination of the peri-islet BM to form the 
subendothelial BM of the intra-islet capillaries by 7 days post-transplant. By day 10, 
islet BMs were restored in the isografts, coinciding with the revascularisation of the 
islet tissue.
Our flow cytometry analyses showed that islet BM matrix proteins are not produced by 
islet beta cells (Fig. 3.7). Instead, the peri-islet deposition of BM matrix proteins co-
incided with the localisation of PEC AM-1 positive VECs that had migrated to the 
periphery of the islets by 3-5 days post-transplant (Fig. 3.6). At 5 days, in particular, the 
peri-islet staining for collagen type IV, components of EHS laminin 111, nidogen-2 and 
perlecan was widespread and extended beyond the islet boundary into the surrounding 
stroma of the graft site. Together these findings suggested that the peri-islet BM matrix 
proteins were most likely secreted by the VECs. In fact, the involvement of endothelial 
cells in BM formation during vasculogenesis and angiogenesis has previously been 
reported (Nikolova et al., 2006). During angiogenesis, endothelial cells were found to 
deposit BM matrix proteins which remained at the site of deposition to form functional 
BMs upon VEC regression (Jin et al., 2005). From 7-10 days post transplant, PEC AM-1 
staining no longer co-incided with the peri-islet BM staining but consistently 
surrounded the intra-islet capillaries, co-localising with intra-islet subendothelial BMs. 
The migration of PECAM-1 positive VECs from the islet periphery marked the 
completion of the peri-islet BM recovery and demonstrated that upon regression, VECs 
leave behind the BM matrix that they secrete. Taken together, our study provides 
evidence that endothelial cells not only function in the revascularisation of engrafted 
islets but also in the recovery of the peri-islet BMs.
In our study, the source of vascular endothelial cells that contributed to the recovery of 
the islet BM is unclear. Residual PECAM-1 positive intra-islet VECs were observed in 
isolated islets (Fig. 3.3, 3.6), and at day 3 post-transplant (Fig. 3.6), but not by 5 days 
after transplantation (Fig. 3.6). These findings suggest that residual donor endothelial 
cells may migrate to the islet periphery to commence BM formation. However, it is also 
possible that recipient-derived VECs that have been shown to be the major contributors 
to graft revascularisation act in concert with donor-derived VECs to reconstruct the 
peri-islet BMs of engrafted islets (Brissova et al., 2004, Brissova et al., 2006, Nyqvist et 
al., 2005, Nyqvist et al., 2011). It is well known that beta cells can produce vascular 
endothelial growth factor (VEGF-A) during islet revascularisation, potentially recruiting
134
recipient VECS to the graft site (Brissova et al., 2006). Both donor and recipient- 
derived VECs may therefore play pivotal roles in producing the key BM matrix proteins 
for the recovery of islet BM after transplantation. Nevertheless, the possibility that other 
cell types such as fibroblasts could also contribute to islet BM recovery cannot be 
excluded (Morini, Brown et al. 2007).
The composition of BMs can exhibit tissue-specific properties and vary at different 
developmental stages and during repair (Erickson and Couchman, 2000). It is therefore 
possible that the site of transplantation may also lead to minor differences in the peri- 
islet BMs of engrafted islets, compared to islets in situ in the pancreas. Our study, 
however, did not identify any differences in the composition of islet BMs reconstituted 
after transplantation beneath the kidney capsule.
In addition to providing a structural function and shaping the architecture of tissues, 
BMs provide important critical survival factors that maintain cell integrity and signals 
that fine-tune the cellular function (LeBleu et al., 2007), e.g., optimal blood glucose 
regulation and homeostasis of the metabolically active islets (Kragl and Lammert, 
2010). The process of BM remodelling that proceeded over a period of 7-10 days and 
the prolonged matrix detachment could therefore lead to anoikis-induced cell death in 
some transplanted islet tissue. For this reason, we suggest that transplanting islets 
embedded in BM matrix proteins or co-transplanting VEC may facilitate the BM 
recovery process and enhance islet integrity and function (Jalili et al., 2011, Pan et al., 
2011, Salvay et al., 2008, Weber and Anseth, 2008).
In islet allografts, signs of islet BM remodelling were observed during the early post-
transplant period, resembling the islet isografts (Fig. 3.8). However, by 5-7 days post-
transplant, rejecting islet allografts were characterised by intense peri-islet and intra-
graft perlecan staining as well as decreased PEC AM-1 staining and lack of intra-islet 
vasculature. Prominent blood vessel-like structures co-stained with perlecan and 
PECAM-1, which were absent in the isografts, were evident at the periphery of islets in 
rejecting allografts. Together these findings suggest that while VECs initially 
commence the deposition of peri-islet BMs in islet allografts, the cue for the formation 
of intra-islet vasculature fails to occur and instead, VECs are diverted to enhance the 
peri-islet and intra-graft vasculature required to transport activated alloreactive T cells 
to the engrafted islet tissue. The factors that regulate this change may involve
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inflammatory cytokines and/or chemokines, resulting in VEC activation, increased 
expression of adhesion molecules, vasodilation and enhanced vascular permeability 
(Pober and Cotran, 1990, Varani et al., 1988). Similar to the isografts, intense perlecan 
staining in the graft stroma was observed in days 5 and 7 allografts. It is possible that 
the increased levels of intra-graft perlecan could hinder leukocyte passage within the 
graft site, a barrier that could be removed by the release of degradative enzymes.
The formation of patent large blood vessels containing DAPI positive nuclei at the 
periphery of islets in the rejecting allografts, suggests a possible route for infiltrating 
leukocytes. Despite the prevalent use of the renal subcapsular space as an experimental 
islet transplant site, studies on leukocyte migration in this model are limited. Previous 
studies by Menger et al revealed a link between intra-graft microvascular development 
and the rejection of islet xenografts. Although normal revascularisation commenced in 
the early post-transplant period, phenotypic changes were noted at the graft site when 
microvascular perfusion was restored. Intravital fluorescence microscopy demonstrated 
a decreased microvascular network, reduced functional capillary density and lower 
capillary red blood cell velocity as well as increased microvascular permeability, 
capillary widening and the incidence of edema. Accumulation of white blood cells 
within the vascular network was also identified at the periphery of islets as post-
capillary venules (Menger et al., 1991). This finding resembles our observation of 
enlarged patent blood vessels at the periphery of islets during islet allograft rejection. In 
the setting of allograft rejection, we postulate that the VECs responsible for the 
formation of enlarged peri-islet vasculature would be derived from the recipient to 
facilitate the delivery of mononuclear cells to the transplant site during rejection. In 
view of this, approaches for promoting the revascularisation of islet allografts such as 
co-transplanting endothelial cells, mesenchymal stem cells (Johansson et al., 2008) or 
incorporating the pro-angiogenic factors such as VEGF (Brissova et al., 2006, Zhang et 
al., 2004) should be administered with caution as there might be a temporal or dose- 
dependent effect on allograft survival, potentially resulting in the undesired effect of 
accelerating allograft rejection.
In our study, we did not observe full recovery of peri-islet BM prior to rejection in the 
CBA (donor)/ C57BL/6 (recipient) strain combination (Fig. 3.8). However, when 
transplantation was performed in reverse donor-recipient mouse strain combination, 
which has a slower rejection tempo, BM recovery was more complete (Fig. 3.9).
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Nevertheless, we found that the lack of intra-islet vascular BMs and the formation of 
peri-islet blood vessels appear to be the consistent features in the allografts. In this 
mouse combination, the peri-islet BM represents an additional barrier to infiltrating 
mononuclear cells. In either situation, it is envisaged that MNCs would require 
specialised degradative enzymes to traverse the subendothelial BMs and to navigate 
through the BM matrix protein-laden graft site to reach the transplanted islets and 
destroy them. It has previously been shown that insulitis MNCs produce HS-degrading 
heparanase to breakdown the peri-islet BM barrier by solubilising HS in the BM 
(Ziolkowski et al., 2012). Likewise, it is possible that infiltrating MNCs express 
heparanase to aid their migration through the graft stroma and across the peri-islet BM. 
Conversely, the absence of islet BMs would render the islet tissue more susceptible to 
MNC infiltration.
In summary, this study has provided a comprehensive analysis of the status of the islet 
BM in situ and following islet isolation and transplantation. We have shown that the 
islets lose their BM during isolation. We propose that the islet BM serves as a reliable 
biomarker for islet integrity and assessment of islet BM should be included as a 
parameter for the evaluation of optimal enzyme preparations for islet isolation. 
Recovery of the islet BM takes place following isotransplantation and is complete by 10 
days post-transplant. We suggest that endothelial cells are the likely source of BM 
matrix proteins for the restoration of the islet BM. This indicates yet another important 
role for the revascularisation of islet tissue, in addition to the nutrient supply required 
for cell viability. In the allograft setting, the recovery of islet BM appears to depend on 
the tempo of allograft rejection. We discovered that intra-islet BMs fail to establish in 
islet allografts. The prolonged lack of matrix support from both peri- and intra-islet 
BMs may negatively impact on the survival of islet beta cells and facilitate MNC 
infiltration. In view of this, efforts should be made to preserve islet BMs during islet 
isolation, optimise beta cell viability and preserve the physical barrier against leukocyte 
invasion. We have also demonstrated in islet allografts, a possible route for the 
migration of infiltrating leukocytes via enlarged peri-islet blood vessels, which form 
preferentially instead of intra-islet capillaries. Increased levels of intra-graft BM matrix 
proteins suggest that MNCs would require degradative enzymes to traverse through the 
graft site. Our study suggests that inhibition of the activity of the degradative enzymes 
may represent a potential approach for impeding leukocyte migration within the graft 
site and across any established peri-islet BMs.
CHAPTER 4 : Status of intra-islet heparan sulfate 
after islet isolation and transplantation
4.0 Introduction
Heparan sulfate proteoglycans (HSPGs) are ubiquitously expressed in basement 
membranes (BMs), extracellular matrices (ECMs) and at the surface of essentially all 
cells. The HSPGs are composed of a core protein to which several linear 
glycosaminoglycan chains, termed heparan sulfate (HS) are covalently attached (Parish, 
2006). There are various types of HSPGs that are distinguished by their core proteins, 
which in turn can influence their distribution amongst tissues (Velleman and Caini, 
2005). By convention, the HSPGs that constantly express HS chains (full-time HSPGs) 
include four syndecans (syndecans 1-4), which are integral membrane proteins and six 
glypicans (glypicans 1-6), which are anchored to the cell surface by 
glycosylphosphatidylinositol (GPI) linkage. The ECM-based HSPGs consist of 
perlecan, agrin and type XVIII collagen. In addition, there are HSPGs which express 
HS chains only under specific conditions (“part-time HSPGs), such as CD44, 
betaglycan and testican (Parish, 2006). HS chains are assembled directly on to HSPG 
core proteins and are composed of repeated disaccharide units of glucosamine and 
uronic acid. The biosynthesis of HS is initiated by enzymatic transfer of a xylose 
residue to the hydroxyl group of serine residues on the core protein. Amino sugars are 
then added to form a common tetrasaccharide linker, with the sequence xylose- 
galactose-galactose-uronic-acid. Initiation of chain polymerisation is followed by the 
alternate addition of glucosamine and glururonic acid residues to the linkage 
tetrasaccharide (Vreys and David, 2007). The linear HS chains can be up to four 
hundred sugar residues in length (approximately 5-70kDa) (Parish, 2006, Parish et al., 
2001). During chain elongation, the HS undergoes further modification of the sulfated 
groups such as N-deacetylation-N-sulfation, 2-O-sulfation, 6-O-sulfation as well as 
epimerisation of glucuronic acid to iduronic acid, which accounts for the extensive 
structural and functional diversity of HSPGs (Hacker et al., 2005).
HS chains play a number of physiological and pathological roles. Under physiological 
conditions, HS in the ECM provides scaffold stability and integrity. The high negative
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charge of HS interacts with positively charged sodium ions, which in turn attracts water 
molecules. This highly hydrated property of HS confers its space-filling and molecular 
sieving properties in BMs (Parish, 2006, Reid, 2011). In addition, the linear HS chains, 
form a formidable barrier in the ECM and BMs against cell invasion (Parish et al., 
2001) .
Due to the extraordinary structural heterogeneity of HS molecules, HS binds to a 
plethora of bioactive molecules such as cytokines, growth factors, chemokines, lipases, 
proteases and cell-adhesion molecules, and serves as a storage depot for them in the 
local microenvironment (Parish, 2006). As a consequence, HS plays an important role 
in several key cellular activities such as development, cell proliferation, cell 
differentiation, angiogenesis and wound healing (Ali et al., 2003, Bishop et al., 2007, 
Parish, 2006). In inflammatory situations, HS chains are cleaved by the endoglycosidase 
heparanase to release their bound bioactive molecules which play an important role in 
modulating the inflammatory response. Moreover, interaction with HS can potentiate 
the activity of proinflammatory mediators and extend their half-life by protecting them 
from proteolytic degradation (Ali et al., 2003). Endothelial HS binds to L-selectin on 
the leukocytes to facilitate cell adhesion to the luminal endothelium. HS also 
immobilises chemokines on the luminal surface of endothelial cells. The HS-bound 
chemokines activate the mtegrin of leukocyte to promote a more stable adhesion (Wang 
et al., 2005). The ability of HS to bind to many chemokines also renders it an important 
mediator in setting up chemokine gradients for leukocyte migration. Following 
transmigration across the vascular endothelium, leukocytes migrate along the 
chemokine gradient of HS-bound or soluble chemokines in the ECM and to sites of 
inflammation (Middleton et al., 2002, Rot, 2010, Schumann et al., 2010).
Studies by Takahashi et al (2009) have identified HS as a critical regulator in postnatal 
islet growth. The authors showed that beta cell-specific exostosin-like 3 knockout 
(ßExtBKO) mice, which possess a selective defect in HS synthesis in islet beta cells, 
displayed atypical organisation and a reduced level of beta cells compared to 
heterozygous mutant control mice. Moreover, loss of HS in the beta cells of ßExtBKO 
mice led to impaired glucose-stimulated insulin secretion (Takahashi et al., 2009). 
Recent findings by Ziolkowski et al. (2012) further highlighted the role of HS in the 
pancreas. Their studies revealed that the high levels of intra-islet HS are essential for the 
survival of islet beta cells. Reconstitution of HS-depleted isolated mouse beta cells with
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HS mimetics protected the beta cells against culture-induced cell death and ROS- 
induced damage. Significantly, the onset and progression of Type 1 diabetes in NOD/Lt 
mice correlated with degradation of HS and other matrix proteins in the islet BM and 
loss of intra-islet and beta cell HS (Irving-Rodgers et al., 2008, Ziolkowski et al., 2012).
It has become evident that islets express extraordinarily high levels of HS that are 
essential for the survival of islet beta cells and normal islet function. In view of the 
crucial role of HS in islet beta cell integrity, one would expect the status of HS would 
bear significant impact on the quality of transplanted islets and the transplant outcome. 
Hence, a detailed study of intra-islet HS following islet isolation and transplantation is 
warranted. Due to the nature of HS synthesis, HS does not exist without the HSPG core 
proteins. In this chapter, we characterise the HSPG core protein components that 
account for the extraordinarily high levels of HS in islets in situ. Additionally, we 
examine the status of HSPG core proteins and HS after isolation and transplantation.
4.1 Results
4.1.1 Characterisation of heparan sulfate proteoglycans in islet beta cells
Previous studies demonstrated that islets in situ express high levels of heparan sulfate 
(HS). However, the heparan sulfate proteoglycan (HSPG) core proteins that are 
responsible for the extraordinarily high expression of HS have not been fully examined 
(Takahashi et al., 2009, Ziolkowski et al., 2012). We therefore examined the 
intracellular expression of various HSPGs in isolated islet cells using single cell flow 
cytometry. These analyses demonstrated strong intracellular staining of the core 
proteins for type XVIII collagen (mean GMFR=23.3±12.9; Fig. 4.1 A, C) and syndecan- 
1 (mean GMFR=6.0±1.0; Fig. 4.1 A, D), moderate staining of the core protein for CD44 
(mean GMFR=3.7±0.8; Fig. 4.1 A, F) and little or negligible staining of the core 
proteins for agrin (mean GMFR=1.8±0.3; Fig. 4.1 A, B) and glypican-2 (mean 
GMFR=0.8±0.2; Fig. 4.1A, E).
4.1.2 Localisation of heparan sulfate and HSPG core proteins and quantification of 
their levels in islets in situ, isolated islets and islet transplants
The distribution of HS and HSPG core proteins in islets in situ, isolated islets and islet 
transplants were assessed using Alcian blue histochemistry and immunohistochemistry,
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Figure 4.1 Intracellular expression of the HSPG core proteins for agrin, 
type XVIII collagen, syndecan-1, glypican-2 and CD44 in islet beta cells by 
flow cytometry
(A) Single colour flow cytometry analyses revealad that CBA islet beta cells 
expressed high intracellular levels of type XVIII collagen, intermediate levels of 
syndecan-1 and CD44 but little, if any agrin and glypican-2. The representative 
fluorescence profiles (B)-(F) show staining with anti-agrin, -type XVIII 
collagen, -syndecan-1, -glypican- 2 and -CD44 monoclonal antibodies, 
respectively. The black line represents staining for respective control isotype 
Igs. The data in (A) shows the mean GMFR+SEM for agrin, type XV11I 
collagen, syndecan-1, glypican-2 and CD44; n=3 experiments/group. Agm, 
agrin; Col 18, type XVIII collagen ; Sdcl, syndecan-1; Gpc2, glypican-2.
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respectively. For the methodology used for assessing the islet area with positive staining 
and the intensity of staining, see Chapter 2, Section 2.8.4 (a) and (b), respectively.
4.1.3 Localisation of heparan sulfate and HSPG core proteins in C57BL/6 and 
CBA islets in situ and isolated islets
Alcian blue histochemistry that selectively stains HS showed that C57BL/6 (Fig. 4.2A) 
and CBA islets in situ (Fig. 4.2E) in the pancreas express high levels of HS (C57BL/6 
islets in situ, % HS+ve islet area=77.18±3.10%, mean staining intensity=0.13±0.02 
A.U; CBA islets in situ, % HS+ve islet area=74.81±3.16%, mean staining 
intensity=0.15+0.01 A.U) (Fig. 4.3), which is consistent with the recent studies by 
Ziolkowski et al. in NODscid, insulitis-free NOD/Lt and BALB/c islets (Takahashi et 
al., 2009, Ziolkowski et al., 2012). Using immunohistochemistry for selected HSPG 
core proteins, we identified the variable distribution of HSPG core proteins throughout 
islets in situ. Specifically, we observed intense intra-islet staining for type XVIII 
collagen (C57BL/6 islets in situ, mean staining intensity=0.42±0.05 A.U; CBA islets in 
situ, mean staining intensity=0.62±0.07 A.U) in the native islets (Figs. 4.4A, E, 4.5B), 
intermediate levels of intra-islet staining for syndecan-1 (C57BL/6 islets in situ, mean 
staining intensity=0.43±0.02 A.U; CBA islets in situ, mean staining intensity=0.43±0.02 
A.U) (Figs. 4.6A, E, 4.7B) and weak staining for CD44 (C57BL/6 islets in situ, mean 
staining intensity=0.18+0.01 A.U; CBA islets in situ, mean staining intensity=0.27±0.02 
A.U) (Figs. 4.8A, E, 4.9B).
Following the isolation of C57BL/6 and CBA islets, there was a dramatic loss of 
approximately 60% intra-islet HS (Isolated C57BL/6 islets, % HS+ve islet 
area= 14.47+1.53% versus islets in situ= 77.18+3.10%, p<0.001; Isolated CBA islets, % 
HS+ve islet area= 16.69+2.00% versus islets in situ= 74.81+3.16%, p<0.001) (Fig. 4.2C, 
G, 4.3A), similar to the 50% loss reported for isolated BALB/c islets. Correspondingly, 
there was a 7-fold reduction in the staining intensity of Alcian blue in C57BL/6 and 
CBA islets (C57BL/6: isolated islets, mean staining intensity=0.02±0.003 A.U versus 
islets in situ, mean staining intensity=0.13+0.02 A.U; CBA: isolated islets, mean 
staining intensity=0.021+0.003 A.U versus islets in situ, mean staining 
intensity=0.15+0.01 A.U) (Fig. 4.3B). In contrast, staining for type XVIII collagen (Fig. 
4.4C, G) generally increased in C57BL/6 and CBA isolated islets (C57BL/6: isolated 
islets, mean staining intensity=0.73±0.04 A.U versus islets in situ, mean staining 
intensity=0.42±0.05 A.U, p<0.01; CBA: isolated islets, mean staining
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Figure 4.2 Distribution of heparan sulfate (HS) in mouse islets in situ in 
the pancreas and in isolated islets using Alcian blue histochemistry
Islets in situ in (A) C57BL/6 and (E) CBA mouse pancreas showed intense 
Alcian blue staining, indicating high levels of intra-islet HS. In contrast, both 
(C) C57BL/6 and (G) CBA isolated islets showed low levels of Alcian blue 
staining, indicating depletion of intra-islet HS. (A, C, E, G) Alcian blue; (B, D, 
F, H) Haematoxylin and eosin. I, islets; A, acinar tissue. Scale bars=100pM.
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Figure 4.3 Quantitative analysis of HS+ve islet area stained with Alcian 
blue in islets in situ in the pancreas and in isolated islets
High levels of heparan sulfate staining were detected in C57BL/6 (mean % 
HS+ve islet area=77.18±3.10%; mean staining intensity, 0.13±0.02 A.U) and 
CBA (mean % HS+ve islet area=74.81±3.16%; mean staining 
intensity=0.15±0.01 A.U) islets in situ in the pancreas. The levels of intra-islet 
HS staining were significantly reduced after isolation of both C57BL/6 (mean % 
HS+ve islet area=14.47±1.53%; mean staining intensity=0.02±0.003 A.U) and 
CBA (mean % HS+ve islet area=16.69±2.00%; mean staining 
intensity=0.02±0.003 A.U) islets. The data is shown as mean % HS+ve islet 
areaiSEM (A) and mean intensity staining±SEM (B). n=28 islets examined in 
C57BL/6 pancreas; n=61 C57BL/6 isolated islets; n=21 islets examined in CBA 
pancreas; n=51 CBA isolated islets. Islets were analysed from 3 independent 
specimens, n=4-31 islets /sample. Statistical analysis was performed using one-
way ANOVA. A.U, arbitrary units; HS, heparan sulfate.
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Figure 4.4 Immunohistochemical localisation of the core protein for the 
HSPG type XVIII collagen in mouse islets in situ in the pancreas and in 
isolated islets using anti-type XVIII collagen mAh
Strong staining for type XVIII collagen was demonstrated throughout (A) 
C57BL/6 and (E) CBA islets in situ. Isolated islets of both strains (C and G) 
displayed uniform and intense staining. Adjacent sections showed no 
background staining with isograft control Ig. (A, C, E, G) anti-type XVIII 
collagen mAb. (B, D, F, H) isotype control, Mouse IgG2bv: . I, islets; A, acinar 
tissue. Scale bars=100pM.
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Figure 4.5 Quantitative analysis of islet area stained for type XVIII 
collagen in mouse islets in situ in mouse pancreas and in isolated islets
Approximately 62.04±3.97% and 68.01 ±2.96% of the islet area stained 
positively for type XVIII collagen in C57BL/6 and CBA islets in situ, 
respectively (C57BL/6 islets in situ, mean staining intensity=0.42±0.05 A.U; 
CBA islets in situ, mean staining intensity=0.62±0.07 A.U). Following islet 
isolation, the islet area stained positively for type XVIII collagen increased to 
88.17±0.86% and 87.26±0.91% in C57BL/6 and CBA islets, respectively 
(Isolated C57BL/6 islets, mean staining intensity^.73±0.04 A.U; Isolated CBA 
islets, mean staining intensity, 0.79±0.07 A.U). The data is shown as mean % 
islet area stained with type XVIII collagen±SEM (A) and mean staining 
intensity±SEM. (B). n=14 islets examined in C57BL/6 pancreas; n=47 C57BL/6 
isolated islets; n=17 islets examined in CBA pancreas; n=24 CBA isolated 
islets. Islets were analysed from 3 independent specimens, n=3-18 islets 
/sample. Statistical analysis was performed using Kruskal-Wallis Test. A.U, 
arbitrary units; Col 18, type XVIII collagen.
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Figure 4.6 Immunohistochemical localisation of the core protein for the 
HSPG syndecan-1 in mouse islets in situ in the pancreas and in isolated 
islets using anti-syndecan-1 mAh
(A) C57BL/6 and (E) CBA islets in situ were moderately stained throughout for 
the HSPG syndecan-1. After isolation, both (C) C57BL/6 but not (G) CBA 
islets showed stronger immunoreactivity with anti-syndecan-1 mAb. Adjacent 
sections showed essentially no background staining with isotype control Ig. (A, 
C, E, G) anti-syndecan-1 mAb. (B, D, F, H) Rat IgG2aK. 1, islets; A, acinar 
tissue. Scale bars=100pM.
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Figure 4.7 Quantitative analysis of islet area stained for syndecan-1 in 
mouse islets in situ in mouse pancreas and in isolated islets
The mean intra-islet area for syndecan-1 staining in C57BL/6 and CBA islets in 
situ were 72.15±3.37% and 68.45±4.09%, respectively (C57BL/6 islets in situ, 
mean staining intensity=0.43±0.02 A.U; CBA islets in situ, mean staining 
intensity=0.43±0.02 A.U). C57BL/6 isolated islet demonstrated a slight increase 
in the sydecan-1 positive area (mean % islet area=83.90±1.09%) whereas % 
mean islet area stained with syndecan-1 in CBA isolated islets was 
65.66±2.14% (Isolated C57BL/6 islets, mean staining intensity=0.65±0.02 A.U; 
Isolated CBA islets, mean staining intensity=0.44±0.02 A.U). The data shows 
the mean % islet area stained with syndecan-1 ±SEM (A) and mean intensity 
staining of syndecan-1 ±SEM (B). n=16 islets examined in C57BL/6 pancreas; 
n=45 C57BL/6 isolated islets; n=14 islets examined in CBA pancreas; n=38 
CBA isolated islets. Islets were analysed from 3 independent specimens, n=4-22 
islets /sample. Statistical analysis was performed using Kruskal-Wallis Test. 
A.U, arbitrary units; Sdcl, syndecan-1.
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Figure 4.8 Immunohistochemical localisation of the core protein for HSPG 
CD44 in mouse islets in situ in the pancreas and in isolated islets using anti- 
CD44 mAh
(A) C57BL/6 and (E) CBA islets in situ showed modest staining for CD44. 
Following isolation, (C) C57BL/6 islets uniformly exhibited intense staining for 
CD44. (G) CBA isolated islets also showed comparable staining for CD44 to 
CBA islets in situ. Adjacent sections showed essentially no background staining 
with the isotype control Ig. (A, C, E, G) anti-CD44 mAb. (B, D, F, H) isotype 
control, Rat IgG2bx. I, islets; A, acinar tissue. Scale bars=100pM.
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Figure 4.9 Quantitative analysis of islet area stained for CD44 in mouse 
islets in situ in mouse pancreas and in isolated islets
There were mouse strain-specific differences in the distribution of CD44 
between C57BL/6 and CBA islets in situ, as well as after isolation. Whereas 
C57BL/6 islets in situ showed a mean CD44+ve islet area of 17.57±5.29%, 
CBA islets in situ showed a higher mean CD44+ve islet area of 40.46±6.74% 
(C57BL/6 islets in situ, mean staining intensity=0.18±0.01 A.U; CBA islets in 
situ, mean staining intensity=0.27±0.02 A.U). Following isolation of C57BL/6 
islets, the CD44 staining significantly increased to a mean of 78.60±1.14% of 
the islet area. In contrast, the mean % islet area stained for CD44 in isolated 
CBA islets was 29.26±5.16% (Isolated C57BL/6 islets, mean staining 
intensity=0.52±0.03 A.U; Isolated CBA islets, mean staining 
intensity=0.28±0.02 A.U). The data shows the mean % islet area stained with 
CD44±SEM (A) and mean intensity staining of CD44±SEM (B). n=26 islets 
examined in C57BL/6 pancreas; n=42 C57BL/6 isolated islets; n=21 islets 
examined in CBA pancreas; n=22 CBA isolated islets. Islets were analysed from 
3 independent specimens, n=4-16 islets /sample. Statistical analysis was 
performed using Kruskal-Wallis Test. A.U, arbitrary units.
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intensity=0.79±0.07 A.U versus islets in situ, mean staining intensity=0.62±0.07 A.U) 
(Fig. 4.4C, G, 4.5B), indicating that islets retain HSPG core proteins during the isolation 
process. The increase in type XVIII staining intensity in isolated CBA islets when 
compared to the CBA islets in situ was not statistically significant. This may be due to a 
relatively weaker staining of the CBA isolated islets in one particular staining series, 
which did not affect the measurement of islet area with positive staining as a lower 
threshold for positive staining was set.
Interestingly, the intra-islet staining pattern for syndecan-1 (Fig. 4.6C, G) and CD44 
(Fig. 4.8C, G) was mouse strain-specific. Isolated C57BL/6 islets (mean staining 
intensity=0.65±0.02 A.U) (Fig. 4.7B) exhibited stronger staining for syndecan-1 
compared to islets in situ (0.43±0.02 A.U) (p<0.001). However, CBA islets in situ 
(0.43±0.02 A.U) and isolated islets (mean staining intensity=0.44±0.02 A.U) showed 
comparable syndecan-1 staining (Fig. 4.7B). Likewise, unlike islets in situ (0.18±0.01 
A.U), isolated C57BL/6 islets (mean staining intensity=0.52±0.03 A.U) (p<0.001) (Fig. 
4.8C) showed an extraordinary 3-fold increase in the intensity of intra-islet CD44 
staining, an effect which was much less pronounced in CBA isolated islets (mean 
staining intensity=0.28±0.02 A.U versus islets in s/7w=0.27±0.02 A.U) (Fig. 4.9B). 
Collectively, our immunohistochemical data suggested that islets lose intra-islet HS 
content but retain their HSPG core proteins during the isolation process.
4.1.4 Localisation of heparan sulfate and HSPG core proteins in C57BL/6 islet 
isografts
Our histochemical and immunohistochemical analyses revealed a significant loss of 
intra-islet HS during the isolation of C57BL/6 and CBA mouse islets, despite the 
preservation of the HSPG core proteins collagen type XVIII, syndecan-1 and CD44 
(Section 4.1.3). In view of the requirement for intracellular HS to maintain islet beta cell 
viability, we investigated whether, intra-islet HS is replenished following 
transplantation. Engrafted C57BL/6 islet isografts at 3 days post-transplant, like isolated 
islets (mean staining intensity=0.02±0.003 A.U), exhibited faint staining for HS (mean 
staining intensity=0.02±0.01 A.U) (Figs. 4.IOC, 4.1 IB), suggesting that intra-islet HS 
levels remained low after transplantation. Staining for HS became stronger and 
remained fairly intense from day 5 onwards (Day 5 isografts, mean staining 
intensity=0.08±0.01 A.U; Day 7 isografts, mean staining intensity=0.06±0.02 A.U; Day 
10 isografts, mean staining intensity=0.07±0.01 A.U) (Figs. 4.10E, G, I, 4.1 IB),
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Figure 4.10 Histochemical identification of heparan sulfate (HS) in mouse 
islets in situ in host pancreas, isolated islets and islet isografts using Alcian 
blue staining
(A) C57BL/6 islets in situ showed intense intra-islet HS staining. However, (B) 
isolated islets showed a substantial loss of intra-islet HS. At day 3, (C) isografts 
displayed weak HS staining within islets. Intra-islet HS staining was increased 
by day 5 post-isotransplant (E) and became more prominent from day 7 (G). (I) 
Intense intra-islet HS staining was observed by day 10 post-transplant. (A, B, C, 
E, G, I) Alcian blue. (D, F, H, J) Haematoxylin and eosin. I, islets; K, kidney 
parenchyma; B, residual blood clots; *, graft revascularisation. Scale 
bars=100pM.
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Figure 4.11 Quantitative analysis of islet area stained with Alcian blue in islets 
in situ in the host pancreas, isolated islets and in islet isografts
High levels of intra-islet HS was expressed by C57BL/6 islets in situ (mean % 
HS+ve islet area: 77.18±3.10%; mean staining intensity=0.13±0.02 A.U). However, 
loss of HS staining was observed in isolated islets (mean % HS+ve islet 
area=14.47±1.53%; mean staining intensity=0.02±0.003 A.U). After
isotransplantation, low levels of HS staining were seen in day 3 isografts (mean % 
HS+ve islet area=15.20±4.48%; mean staining intensity=0.02±0.01 A.U), and 
resembled the HS content of isolated islets. Thereafter, an increased expression of 
intra-islet HS was exhibited by isografts at days 5, 7 and 10 post-transplant (Day 5 
isografts, mean % HS+ve islet area=47.04±4.30%; mean staining 
intensity=0.08±0.01 A.U; Day 7 isografts, mean % HS+ve islet area=40.00±4.34%; 
mean staining intensity=0.06±0.01 A.U; Day 10 isografts, mean % HS+ve islet 
area=40.47±5.99%; mean staining intensity=0.06±0.01 A.U). Nevertheless, the HS 
content of engrafted islet at 10 days post-transplant was approximately 2-fold less 
than that of islets in situ in the donor pancreas tissue. The data shows the mean % 
islet area stained with Alcian blueiSEM (A) and mean intensity of Alcian blue 
stainingiSEM (B). The total number of islets examined/group, were: n=28 
C57BL/6 islets in situ; n=61 isolated C57BL/6 islets; n= 6 islets at day 3 post-
transplant; n= 25 islets at day 5 post-transplant; n= 9 islets at day 7 post-transplant; 
n= 22 islets at day 10 post-transplant. Data were analysed from 3 independent 
specimens, n=l-31 islet(s) /sample. Statistical analysis was performed using 
Kruskal-Wallis Test. *p<0.05; **p<0.01; ***p<0.001. A.U, arbitrary units; V, 
versus; HS, heparan sulfate.
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(A) (B)
*  *  *
C57BL/6 Isolated d3 d5 d7 dlO
Islets C57BL/6 ------------------------------------------------
in situ islets Isografts
C57BL/6 Isolated d3 d5 d7 dlO
Islets C57BL/6 ------------------------------------------------
in situ islets Isografts
Samples P value (area) P value 
(mean 
intensity)
C57BL/6 islets in situ  V  isolated islets <0.001 <0.001
C57BL/6 islets in situ  V  day 3 islet isografts <0.001 <0.001
C57BL/6 islets in situ  V  day 5 islet isografts <0.05 n.s
C57BL/6 islets in situ  V day 7 islet isografts <0.01 n.s
C57BL/6 islets in situ  V  day 10 islet isografts <0.01 n.s
Isolated C57BL/6 islets V  day 3 islet isografts n.s n.s
Isolated C57BL/6 islets V  day 5 islet isografts <0.001 <0.001
Isolated C 57BL/6 islets V  day 7 islet isografts <0.001 <0.001
Isolated C57BL/6 islets V  day 10 islet isografts <0.01 <0.001
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although the HS content was approximately 2-fold less than that of islets in situ 
(C57BL/6 islets in situ, mean staining intensity=0.13+0.02 A.U) (Fig. 4.10A). Alcian 
blue histochemistry for C57BL/6 islets isografts suggested that intra-islet HS recovers 
substantially after transplantation. We attribute this reconstitution to de novo synthesis 
in islet beta cells, as previously reported during islet development (Takahashi et al., 
2009).
There was a 2-fold decrease in levels of intra-islet type XVIII collagen (Fig. 4.12C) and 
syndecan-1 (Fig. 4.14C) staining in day 3 C57BL/6 isografts (type XVIII collagen, 
mean staining intensity=0.41±0.15 A.U; syndecan-1, mean staining intensity, 0.31+0.05 
A.U), relative to isolated islets (type XVIII collagen, mean staining intensity=0.73±0.04 
A.U; syndecan-1, mean staining intensity=0.65±0.02 A.U) (Figs. 4.13B, 4.15B). This 
may be due to the loss of core proteins results from poor vascularisation and hypoxic 
conditions early after transplantation. Nonetheless, intra-islet staining for type XVIII 
collagen (Fig. 4.13E) and syndecan-1 (Fig. 4.15E) was later improved in islet isografts 
by 5 days post-transplant (type XVIII collagen, mean staining intensity=0.87+0.08 A.U; 
syndecan-1, mean staining intensity=0.50±0.02 A.U) and remained strong thereafter 
(type XVIII collagen, mean staining intensity, day 7 isografts=0.83±0.06 A.U; day 10 
isografts=0.44±0.08 A.U; syndecan-1, mean staining intensity, day 7 
isografts=0.47±0.02 A.U; day 10 isografts=0.63±0.03 A.U) (Figs. 4.12G, I, 4.13B, 
4.14G, I, 4.15B). It is notably that the low intensity of type XVIII staining in day 10 
isografts (mean staining intensity=0.44±0.08 A.U) was unusual. It is most likely caused 
by the weak staining in one particular staining series but this issue did not impact on the 
measurement of type XVIII collagen+ve islet area. In general, the measurement of 
intensity of type XVIII collagen staining in the isografts did not show statistical 
significance (due probably to the weak staining in one particular staining series), but the 
trend for the expression reflected the measurement of type XVIII collagen+ve islet area 
(Fig. 4.13).
Strong staining for CD44 was observed in C57BL/6 islet isografts at day 3 (mean 
staining intensity=0.31+0.04 A.U), day 5 (mean staining intensity=0.36±0.02 A.U), day 
7 (mean staining intensity=0.3 2+0.01 A.U), and day 10 (mean staining 
intensity=0.40±0.02 A.U) post-transplant (Figs. 4.16C, E, G, I, 4.17B). The levels of 
intra-islet CD44 staining in isografts were approximately 2-fold higher than that of 
islets in situ (mean staining intensity=0.18+0.01 A.U) (Figs. 4.16A, 4.17B). Taken
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Figure 4.12 Localisation of type XVIII collagen in mouse islets in situ in 
host pancreas, isolated islets and islet isografts by immunohistochemistry 
using anti-type XVIII collagen mAb
(A) C57BL/6 native islets showed strong uniform staining for type XVIII 
collagen within islets. (B) Isolated islets stained heavily with type XVIII 
collagen. (C) A slight reduction in type XVIII collagen staining was seen in day 
3 isografts compared to (B) isolated islets. Thereafter, uniform and intense 
staining for type XVIII collagen was seen in isografts at days 5, 7 and 10 post-
transplant (E, G, I) . No background staining was observed when adjacent 
sections were stained with isotype control Ig. (A, B, C, E, G, I) anti-type XVIII 
collagen mAb. (D, F, H, J) isotype control, Mouse IgG2bic. I, islets; K, kidney 
parenchyma; B, residual blood clots. Scale bars=100pM.
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Figure 4.13 Quantitative analysis of islet area stained with type XVIII 
collagen in islets in situ in the host pancreas, isolated islets and in islet 
isografts
The levels of type XVIII collagen staining increased in C57BL/6 isolated islets 
(mean % type XVIII collagen+ve islet area=88.17±0.86%; mean staining 
intensity=0.73±0.04 A.U) compared to islets in situ (mean % type XVIII 
collagen+ve islet area=62.04±3.97%; mean staining intensity, 0.42±0.05 A.U) . 
Compared to isolated islets, the intra-islet levels of type XVIII collagen was 
reduced in islet isografts at 3 days post-transplant (mean % type XVIII 
collagen+ve islet area=38.37± 12.06%; mean staining intensity=0.41±0.15 A.U). 
Thereafter, a rise in intra-islet type XVIII collagen was observed in isografts at 
days 5, 7 and 10 post-transplant (Day 5 isografts, mean % type XVIII 
collagen+ve islet area=87.61±1.23%; mean staining intensity=0.87±0.08 A.U; 
Day 7 isografts, mean % type XVIII collagen+ve islet area=80.99±1.41%; mean 
staining intensity=0.83±0.06 A.U; Day 10 isografts, mean % type XVIII 
collagen+ve islet area=74.08±2.04% ; mean staining intensity=0.44±0.08 A.U). 
The data shows the mean % islet area stained with type XVIII collagen±SEM 
(A) and mean intensity of type XVIII collageniSEM (B). The total number of 
islets examined/group, were as follows: n=14 C57BL/6 islets in situ; n=47 
isolated C57BL/6 islets; n= 10 islets at day 3 post-transplant; n= 25 islets at day 
5 post-transplant; n= 33 islets at day 7 post-transplant; n= 24 islets at day 10 
post-transplant. Data were analysed from 3 independent specimens, n=l-12 
islet(s) /sample. Statistical analysis was performed using Kruskal-Wallis Test. 
**p<0.01; ***p<0.001. A.U, arbitrary units; V, versus; Coll8, type XVIII 
collagen.
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Islets C57BL/6 ------------------------------------------------
in situ islets Isografts
S a m p le s P v a lu e  (a rea ) P v a lu e  
(m ean  
in te n s ity )
C 5 7 B L /6  is le ts  in  s itu  V  iso la ted  is le ts <0.001 <0.01
C 5 7 B L /6  is le ts  in  s itu  V  d a y  3 is le t iso g ra fts n .s n.s
C 5 7 B L /6  is le ts  in  s itu  V  d ay  5 is le t iso g ra fts <0.001 <0.01
C 5 7 B L /6  is le ts  in s itu  V  d a y  7 is le t iso g ra fts < 0 .05 <0.01
C 5 7 B L /6  is le ts  in  s itu  V  d a y  10 is le t iso g ra fts n .s n .s
Iso la ted  C 5 7 B L /6  is le ts  V  d ay  3 is le t iso g ra fts <0.001 n.s
Iso la ted  C 5 7 B L /6  is le ts  V  d a y  5 is le t iso g ra fts n .s n.s
Iso la ted  C 5 7 B L /6  is le ts  V  d ay  7 is le t iso g ra fts <0.01 n.s
Iso la ted  C 5 7 B L /6  is le ts  V  d ay  10 is le t iso g ra fts <0.001 n.s
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Figure 4.14 Localisation of sydecan-1 in mouse islets in situ in host 
pancreas, isolated islets and islet isografts by immunohistochemistry using 
anti-syndecan-1 mAb
(A) C57BL/6 native islets displayed modest staining for syndecan-1. (B) 
Following isolation, syndecan-1 was strongly stained in islets. (C)
Engrafted C57BL/6 islets at day 3 post-transplant showed reduced syndecan-1 
staining compared to isolated islets. (E, G, I) Islet isografts at days 5, 7 and 10 
remained moderately stained with anti-sydecan-1 mAb. No background staining 
was detected when adjacent sections were stained with isotype control Ig. (A, B, 
C, E, G, I) anti-syndecan-1 mAb. (D, F, H, J) isotype control, Rat IgG2aK. I, 
islets; K, kidney parenchyma; B, residual blood clots. Scale bars=100pM.
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Figure 4.15 Quantitative analysis of islet area stained with syndecan-1 in islets in 
situ in the host pancreas, isolated islets and in islet isografts
C57BL/6 isolated islets (mean % syndencan-l+ve islet area=83.90±1.09%; mean 
staining intensity=0.65±0.02 A.U) showed increased syndecan-1 expression relative 
to native islets in the pancreas (mean % syndecan-l+ve islet area=72.15±3.37%; 
mean staining intensity=0.43±0.02 A.U). There was a decrease in sydecan-1 staining 
at 3 days post-isotransplantation (mean syndecan-l+ve islet area=38.12±8.01%; 
mean staining intensity=0.31±0.05 A.U). The levels of syndecan-1 increased 
thereafter as shown by isografts at days 5, 7, and 10 post-transplant (Day 5 isografts, 
mean syndecan-l+ve islet area=73.06±2.78%; mean staining intensity=0.50±0.02 
A.U; Day 7 isografts, mean % syndecan-l+ve islet area=65.84±2.91%; mean staining 
intensity=0.47±0.02 A.U; Day 10 isografts, mean % syndecan-l+ve islet 
area=81.63±2.08%; mean staining intensity=0.63±0.03 A.U). The data shows the 
mean % islet area stained with syndecan-1 ±SEM (A) and mean intensity of 
syndecan-1 ±SEM (B). The total number of islets examined/group, were as follows: 
n=16 C57BL/6 islets in situ; n=45 isolated C57BL/6 islets; n= 7 islets at day 3 post-
transplant; n= 24 islets at day 5 post-transplant; n= 31 islets at day 7 post-transplant; 
n= 21 islets at day 10 post-transplant. Data were analysed from 3 independent 
specimens, n=l-22 islet(s) /sample. Statistical analysis was performed using 
Kruskal-Wallis Test. **p<0.01; ***p<0.001. A.U, arbitrary units; V, versus; Sdcl, 
syndecan-1.
C57BL/6 Isolated d3 d5 d7 dlO C57BL/6 Isolated d3 d5 d7 dlO
Islets C57BL/6 ----------------------------------------------------- Islets C57BL/6 -------------------------------------------------
in situ islets Isografts jn 5ltu islets Iscgrafts
Sam ples P value (area) P value  
(m ean  
intensity)
C 5 7 B L /6  is le ts  in s itu  V  iso la te d  is le ts < 0 .05 <0.001
C 5 7 B L /6  is le ts  in  s itu  V  d a y  3 is le t iso g ra fts n .s n.s
C 5 7 B L /6  is le ts  in s itu  V  d ay  5 is le t iso g ra fts n .s n.s
C 5 7 B L /6  is le ts  in  s itu  V  d a y  7 is le t iso g ra fts n .s n.s
C 5 7 B L /6  is le ts  in  s itu  V  d ay  10 is le t iso g ra fts n .s <0.001
Iso la ted  C 5 7 B L /6  is le ts  V  d ay  3 is le t iso g ra fts <0.001 <0.001
Iso la ted  C 5 7 B L /6  is le ts  V  d ay  5 is le t iso g ra fts <0.01 <0.01
Iso la ted  C 5 7 B L /6  is le ts  V  d a y  7 is le t iso g ra fts <0.001 <0.001
Iso la ted  C 5 7 B L /6  is le ts  V  d a y  10 is le t iso g ra fts n .s n.s
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Figure 4.16 Localisation of CD44 in mouse islets in situ in host pancreas, 
isolated islets and islet isografts by immunohistochemistry using anti-CD44 
mAb
(A) Weak staining for CD44 was localised within C57BL/6 islets in situ. (B) In 
contrast, isolated islets showed intense CD44 staining. (C, E, G, I) After 
isotransplantation, CD44 staining in isografts at days 3, 5, 7 and 10 remained 
stronger than that of islets in situ. No background staining was observed when 
adjacent sections were stained with isotype control Ig. (A, B, C, E, G, I) anti- 
CD44 mAb. (D, F, H, J) isotype control, Rat IgG2bK. I, islets; K, kidney 
parenchyma; B, residual blood clots. Scale bars=100pM.
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Figure 4.17 Quantitative analysis of islet area stained with CD44 in islets in 
situ in the host pancreas, isolated islets and in islet isografts
There was significant increase in CD44 staining after isolation (mean % 
CD44+ve islet area=78.60±1.14%; mean staining intensity=0.52±0.03 A.U) as 
compared to islets in situ (mean % CD44+ve islet area=17.57±5.29%; mean 
staining intensity=0.18±0.01 A.U). Levels of CD44 staining remained 
consistently high following isotransplantation as demonstrated by isografts at 
days 3, 5, 7 and 10 post-transplant (Day 3 isografts, mean CD44+ve islet 
area=59.78±6.00%; mean staining intensity=0.31±0.04 A.U; Day 5 isografts, 
mean CD44+ve islet area=69.27±2.59%; mean staining intensity=0.36±0.02 
A.U; Day 7 isografts, mean % CD44+ve islet area=60.64±2.64%; mean staining 
intensity=0.32±0.01 A.U; Day 10 isografts, mean % CD44+ve islet 
area=75.97±2.08% ; mean staining intensity=0.40±0.02 A.U). The data shows 
the mean % islet area stained with CD44±SEM (A) and mean intensity of 
CD44±SEM (B). The total number of islets examined/group, were as follows: 
n=26 C57BL/6 islets in situ; n=42 isolated C57BL/6 islets; n= 7 islets at day 3 
post-transplant; n= 21 islets at day 5 post-transplant; n= 25 islets at day 7 post-
transplant; n= 19 islets at day 10 post-transplant. Data were analysed from 3 
independent specimens, n=l-16 islet(s) /sample. Statistical analysis was 
performed using Kruskal-Wallis Test. *p<0.05; **p<0.01; ***p<0.001. A.U, 
arbitrary units; V, versus.
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together, the staining intensity for the HSPG core proteins for type XVIII collagen, 
syndecan-1 and CD44 was generally more intense in the C57BL/6 islet isografts when 
compared to islets in situ. It is possible that the lower HS content in the isografts 
relative to islets in situ, has led to increased accessibility of the epitopes for the anti- 
HSPG core proteins antibodies and resulted in stronger staining for the HSPG core 
proteins in the isografts.
4.1.5 Localisation of heparan sulfate and core proteins in CBA islet allografts in 
C57BL/6 recipients
Our study of C57BL/6 islet isografts has demonstrated the restoration of intra-islet HS 
after transplantation (Section 4.1.4). The time frame for the recovery correlated with the 
remodelling of islet BM in the isografts, which takes approximately 10 days to complete 
(Chapter 3, Section 3.1.4). Signs of islet BM and HS recovery were noted as early as 3 
days post-transplant. Thereafter, progressive deposition of BM matrix proteins at the 
islet periphery and around intra-islet capillaries to form the subendothelial BM, 
accompanied by improved intra-islet HS content was evident in isografts at 5-7 days 
post-transplant. Recovery of islet BM and the intra-islet HS were illustrated in day 10 
isografts, with full assembly of the islet BM and subendothelial BM of intra-islet 
capillaries, as well as intense intra-islet HS staining. Likewise, the islet BM in CBA 
islet allografts in C57BL/6 recipient mice showed early signs of recovery. However, 
thereafter the BM remodelling was impeded during the onset of the rejection response. 
Instead, BM matrix proteins were diverted to form enlarged blood vessels at the islet 
periphery at days 5-7 post-transplant. The islet allografts were consistently devoid of the 
intra-islet subendothelial BM and display high levels of BM matrix proteins in the graft 
stroma. In view of the different remodelling of islet BMs between the islet isografts and 
allografts, we investigated the status of HS and HSPG core proteins following 
allotransplantation, where the islet tissue is subjected to immune rejection.
Allografts at 3 days post-transplant (Figs 4.18C) displayed low levels of HS staining (% 
HS+ve islet area=9.72±1.82%; mean staining intensity=0.01+0.01 A.U) (Fig. 4.19) 
similar to corresponding C57BL/6 isografts (% HS+ve islet area= 15.20+4.48%; mean 
staining intensity=0.02±0.01 A.U) (Fig. 4.10C). A transient 4-fold increase in 
percentage of islet area with Alcian blue staining or 6-fold increase in staining intensity 
for HS was seen in islet allografts at 5 days post-transplant (% HS+ve islet area=37.38 
±3.81%, p<0.05; mean staining intensity=0.05±0.01 A.U, p<0.05) (Figs. 4.18E, 4.19),
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Figure 4.18 Identification of heparan sulfate (HS) in mouse islets in situ in 
the pancreas, isolated islets and in islet allografts using Alcian blue 
histochemistry
(A) HS staining was distributed throughout CBA native islets. (B) Substantial 
loss of HS staining was detected in isolated islets. (C) CBA (H-2k) islet 
allografts in C57BL/6 (H-2b) mice at day 3 showed little intra-islet HS staining. 
(E) Intra-islet HS staining became more intense by day 5 post-transplant. By day 
7, HS staining in islet allografts was localised to the central core of the islets (G) 
and was not observed around the periphery of the islets where there was local 
damage due to infiltrating mononuclear cells (H). (I) By day 10 post-transplant, 
islet allografts showed negligible HS staining associated with islet remnants and 
the majority of the staining was detected in the graft stroma. (A, B, C, E, G, I) 
Alcian blue. (D, F, H, J) Haematoxylin and eosin. I, islets; DI, damaged islets; 
IR, islet remnants; MNCs, mononuclear cells;
K, kidney parenchyma. Scale bars=100pM.
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Figure 4.19 Quantitative analysis of islet area stained for Alcian blue in 
islets in situ in the host pancreas, isolated islets and in islet allografts
CBA islets in situ like C57BL/6 pancreatic islets in situ, demonstrated a high 
HS content, with approximately 74.81 ±3.16% of islet area stained strongly with 
Alcian blue (mean staining intensity=0.15±0.01 A.U). A dramatic
(approximately 60%) loss of intra-islet HS was observed following the isolation 
(mean staining intensity=0.02±0.003 A.U). At 3 days post-transplant, engrafted 
allogeneic islets continued to show a decline in HS content, with only 
9.72± 1.82% HS+ve islet tissue present at the graft site (mean staining 
intensity=0.001 ±0.001 A.U). By 5 days post-transplant, there was a significant 
2-fold increase to 37.39±3.81% HS+ve islet tissue (mean staining 
intensity=0.05±0.01 A.U), compared to isolated CBA islets. The mean % 
HS+ve islet tissue in islet allografts at day 7 was 22.59±3.89% (mean staining 
intensity=0.03±0.01 A.U), resembling the HS content of isolated islets. Little, if 
any, HS+ve staining of residual islet tissue was observe by 10 days (mean % 
HS+ve islet area=4.50±l .47%; mean staining intensity, 0.03±0.01 A.U). The 
data shows the mean % islet area stained with Alcian bluetSEM (A,B) and 
mean intensity of Alcian blue staining±SEM (C,D). The total number of islets 
examined/group, were as follows: n=21 CBA islets in situ\ n=51 isolated CBA 
islets; n= 8 islets at day 3 post-transplant; n= 13 islets at day 5 post-transplant; 
n= 20 islets at day 7 post-transplant; n= 5 islets at day 10 post-transplant. Data 
were analysed from 3 independent specimens, n=l-22 islet(s) /sample. 
Statistical analysis was performed using Kruskal-Wallis Test. *p<0.05. A.U, 
arbitrary units; V, versus; HS, heparan sulfate.
181
M
ea
n 
in
te
n
si
ty
 o
f 
H
S
st
ai
ni
ng
 i
n 
is
le
ts
 (
A
.U
) 
H
S
+
v
e
 i
s
le
t 
a
re
a
 (
%
(A) (B)
10CH
C57BL/6 Isolated d3 d5 d7 dlO
Islets C57BL/6 ----------------------------------------------
in situ islets Isografts
Islets CBA -----------------------------
in situ islets Allografts
(C) (D)
0.2CH
C57BL/6 Isolated d3 d5 d7 dlO
Islets C57BL/6 -----------------------------------------
in situ islets Isografts
CBA Isolated d3 d5 d7 dlO
Islets CBA -----------------------------------------
in situ islets Allografts
S am p le s P v a lu e  
(a rea )
P v a lu e  
(m e a n  
in te n s ity )
CBA islets in situ V isolated islets <0.001 <0.001
CBA islets in situ V day 3 islet allografts <0.001 <0.001
CBA islets in situ V day 5 islet allografts n.s n.s
CBA islets in situ V day 7 islet allografts <0.001 <0.001
CBA islets in situ V day 10 islet allografts <0.001 <0.05
Isolated CBA islets V day 3 islet allografts n.s n.s
Isolated CBA islets V day 5 islet allografts <0.05 <0.05
Isolated CBA islets V day 7 islet allografts n.s n.s
Isolated CBA islets V day 10 islet allografts n.s n.s
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relative to day 3 allografts (Fig. 4.19). In contrast to islet isografts, HS+ve islets 
significantly declined in day 7 islet allografts (% HS+ve islet area=22.59±3.89%, mean 
staining intensity=0.03±0.01 A.U) (Figs. 4.18G, 4.19) and HS-depleted islet tissue was 
observed, particularly at the islet periphery, in close proximity to peri-islet mononuclear 
cells (MNCs). By day 10, HS staining was seen associated with the remnant islet tissue 
(% HS+ve islet area=4.50±1.47%, mean staining intensity=0.03±0.01 A.U), and most of 
the Alcian blue staining was localised in the graft stroma (Fig. 4.181, 4.19). 
Collectively, this histochemical study in allografts revealed that islet HS undergoes a 
transient recovery early post-transplant before the onset of immune rejection. However, 
intra-islet HS was lost as rejection progressed, culminating in complete destruction of 
the islet tissue by 10 days post-transplant.
In contrast, staining for type XVIII collagen remained intense after islet 
allotransplantation (mean staining intensity, day 3 allografts=0.41+0.08 A.U; day 5 
allografts=0.46±0.06 A.U; day 7 allografts=0.50±0.05 A.U; day 10 allografts, 
0.31+0.12 A.U) (Figs. 4.20C, E, G, I, 4.21), indicating that type XVIII collagen 
expression within islet tissue was not affected by the rejection process. Nevertheless, 
the islet content of the grafts significantly decreased due to allograft rejection (Chapter 
3, Fig. 3.2). In contrast to the isografts, which exhibited increased syndecan-1 staining 
over time, the intensity of staining for syndecan-1 in the allografts at day 3 (mean 
staining intensity=0.37±0.03 A.U), day 5 (mean staining intensity=0.29±0.02 A.U), day 
7 (mean staining intensity=0.31+0.02 A.U) and day 10 (mean staining 
intensity=0.29±0.01 A.U) was lower than that of islets in situ (mean staining intensity, 
0.43+0.02 A.U) (Figs. 4.22C, E, G, I, 4.23). This lower level of expression could be 
attributed to transfer of syndecan-1 to the surface of the beta cells or to a failure to 
maintain adequate synthesis in the presence of immune rejection. After 
allotransplantation, CD44 expression became apparent on the surface of islet cells and 
the levels of intra-islet CD44 staining were consistently low (mean staining intensity, 
day 3 allografts=0.25±0.03 A.U; day 5 allografts=0.21+0.01 A.U; day 7 
allografts=0.22±0.01 A.U; day 10 allografts=0.26±0.04 A.U versus CBA islets in 
57/w=0.27±0.02 A.U and isolated CBA islets=0.28±0.02 A.U) (Figs. 4.24C, E, G, I, 
4.25). At 5-10 days post-transplant, CD44 staining was strongly expressed on 
infiltrating MNCs during islet allograft rejection (Fig. 4.24E, G, I). However, it is 
unclear whether this CD44 expression on the MNCs reflects CD44 acting as a HSPG.
1 «^
Figure 4.20 Localisation of type XVIII collagen in mouse islets in situ in 
host pancreas, isolated islets and islet allografts by immunohistochemistry 
using anti-type XVIII collagen mAb
(A) Strong staining for type XVIII collagen was observed throughout CBA 
native islets. (B) Isolated CBA islets were stained intensely for type XVIII 
collagen. (C, E, G, I) Strong intra-islet staining for type XVIII collagen was 
detected within islet allografts at days 3, 5, 7 and 10 post-transplant, irrespective 
of the integrity of the islet tissue. No background staining was observed when 
adjacent sections were stained with isotype control Ig. (A, B, C, E, G, I) anti-
type XVIII collagen. (D, F, H, J) isotype control, Mouse IgG2bK. I, islets; DI, 
damaged islets; IR, islet remnants; MNCs, mononuclear cells; K, kidney 
parenchyma; B, residual blood clots. Scale bars=100pM.
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Figure 4.21 Quantitative analysis of islet area stained for type XVIII 
collagen in islets in situ in the host pancreas, isolated islets and in islet 
allografts
There was a significant increase in type XVIII collagen expression following the 
isolation (CBA islets in situ, mean % type XVIII collagen+ve islet 
area=68.01±2.96%; mean staining intensity=0.62±0.07 A.U; Isolated CBA 
islets, mean % type XVIII collagen+ve islet area=87.27±0.91%; mean staining 
intensity=0.79±0.07 A.U). Type XVIII collagen staining decreased after 
allotransplantation as compared to isolated islets. However, the levels of type 
XVIII collagen staining remained consistently high at days 3, 5, 7 and 10 post-
transplant (Day 3 allografts, mean % type XVIII collagen+ve islet 
area=59.56±6.36%; mean staining intensity=0.41±0.08 A.U; Day 5 allografts, 
mean % type XVIII collagen+ve islet area=68.46±3.00%; mean staining 
intensity=0.46±0.06 A.U; Day 7 allografts, mean % type XVIII collagen+ve 
islet area=69.00±3.00%; mean staining intensity=0.50±0.05 A.U; Day 10 
allografts, mean % type XVIII collagen+ve islet area=53.75± 12.45% ; mean 
staining intensity=0.31±0.12 A.U). The data shows the mean % islet area 
stained with type XVIII collageniSEM (A,B) and mean intensity of type XVIII 
collageniSEM (C,D). The total number of islets examined/group, were as 
follows: n=17 CBA islets in situ; n=24 isolated CBA islets; n= 14 islets at day 3 
post-transplant; n= 16 islets at day 5 post-transplant; n= 14 islets at day 7 post-
transplant; n= 6 islets at day 10 post-transplant. Data were analysed from 3 
independent specimens, n= 1-12 islet(s) /sample. Statistical analysis was 
performed using Kruskal-Wallis Test. A.U, arbitrary units; V, versus; Col 18, 
type XVIII collagen.
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Figure 4.22 Localisation of syndecan-1 in mouse islets in situ in host 
pancreas, isolated islets and islet allografts by immunohistochemistry using 
anti-syndecan-1 mAb
CBA islets in situ (A) and isolated islets (B) stained positively for syndecan-1. 
At day 3 (C), day 5 (E) and day 7 (G) post-transplant, CBA allogeneic islet 
tissue stained weakly for syndecan-1. By day 10, islet allografts showed only 
scattered syndecan-1+ve cells amongst the mononuclear cell infiltrate at the 
graft site. No background staining was observed when adjacent sections were 
stained with isotype control Ig. (A, B, C, E, G, I) anti-syndecan-1 mAb. (D, F, 
H, J) isotype control, Rat IgG2aic. . I, islets; DI, damaged islets; IR, islet 
remnants; MNCs, mononuclear cells; K, kidney parenchyma; B, residual blood 
clots. Scale bars=100pM.
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Figure 4.23 Quantitative analysis of islet area stained for syndecan-1 in 
islets in situ in the host pancreas, isolated islets and in islet allografts
The levels of sydecan-1 expression remained largely unaltered following 
isolation and early after transplant at day 3 (Day 3 allografts, mean % syndecan- 
1+ve islet area=51.67±8.57%; mean staining intensity, 0.37±0.03 A.U). 
Syndecan-1+ve islet tissue was reduced from 5 days post-transplant. (Day 5 
allografts, mean % syndecan-1+ve islet area=24.87±5.41%; mean staining 
intensity, 0.29±0.02 A.U; Day 7 allografts, mean % syndecan-1+ve islet 
area=33.14±6.74%; mean staining intensity=0.31±0.02 A.U; Day 10 allografts, 
mean % syndecan-1+ve islet area=33.69±8.93% ; mean staining
intensity=0.29±0.01 A.U). The data shows the mean % islet area stained with 
syndecan-1 ±SEM (A,B) and mean intensity of syndecan-1 ±SEM (C,D). The 
total number of islets examined/group, were as follows: n=14 CBA islets in situ; 
n=38 isolated CBA islets; n= 9 islets at day 3 post-transplant; n= 15 islets at day 
5 post-transplant; n= 16 islets at day 7 post-transplant; n= 5 islets at day 10 post-
transplant. Data were analysed from 3 independent specimens, n=l-20 islet(s) 
/sample. Statistical analysis was performed using Kruskal-Wallis Test. *p<0.05; 
***p<0.001. A.U, arbitrary units; V, versus; Sdcl. syndecan-1.
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Figure 4.24 Localisation of CD44 in mouse islets in situ in host pancreas, 
isolated islets and islet allografts by immunohistochemistry using anti- 
CD44 mAb
CBA native islets (A) showed weak intracellular CD44 staining whereas 
scattered patches of intracellular CD44 staining was observed in CBA isolated 
islets (B). At day 3 post-transplant, CD44 appeared to be expressed on the 
surface of islet cells and no or little intracellular staining was observed (C). (E, 
G, I) At 5-10 days post-transplant, little CD44 staining was expressed on the 
remaining islet tissue but infiltrating MNCs were CD44+ve. No background 
staining was observed when adjacent sections were stained with isotype control 
Ig. (A, B, C, E, G, I) anti-CD44 mAb. (D, F, H, J) isotype control, Rat IgG2bic. 
I, islets; DI, damaged islets; IR, islet remnants; MNCs, mononuclear cells; K, 
kidney parenchyma; B, residual blood clots. Scale bars=100pM.
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Figure 4.25 Quantitative analysis of islet area stained for CD44 in islets in 
situ in the host pancreas, isolated islets and in islet allografts
The mean % CD44+ve islet area in isolated CBA islets (mean % CD44+ve islet 
area=29.26±5.16%; mean staining intensity=0.28±0.02 A.U) showed a 11% 
decline compared to CBA islets in situ (mean % CD44+ve islet 
area=40.46±6.74%; mean staining intensity=0.27±0.02 A.U), but this difference 
was not statistically significant. The CD44+ve islet area increased 2-fold at 3 
days post-transplant (Day 3 allografts, mean % CD44+ve islet
area=40.71±5.51%; mean staining intensity=0.25±0.03 A.U) compared to the 
isolated islets, this was attributed to widespread cell-surface staining of islet 
cells. While the levels of CD44 expression remained consistent during allograft 
rejection (Day 5 allografts, mean % CD44+ve islet area=24.32±4.70%; mean 
staining intensity=0.21±0.01 A.U; Day 7 allografts, mean % CD44+ve islet 
area=25.61±4.78%; mean staining intensity=0.22±0.01 A.U; Day 10 allografts, 
mean % CD44+ve islet area=29.65±7.24% ; mean staining intensity=0.26±0.04 
A.U)., the % of islet tissue at the graft site significantly declined to <10% 
(Chapter 3, Fig. 3.2). The data shows the mean % islet area stained with 
CD44±SEM (A,B) and mean intensity of CD44±SEM (C,D). The total number 
of islets examined/group, were as follows: n=14 CBA islets in situ; n=15 
isolated CBA islets; n= 8 islets at day 3 post-transplant; n= 12 islets at day 5 
post-transplant; n= 17 islets at day 7 post-transplant; n= 5 islets at day 10 post-
transplant. Data were analysed from 3 independent specimens, n= 1-10 islet(s) 
/sample. Statistical analysis was performed using one-way ANOVA. A.U, 
arbitrary units; V, versus.
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In summary, our study suggested that islet allografts undergo HS recovery early post-
transplant. However, intra-islet HS is lost during immune rejection, despite evidence for 
islet tissue remaining at the graft site. This stands in stark contrast with the HSPG core 
proteins type XVIII collagen and CD44, which showed comparable intra-islet 
expression in the allografts compared to islets in situ. This suggests that islet HS is 
selectively lost while the majority of the HSPG core proteins are preserved until islet 
destruction due to graft rejection. High levels of CD44 expression was localised in the 
infiltrating MNCs, possibly representing T cells, B cells and macrophages. Conversely, 
reduction in intracellular levels of syndecan-1 in the islet allografts suggested possible 
transfer of syndecan-1 to the cell surface of the islet cells or inadequate synthesis of the 
HSPG core protein in the presence of immune rejection. Taken together, our data 
suggested that intra-islet HS represents a target during the rejection of islet allografts.
4.2 Discussion
Our study shows that islets in situ of C57BL/6 and CBA mice displayed extraordinarily 
high levels of heparan sulfate (HS) within islets (Fig. 4.2). This is consistent with 
previous studies showing intense levels of HS expressed within C57BL/6 neonatal and 
adult islets as well as BALB/c and NOD/SC ID adult islets (Takahashi et al., 2009, 
Ziolkowski et ah, 2012).
Roles for HS in islet biology have emerged in recent years. It has recently been 
established that intra-cellular HS is vital for the survival of islet beta cells, most 
probably by acting as an anti-oxidant. It is well documented that free radicals are 
capable of depolymerising glomerular basement membrane (BM) HS in several renal 
disease models including Adriamycin nephropathy in rats, murine lupus nephritis and 
diabetic nephropathy in humans (Raats et ah, 1997, Tamsma et ah, 1994, van Bruggen 
et ah, 1995).
Islet beta cells are highly metabolically active due to their function in controlling blood 
glucose levels by producing insulin. High levels of intracellular reactive oxygen species 
(ROS) are generated in beta cells during insulin biosynthesis and through oxidative 
phosphorylation in mitochondria to meet the high energy demand (Riemer et ah, 2009, 
Yuan et ah, 1999). Hence, it is conceivable that the capture of free radicals by HS 
represents a defence mechanism for preventing oxidative damage in beta cells
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(Ziolkowski et al., 2012). The role for intra-islet HS as a free radical sink may therefore 
compensate for the low levels of free radical scavenging enzymes in islet beta cells 
(Rabinovitch and Suarez-Pinzon, 1998). Interestingly, HS functions as a storage depot 
for extracellular superoxide dismutase (SOD), an important free radical scavenger 
enzyme (Kliment et al., 2008). Whether this storage role for HS also functions 
intracellularly in beta cells is unknown.
Although the Alcian blue histochemistry for islets in situ suggests the abundance of 
intracellular HS levels within islets. It is also likely that HS was expressed at the cell 
surface and in islet BMs. In particular, our immunofluorescence staining for perlecan 
supports to the notion that HS is present in the islet BM (Chapter 3, Section 3.1.3). In 
addition to its barrier function, HS can serve as a storage depot for a wide range of 
bioactive molecules such as growth factors, cytokines, proteases and cell adhesion 
molecules to maintain islet cell integrity and function (Ali et al., 2003, Parish, 2006).
Our study has identified the presence of several heparan sulfate proteoglycans within 
islets. These include the “full time” heparan sulfate proteoglycans (HSPGs), type XVIII 
collagen and syndecan-1 as well as the “part-time” HSPG, CD44 (Fig. 4.1). These 
HSPGs are likely to contribute to the high levels of HS within mouse islets and islet 
beta cell in the pancreas. However, we were not able to detect agrin and glypican-2 in 
islet cells. A previous study by Takahashi et al. reported mRNA expression for 
syndecans 2-4, glypicans-1 and -4, perlecan, agrin and type XVIII collagen in adult 
mouse islet beta cells. There was no transcript expression for syndecan-1 or glypicans- 
2, -3, -5 and -6 in the individual islet cells (Takahashi et al., 2009). Recently, using 
immunofluorescence detection, Cheng et al. showed the expression of syndecan-4 in 
islets in situ. However, syndecan-1, glypican-1, betaglycan, agrin and type XVIII 
collagen were not detected in their study (Cheng et al., 2012). The discrepancies 
between different studies may be due to different antibodies, methods for antigen 
retrieval, reagents and detection techniques used by the independent research groups.
The localisation of HSPGs inside beta cells is unique, as HSPGs are conventionally 
expressed on the cell surface or in BMs and extracellular matrices (ECMs) (Bemfield et 
al., 1999, Sarrazin et al., 2011, Velleman and Caini, 2005). Collectively, the high levels 
of HSPG core proteins within islets account for the extraordinary high levels of 
intracellular HS in islet beta cells, since HS cannot be expressed in the absence of
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HSPG core proteins. By providing the beta cell HS, the HSPG core proteins in beta cells 
indirectly contribute to beta cell survival. Whether the HSPG core proteins in beta cells 
have additional functions is unclear.
Knock-out models of different HSPG core proteins such as type XVIII collagen and 
syndecan-1 have not exhibited abnormalities in the pancreas. This may be due to 
functional redundancy, with other HSPG core proteins substituting for the deleted 
HSPG (Cheng et al., 2012, Sarrazin et al, 2011). Type XVIII collagen is known to have 
anti-angiogenic effects via the generation of endostatin. Type XVIII collagen is also 
involved in lipid metabolism by interacting with liproprotein lipase (lpl) (Bishop et al., 
2010). Lpl is expressed in islets and is involved in insulin secretion (Pappan et al., 
2005). It is therefore possible that type XVIII collagen also regulates intracellular levels 
of lpl within islets.
Syndecan-1 is a cell surface HSPG, which consists of a structurally diverse ectodomain 
to which the HS chains are bound, a single transmembrane domain and a highly 
conserved cytoplasmic domain. Syndecan-1 can modulate cytoskeletal organisation via 
its cytoplasmic domain interacting with F-actin (Zimmermann and David, 1999). It is 
well established that the actin cytoskeleton helps to control glucose homeostasis by 
facilitating exocytotic insulin secretion from beta cells upon glucose stimulation 
(Easom, 2000). A role for syndecan-1 in the cytoskeletal organisation of beta cells for 
insulin release awaits further investigation.
Based on the immunohistochemical studies, weak staining for CD44 was observed in 
islets in situ (Figs. 4.8, 4.9). Notably, we detected mouse strain-specific expression of 
CD44 in islets in situ where CBA islets were stained more intensely than islets of 
C57BL/6 mice in the pancreas. In fact, variation of CD44 transcript expression among 
mouse strains is not uncommon. There are reports in the literature that C57BL/6 
thymocytes express lower levels of CD44 antigens, compared to BALB/c thymocytes 
(Haegel and Ceredig, 1991, Lynch and Ceredig, 1989). However, the intrinsic factors 
that account for the strain variation of CD44 expression and the functional significance 
of this difference remains to be elucidated. Additionally, since the anti-CD44 mAb used 
in this study recognises various CD44 isoforms, i.e., with and without HS moieties, we 
were unable to confirm whether the intra-islet CD44 detected in our studies represents a 
HSPG.
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Alcian blue histochemistry that selectively stains HS demonstrated depletion of HS in 
islets isolated from C57BL/6 and CBA mice (Fig. 4.2). This data is in line with the 
findings by Ziolkowski et al. which showed the loss of intra-islet HS following the 
isolation of BALB/c islets (Ziolkowski et al., 2012). However, our current study further 
demonstrated that unlike intra-islet HS, the HSPG core proteins were preserved 
following islet isolation, as illustrated by the enhanced staining for type XVIII collagen, 
syndecan-1 and CD44, compared to islets in situ (Figs. 4.4-4.9). This may due to the 
increased exposure of the epitopes in isolated islets for antibody recognition, resulting 
from the loss of HS during the isolation process. Since intracellular HS is required for 
beta cell viability, the significant loss of HS may account for the high incidence of islet 
cell death or primary non-function in islet transplants (Chhabra and Brayman, 2011, 
Piemonti et al., 2010). Efforts to replenish HS or to prevent HS loss prior to 
transplantation will be investigated in Chapter 5.
Notably, there was a striking strain-specific increase in CD44 levels within C57BL/6 
islets following isolation (Figs 4.8, 4.9). CD44 expression can be induced by cytokines 
such as IL-1 and TNF-a during tissue remodelling (Pure and Cuff, 2001). It is possible 
that the upregulation of CD44 in the isolated islets may also facilitate HS recovery as 
the presence of core protein is essential for the initiation of the biosynthesis of HS. 
However, the functional significance of this strain-specific CD44 stimulation remains to 
be investigated.
In contrast to isolated islets, the intra-islet HS progressively increased in transplanted 
islet tissue with the duration of engraftment, suggesting that intra-islet HS is synthesised 
de novo following isotransplantation. However, the levels of HS staining achieved by 
10 days were less than that observed in islets in situ (Figs 4.10, 4.11)). It is also possible 
that the sulfation status of intra-islet HS varied between the native islets and islet 
transplants, thereby influencing the intensity of staining with Alcian blue. Altered 
sulfation status has been reported during development, aging, injury and diseases 
(Brickman et al., 1998, Challacombe and Elam, 1995, David et al., 1992, Jayson et al., 
1998, Lindahl et al., 1998, Winterbourne and Mora, 1981). During the transition of 
human colon adenoma cells to malignancy, Jayson et al. noted that although the overall 
molecular organisation of HS is preserved, there is a distinct reduction in iduronic acid 
2-O-sulfate and N-sulfation and an increase in the level of 6-O-sulfation in the
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malignant colon carcinoma cells, compared to the adenoma cells (Jayson et al., 1998). 
In addition, the progression from proliferation of neural precursor cells to neuronal 
differentiation was accompanied by an increase in patterns of 6-O-sulfation, total chain 
length and the number of sulfated domains of the HS moieties. These structural 
modifications of HS conferred a switch in affinity from FGF-2 to FGF-1, a growth 
factor which is critical in cell differentiation (Brickman et ah, 1998). Collectively, these 
studies suggested that HS is able to undergo structural modifications in polymer 
sulfation, chain length and complexity, in response to the environmental cues. In view 
of these studies, it is possible that the regenerated HS in the islet transplants is 
structurally distinct from the islets in situ, due to the different environmental cues 
during tissue remodelling. This notion remains to be explored.
After transplantation, diminished staining for type XVIII collagen and syndecan-1 core 
proteins was detected in day 3 transplants, compared to isolated islets (Figs 4.12-4.15).
It is possible that the synthesis of the HSPGs declined early post-transplant due to the 
poor vascularisation and hypoxic conditions that ensue after isolation and implantation. 
The staining for type XVIII collagen and syndecan-1 improved by 5 days post-
isotransplantation, suggesting de novo synthesis of HSPG core proteins following 
revascularisation. Thereafter, isografts at later time points exhibited intense staining for 
type XV111 collagen and sydecan-1 consistently in the engrafted islet tissue. In addition, 
the intensity of CD44 staining in C57BL/6 isolated islets increased dramatically by 3- 
fold and continued to stain more strongly following isotransplantation than islets in situ 
(Figs 4.8, 4.9, 4.16, 4.17). Increased CD44 levels may be required for tissue 
remodelling in the islet isografts as CD44 has been shown to bind to MMP-7 and -9, 
which participate in matrix turnover (Yu and Stamenkovic, 2000, Yu et al., 2002). 
Since the synthesis of HS requires the presence of HSPG core proteins (Vreys and 
David, 2007), it is likely that the increased expression of the HSPG core proteins 
observed in the islet isografts facilitated the reconstitution of intra-islet HS in the 
engrafted islet tissue. To address this question, islet isotransplantation performed using 
different HSPG core protein knock-out mice could be used to study the role of the 
HSPG core protein in the recovery of HS after islet transplantation.
For islet allografts in normal untreated recipient mice, we observed a 3-fold increase in 
the intra-islet area stained positively for HS by 5 days post-transplant, relative to CBA 
isolated islets (Figs 4.18, 4.19). Thereafter, the HS+ve islet area decreased at 7-10 days,
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suggesting that intra-islet HS is lost during allograft rejection. However, the loss of HS 
precedes the complete destruction of islet tissue during rejection. Intra-islet depletion of 
HS that is critical for the survival for islet beta cells may therefore contribute to the 
failure of islet transplants.
In allografts, the intensity of staining for intra-islet type XVIII collagen remained stable 
in residual islet tissue (Figs 4.20, 4.21), suggesting that the core proteins for type XVIII 
collagen were less vulnerable than HS to damage during islet graft rejection. In contrast, 
decreased staining for syndecan-1 was observed during graft rejection (Figs 4.22, 4.23). 
Unlike corresponding isografts, allografts did not show increased staining in sydencan- 
1+ve islet tissue after 3 days post-transplant but instead demonstrated a continued 
decline in expression. It is possible that the decreased levels of syndecan-1 in the 
rejecting allografts may be due to syndecan-1 shedding at the cell surface, depleting the 
intracellular store of syndecan-1. Syndecan shedding, depicted by the removal of the 
ectodomain of syndecan, is a common phenomenon during inflammatory responses and 
is mediated by MMPs that are upregulated as a result of the rejection response. Notably, 
MMPs such as MT1-MMP, MT3-MMP, MMP-7 and 9 as well as ADAM 17 (TACE), 
the member of the ADAM family of disintegrin and metallopproteinase membrane- 
anchored proteinases have been linked to syndecan-1 shedding (Brule et al., 2006, Chen 
et ah, 2009, Endo et al., 2003, Li et ah, 2002, Pruessmeyer et ah, 2010).The shed 
ectodomain has also been implicated in tumour invasion, presumably by releasing 
molecules that promote cell growth and cell migration. In addition, shedding may act as 
a positive feedback loop to evoke the release and activation of latent MMPs that bind to 
syndecan to amplify the inflammatory response. The upregulation of MMP7 transcripts 
has recently been detected in rejecting islet allografts. Hence, it is possible that MMPs 
have a similar function during allograft rejection (Manon-Jensen et ah, 2010).
Little variation was observed in intra-islet CD44 expression in the CBA islet allografts 
in C57BL/6 recipient mice (Figs 4.24, 4.25). However, the infiltrating MNCs were 
found to carry CD44 on their cell surface (Fig 4.24). It is well known that CD44 acts as 
an adhesion molecule responsible for the migration of leukocytes (Ponta et ah, 2003, 
Pure and Cuff, 2001). T cells, B cells and macrophages, which are the common 
leukocytes in rejecting grafts, can express CD44. However, the adhesive function of 
CD44 requires the expression of the non-sulfated glycosaminoglycan, hyaluronic acid 
(HA). The heterotypic interaction between CD44 and HA molecules of leukocytes and
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endothelial cells has been reported to mediate rolling and firm binding of leukocytes to 
the endothelium during leukocyte extravasation (Goodison et al., 1999, Ponta et al., 
2003, Pure and Cuff, 2001). Nevertheless, the upregulation of CD44 HSPG (with HS 
moieties) by leukocytes during inflammatory responses has been noted. The CD44 
HSPG increases the storage capacity of the proinflammatory HS-bound molecules such 
as growth factors and chemokines. (Jackson, 1997). However, it should be noted that we 
were unable to determine whether the leukocyte-derived CD44 identified in our study, 
expressed HS chains due to the anti-CD44 mAb detecting all the isoforms of CD44.
In summary, our findings demonstrated initiation of the recovery of intra-islet HS in 
islet allgorafts early post-transplant, followed by the loss of islet HS as rejection 
progressed. These findings indicated that islet HS represents a potential target for 
destruction during the allograft rejection response. The selective loss of HS, in contrast 
to the HSPG core proteins, suggests the catalytic activity of the endoglycosidase, 
heparanase that cleaves HS specifically. Indeed, the HSPG core proteins in engrafted 
islets appeared to be more resilient to damage during islet allograft rejection than the HS 
chains. The generation of reactive oxygen species or other reactive chemical species 
may also contribute to the degradation of HS chains of HSPGs. Studies of the possible 
mechanisms that target HS during islet isolation and transplantation will be further 
explored in Chapters 5 and 6.
CHAPTER 5 : Replacement and preservation of islet 
heparan sulfate
5.0 Introduction
While the surgical process of transplanting pancreatic islets (often referred to as 
“cellular” transplantation) is a relatively straightforward procedure, compared to 
immediately vascularised organ transplants, the preparation of islets for implantation is 
complex. The islets are isolated from the pancreas by enzymatic dissociation from the 
surrounding exocrine (acinar) pancreatic tissue (Kin et al., 2007). This procedure 
exposes the islets to harsh physiological insults of osmotic, mechanical and oxidative 
stress (Bottino et al., 2002). As a result of the isolation procedure, the islets are severed 
from their rich vasculature, complex innervation and surrounding trophic support, 
which renders them vulnerable to hypoxia and inflammatory damage (Morini et al., 
2007, Persson-Sjögren et al., 2000). Recently, Ziolkowski et al. identified the loss of 
intra-islet heparan sulfate (HS) in isolated islets as an important factor contributing to 
beta cell death following isolation (Ziolkowski et al., 2012). In view of the critical role 
of HS in maintaining islet beta cell survival, it is likely that primary non-function of 
islet transplants particularly in experimental models (Hsu et al., 2001, Kenmochi et al., 
1996) and the need for extraordinarily high numbers of islets for clinical transplantation, 
are in part, due to the massive loss of HS from islet beta cells during the isolation 
procedure. Indeed, the large number of islets needed to restore normoglycaemia in 
diabetic transplant patients further compounds the difficulty of finding sufficient human 
donor pancreata for clinical islet transplantation (Shapiro et al., 2000).
In recent years, there has been a tremendous improvement in the yield and quality of 
human islets for transplantation. Advances in pancreas procurement and preservation, 
islet isolation techniques and improved immunosuppressive protocols have substantially 
reduced the number of islets (per transplant) required to restore normoglycemia (Hanley 
et al., 2008, Hering et al., 2004, Kin et al., 2007, Merani and Shapiro, 2006, Shapiro, 
2011). Numerous islet preconditioning methods have been assessed by different 
research groups, with the aim of enhancing islet function and viability. Improved islet 
yield and insulin function were observed in islets cultured in collagen-embedded
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matrices or culture medium containing bioactive molecules such as the human 
glucagon-like peptide (GLP) analogue and Liraglutide (an antioxidant superoxide 
dismutase (SOD) mimic) that protect islets against oxidative stress, inflammatory 
response and apoptosis (Bottino et al., 2002, Toso et ah, 2010, Wang and Rosenberg, 
1999).
A highly novel approach for enhancing the quality of islets prior to transplantation is to 
replace intra-islet HS. Previously, Ziolkowski et al. showed that the viability of islet 
beta cells is significantly enhanced by culturing the islet beta cells with HS mimetics. 
Dissociated islet cells (beta cells) were cultured with HS mimetics including heparin, 
highly sulfated HS (HShl) and PI-88 (Chapter 1, Section 1.13.9c) for 1-2 days. A 
significant decrease in beta cell death was observed after in vitro treatment with highly 
sulfated HS mimetics, when compared with non-treated controls. Confocal microscopy 
analysis using FITC-conjugated heparin confirmed the substantial uptake of the HS 
mimetic into the islet beta cells. Importantly, replacement of the lost beta cell HS with 
highly sulfated mimetics exerted a protective effect not only against culture-induced 
death but also against oxidative damage. Islet beta cells co-cultured with HS mimetics 
exhibited remarkable resistance to death induced by acute exposure to hydrogen 
peroxide (H2O2), a source of reactive oxygen species (ROS). These findings further 
suggested that culture-induced death may at least, in part be attributed to the local 
generation of ROS (Ziolkowski et al., 2012). Hence, we applied a similar rationale to 
the culture of whole islets in our study. We proposed that HS replacement in whole 
mouse islets via culture with exogenous HS mimetics could improve the molecular 
composition and survival of islets and thus reduce the number of islets required for 
transplantation and the re-establishment of normoglycaemia. However, in contrast to 
isolated islet beta cells, we reasoned that the complexity of the multicellular structure of 
islets could provide an additional challenge for the effective cellular uptake of the large, 
highly negatively charged HS mimetics (molecular weight of 10-15 kDa).
Amongst the panel of HS mimetics (see Appendix 19) assessed in this study as HS 
“replacers” for isolated islets, were derivatives of porcine intestinal mucosal heparin. 
Porcine mucosal heparin is available commercially and has a molecular weight of 12- 
15kDa (Linhardt and Gunay, 1999). The heparin was modified in several ways in an 
attempt to facilitate islet and islet cell uptake. These modifications included size 
reduction, addition of a lipophilic moiety, alteration of the sulfation status and
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periodate-mediated glycol splitting of chemical bonds in the uronic acid residues to 
enhance the flexibility of the chemical joints along the glycosaminoglycan (GAG) 
chains. Cell-penetrating agents including protamine, chitosan, cetylpyridirium chloride 
and sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) were also examined for 
their ability to facilitate cellular uptake.
Experiments were also designed to investigate the underlying mechanism responsible 
for the loss of intra-islet HS during islet isolation process. It is well established that 
heparanase, the endoglycosidase that selectively degrades HS, generates HS fragments 
of 5-7 kDa (10-20 sugar residue equivalents) (Gingis-Velitski et al., 2007, Vlodavsky 
and Friedmann, 2001). Heparanase-mediated cleavage of HS is involved in a variety of 
inflammatory and pathological events such as tissue remodelling, angiogenesis, cancer 
metastasis, cell invasion and autoimmunity (Edovitsky et al., 2006, Nakajima et al., 
1984, Parish, 2006, Parish et al., 2001, Patel et al., 2007, Vlodavsky and Friedmann, 
2001, Vlodavsky et al., 1983). Heparanase is synthesised initially in a pre-pro form, 
which is then processed to an inactive form (65kDa) via the removal of a signal peptide. 
The immature or “proheparanase” undergoes further cleavage with the removal of a 
linkage peptide which allows the formation of an active heterodimer consisting of non- 
covalently linked 50 kDa and 8 kDa subunits (Vreys and David, 2007). The activation 
of heparanase is required for its enzymatic activity (i.e., degradation of HS) and is 
mediated by Cathepsin L, a ubiquitous lysosomal cysteine protease (Abboud-Jarrous et 
al., 2008, Fairbanks et al., 1999, Levy-Adam et al., 2003).
Cathepsin L is also synthesised as a pre-pro molecule, i.e preprocathepsin L. Upon 
translation, it is transported to the Golgi region where it is processed to immature 
procathepsin L, with a molecular weight of 37-39 kDa (Probst et al., 2006, Reiser et al., 
2010). Procathepsin L undergoes autoproteolytic cleavage to active cathepsin L in the 
acidic environment within lysosomes. Active cathepsin L either consists of a single 
chain of 30 kDa or a two-chain form assembled from two separate domains of 25 kDa 
and 5 kDa (Ishidoh et al., 1998).
In addition to the enzymatic degradation of HS by heparanase, excessive levels of free 
radicals are known to depolymerise HS (Raats et al., 1997). Free radicals including 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) are chemically 
unstable molecules with unpaired electrons in their atomic or molecular orbitals. The
propensity for free radicals to exist with balanced pair electrons results in electron 
donation from other molecules, converting the molecules to secondary radicals. The 
uncontrolled electron transfer cascade can disturb normal cell biology, impact on cell 
survival by triggering apoptosis and eventually lead to damaging pathology (Sies, 
1997).
Free radicals are commonly generated during inflammation. It has been reported that 
ROS can depolymerise glycosaminoglycans (GAGs) including hyaluronan, chondroitin 
sulfate, dermatan sulfate and heparan sulfate to varying degrees, with the sulfated GAGs 
being more resistant to oxidative damage than the nonsulfated GAGs (Moseley et al., 
1995). Despite sulfated GAGs being protected from oxidative damage, numerous 
studies have demonstrated the degradation of heparin, a highly sulfated form of HS by 
ROS (Liu and Perlin, 1994, Metcalfe et al., 1990, Nagasawa et al., 1992, Volpi et al., 
1992). The susceptibility of heparan sulfate to depolymerisation by ROS was further 
demonstrated by Raat et al. in the context of glomerulopathies, which were often 
associated with the loss of glomerular BM HS. The authors noted decreased recognition 
of the rat glomerular BM HS by antibody directed against HS in the presence of 
hypoxanthine (HX)-xanthine oxidase (XO)-induced ROS. The HX-XO system 
generated superoxide radicals (O2") and hydroxyl radicals including H2O2 and OH. In 
addition, electrophoresis analysis revealed fragmentation of HS, confirming that HS is 
susceptible to depolymerisation by ROS. In parallel, they demonstrated that in vivo 
treatment with the hydroxyl radical scavenger, dimethylthiourea (DMTU), prevented 
induction of Adriamycin-induced nephropathy and preserved glomerular HS in 
challenged rats (Raats et al., 1997).
It is known that islet isolation induces oxidative stress. In this chapter, we set out to 
evaluate the role of ROS in the loss of islet HS during the process of islet isolation. Our 
approach was to assess the ability of the hydroxyl radical scavengers, butylated 
hydroxyanisole (BHA) and dimethylthiourea (DMTU) to preserve islet HS during islet 
isolation. Likewise, we examined whether 4, 4’-diisothiocyanostilbene-2, 2’-disulfonic 
acid (DIDS), a chloride ion channel blocker that has been shown to inhibit ROS- 
induced apoptosis (Wang et al., 2005), can prevent the loss of islet HS during islet 
isolation. In addition, we investigated whether the duration of culture could impact on 
the intra-islet HS levels.
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In the clinic, islets are generally cultured for up to 72 hrs prior to transplantation (Froud 
et al., 2005, Hering et al., 2004, Markmann et al., 2003, Ryan et al., 2005, Wamock et 
al., 2005). The culture of isolated islets offers a number of potential benefits for islet 
transplantation. Since exocrine cells do not survive well in vitro, transient in vitro 
culture reduces exocrine contamination (Lardon et al., 2004, Singh et al., 2008). 
Exocrine contamination is detrimental to islet survival and function because the 
digestive enzymes secreted by residual acinar cells can result in islet cell autolysis. 
Indeed, islets transplanted with associated exocrine tissue have shown impaired insulin 
secretion (Gray et al., 1988). Contaminating exocrine components may also interfere 
with the revascularisation process. Islets transplanted with associated exocrine tissue 
showed decreased vascular density compared to purified islets. Importantly, the 
contaminating exocrine tissue is immunogenic as more mononuclear cells (MNCs) were 
observed in the exocrine tissue-contaminating islet grafts compared to purified islet 
grafts in Syrian golden hamsters (Heuser et al., 2000). Thus, elimination of the exocrine 
component via islet purification and culture provides a means for preserving islet 
integrity and function and for reducing tissue immunogenicity.
In the 1970s, culture of hand-picked mouse isolated islets in a high oxygen gas phase 
reduced the immunogenicity of isolated islets by removing immunostimulatory donor 
passenger leukocytes, a finding that helped to dismiss the previously held notion that 
foreign antigen on tissue parenchymal cells was the barrier to successful 
allotransplantation (Lafferty et al., 1983). Whilst from a practical stance, this culture 
technique has not been adopted for clinical islet transplantation, short-term culture of 
human islets, enables early interventions to be initiated in patients. These include the 
induction of immunosuppression (Froud et al., 2008, Hering et al., 2004) and islet 
preconditioning by co-culturing islets with angiogeneic factor, anti-apoptotic factors 
and antioxidants to enhance the quality of the islets and improve transplant outcome 
(Bottino et al., 2002, Chhabra and Brayman, 2011, Zhu et al., 2010).
In the clinical setting, islet culture allows time for quality testing and provides time for 
the logistics of patient identification, notification and mobilisation (Goss et al., 2004, 
Johnson and Jones, 2012, Noguchi et al., 2010). However, it has also been reported that 
the culture of human and mouse islets results in 10-20% loss of islet cell mass and 
deterioration of function (Keymeulen et al., 2006, Kin et al., 2008, King et al., 2005, 
Noguchi et al., 2008). Since islet culture is a standard procedure for current clinical islet
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transplantation, we therefore sought to examine the effect of islet culture on the 
recovery of intra-islet HS.
In this chapter, two separate approaches are evaluated for improving islet HS content, 
i.e, HS replacement and preservation of intra-islet HS. We examine whether heparanase 
or the local generation of free radicals play a role in the loss of islet HS during isolation. 
Furthermore, we investigate the effect of islet culture on the intrinsic recovery of islet 
HS. These studies have the potential to improve the quality of isolated donor islets and 
to reduce the number of islets required to reverse normoglycaemia after transplantation.
5.1 Results
5.1.1 Calcein AM uptake by isolated islets in vitro
Islets were separated from the surrounding acinar tissue during the isolation process by 
hand-picking (Chapter 2, Section 2.3). It is likely that isolated islets undergo injury at 
their periphery, a process which could potentially interfere with the uptake of 
exogenous compounds. In order to assess the capacity for an exogenous compound (see 
Appendix 19) to be taken up by whole islets, we incubated C57BL/6 isolated islets with 
calcein-acetoxymethyl (AM) overnight (0.4 pM) (Chapter 2, Section 2.12.1). Calcein 
AM is a cell-permeant dye with a molecular weight of 994.9 Da. The addition of the 
AM-ester group to calcein renders it a non-fluorescent, uncharged small molecule that 
can easily permeate the cell membrane. Once it is inside the cells, the lipophilic ester 
group of the calcein AM is cleaved by intracellular esterases. As a result, calcein is 
converted to a fluorescent, charged form and retained intracellularly (Decherchi et al., 
1997).
Confocal microscopy revealed high levels of calcein fluorescence in whole islets after 
culture for 1 day (Fig. 5 .IB) while little or no fluorescence signal was detected in islets 
cultured without Calcein-AM (Fig. 5.1 A). Morphometric analyses of confocal images 
revealed that the mean % calcein+ve islet area was 71.74±1.79% whereas the control 
untreated islets showed a mean % calcein+ve islet area o f 0.02+0.01% (pO .001) (Fig. 
5.1C). In parallel, whole islets from the same Calcein-AM-treated and control groups 
were dispersed into single cells and examined for calcein uptake using flow cytometry 
(Chapter 2, Section 2.12.3). Similarly, high levels of calcein AM uptake were exhibited 
by the dissociated islet cells (mean calcein+ve islet cells=71.49+2.35%), compared to
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Figure 5.1 Calcein AM is efficiently taken up by islet cells in whole islets
Representative confocal images show that in contrast to control C57BL/6 
mouse islets cultured without Calcein-AM for 1 day, which showed little 
background fluorescence (A), islet cultured for 1 day with 0.4 pM Calcein-AM 
displayed intense fluorescence throughout the islets (B). (C) Morphometry 
analysis using Image J software revealed that 71.74±1.79% of the islet area 
was calcein+ve compared to 0.02±0.01% of the control islets, which showed 
background fluorescence. (D) Islet cells dispersed from the isolated islets in 
(C) and analysed by flow cytometry showed that 71.49±2.35% of the islet cells 
were calcein+ve, compared to 0.05±0.01% control islet cells. Data represents 
(A) mean % calcein+ve islet area±SEM and (B) mean % calcein+ve islet 
cells±SEM. Data were analysed from 3 independent experiments, n=4-9 
islets/sample; 15-42 images/sample; n=4 experiments for flow cytometry 
analysis. Scale bar=250pm.
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control calcein AM
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the negative control (mean calcein+ve islet cells=0.05±0.01%) (p=0.03) (Fig. 5.ID). 
These findings confirmed the morphometric analyses of confocal images and 
demonstrated the feasibility of the intracellular delivery of an exogenous fluorescently- 
labelled compound into whole islets in vitro.
5.1.2 Uptake of exogenous HS by isolated islets in vitro
A panel of FITC-labelled porcine mucosal heparin-derived HS mimetics (see Appendix 
19) was tested for the ability to penetrate isolated islets and enter islet cells. C57BL/6 
isolated islets were cultured with individual FITC-labelled compounds (50pg/ml) 
overnight at 37°C (Chapter 2, Section 2.12.1). Compared to untreated 1 day-cultured 
islets that served as negative controls (Figs. 5.2-5.5 (A, C, E)), isolated islets incubated 
with FITC-HS mimetics (Figs. 5.2-5.5 (B, D, F)) showed variable uptake of 12 FITC- 
HS mimetics after one day of culture. For islets treated with BT-443 (Fig. 5.2D), BT- 
464 (Fig. 5.4F), BT-454 (Fig. 5.5B), BT-459 (Fig. 5.5D) and BT-461 (Fig. 5.5F), FITC- 
HS localisation appeared to be restricted to the peripheral islet cells. This series of 
FITC-HS mimetics have been labelled “Panel A”. In addition to peripheral uptake, 
intra-islet FITC-positive sites localised distant from the islet periphery were also 
observed for islets incubated with heparin (Fig. 5.2B), BT-446 (Fig. 5.2F), BT-426 (Fig. 
5.3B), BT-487 (Fig. 5.3D), PI-88 (Fig. 5.3F), BT-447 (Fig. 5.4B) and BT-463 (Fig. 
5.4D). Z-stack analyses confirmed the intra-islet sites of HS uptake. This set of HS- 
mimetics was identified as “Panel B”, as they were shown to penetrate further into the 
islet cell mass than HS-mimetics in Panel A. In contrast, islets treated with BT-487 
conjugated with the cell-penetrating compound SNAC (sodium N-[8-(2- 
hydroxybenzoyl) amino] caprylate) (see Appendix 19) showed damaged islet 
morphology (Fig. 5.6B), suggesting that the treatment was toxic to the islets. The strong 
fluorescence observed in the treated islets probably resulted from the loss of membrane 
integrity in the damaged islet cells, allowing passive influx of the fluorescent compound 
(Fig. 5.6A). These specimens were excluded from quantitative analysis due to drug- 
associated toxicity.
Quantitative morphometric analysis of the FITC-positive islet area shown in the 
confocal images (Fig. 5.1 A) suggested that BT-426 expressed the highest mean islet 
uptake (mean FITC-positive islet area=3.10±0.33%, pO.OOOl) amongst the panel of 
FITC-HS mimetics. Compared to FITC-heparin-treated islets (mean FITC+ve islet 
area=0.67±0.11%), the other modified heparin-derived HS mimetics that demonstrated
Figure 5.2 Localisation of FITC-labelled HS mimetics (heparin, BT-443, BT- 
446) after overnight culture with isolated C57BL/6 mouse islets
Confocal microscopy revealed that isolated C57BL/6 mouse islets cultured 
overnight with the FITC-labelled HS mimetic at 50 pg/ml, (D) BT-443 
demonstrated mainly uptake at the islet periphery. In addition to peripheral uptake 
of FITC-HS mimetic, intra-islet FITC-positive fluorescent sites were observed 
after treatment with (B) heparin and (F) BT-446-treated islets. (A, C, E) Untreated, 
1 day-cultured controls showed negligible background fluorescence. Scale 
bar=250pm.
(A) Control (B) Heparin
(E) Control (F) BT-446
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Figure 5.3 Localisation of FITC-labelled HS mimetics (BT-426, BT-487, PI- 
88) after overnight culture with isolated C57BL/6 mouse islets
Confocal microscopy images show intra-islet sites of FITC+ve fluorescence close 
to the islet periphery and scattered within the intra-islet cell mass after overnight 
culture of C57BL/6 isolated islets with FITC-labelled HS mimetic (50 pg/ml), (B) 
BT-426, (D) BT-487 and (F) PI-88. (A, C, E) Negligible background fluorescence 
was observed in overnight cultured control islets. Scale bar= 250pm.
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Figure 5.4 Localisation of FITC-labelled HS mimetics (BT-447, BT-463, 
BT-464) after overnight culture with isolated C57BL/6 mouse islets
Confocal microscopy showed that FITC-labelled HS was localised within 
islets as well as at the islet periphery of C57BL/6 isolated islet cultured 
overnight with (B) BT-447 (50 pg/ml) and (D) BT-463 (50 pg/ml). (F) BT- 
464-treated islets (50 pg/ml) showed mainly FITC-labelling at the islet 
periphery. The fluorescence associated with the core of an individual islet 
treated with BT-463 and BT-464 (see arrows) was probably background 
staining due to centrol necrosis in those islets. (A, C, E) Control cultured islets 
showed only background levels of fluorescence. Scale bar= 250pm.
216
(A) Control (B) BT-447
(C) Control
1
(D) BT-463
(E) Control (F) BT-464
217
Figure 5.5 Localisation of FITC-labelled HS mimetics (BT-454, BT-459, 
BT-461) after overnight culture with isolated C57BL/6 mouse islets
Confocal microscopy revealed numerous sites of FITC-positive fluorescence 
localised close to the periphery of the islets treated with (B) BT-454 (50 
pg/ml). C57BL/6 isolated islets cultured with (D) BT-459 (50 pg/ml) and (F) 
BT-461 (50 pg/ml) displayed only a few fluorescent foci (BT-459) or low 
fluorescence (BT-461). A fluorescent region was identified in an islet cultured 
with (D) BT-459, which was probably background staining of necrotic islet 
tissue (see arrow). (A, C, E) The control islets analysed in parallel with islets 
treated with BT-454 and BT-459 also showed a small intra-islet region of 
fluorescence in a single islet but all other control islets showed negligible 
background fluorescence. Scale bar=250pm.
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(A) SNAC-FITC-487 (B) Bright field
Figure 5.6 Localisation of FITC-labelled-SNAC-BT-487 after overnight culture 
with isolated C57BL/6 mouse islets
Isolated islets cultured with (B) SNAC-BT-487 at 50pg/ml for 1 day showed gross 
damage as indicated by the ruffled appearance at the islet periphery. (A) The intense 
fluorescence shown in the treated islets was probably due to the loss of membrane 
integrity and subsequent intracellular accumulation of the fluorescent compound. 
Scale bar=250pm.
220
Figure 5.7 Quantitative analysis of FITC-labelled HS mimetics uptake by 
whole islets
(A) Morphometric analysis of confocal images showed that isolated C57BL/6 islets 
cultured (50 pg/ml) with FITC-BT-426 demonstrated the highest uptake, as 
indicated by 3.10±0.33 % FITC+ve islet area. Islets cultured with FITC-PI-88 
(1.96±0.26%), BT-447 (1.81 ±0.16%), BT-487 (1.62±0.17%), BT-446
(1.52±0.23%), BT-463 (0.73±0.10%) and heparin (0.67±0.11%) showed significant 
uptake. Isolated islets cultured in the presence of FITC-BT-443 (0.24±0.05%), 464 
(0.23±0.04%), BT-454 (0.12±0.03%), BT-459 (0.26±0.06%) and BT-461
(0.19±0.03%) exhibited a lower FITC+ve islet area compared to heparin-treated 
islets. (B) Flow cytometry analysis of beta cells isolated from islets±treatment in 
culture with FITC-HS mimetics revealed that islets treated with FITC-BT-446 
showed the highest uptake from the panel of HS mimetics, with 6.97± 1.57%, beta 
cells being FITC+ve. Analysis of beta cells from islets treated with FITC-BT-454 
(5.62±2.53%), BT-487 (4.86±1.37%), BT-463 (4.00±1.52%), BT-426
(3.61 ±0.48%), BT-447 (3.49±0.23%) showed uptake similar to heparin
(2.96±0.47%). Single islet cells treated with BT-443 (1.96±0.54%), PI-88 
(2.1 ±0.324%), BT-464 (0.81±0.22%), BT-459 (1.72±1.08%) and BT-461
(1.99±1.05%) showed lower HS uptake than islet cells treated with heparin. Data 
represents mean % FITC+ve islet area±SEM and (B) mean %FITC+ve beta 
cells±SEM. Data were analysed from 3 independent experiments, n=4-9 
islets/sample; 15-42 images/sample; n=4 experiments for flow cytometry analysis. 
Statistical analysis was performed between heparin and heparin-modified HS 
mimetics using unpaired Student’s t test or Mann-Whitney Test. **p<0.001;
***p<0.0001.
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a comparable or higher FITC+ve islet area included: BT-447 (mean FITC-positive islet 
area=1.81±0.16%, p<0.0001), BT-487 (mean FITC-positive islet area=1.62±0.17%, 
p<0.0001), BT-446 (mean FITC-positive islet area=1.52±0.23%, pO.OOOl) and BT-463 
(mean FITC-positive islet area=0.73±0.10%). Islets treated with FITC-PI-88, a highly 
sulfated oligosaccharide which is not a heparin derivative, showed a mean FITC+ve 
islet area of 1.96+0.26%, pO.OOOl. Islets treated with other FITC-heparin derivatives 
consistently showed a FITC positive islet area lower than FITC-heparin (0.67+0.11%): 
BT-459 (mean FITC-positive islet area=0.26±0.06%, pO.OOOl), BT-443 (mean FITC- 
positive islet area=0.24±0.05%, pO.OOl), BT-464 (mean FITC-positive islet 
area=0.23±0.04%, pO.OOOl), BT-461 (mean FITC-positive islet areaO. 19+0.03%, 
pO.OOOl) and BT-454 (mean FITC-positive islet area=0.12+0.03%, pO.OOOl). These 
findings suggested that these heparin-modified HS mimetics (BT-443, BT-454, BT-459, 
BT-461 and BT-464) did not show enhanced uptake by whole islets compared to 
heparin uptake.
The remaining islets from the treatment groups which were not used for confocal 
microscopy, were then dispersed into single cells to assess intracellular uptake of HS 
mimetics by beta cells, using flow cytometry (Chapter 2, Section 2.12.3) (Fig. 5.7B). 
Compared to control cultured islets, significantly higher uptake of HS-mimetics was 
seen in beta cells isolated following co-culture of FITC-HS mimetics with whole islets. 
Interestingly, the HS uptake profile by beta cells showed slight variation when 
compared with the quantitative analysis of FITC-positive islet area performed on the 
confocal images (Fig. 5.7A). Based on flow cytometry analysis (Fig. 5.7B), the most 
prominent uptake of HS mimetics was observed in BT-446-treated samples (% 
FITC+ve beta cells=6.97±1.57%). Other FITC-HS mimetics showed higher levels of 
HS uptake than FITC-heparin (% FITC+ve beta cells=2.96+0.47%) included BT-454 
(% FITC+ve beta cells=5.62±2.53%), BT-487 (% FITC+ve beta cells=4.86±1.37%), 
BT-463 (% FITC+ve beta cells=4.00±1.52%), BT-426 (% FITC+ve beta 
cells=3.61+0.48%) and BT-447 (% FITC+ve beta cells=3.49±0.23%). In contrast, 
FITC-HS mimetics, e.g., PI-88 (% FITC+ve beta cells=2.08±0.33%), BT-443 (% 
FITC+ve beta cells=l.96+0.54%), BT-461 (% FITC+ve beta cells=l .99+1.05%), BT- 
459 (% FITC+ve beta cells=1.72±1.08%) and BT-464 (% FITC+ve beta 
cellsO.81+0.22%), did not show improved HS-mimetics uptake by whole islets beyond 
that of heparin. In contrast to confocal microscopy (Fig. 5.7A), the flow cytometry 
analysis (Fig. 5.7B) showed that the HS uptake by beta cells between heparin and other
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heparin-modified compounds was not statistically significant, which is likely due to the 
smaller sample size in this study.
5.1.3 The role of heparanase in the loss of intra-islet HS during islet isolation 
5.1.3.1 Localisation and expression of heparanase and cathepsin L in islets in situ 
and after isolation
In order to determine the underlying mechanism(s) contributing to the loss of intra-islet 
HS during islet isolation, we examined the localisation and expression of heparanase, 
the HS-degrading endoglycosidase in C57BL/6 and CBA islets in situ and in isolated 
islets. Immunohistochemistry for heparanase identified low levels of heparanase 
expressed within islets in situ of C57BL/6 (Fig. 5.8A) and CBA (Fig. 5.8G) mouse 
strains. The heparanase staining appeared to depict cell surface expression on individual 
intra-islet cells. Following isolation, the cell surface staining became more prominent in 
C57BL/6 (Fig. 5.8D) and CBA (Fig. 5.8J) isolated islets. Occasionally, a few intra-islet 
cells stained strongly for heparanase at the cell surface, possibly representing passenger 
leukocytes trapped within the isolated islets (see asterisks, Fig. 5.8D, J).
Morphometry analysis showed that islet area stained with cell surface heparanase 
increased 6-7-fold following isolation when compared with that of islets in situ 
(p<0.001)(Fig. 5.9A). In native islets, the mean cell surface heparanase positive islet 
area was 1.72±0.27% and 2.89±0.52% in C57BL/6 and CBA mice, respectively. The 
mean islet area with positive cell surface heparanase staining in C57BL/6 and CBA 
isolated islets was 11.70±0.89% and 16.98+0.75%, respectively.
In this study, we also examined the localisation and expression of cathepsin L, the 
cysteine protease that converts inactive proheparanase to catalytically active heparanase 
with HS-degrading activity. Surprisingly, we found intense and uniform staining for 
cathepsin L distributed throughout islets in situ in C57BL/6 (Fig. 5.10A) and CBA (Fig. 
5.7G) mice. The intensity of staining for cathepsin L became stronger in C57BL/6 
isolated islets (Fig. 5.7D) and remained comparable to native islets in CBA isolated 
islets (Fig. 5.7J).
Quantitative analysis of cathepsin L+ve staining within islets (Fig. 5.11) revealed a 2- 
fold increase in C57BL/6 isolated islets (mean % cathepsin L+ve islet 
area=73.43±2.30%; mean staining intensity=0.84+0.03 A.U) compared to native islets
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Figure 5.8 Immunohistochemical localisation of heparanase in mouse islets in 
situ in the pancreas and in isolated islets using anti-HP130 mAh
(A) C57BL/6 and (G) CBA islets in situ exhibited cell surface heparanase staining 
(see arrows) within the islets with C57BL/6 islets exhibiting only weak-intra-islet 
heparanase staining. After isolation, the cell surface heparanase appeared to be more 
intense in (D) C57BL/6 and (J) CBA isolated islets. A few intra-islet cells were 
strongly stained with heparanase (see asterisks) . (C, F, I, L) Negligible staining was 
seen in specimens stained with isotype control, mouse IgGlK. Arrow, cell surface 
staining. (A, D, G, J) anti-HP 130 mAb. (B, E, H, K) mouse IgGlK. (C, F, I, L) 
Haematoxylin and eosin. Scale bar= 100pm.
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Figure 5.9 Quantitative analysis of the islet area stained for heparanase in 
mouse islets in situ in the mouse pancreas and in isolated islets
Morphometric analysis of heparanase immunostaining in C57BL/6 (mean % 
heparanase+ve islet area, 1.72±0.27%; mean staining intensity, 0.19±0.001 A.U) and 
CBA (mean % heparanase+ve islet area=2.89±0.52%; mean staining 
intensity=0.21 ±0.002 A.U) islets in situ in the pancreas revealed a low distribution of 
heparanase. In contrast, the distribution of heparanase in isolated islets (Isolated 
C57BL/6 islets, mean % heparanase+ve islet area=l 1.70±0.89%; mean staining 
intensity=0.26±0.01 A.U; Isolated CBA islets, mean % heparanase+ve islet 
area=16.98±0.75%; mean staining intensity=0.27±0.01 A.U) was increased by 5.9- 
fold, compared to corresponding islets in situ. The data shows the mean % islet area 
stained with heparanase±SEM (A) and mean intensity staining of heparanase±SEM 
(B). n=19 islets examined in C57BL/6 pancreas; n=70 C57BL/6 isolated islets; n=13 
islets examined in CBA pancreas; n=73 CBA isolated islets. Islets were analysed 
from 3 independent specimens, n=3-24 islets/sample. Statistical analysis was 
performed using Kruskal-Wallis Test. Hpse, Heparanase.
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Figure 5.10 Immunohistochemical localisation of cathepsin L in mouse islets 
in situ in the pancreas and in isolated islets using anti-cathepsin L mAb
Strong and uniform staining for cathepsin L was distributed throughout (A) 
C57BL/6 and (G) CBA islets in situ. (D) C57BL/6 isolated islets were more 
intensely stained for cathepsin L compared to the native islets whereas (J) CBA 
isolated islets showed comparable staining with (G) CBA islets in situ. (C, F, I, L) 
Isotype control showed only background staining. (A, D, G, J) anti-cathepsin L 
mAb. (B, E, H, K) rat IgG2aK . (C, F, I, L) Haematoxylin and eosin. Scale 
bar= 100 pm.
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Figure 5.11 Quantitative analysis of islet area stained for cathepsin L in mouse 
islets in situ in mouse pancrease and in isolated islets
C57BL/6 isolated islets displayed high levels of cathepsin L expression (mean % 
cathepsin L+ve islet area, 73.43±2.30%; mean staining intensity, 0.84±0.03 A.U) 
compared to islets in situ (mean % cathepsin L+ve islet area=35.00±4.73%; mean 
staining intensity=0.53±0.04 A.U) whereas both CBA islets in situ (mean % 
cathepsin L+ve islet area=47.43±5.17%; mean staining intensity=0.59±0.04 A.U) and 
isolated islets (mean % cathepsin L+ve islet area=58.84±1.50%; mean staining 
intensity=0.66±0.01 A.U) exhibited similar levels of intra-islet cathepsin L staining. 
The data shows the mean % islet area stained with heparanase±SEM (A) and mean 
intensity staining of heparanase±SEM (B). n=30 islets examined in C57BL/6 
pancreas; n=51 C57BL/6 isolated islets; n=21 islets examined in CBA pancreas; 
n=93 CBA isolated islets. Islets were analysed from 3 independent specimens, n=5- 
23 islets/sample. Statistical analysis was performed using Kruskal-Wallis Test. Ctsl, 
cathepsin L.
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(mean % cathepsin L+ve islet area=35.00±4.73%; mean staining intensity=0.53±0.04 
A.U) (p<0.001). However, the increase in the localisation of cathepsin L in CBA 
isolated islets (mean % cathepsin L+ve islet area=58.84±1.50%; mean staining 
intensity=0.66±0.01 A.U) was not significantly different to the localisation of cathepsin 
L in native islets (mean % cathepsin L+ve islet area=47.43±5.17%; mean staining 
intensity=0.59±0.04 A.U).
Despite the increased localisation of heparanase in isolated islets (Figs. 5.8-5.9), 
Western blotting analysis (Chapter 2, Section 2.11) revealed that the intra-islet 
heparanase detected was mainly in the inactive form (Fig. 5.12A). Similarly, Western 
blotting for the cysteine protease, cathepsin L demonstrated that the cysteine protease 
was predominantly in its inactive form (Fig. 5.12B). Taken together, these findings 
indicate that heparanase is not activated during the islet isolation process and hence is 
unlikely to contribute to the loss of islet HS in isolated islets.
5.1.3.2 Intra-islet HS content in wild-type, heparanase knockout (B6.Hpse-KO) 
and cathepsin L knockout (B6.CtsL-KO) isolated islets
In parallel with our Western blotting analyses of heparanase and cathepsin L in isolated 
C57BL/6 and CBA islets (see Section 5.1.3.1), we investigated the HS content of islets 
isolated from B6.Hpse-KO and B6.Ctsl-KO mice. Figure 5.13 shows that B6.Hpse-KO 
and B6.Ctsl-KO islets in situ expressed normal levels of intra-islet HS (C57BL/6, mean 
% HS+ve islet area=77.18±3.10%; Hpse-KO, mean % HS+ve islet area=72.18+2.63%; 
Ctsl-KO, mean % HS+ve islet area=62.33±4.13%) (Fig. 5.13 B, C), but isolated islets 
from Hpse-KO (mean % HS+ve islet area= 12.07+2.07%) (Fig. 5.13E) and Ctsl-KO 
(mean % HS+ve islet area=6.18+0.89%) (Fig. 5.13F) mice lost their HS to a similar 
degree to C57BL/6 wild-type controls (mean % HS+ve islet area=14.47±1.53%) (Fig 
5.13D). A significant 5-10- fold decrease in % HS positive islet area (pO.OOl) was 
detected in the isolated islets compared to corresponding islets in situ (Fig. 5.13G). This 
study confirmed our Western blotting analyses of the activation status of heparanase 
and cathepsin L in isolated islets and clearly demonstrated that heparanase is not the 
principle mechanism responsible for the loss of islet HS during the islet isolation 
process.
Figure 5.12 Detection of active and inactive heparanase and cathepsin L protein 
in isolated islets by Western blotting
(A) Inactive proheparanase but not active heparanase was detected in C57BL/6 (band 
intensity=1767 A.U) and CBA isolated islets (band intensity=7108). (B) In contrast, 
low levels of active cathepsin L were identified in C57BL/6 (band intensity=55 A.U) 
and CBA (band intensity=57 A.U) isolated islets but inactive cathepsin L were more 
strongly detected in both isolated islets (band intensity, C57BL/J=68; CBA=74). This 
data is representative of n=2 experiments. For each experiment, C57BL/6 and CBA 
isolated islets were each pooled from 2 separate islet preparations (5 
donors/preparation).
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Figure 5.13 Localisation of heparan sulfate in isolated islets from wildtype, 
heparanase knockout (B6.Hpse-KO) and cathepsin L knockout (B6.Ctsl-KO) 
mice using Alcian blue histochemistry
Alcian blue histochemistry showed intense staining for HS in islets in situ of (A, G) 
wildtype (% mean HS+ve islet area=77.18±3.10%), (B, G) B6.Hpse-KO (% mean 
HS+ve islet area=72.19±2.63%) and (C, G) B6.Ctsl-KO (% mean HS+ve islet 
area=62.33±4.13%) mice. Following isolation, the HS content of islets isolated from 
(E, G) B6.Hpse-KO (% mean HS+ve islet area=12.07±2.07%) and (F, G) B6.Ctsl- 
KO (% mean HS+ve islet area=6.18±0.89%) and control (D, G) wildtype mice (% 
mean HS+ve islet area=14.47±l .53%). was significantly decreased compared to islets 
in situ and showed comparable weak HS staining. The data is shown as mean % 
HS+ve islet areatSEM. Data were analysed from 3 independent specimens of pooled 
isolated islets (n=5 donors/islet isolation) n=23-61 islets/sample. Statistical analysis 
was performed using Kruskal-Wallis Test. Scale bar=100pm.
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5.1.4 The role of reactive oxygen species (ROS) in the loss of intra-islet HS during 
islet isolation
To investigate the role of ROS in the loss of HS in the isolated islets, we incorporated 
antioxidants into the islet isolation process. Donor C57BL/6 mice received butylated 
hydroxyanisole (BHA) at 120 mg/kg i.p one hour before collagenase digestion of the 
pancreas, dimethylthiourea (DMTU; 50 mM) was also incorporated into the collagenase 
solution and isolation medium (Chapter 2, Section 2.13.1). This study demonstrated that 
the combination of BHA (in vivo) and DMTU (in vitro) treatment significantly 
preserved intra-islet HS during the isolation process. Alcian blue histochemistry showed 
patchy HS staining distributed throughout C57BL/6 islets isolated with BHA and 
DMTU treatment (Fig. 5.14C), compared to the negligible staining seen in non-treated 
islets (Fig. 5.14 B). BHA and DMTU treatment of B6.Hpse-KO islets (% HS+ve islet 
area=33.93±3.10%) (Fig. 5.14E, F) did not show increased HS levels beyond that of 
BHA and DMTU-treated wild-type C57BL/6 islets (% HS+ve islet area=44.42±2.59%), 
further confirming that heparanase is not the primary contributing factor to the loss of 
HS during islet isolation. Although morphometric analyses (Fig. 5.14F) demonstrated a 
significant 2-fold increase in HS contents (% HS+ve islet area=44.42±2.58%) in the 
antioxidant-treated C57BL/6 islets compared to non-treated controls (% HS+ve islet 
area=20.86±1.96%, p<0.001), the levels of HS staining in the treated islets remained 
significantly less than that of C57BL/6 islets in situ (% HS+ve islet area=77.18±3.10%, 
p<0.001), which exhibited strong and uniform HS staining (Fig. 5.14A).
Calcein-AM/propidium iodide (PI) staining (Chapter 2, Section 2.13.2) was performed 
to assess the islet cell viability after islets were isolated using combined BHA and 
DMTU treatment. Calcein-AM is a cell-permeant dye that stains live cells specifically 
whereas propidium iodide is a cell-inpermeant dye that selectively stains dead cells. 
This analysis demonstrated that islets from BHA+DMTU-treated and untreated groups 
stained with calcein-AM (Fig. 5.15A, B, E, F). However, PI positive cells were more 
frequently identified within the untreated islets (Fig. 5.15C, E) compared to the BHA 
and DMTU-treated islets (Fig. 5.15D, F). Quantitative analysis revealed a significant 
2.5-fold reduction of PI positive cells in the treated islets (mean % Pl+ve islet 
area=0.82+0.06%) compared to the untreated controls (mean % Pl+ve islet 
area= 1.99+0.16%, p<0.0001) (Fig. 5.16). Together, these findings indicate that 
antioxidant treatment significantly improved the intra-islet HS content and the viability 
of islet cells in isolated islets.
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Figure 5.14 Assessment of heparan sulfate levels in C57BL/6 and B6.Hpse-KO 
islets with BHA+DMTU treatment
C57BL/6 islets isolated using BHA (120 mg/kg i.p) + DMTU (50 mM) treatment 
showed widespread but patchy intra-islet HS, with the distribution showing a 
significant 2-fold increase in HS content (% mean HS+ve islet area=44.42±2.58%) 
(C, F), compared to non-treated islets (% mean HS+ve islet area=20.86±1.96%) (B, 
E). BHA+DMTU-treated B6.Hpse-KO isolated islets (% mean HS+ve islet 
area=33.93±3.10%) (F, E) showed comparable levels of HS to BHA+DMTU 
C57BL/6J islets. In comparison to BHA+DMTU treated islets, the HS content of 
C57BL/6 islets in situ remained significantly higher, with the HS+ve islet area of 
77.18±3.10% (A, F). The data is shown as mean % HS+ve islet area±SEM. Data 
were analysed from 3 independent experiments, n=28-55 islets/sample. Statistical 
analysis was performed using Kruskal-Wallis Test. Scale bar= 100pm.
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Figure 5.15 In vitro islet cell viability assessment for combined BHA- 
DMTU-treated isolated C57BL/6 islets using Calcein AM/Propidium 
Iodide (PI) staining
Confocal microscopy showed strong calcein positive in (A, E) control 
untreated and (B, F) combined BHA-DMTU-treated isolated C57BL/6 islets, 
indicating the localisation of viable islet cells. (C, E) Pi-positive staining, 
indicating dead islet cells, however, was more pronounced and widespread in 
untreated islets, compared to (D, F) BHA-DMTU treated islets. These data 
are representative of 3 experiments. Scale bar=250pm.
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Figure 5.16 Quantitative analysis of propidium iodide (Pl)-positive islet 
area in C57BL/6 islets isolated with BHA+DMTU treatment
Morphometric analysis of confocal images revealed that control untreated 
C57BL/6 islets expressed a higher Pi-positive content (% mean Pi-positive islet 
area=1.99±0.16%) compared to combined BHA+DMTU-treated islets (% mean 
Pi-positive islet area=0.82±0.06%). The data is shown as mean % Pl+ve islet 
area±SEM Data were analysed from n=3 independent experiments, n=52-81 
islets/sample. Statistical analysis was performed using the Mann-Whitney Test.
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Our transplantation studies have previously demonstrated that engrafted mouse islets at 
3 days after isotransplantation are HS-deficient (Chapter 4, Section 4.1.4), a finding that 
is consistent with the HS depletion of freshly isolated islets (Chapter 4, Section 4.1.3). 
In view of the significant improvement in the HS content of islets isolated with 
antioxidant treatment, we investigated whether this modified method of islet isolation 
resulted in HS-replete islets early after transplantation. We argued that such a finding 
would likely indicate improved islet viability, a property which in turn could potentially 
reduce the mass of islets needed to restore normoglycaemia after transplantation. Figure 
5.17 showed that while anti-oxidant treatment during the harvest of donor islets led to 
the successful engraftment of the islets (Fig. 5.17B, D), their HS content (% mean 
HS+ve islet area=26.61+7.21%) was comparable to engrafted control islets (% mean 
HS+ve islet area=30.22±6.34%) (Fig. 5.17E). The failure to observe improved intra-
islet HS in BHA+DMTU-treated islets at 3 days post-transplant suggests that the intra-
islet HS underwent further degradation during the surgical procedure of transplantation 
beneath the kidney capsule and/or during engraftment, possibly due to additional 
oxidative damage.
4, 4’-diisothiocyanostilbene-2, 2’-disulfonic acid (DIDS), a chloride ion (Cf) channel 
blocker with anti-oxidant properties has previously been shown to improve the viability 
of isolated rat islets (Anazawa et al., 2011). For this reason, we examined whether 
DIDS could potentially preserve islet HS during islet isolation. Supplementation of the 
collagenase solution and isolation medium with 200 pM DIDS significantly protected 
islets from HS depletion during the isolation process. Compared to the widespread, 
strong staining for HS in C57BL/6 islets treated with DIDS (Fig. 5.18C), untreated 
control islets characteristically showed little HS staining (Fig. 5.18B). Quantitative 
analysis by morphometry (Fig. 5.18D) confirmed a significant 2.7-fold increase in the 
HS content of DIDS-treated islets (mean % HS+ve islet area=42.59±4.86%) compared 
to non-treated islets (mean % HS+ve islet area= 16.00+5.09%, pO.001). However, 
DIDS treatment like the treatment with the BHA+DMTU anti-oxidants, failed to fully 
restore the HS content of the isolated islets to the normal levels observed in islets in situ 
in the pancreas (mean % HS+ve islet area=77.18±3.10%, p<0.001). (Fig. 5.18A,D).
Similar to BHA+DMTU-treated islets, DIDS-treated C57BL/6 islets transplanted to 
syngeneic recipient mice lost their in vitro-preserved HS content by 3 days post-
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Figure 5.17 Assessment of heparan sulfate levels in isografts of BHA+DMTU- 
treated C57BL/6 islets at 3 days post-transplants
Alcian blue histochemical staining of isografts (A) non-treated and (B) BHA (120 
mg/kg i.p)+DMTU (50 mM) -treated islets showed HS-depleted islets with only 
scattered patches of HS staining at 3 days post-transplant. (C, D) Haematoxylin and 
eosin histological staining revealed the presence of residual blood clots (see asterisks) 
at the graft site in both control and treated isografts. (E) Quantitative analysis of the 
HS content of the engrafted islets showed no significant difference between the 
untreated controls (% mean HS+ve islet area=30.23±6.34%) and the BHA+DMTU- 
treated (% mean HS+ve islet area=26.61±7.21%) islet isografts. The data is shown as 
mean % HS+ve islet areaiSEM. Data were analysed from 3 independent 
experiments, n=9-15 engrafted islets/sample. Statistical analysis was performed using 
the unpaired Student’s t-test. (A, B) Alcian blue. (C, D) Haematoxylin and eosin. 
Scale bar= 100pm.
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Figure 5.18 Assessment of heparan sulfate levels in DIDS-treated isolated 
C57BL/6 islets
Alcian blue histochemistry showed strong uniform HS staining in C57BL/6 islet in 
situ in the pancreas (A), little staining in untreated isolated C57BL/6 islets (B) and 
widespread intense staining for HS in DID-treated islets (C), with the distribution 
of staining intermediate between control islets in situ and after isolation. (D) 
Quantitative analysis of the intra-islet HS content by morphometry revealed a 
significant 2.7-fold higher level of HS in DIDS-treated islets (% mean HS+ve islet 
area=42.59±4.86%) compared to untreated control islets (% mean HS+ve islet 
area=T6.00±5.09%). However, the HS content of DIDS-treated islets remained 
significantly less than islets in situ (% mean HS+ve islet area=77.18±3.10%). The 
data is shown as mean % HS+ve islet area±SEM. Data were analysed from 3 
independent experiments, n= 13-28 islets/sample. Statistical analysis was 
performed using one-way ANOVA. Scale bar= 100pm.
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transplant and exhibited weak HS staining (mean % HS+ve islet area=3.40±0.73%) 
(Fig. 5.19B, E) similar to non-treated islet grafts (mean % HS+ve islet 
area=3.24±0.82%) (Fig 5.19A, E). This finding indicated that the in vz/ro-preserved islet 
HS in the DIDS-treated islets were subjected to degradation early after transplantation, 
possibly due to further oxidative damage during transplant surgery.
5.1.5 Effect of islet culture on the recovery of intra-islet HS
Prior to clinical islet transplantation, isolated human islets are generally maintained in 
culture for up to 3 days (Froud et al., 2005, Hering et al., 2004, Markmann et al., 2003, 
Ryan et al., 2005, Wamock et al., 2005). We therefore examined whether intra-islet HS 
was recovered during the culture of isolated mouse islets. Examination of islet 
morphology showed that 4-day cultured C57BL/6 islets (Fig. 5.20B) were characterised 
by a smooth periphery, unlike uncultured freshly isolated islets (Fig. 5.20A) which 
generally showed a “ruffled” boundary. These properties suggested that during culture 
the islets undergo some recovery from the damage inflicted by the collagenase-mediated 
isolation procedure. Based on Alcian blue histochemistry, 4-day cultured islets showed 
some improvement in the HS content, compared to freshly isolated islets (Fig. 5.20A, 
B), but the HS content remained low compared to islets in situ. Quantitative analysis of 
the islet content of HS (Fig. 5.20C) revealed a 3-fold increase in HS staining in the 4- 
day cultured islets (mean % HS+ve islet area=6.30±1.17%) compared to freshly isolated 
islets (mean % HS+ve islet area=2.04+0.40%, p<0.0009). Note that the HS+ve islet area 
of C57BL/6 islets in situ is normally 77.18+3.10%.
After transplantation, 4 day-cultured islet isografts at 3 days post-transplant (Fig. 5.2IB, 
E) exhibited weak HS staining (mean % HS+ve islet area=l 1.44+1.98%), comparable to 
control isografts of freshly isolated islets (mean % HS+ve islet area=l 1.84+2.92%) 
(Fig. 5.21 A, E). This finding suggested that culture of the islets before transplantation 
did not improve the HS content of engrafted islets in the early post-transplant period.
5.2 Discussion
Our laboratory has established that islet heparan sulfate (HS) plays a critical role in 
protecting islet beta cells from free radical-mediated damage, by acting as an 
antioxidant or free radical sink (Ziolkowski et al., 2012). It was suggested that islet HS 
detoxifies endogenous ROS generated from the formation of disulfide bonds during
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Figure 5.19 Assessment of heparan sulfate levels in isografts of DIDS-treated 
C57BL/6 islets at 3 days post-transplant
After isotransplantation, (B) DIDS-treated islets and (A) untreated islets exhibited 
weak intra-islet HS staining by 3 days post-transplant. (C, D) Haematoxylin and 
eosin histological staining revealed the presence of residual blood clots (see asterisks) 
at the graft site in both control and treated isografts. (E) Quantitative analysis of the 
HS content of the engrafted islets showed no significant difference between the 
untreated controls (% mean HS+ve islet area=3.24±0.82%) and the DIDS-treated (% 
mean HS+ve islet area=3.40±0.73%) islet isografts. The data is shown as mean % 
HS+ve islet area±SEM. Data were analysed from 3 independent experiments, n=4-6 
engrafted islets/sample. Statistical analysis was performed using unpaired Student’s t- 
test. (A, B) Alcian blue. (C, D) Haematoxylin and eosin. Scale bar= 100pm.
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Figure 5.20 Heparan sulfate content of C57BL/6 islets after culture for 4 
days
Alcian blue histochemistry demonstrated that compared to freshly isolated 
control C57BL/6 islets which showed weak or little HS staining (A), islets 
cultured for 4 days in 10% C 02, 90% air expressed slightly improved HS 
staining (B). (C) Quantitative analysis of the HS content of the islets before and 
after culture revealed that the HS content of the 4 day cultured islets (% mean 
HS+ve islet area=6.30±1.17%) was 3-fold higher than uncultured islets (% 
mean HS+ve islet area=2.04±0.40%). Note the % HS+ve islet area of C57BL/6 
islets in situ in the donor pancreas is generally 77.18±3.10%. The data is shown 
as mean % HS+ve islet area SEM. Data were analysed from 3 independent 
experiments, n=5-17 islets/sample. Statistical analysis was performed using 
unpaired Student’s t-test. (A, B) Alcian blue. Scale bar=100pm.
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Figure 5.21 Heparan sulfate content of 4-day cultured C57BL/6 islets at 3 
days post-isotransplantation
Isografts of (C) uncultured and (D) 4-day cultured C57BL/6 islets at 3 days post-
transplant consisted of vascularised islets with residual clotted donor blood visible 
(see asterisks) at the graft site. (A, B) Alcian blue histochemical staining 
demonstrated only scattered patches of HS staining in both uncultured isografts (% 
mean HS+ve islet area=l 1.84±2.92%) and 4 day-cultured islet isografts (% mean 
HS+ve islet area=l 1.44±1.98%). The data is shown as mean % HS+ve islet 
area±SEM. Data were analysed from 3 independent experiments, n=2-5 engrafted 
islets/sample. Statistical analysis was performed using unpaired Student’s t-test. 
(A, B) Alcian blue. (C, D) Haematoxymin and eosin. Scale bar= 100pm.
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insulin biosynthesis and/or protein folding in mitochondria as a result of mitochondrial 
oxidative phosphorylation (Newsholme et al., 2007, Riemer et al., 2009, Yuan et al., 
1999). However, islets lose intra-islet HS following their isolation (Ziolkowski et ah, 
2012). The depletion of islet HS, may in part, contribute to the isolation-induced cell 
death in islets. This notion prompted us to explore approaches for preserving or 
replacing the lost islet HS using exogenous HS. Ziolkowski et al. demonstrated proof of 
this principle by showing that HS replacement in islet beta cells resulted in significant 
improvement in beta cell survival, compared to non-treated beta cells, after 2 days of 
culture with heparin, a highly sulfated analogue of HS, highly sulfated HS or PI-88, a 
highly sulfated HS mimetic (Ziolkowski et ah, 2012). In our study, we investigated 
whether culturing isolated islets with exogenous HS, led to replacement of intra-islet 
beta cell HS.
In contrast to the culture of isolated beta cells with HS/HS mimetics (Ziolkowski et ah, 
2012), overnight culture of isolated islets with FITC-labelled HS mimetics showed low 
levels of intracellular HS uptake. Based on confocal microscopy analysis, the uptake of 
most of the FITC-labelled HS compounds (BT-443, BT-454, BT-459, BT-461 and BT- 
464) was localised close to the periphery of the islets. Sparse intra-islet distribution of 
FITC-labelled HS was observed in islets cultured with heparin, BT-426, BT-446, BT- 
447, BT-463, BT-487 and Pl-88, suggesting minimal penetration of exogenous HS into 
the core of the islets (Figs. 5.2-5.5, 5.7). Interestingly, the levels of HS uptake varied 
when the cultured islets were dissociated into single cells and measured for the uptake 
of intracellular FIT-HS mimetics by flow cytometry (Fig. 5.7). Compounds that 
demonstrated high levels of HS uptake included BT-446, BT-454, BT-463 and BT-487. 
However, the level of HS uptake of these compounds varied considerably, suggesting 
that the high levels of HS intake may have been due to experimental variables. 
Nevertheless, these studies suggested that chemically modified heparins showed 
encouraging islet cell uptake compared to unmodified heparin. Several issues confront 
the successful intracellular delivery of HS. First, HS is highly anionic and is a large 
macromolecule (5-70 kDa), These properties pose a physical challenge for traversing 
lipid membranes, as cell penetration favours uncharged and small molecules (<500Da) 
(Iozzo, 2005, Maikov et al., 2002, Parish, 2006, Walter and Gutknecht, 1986). 
Additionally, the multicellular structure of islets (de Freitas et al., 1998) further acts as 
an additional barrier for intracellular uptake of HS.
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To our surprise, highly sulfated BT-447, which is highly negatively charged, showed 
reasonable uptake into islets (mean FITC-positive islet area=1.81±0.16%; % FITC+ve 
beta cells=3.49±0.23%) (Fig. 5.7). It is possible that the sulfated groups favoured 
interaction between the HS mimetics and islet cell membranes via charge-independent 
binding, circumventing a charge repulsion effect of two negatively charged entities. 
However, this notion remains to be investigated.
Compared to heparin, addition of a lipophilic moiety (BT-463 and BT-464) or cell 
penetrating peptides (BT-454, BT-459, BT-461) did not improve islet uptake. It is 
possible that these compounds have higher molecular weight that impeded penetration 
into the islets. Although these studies failed to identify a HS compound that could be 
easily delivered to islets, our findings have highlighted several important properties 
which should be considered in designing new HS mimetics with improved bio-delivery 
properties, e.g., size reduction (BT-446 and BT-426) and glycol splitting of heparin 
(BT-446, BT-426 and BT-487) to enhance chemical joint flexibility.
Numerous gene or protein delivery strategies to cells require cell membrane HSPGs to 
act as a plasma membrane carrier for efficient cellular internalisation of the gene or 
protein of interest. These include the cell penetrating peptides, HIV-transactivator 
(TAT), polyarginines and polylysines as well as cationic liposomes such as 
Lipofectamine and Transfectam (Belting, 2003). As a consequence, these approaches 
may not be optimal for isolated islets which are HS-deficient. Indeed, exogenous HS 
may act as a competitive inhibitor that prevents interaction between the cell penetrating 
peptides/ cationic liposomes and the residual cell surface HS (Belting 2003).
Future experiments to replace intra-islet HS following islet isolation could include the 
intra-islet delivery and overexpression of genes required for the biosynthesis of HS such 
as exostosin (Ext) and sulfotransferase. Extl, Ext2, Ext-like2, Ext-like3, N- 
deacetylase/N-sulfotransferases and HS sulfotransferases are expressed in mouse islet 
beta cells (Takahashi et al., 2009). Enhanced expression of these HS biosynthetic and 
modification enzymes via ex vivo gene delivery to the isolated islets may promote the 
restoration of islet HS post-isolation. Both viral vectors (eg. adenoviral, adeno- 
associated viral, Herpes Simplex Virus, retroviral (lentiviral) and non-viral vectors (eg. 
Effectene and polyethylenimine) have been used to successfully deliver genes encoding 
proangiogenic factors such as VEGF, hepatocyte growth factor (HGF) and fibroblast
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growth factor (FGF) as well as anti-apoptotic genes including Bcl-2 and X-linked 
inhibitor of apoptosis protein (XIAP) to islets (Dupraz et ah, 1999, Emamaullee et ah, 
2005, Hughes et ah, 2010, Panakanti and Mahato, 2009, Zhang et ah, 2004). Similarly, 
such gene transfer vectors could be used to transiently express one or more genes 
encoding enzymes for the biosynthesis of HS in the beta cells of isolated islets.
Future work should also be done to elucidate the molecular pathway involved in HS 
uptake. It is known that the internalisation of endogenous cell surface HS involves the 
endocytosis of the HSPG core proteins (Gingis-Velitski et ah, 2004). Whether the 
uptake of exogenous HS follows a similar pathway is unclear.
Our immunohistochemistry data demonstrated that islets in situ express low levels of 
heparanase at the cell surface (Fig. 5.8). Flow cytometry analyses have also revealed 
intracellular heparanase in isolated beta cells (Ziolkowski et ah, 2012). We postulate 
that islet/ beta cell heparanase is likely to be required for the turnover of intracellular 
HS, as previously reported (Fux et ah, 2009). HS has a short half-life of 2-6 hours for 
transmembrane HSPGs (eg. syndecans) and 25 mins for glycosylphosphatidylinositol 
(GPI)-anchored HPSGs (eg. glypicans). In contrast, heparanase has a relatively stable 
half life of approximately 30 hours. The co-localisation of both HS and heparanase in 
endosomes and lysosomes, the intra-cellular compartments where degradation of HS 
takes place, support a regulatory role for heparanase in HS metabolism (Fux et ah, 
2009, Gingis-Velitski et ah, 2004, Yanagishita and Hascall, 1992).
Our immunohistochemical studies demonstrated that cathepsin L is abundantly 
expressed within islets (Fig. 5.10), suggesting that islet-derived heparanase could be 
activated by intra-islet cathepsin L to regulate HS turnover. In general, cathepsin L acts 
as a “house-keeping” enzyme with its proteolytic function contributing to normal 
protein maturation and function and to the terminal breakdown of proteins delivered to 
lysosomes by endocytosis or autophagocytosis. (Reiser et ah, 2010). It is also becoming 
increasingly evident that cathepsin L has specialised regulatory roles. Cathepsin L is 
involved in MHC class II antigen processing in the thymus for the development of 
CD4+ T cells and in proenzyme processing, including enkephalin and neuropeptide Y 
(Funkelstein et ah, 2008, Nakagawa et ah, 1998, Yasothomsrikul et ah, 2003). In view 
of its role in cleaving proenzymes and its abundant distribution within islets, it is 
possible that cathepsin L may be involved in insulin processing. Previous reports have
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documented a role for a thiol protease of approximately 31.5 kDa in converting 
proinsuin to insulin (Docherty et al., 1982). Interestingly, cysteine proteases like 
cathepsin L are also known as thiol proteinases, and active cathepsin L consists of a 
single chain of 30kDa or a dimer comprising 25kDa and 5kDa subunits (Ishidoh et al., 
1998). Thus, it is plausible that cathepsin L may participate in insulin processing, aiding 
prohormone convertases (Steiner et al., 1996). Alternatively, it could be speculated that 
cathepsin L acts as a house-keeping enzyme in islet beta cells, degrading vesicular 
membrane proteins once insulin is secreted. This notion remains to be investigated.
Following islet isolation, our studies suggested that cell surface heparanase levels are 
up-regulated in isolated islets (Figs. 5.8, 5.9) In addition, islets express high levels of 
cathepsin L, both before and after islet isolation (Figs. 5.10, 5.11). Despite the 
heightened levels of expression, heparanase in isolated islets exists mainly as inactive 
proheparanase. Similarly, cathepsin L was found to be present predominantly as an 
inactive proenzyme in isolated islets (Fig. 5.12). Together these properties argue against 
the activation of heparanase during the isolation of mouse islets. Our study also 
revealed that isolated islets from heparanase knockout and cathepsin L knockout mouse 
strains exhibited loss of intra-islet HS following isolation, comparable to wild-type 
isolated islets (Fig. 5.13). Taken together, our findings suggest that heparanase is not 
likely to be the primary mechanism responsible for the loss of HS during islet isolation.
It is known that high levels of reactive oxygen species (ROS) depolymerise HS. Raats et 
al. demonstrated that hydroxyl radicals were able to depolymerise glomerular BM HS 
and resulted in albuminuria and nephropathy (Raats et al., 1997). In our study, in vivo 
treatment of islet donors with the chemical hydroxyl radical scavenger, butylated 
hydroxyanisole (BHA) and inclusion of the hydroxyl scavenger, dimethylthiourea 
(DMTU) during the islet isolation procedure significantly preserved intra-islet HS levels 
and improved cell viability in isolated islets (Figs. 5.14-5.16). These findings suggest 
that the loss of HS in isolated islets is at least in part, due to the presence of hydroxyl 
radicals. BHA is an aromatic free radical scavenger, which has the ability to remove not 
only hydroxyl radicals (OH) but also secondary radical species such as peroxyl radicals 
(ROO). In contrast, as an aliphatic hydroxyl free radical scavenger, DMTU targets 
hydroxyl radicals exclusively (Cowden et al., 1985).
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Likewise, treatment with DIDS (4,4'-diisothiocyano- stilbene-2,2'-disulfonic acid), a 
chloride ion (CL) channel blocker significantly protected islet HS from isolation- 
induced depletion (Fig. 5.18). Inhibition of the Cf channel has been shown to inhibit 
ROS-induced apoptosis in several pathological settings including ischemia-reperfusion 
in mouse cardiomyocytes and lung fibrosis (Mizoguchi et al., 2002, Qi et al., 2009, 
Wang et al., 2005). Recently, Anazawa et al. reported improvement in the yield of islets 
and islet viability by inhibiting Cf channels using DIDS during islet isolation. They 
further demonstrated enhanced function of marginal mass islet transplants and an 
improved insulin profile in response to intraperitoneal glucose challenge in the 
transplant recipients (Anazawa et al., 2011). Despite the documented efficacy of DIDS 
supplementation in these studies, the mode of action of the Cf channel blocker in 
preventing ROS-induced damage remains controversial.
Sharmeen et al. reported a link between Cf influx and an increase in intracellular ROS 
in leukemic cells (Sharmeen et al., 2010). Qi et al further proposed that a Cf channel 
may act as a port of entry for superoxide radicals. Cf channel inhibition may thus lower 
the intracellular levels of ROS (Qi et al., 2009). Conversely, Wang et al. suggested the 
levels of intracellular ROS was not affected by Cf channel inhibition but instead ROS- 
induced apoptosis was abolished, indicating that Cf ions act downstream following the 
generation of ROS (Wang et al., 2005). In addition to Cf channels, DIDS has been 
shown to block the voltage-dependant anion channel (VDAC) at the outer membrane of 
mitochondria. VDAC is a crucial channel for regulating mitochondrial metabolism by 
allowing movement of respiratory substrates including ADP, ATP, pyruvate and 
creatine phosphate between the mitochondria and cytosol. VDAC has also been shown 
to mediate cyctochrome C release that triggers the activation of a series of caspases 
during apoptosis. DIDS treatment resulted in VDAC closure and hence, prevented the 
apoptosis signalling cascade. It has also been reported that VDAC closure prevented the 
entry of mitochondrial ROS into the cytosol to cause further intracellular oxidative 
damage. Nevertheless, the role of VDAC in apoptosis remains controversial. It is 
suggested that VDAC may exert anti- or pro-apoptotic effects depending on the cellular 
needs and metabolic stress (Lemasters and Holmuhamedov, 2006, Shore, 2009). Our 
finding that HS is preserved in DIDS-treated islets may be due to the reduction of 
intracellular ROS by blocking the entry of the exogenous or mitochontrial ROS. 
Nevertheless, the HS preserved in islets due to DIDS treatment would be expected to act
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as an antioxidant to neutralise the damaging effect of ROS and enhance beta cell 
viability.
BHA+DMTU- or DIDS-treated islet isografts showed marked loss of their intra-islet HS 
by 3 days post-transplant (Figs. 5.17, 5.19). It is possible that physiological insults such 
as hypoxia and the accumulation of excessive intracellular ROS following 
transplantation induced the loss of intra-islet HS. We suggest that future experiments 
should explore peri-transplant administration of antioxidants as well as antioxidant 
supplementation during the isolation process to more robustly preserve intra-islet HS. 
Furthermore, efforts should also be made to investigate the use of potentially new 
potent antioxidants that are able to prevent the generation of other endogenous oxidants.
It is well established that the islet isolation process induces oxidative stress (Bottino et 
al., 2002). Numerous studies have demonstrated improvement in islet cell survival and 
function via treatment with antioxidants such as vitamins (tocopherol, ascorbic acid), 
metabolites (glutamine, bilirubin) and enzyme mimetics (SOD mimetics) in vitro during 
isolation or in vivo during the peri-transplant period (Avila et al., 2005, Bottino et al., 
2002, Brown et al., 2005, Tajiri and Grill, 1999). Islets lose their vasculature and the 
peri-islet BM (see Chapter 3) as a result of the trauma-associated with the enzymatic 
islet isolation process (Morini et al., 2007, Persson-Sjögren et al., 2000). Such 
physiological deprivation can lead to the generation of ROS. The loss of vasculature 
may create a hypoxic environment that favours the generation of ROS (Itoh et al., 
2012). Additionally, the loss of the islet BM can trigger anoikis, a matrix-detachment 
induced cell death (Grossmann, 2002, Thomas et al., 2001, Thomas et al., 1999, Wang 
and Rosenberg, 1999). Indeed, Li et al. (1999) have reported a dramatic rise in 
intracellular ROS in EDTA-detached endothelial cells (Li et al., 1999). Likewise, 
isolated islets that lose their BM during the isolation process may lead to an elevation in 
intracellular ROS. In support of this notion, our laboratory has demonstrated high levels 
of intracellular ROS in freshly isolated beta cells by flow cytometry (unpublished data). 
Moreover, other non-endocrine cells such as islet resident macrophages, endothelial 
cells and possibly the digested acinar tissues may release ROS in response to stimuli 
during islet isolation (Steiner et al., 1997, Telek et al., 2001, Wiegand et al., 1993).
In addition to ROS, reactive nitrogen species (RNS) such as nitric oxide (NO) 
represents a major mediator of islet damage. Elevated NO levels have also been
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detected in freshly isolated islets (Corbett et al., 1992, Pavlovic et al., 1999). Exposure 
of islet beta cells to cytokine simulates the expression of inducible nitric oxide synthase 
(iNOS), which leads to the production of NO. Other cell types within islets are also 
known to produce NO, namely, ductal cells, endocrine cells and macrophages (Thomas 
et al., 2002). It is becoming increasingly evident that RNS can mediate the degradation 
of HS. In particular, peroxynitrite, which is commonly formed at sites of inflammation 
via a reaction between superoxide and NO radicals, can cause fragmentation of HS 
(Kennett and Davies, 2007, Kennett et al., 2010). It is therefore worth assessing the role 
of RNS in the loss of islet HS during isolation. This task could be approached by 
examining intra-islet HS in islets isolated from iNOS knockout mice, which are 
defective in NO production.
In the clinical setting, human islets are normally cultured for 48-72 hours before 
transplantation. Our study showed slight recovery of intra-islet HS in 4 day-cultured 
islets (Fig. 5.20). However, this process is offset by other risk factors imposed upon 
islet culture. Numerous studies have demonstrated that islets deteriorate rapidly in 
culture, as shown by increased apoptosis (Noguchi et al., 2010). In addition, a gradual 
reduction in insulin secretion in response to a glucose challenge was identified as the 
duration of islet culture increased (Vivot et al., 2011). Up-regulation of 
proinflammatory mediators including IL-6, 1L-8, CXCL-1, VC AM and increased NF- 
kB proflammatory signalling were also noted in cultured islets (Negi et al., 2012, Vivot 
et al., 2011). We have discovered that cultured islets do not regain their islet BM after 4 
days of culture (Chapter 3, Section 3.1.3), suggesting that islet cells are likely to 
become susceptible to anoikis-induced cell death. Additionally, isolated islets deprived 
of their blood supply are exposed to a hypoxic environment during culture in a 10% 
CCVair gas phase. Islets are therefore subject not only to the trauma of isolation but 
also culture-related insults. Taken together, islet culture may allow time for the onset of 
HS recovery but this process is likely to be offset by culture-induced insults.
Similar to BHA+DMTU- or DIDS-treated islets (Figs. 5.17, 5.19), 4-day cultured islets 
failed to exhibit improved HS levels post-transplant (Fig. 5.21). Instead, the HS content 
of 4-day cultured islets was similar to control uncultured islets at day 3 post-transplant. 
This suggested that the hypoxic environment immediately after transplantation and 
before revascularisation possibly further contributes to the depletion of intra-islet HS.
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In summary, our study has unveiled a role for ROS in the loss of intra-islet HS during 
the islet isolation. Thus, we advocate that antioxidant and/or DIDS treatment during the 
islet isolation process represents a promising strategy to improve intra-islet HS, a 
critical requirement for the survival of islet beta cells. In addition, we have found that 
islet culture resulted in a marginal improvement in intra-islet HS content. Despite our 
failure to identify HS mimetics capable of replacing the lost HS in islets, we have 
highlighted several important aspects that should be taken into consideration in 
developing HS mimetics that could overcome the uptake barrier. HS mimetics should be 
small in size, flexible in chemical joints and have reduced charge to favour delivery of 
the compounds into the islet cells.
In this chapter, HS protection rather than HS replacement was found to be an effective 
approach for maintaining beta cell HS in isolated islets. Our studies revealed a role for 
ROS, and not heparanase, as the likely mechanism leading to HS depletion during the 
process of islet isolation. The addition of antioxidants or a chloride ion channel blocker 
in the isolation procedure was found to significantly improve the HS content of islets, 
most probably by reducing the intracellular levels of ROS. Conversely, the maintenance 
of islets in culture does not promote efficient endogenous synthesis of HS in beta cells, 
possibly due to the culture-induced risk factors that offset the HS recovery process. 
Nevertheless, isografts of islets in which intra-islet HS was preserved pre-transplant, 
failed to maintain their intra-islet HS, suggesting that in vivo strategies also need to be 
employed to prevent post-transplant loss of islet HS. We propose that the preservation 
of islet HS pre- and early post-transplant could improve islet quality and thereby reduce 
the number of islets required to restore normoglycaemia in transplant recipients.
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CHAPTER 6 : The role of heparanase in the 
rejection of islet allografts
6.0 Introduction
The findings presented in Chapter 4 provide evidence that intra-islet HS that is critical 
for the survival of islet beta cells is recovered in islet isografts by 10 days post-
transplant. In contrast, islet allografts show signs of recovery of intra-islet HS early 
post-transplant. Thereafter, the partially recovered intra-islet HS is lost as rejection 
progressed, prior to complete destruction of the islet cell mass. The loss of intra-islet HS 
in the rejecting allografts therefore suggested the possible contribution of HS-degrading 
mechanisms to the rejection response. This chapter therefore set out to examine the role 
of the HS-degrading enzyme heparanase, in the rejection of islet allografts.
Allograft rejection encompasses a series of immunological events including 
allorecognition, T cell activation and leukocyte recruitment to the graft site (Le Moine 
et al., 2002, Wood and Goto, 2012). Leukocyte recruitment requires extravasation (or 
diapedesis), a process by which leukocytes migrate out of the blood circulatory system 
to the target site. In most instances, leukocyte migration occurs at post-capillary venules 
that comprise an endothelial cell monolayer and an underlying basement membrane 
embedded with pericytes (the contractile cells that wrap around the endothelium) 
(Sorokin, 2010). Leukocyte extravasation is a multistep process requiring (i) leukocyte 
rolling on the apical side of endothelium, (ii) chemokine-induced activation of integrins 
by the leukocytes, (iii) leukocyte arrest, (iv) integrin-mediated adhesion of the 
leukocytes to endothelial cells and (v) movement of the leukocytes between (para- 
cellular) or across (transcellular) the endothelial cells. Leukocytes must then traverse the 
subendothelial basement membrane (BM) barrier before they migrate to the graft site 
(Ley et al., 2007). Upon arrival at the graft site, leukocytes deploy various effector 
mechanisms to destroy the allogeneic transplant tissue (Le Moine et al., 2002, Wood 
and Goto, 2012).
Amongst the sequence of steps in leukocyte recruitment, traversing subendothelial BMs 
stands out as the rate-limiting step (Bartholomaus et al., 2009, Marchesi and Florey,
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1960). BMs are made up of interweaving networks of the matrix proteins collagen type 
IV and laminin stabilised or linked by nidogen and perlecan (Timpl and Brown, 1996). 
The interactions between the different matrix proteins in BMs provide the scaffold and 
architecture for underlying cells and characteristically confer a physical barrier to 
invading cells. Notably, the linear structure of HS in the heparan sulfate proteoglycan 
(HSPG) perlecan contributes significantly to this barrier function (Ishida et al., 2004, 
Parish, 2006).
Upon extravasation, a range of degradative enzymes that target different matrix proteins 
are deployed to break down the subendothelial BM and facilitate leukocyte migration. 
Matrix-degrading enzymes secreted by neutrophils, lymphocytes, monocytes, 
endothelial cells and platelets have been found to participate in BM degradation during 
inflammation. These proteolytic enzymes include elastase, matrix metalloproteases, 
cysteine proteases (cathepsins), serine proteases (plasminogen activator), sulfatases and 
heparanase (Bartlett et al., 1995, Lukes et al., 1999, Obermajer et al., 2008).
Heparanase is well recognised for its involvement in numerous physiological and 
pathological processes, including embryonic development, cell growth, tissue 
remodelling, tumour cell metastasis, invasion, angiogenesis, autoimmunity and 
inflammation (Edovitsky et al., 2006, Nakajima et al., 1984, Parish, 2006, Parish et al., 
2001, Patel et al., 2007, Vlodavsky and Friedmann, 2001, Vlodavsky et al., 1983, 
Ziolkowski et al., 2012). Heparanase is an endo-ß-D-glucuronidase that cleaves HS of 
heparan sulfate proteoglycans by hydrolysing the glycosidic bonds between 
glucosamine and uronic acid residues, yielding HS fragments of 5-7 kDa in size (10-20 
sugar residues equivalent) (Pikas et al., 1998). Extensive studies have shown that 
mammalian cells express only a single functional heparanase enzyme, highlighting its 
potential as a target for preventing HS degradation-mediated pathology (Hulett et al., 
1999, Toyoshima and Nakajima, 1999). Due to the widespread activity of heparanase in 
health and disease, its expression and activity, like most degradative enzymes, is tightly 
regulated at transcriptional and post-translational levels including heparanase processing 
(Chapter 1, Section 1.13.1), subcellular localisation (Chapter 1, Section 1.13.6) and 
regulated secretion (Chapter 1, Section 1.13.7).
Heparanase is initially synthesised as a 65 kDa inactive precursor (proheparanase). For 
conversion to its catalytically active form for degrading HS, the proheparanase is
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cleaved by the lysosomal protease, cathepsin L to remove a 6 kDa linker segment 
(Abboud-Jarrous et al., 2008, Zetser et al., 2004). The resulting 50 kDa and 8 kDa 
(human) or 48 kDa and 8 kDa (mouse) subunits associate to form a heterodimer, 
representing the active enzyme heparanase (Fairbanks et ah, 1999, Levy-Adam et ah, 
2003, Zetser et ah, 2004).
Under normal conditions, heparanase expression is restricted to several cell types such 
as placental trophoblasts, blood borne cells and keratinocytes (Edovitsky et ah, 2006, 
Vlodavsky et ah, 1992, Vreys and David, 2007). Increased heparanase expression by 
different cellular sources in pathological settings is well documented. For example, 
heightened expression of heparanase in tumour cells is associated with reduced post-
operative survival, increased tumour growth and enhanced tumour vascularity 
(Davidson et ah, 2007, Doweck et ah, 2006, Ilan et ah, 2006, Kelly et ah, 2003, 
Vlodavsky et ah, 2007). In addition, upregulation of heparanase levels can be found in 
endothelial cells, T cells, B cells, macrophages, dendritic cells, neutrophils, platelets, 
monocytes, Langerhan cells, astrocytes, smooth muscle cells under various pathological 
circumstances (Bartlett et ah, 1995, Freeman and Parish, 1997, Marchetti et ah, 2000, 
Matzner et ah, 1985, Naparstek et ah, 1984, Sewell et ah, 1989, Vlodavsky et ah, 1992, 
Vreys and David, 2007).
Heparanase is a potent matrix-degrading enzyme which facilitates leukocyte migration 
across BM barriers by degrading BM HS (Dempsey et ah, 2000, Li and Vlodavsky, 
2009, Parish, 2006). In addition to its structural role, BMs provide a permissive 
microenvironment for cross talk between cells and the BM matrix proteins to regulate 
the activity of a variety of BM-bound bioactive factors which reside within the BMs 
(Sorokin, 2010, Teti, 1992). Thus, preserving BM integrity is essential for maintaining 
cell health and function. Conversely, breaches of BM integrity greatly disturb the cell- 
ECM signalling and dysregulate the activity of various bioactive molecules, leading to a 
pathological response. Importantly, HS of BM HPSGs serves as a rich reservoir for a 
wide array of bioactive molecules. These include cytokines, chemokines, growth 
factors, tissue remodelling factors, coagulation factors, cell adhesion molecules, 
lipoproteins, lipases, proteases, angiogenic and anti-angiogeneic factors (Parish, 2006, 
Vlodavsky and Friedmann, 2001). Degradation of HS mediated by heparanase releases 
the bioactive fragments that can greatly influence inflammatory responses. In relation to 
this, heparanase expression was shown to promote angiogenesis as well as cell growth,
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differentiation, migration and adhesion (Parish et al., 2001, Vlodavsky and Friedmann, 
2001, Vreys and David, 2007).
It is becoming increasingly evident that heparanase is able to also express non- 
enzymatic functions (Gilat et al., 1995). It is noteworthy that heparanase exhibits 
maximal enzymatic activity between pH 5.4-6.8. Under physiological pH (pH 7.2-7.4), 
heparanase promotes cell adhesion, which in turn, facilitates T cell rolling and arrest 
from rolling under shear flow conditions, in an integrin-dependent manner. Heparanase- 
mediated adhesion augments intracellular signal transduction that results in enhanced 
tyrosine phosphorylation of paxillin (a cytoskeletal protein) and subsequent 
reorganisation of the actin skeleton as well as increased gene expression of VEGF, 
tissue factor (TF) and cyclooxgenase-2 (COX2), that further contributes to cell adhesion 
and migration (Fux et al., 2009, Gilat et al., 1995, Goldshmidt et al., 2003, Sotnikov et 
al., 2004). Hence, depending on the local tissue pH, heparanase can function as a HS- 
degrading endoglycosidase (under acidic conditions) or promote cell adhesion at 
physiological pH (Gilat et al., 1995).
Cathepsin L is a cysteine protease that is responsible for the activation of heparanase 
(Abboud-Jarrous et al., 2008). Immature pro-cathepsin L undergoes autolysis at acidic 
pH to form active cathepsin L in late endosomes anchor lysosomes (lshidoh et al., 1998, 
Probst et al., 2006, Reiser et al., 2010). Cathepsin L is capable of cleaving several ECM 
components (e.g., collagens, fibronectin and elastin) (Kumar et al., 2012) and is 
responsible for protein maturation, terminal protein degradation and proenzyme 
processing. It is also involved in the degradation of invariant chain (Ii) during antigen 
processing for MHC class II molecules. In view of its versatile proteolytic function, it is 
therefore not surprising that cathepsin L is implicated in a series of pathological events 
such as autoimmune diseases, tumour metastasis and invasion (Reiser et al., 2010).
Recently, Ziolkowski et al. identified a critical role for heparanase expression in the loss 
of intra-islet HS during the onset and progression of Type 1 diabetes (T1D) in NOD/Lt 
mice. Alcian blue histochemistry that selectively stains heparan sulfate revealed well- 
preserved HS within intact insulitis-free NOD/Lt islets whereas disrupted HS staining 
was demonstrated in islets with destructive insulitis. Quantitative analysis of alcian blue 
histochemistry further demonstrated a progressive reduction of intra-islet HS during 
T1D disease development. High levels of heparanase transcripts, which correlated with
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the mRNA expression for CD45, a common leukocyte marker, were detected in 
prediabetic and onset diabetic NOD/Lt islets. In line with this finding, 
immunohistochemistry showed intense levels of heparanase protein localised at the cell 
surface of insulitis mononuclear cells (MNCs). Western blotting further showed that 
insulitis MNCs produce catalytically active heparanase at the time of T1D onset. These 
findings suggested that heparanase degrades islet BM HS, allowing insulitis MNCs to 
traverse the islet BM barrier, and induce beta cell death. Indeed, the production of active 
heparanase by insulitis MNCs was identified as the signal initiating the onset of 
destructive autoimmune disease. Thereafter, the local production of active heparanase 
within islets led to a progressive depletion of intra-islet HS, beta cell death, loss of 
insulin production, and eventually T1D. In support of this proposed effector 
mechanism, in vivo treatment with heparanase inhibitor PI-88 significantly preserved 
intra-islet HS and significantly reduced the incidence of T1D in NOD/Lt mice by 50%. 
Together, these findings revealed that heparanase represents a novel effector mechanism 
in T1D by degrading islet-associated HS that is critical for the survival of islet beta cells 
(Ziolkowski et al., 2012).
In view of the involvement of heparanase in T1D and the findings that islets lose HS 
during allograft rejection (Chapter 4), an investigation was undertaken to examine the 
role of heparanase in the rejection of pancreatic islet allografts and to determine if novel 
HS mimetics/heparanase inhibitors protect islet allografts from immune destruction.
6.1 Results
6.1.1 Expression and localisation of heparanase (Hpse) and cathepsin L (Ctsl) in 
islet isografts
C57BL/6 islets were isolated and transplanted beneath the kidney capsule of isogeneic 
C57BL/6 recipient mice. Isografts were harvested at 3-7 days post-transplant and frozen 
for RNA extraction (Chapter 2, Section 2.6.4). In addition, isografts retrieved at 3-10 
days post-transplant were fixed in formalin for immunohistochemistry (Chapter 2, 
Section 2.6.1). Real-time RT-PCR analyses (Chapter 2, Section 2.7) revealed a 7-9-fold 
increase in heparanase transcript expression in islet isografts at 3-7 days post-transplant, 
compared to freshly isolated islets (Fig. 6.1 A). Immunohistochemical staining for 
heparanase protein demonstrated localisation of heparanase predominantly at the cell 
surface of islet cells, particularly in isolated islets (Fig. 6.2B) and during the early post-
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Figure 6.1 Expression of heparanase and CD45R transcripts in isolated 
islets and islet isografts
(A) Quantitative real-time RT-PCR analyses demonstrated that heparanase 
transcripts increased 6-8-fold in islet isografts, relative to isolated islets 
whereas (B) CD45R mRNA expression increased 10-22-fold in islet isografts 
compared to isolated islets. Normal C57BL/6 mouse kidney was included as 
a reference control for comparative CT analyses. Data represents mean±SEM. 
n=4 independent experiments *p<0.05; **p<0.01; ***p<0.001. (K) kidney. . 
Statistical analysis was performed using one-way ANOVA.
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Figure 6.2 Localisation of heparanase in mouse islets in situ in host 
pancreas, isolated islets and islet isografts by immunohistochemistry using 
anti-heparanase mAb
(A) Immunohistochemical staining of C57BL/6 mouse pancreas revealed that 
C57BL/6 islets in situ weakly expressed heparanase protein. (B) Cell surface 
staining (see arrows) for heparanase was observed in isolated islets. (C, E, G) 
Strong cell surface staining for heparanase was consistently displayed by islet 
isografts at days 3, 5 and 7 post-transplant. (I) Consistently, cell surface 
heparanase staining became weaker by 10 days post-isotransplantation. (A, B, 
C, E, G, I) anti-HP 130 mAb. (D, F, H, J) Haematoxylin and eosin. 1, islets; K, 
kidney parenchyma; B, residual blood clots; *, graft revascularisation. Scale 
bars=100pM.
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transplant period (Fig. 6.2C, E). There were no major differences in heparanase 
expression between isolated islets (mean Hpse+ve islet area=l 1.70±0.89%) and 
isografts (Day 3 isografts, mean % Hpse +ve islet area= 9.11±2.22%; Day 5 isografts, 
mean Hpse +ve islet area= 7.36±1.20%; Day 7 isografts, mean Hpse +ve islet 
area=9.67±0.94%), except for day 10 isografts (mean Hpse +ve islet area=3.20+0.25%, 
pO.OOl) (Fig. 6.21), which showed a significant 3.7-fold reduction in the % Hpse+ve 
islet area (Fig. 6.3A). In contrast, the Hpse+ve islet area in days 3-7 isografts was 4.3- 
5.6-fold higher than islets in situ in the pancreas (Fig. 6.3A). Interestingly, opposite 
trends were observed for the expression of heparanase between mRNA and protein in 
the isografts relative to the isolated islets (Figs. 6.1 A, 6.3). This finding suggests that 
heparanase mRNA is upregulated following transplantation, but the protein was not 
synthesised in the absence of appropriate stimuli.
In comparison to C57BL/7 isles in situ (C57BL/6 islets in situ, mean % Ctsl+ve islet 
area=35.00+4.73%; mean staining intensity=0.54±0.04 A.U) (Fig. 6.5A), there was a 
significant increase in cathepsin L protein in the isolated islets (Isolated C57BL/6 islets, 
mean % Ctsl+ve islet area=73.43±2.30%; mean staining intensity=0.84±0.03 A.U; 
pO.OOl) (Fig. 6.5B). An approximately 2-fold increase in cathepsin L transcript 
expression was detected in isografts, compared to freshly isolated islets (Fig. 6.4A). 
Immunohistochemistry for cathepsin L showed that the levels of cathepsin L protein 
expression decreased following isotransplantation (Day 3 isografts, mean% Ctsl+ve 
islet area=30.35±8.81%; mean staining intensity=0.44±0.08 A.U; Day 5 isografts, mean 
% Ctsl+ve islet area=48.34±5.60%; mean staining intensity=0.57±0.05 A.U; Day 7 
isografts, mean% Ctsl+ve islet area=44.60±4.41%; mean staining intensity=0.57±0.03 
A.U; Day 10 isografts, mean % Ctsl+ve islet area=62.00+4.00% ; mean staining 
intensity=0.72±0.04 A.U). Similar to heparanase expression, there was an opposite 
trend in cathepsin L expression at mRNA and protein levels between isolated islets and 
isografts (Figs. 6.4A, 6.6). The discrepancy between the cathepsin L mRNA and protein 
levels could be due to the increased transcription of cathepsin L triggered by the 
isolation-induced physiological insults. However, mRNA translation into protein was 
not apparent.
Interestingly, a 10-22-fold rise in CD45R transcript expression was observed in the 
isografts when compared with the isolated islets (Figs. 6.IB, 6.4B). We attribute the 
increased CD45 transcript expression to a mild inflammatory response induced by
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Figure 6.3 Morphometric analysis of islet area stained for heparanase in islets 
in situ in the host pancreas, isolated islets and in islet isografts.
Morphometric analyses of heparanase immunohistochemistry showed that 
C57BL/6 isolated islets (mean Hpse+ve islet area=l 1.70±0.89%; mean staining 
intensity=0.26±0.01 A.U) exhibited an increase in heparanase when compared with 
islets in situ (mean Hpse+ve islet area=1.72±0.27%; mean staining
intensity=0.19±0.04 A.U). The % Hpse+ve islet area remained consistently high 
after isotransplantation as depicted by islet isografts at 3, 5, and 7 post-transplant 
(Day 3 isografts, mean Hpse+ve islet area= 9.11 ±2.22%; mean staining 
intensity=0.29±0.01 A.U; Day 5 isografts, mean Hpse+ve islet area= 7.36±1.20%; 
mean staining intensity=0.23±0.01 A.U; Day 7 isografts, mean Hpse+ve islet 
area=9.67±0.94%; mean staining intensity=0.25±0.01 A.U). By day 10 post-
transplant, a 6.47% decrease in the Hpse+ve islet area (mean staining 
intensity=0.21±0.01) was observed, compared to day 7 isografts. The data shows the 
mean % islet area stained with heparanaseiSEM (A,B) and mean intensity of 
heparanaseiSEM (C,D). The total number of islets examined/group, were as 
follows: n=19 C57BL/6 islets in situ; n=60 isolated C57BL/6 islets; n= 9 islets at 
day 3 post-transplant; n= 33 islets at day 5 post-transplant; n= 33 islets at day 7 
post-transplant; n= 33 islets at day 10 post-transplant. Data were analysed from 3 
independent specimens, n=l-24 islet(s) /sample. Statistical analysis was performed 
using Kruskal-Wallis Test. **p<0.01; ***p<0.001. Hpse, heparanase.
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(A) (B)
C57BL/6 Isolated d3 d5 d7 dlO C57BL/6 Isolated d3 d5 d7 dlO
Islets C57BL/6 ----------------------------------------------------  Islets C57BL/6
in situ islets Isografts /n situ islets Isografts
Sam ples P value  
(area)
P value  
(m ean  
intensity)
C57BL/6 islets in situ  V  isolated islets <0.001 <0.001
C57BL/6 islets in situ  V  day 3 islet isografts <0.001 <0.01
C57BL/6 islets in situ  V  day 5 islet isografts <0.01 n.s
C57BL/6 islets in situ  V  day 7 islet isografts <0.001 <0.01
C57BL/6 islets in situ  V  day 10 islet isografts n.s n.s
Isolated C57BL/6  is lets V day 3 islet isografts n.s n.s
Isolated C 57BL/6 is lets V  day 5 islet isografts <0.05 n.s
Isolated C 57BL/6  islets V day 7 islet isografts n.s n.s
Isolated C 57BL/6  is lets V day 10 islet isografts <0.001 <0.05
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Figure 6.4 Expression of cathepsin L and CD45R mRNAs in isolated islets, 
islet isografts and mouse kidneys
Quantitative real-time RT-PCR analyses demonstrated an increase in cathepsin L 
mRNA expression (up to 2-fold) in C57BL/6 islet isografts at 3-7 days post-
transplant. (B) There was a 10-22-fold increase in CD45R transcript expression in 
islet isografts at 3-7 days post-transplant, relative to isolated islets. Normal 
C57BL/6 mouse kidney was included as a reference control for comparative CT 
analyses. Data represents meaniSEM. n=4 independent experiments. *p<0.5; 
***p<0.001. (K) kidney. Statistical analysis was performed using one-way 
ANOVA.
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Figure 6.5 Localisation of cathepsin L in mouse islets in situ in host pancreas, 
isolated islets and islet isografts by immunohistochemistry using anti- 
cathepsin L mAb
(A) Immunostaining of C57BL/6 mouse pancreas revealed strong and uniform 
localisation of cathepsin L was seen within C57BL/6 native islets. (B) Isolated 
C57BL/6 islets also displayed strong intra-islet staining for cathepsin L (see 
arrows). (C, E, G) Intra-islet staining for cathepsin L remained intense in islet 
isografts at 3-10 days post-transplant. (A, B, C, E, G, I) anti-cathepsin L mAb. (D, 
F, H, J) Haematoxylin and eosin. 1, islets; K, kidney parenchyma; B, residual 
blood clots; *, graft revascularisation. Scale bars=100pM.
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Figure 6.6 Quantitative analysis of islet area stained with cathepsin L in 
islets in situ in the host pancreas, isolated islets and in islet isografts.
Morphometric analyses of cathepsin L immunohistochemistry demonstrated an 
increase in the levels of cathepsin L in C57BL/6 isolated islets (Isolated C57BL/6 
islets, mean % Ctsl+ve islet area=73.43±2.30%; mean staining
intensity=0.84±0.03 A.U), compared to islets in situ (C57BL/6 islets in situ, 
mean % Ctsl+ve islet area=35.00±4.73%; mean staining intensity=0.54±0.04 
A.U). The levels of cathepsin L staining significantly decreased in islet isografts 
at 3-7 days post-transplant (Day 3 isografts, mean % Ctsl+ve islet 
area=30.35±8.81%; mean staining intensity=0.44 0.08 A.U; Day 5 isografts, 
mean % Ctsl+ve islet area=48.34±5.60%; mean staining intensity=0.57±0.05 
A.U; Day 7 isografts, mean % Ctsl+ve islet area=44.60±4.41%; mean staining 
intensity=0.57±0.03 A.U), compared to isolated islets and resembled islets in situ. 
In contrast, by day 10 post-transplant (Day 10 isografts, mean % Ctsl+ve islet 
area=61.99±4.41% ; mean staining intensity=0.72±0.04 A.U), cathepsin L protein 
expression was similar to isolated islets. The data shows the mean % islet area 
stained with cathepsin L±SEM (A,B) and mean intensity of cathepsin L±SEM 
(C,D). The total number of islets examined/group, were as follows: n=30 
C57BL/6 islets in situ\ n=51 isolated C57BL/6 islets; n= 9 islets at day 3 post-
transplant; n= 30 islets at day 5 post-transplant; n= 33 islets at day 7 post-
transplant; n= 34 islets at day 10 post-transplant. Data were analysed from 3 
independent specimens, n=l-39 islet(s) /sample. Statistical analysis was 
performed using Kruskal-Wallis Test. ***p<0.001. Ctsl, cathepsin L.
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surgical-related trauma. In support of this notion, F4/80+ve macrophages were detected 
in isografts at days 3 and 7 post-transplant (Fig. 6.7).
6.1.2 Expression and localisation of heparanase and cathepsin L in islet allografts
In allografts of CBA islets (H-2k) transplanted to C57BL/6 (H-2b) recipient mice, 
heparanase transcript expression was up-regulated 1.7-2.0-fold at days 3-4 post 
transplant and 2.9-4.2-fold at 5-7 days post-transplant, compared to corresponding 
isografts (Fig. 6.8A). In addition, there was a 1.3-2.4 fold increase in CD45R (a 
common leukocyte marker) expression in allografts at days 3-4 post transplant and a7.2- 
11.6-fold increase at 5-7 days post-transplant, compared to corresponding isografts (Fig. 
6.8B). Interestingly, both intra-graft heparanase and CD45R mRNAs exhibited similar 
kinetics of increased expression, suggesting that heparanase transcripts were probably 
produced by the infiltrating mononuclear cells (MNCs) during allograft rejection, 
particularly at 5-7 days post-transplant (Fig. 6.9E, G)). Consistent with the transcript 
analyses, immunohistochemical data showed little if any intra-islet heparanase staining 
in allografts in the early post-transplant period, particularly at day 3 (mean % Hpse+ve 
islet area= 12.53+2.15%) (Fig. 6.9C). Thereafter, intra-graft staining for heparanase 
became increasingly evident in rejecting islet allografts (Day 5 allografts, mean % 
Hpse+ve islet area=16.78±1.42%; Day 7 allografts, mean % Hpse+ve islet 
area=29.36±1.06%; Day 10 allografts, mean % Hpse+ve islet area=40.34±4.19%) (Figs. 
6.9E, G, I, 6.10). Strikingly, heparanase was predominantly localised in the MNCs 
infiltrate the graft site and not in the donor islet tissue (Figs 6.9). There were also some 
isolated cells within the engrafted islets that strongly expressed heparanase at their cell 
surface in the rejecting allografts at days 5-7 post-transplant (Fig. 6.9E, G). It is unclear 
whether these heparanase+ve intra-islet cells were islet endocrine cells or invading 
MNCs. Western blotting analysis demonstrated that active heparanase protein was 
expressed at 48-fold higher levels in day 7 allografts compared to the corresponding 
isografts (Fig. 6.11). Similar levels of inactive heparanase were detected in both 
isografts and allografts at 7 days post-transplant (Fig. 6.11). Taken together, these 
findings are consistent with a significant increase in intra-graft heparanase expression 
attributable to infiltrating MNCs during islet allograft rejection.
In relation to cathepsin L, real time RT-PCR analysis indicated a decrease in transcript 
expression in the allografts compared to the isografts (Fig. 6.12A), inversely correlating 
with transcript expression for CD45R (Figure 6.12B). In contrast to heparanase,
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Figure 6.7 Localisation of macrophages in day 3 and day 7 islet isografts 
by immunohistochemistry using F4/80 mAb
Immunohistochemical localisation of macrophages in islet isografts at days 3 
and 7 post-transplant revealed a low accumulation of macrophages in day 3 
isografts (A) and an intense intra-graft macrophage population (see arrows) in 
day 7 isografts (C). (A, C) F4/80 mAb. (B, D) Haematoxylin and eosin. I, 
islets; K, kidney parenchyma; B, residual blood clots; *, graft 
revascularisation. Scale bars=100pM.
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Figure 6.8 Expression of heparanase and CD45R transcripts in isolated 
islets, islet isografts and allografts
Quantitative real-time RT-PCR analyses demonstrated that heparanase 
mRNA expression increased 6-8-fold in islet isografts compared to isolated 
islets whereas hepanarase mRNA expression in islet allografts increased 1.7- 
2.0-fold at 3-4 days and 2.9-4.2-fold at 5-7 days, compared to corresponding 
islet isografts. CD45R mRNA expression increased 10-22-fold in islet 
isografts relative to isolated islets. In allografts, CD45R mRNA expression 
increased 1.3-2.4 -fold at 3-4 days and was 7.2-11.6-fold higher at 5-7 days, 
compared to corresponding islet isografts. The expression of intra-graft 
heparanase mRNA correlated with intra-graft expression of CD45R in the 
islet allografts. Normal C57BL/6 mouse kidney was included as a reference 
control for comparative CT analyses. Data represents meaniSEM. n=4 
independent experiments *p<0.05; ***p<0.001. (K) kidney. Statistical 
analysis was performed using one-way ANOVA.
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Figure 6.9 Localisation of heparanase in mouse islets in situ in host pancreas, 
isolated islets and islet allografts by immunohistochemistry using anti- 
heparanase mAb
Immmunostaining of CBA mouse pancreas identified weak expression of 
heparanase in islets in situ. In contrast, more intense cell surface staining was 
shown in CBA isolated islets (B). Allografts exhibited little or no intra-islet 
staining for heparanase (C, E, G, I). Islet allografts at days 5, 7 and 10 post-
transplant (E, G, I) were characterised by intense staining for heparanase in 
infiltrating mononuclear cells (MNCs) and only weak, if any, intra-islet staining. 
(A, B, C, E, G, I) anti-heparanase HP 130 mAb. (D, F, H, J) Haematoxylin and 
eosin. I, islets; DI, damaged islets; IR, islet remnants; MNCs, mononuclear cells; 
K, kidney parenchyma. Scale bars=100pM.
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Figure 6.10 Quantitative analysis of the Hpse+ve islet area in islets in situ in 
the host pancreas, isolated islets and in islet allografts
(A, B) C57BL/6 islet isografts from 3-10 days post-transplant displayed a 
decrease in heparanase expression within the graft site (Day 3 isografts, mean % 
Hpse+ve islet area=17.47±2.19%; mean staining intensity=0.23±0.01 A.U; Day 5 
isografts, mean % Hpse+ve islet area=12.39±2.62%; mean staining 
intensity=0.24±0.02 A.U; Day 7 isografts, mean % Hpse+ve islet 
area=8.49±1.99%; mean staining intensity=0.26±0.02 A.U; Day 10 isografts, 
mean % Hpse+ve islet area=6.87±1.71% ; mean staining intensity=0.22±0.01 
A.U). In contrast, intragraft heparanase staining increased in corresponding CBA 
islet allografts in C57BL/6 recipient mice (Day 3 allografts, mean % Hpse+ve 
islet area=12.53±2.15%; mean staining intensity=0.20±0.01 A.U; Day 5 
allografts, mean % Hpse+ve islet area=16.78±1.42%; mean staining 
intensity=0.25±0.01 A.U; Day 7 allografts, mean % Hpse+ve islet 
area=29.36±1.06%; mean staining intensity=0.29±0.01 A.U; Day 10 allografts, 
mean % Hpse+ve islet area=40.34±4.19% ; mean staining intensity=0.34±0.01 
A.U). The data shows the mean % islet area stained with heparanase±SEM (A,B) 
and mean intensity of heparanaseiSEM (C,D). The total number of islets 
examined/group, were as follows: n= 15 islets at day 3 post-transplant; n= 21 
islets at day 5 post-transplant; n= 20 islets at day 7 post-transplant; n= 10 islets at 
day 10 post-transplant. Data were analysed from 3 independent specimens, n=2- 
10 islet(s) /sample. Statistical analysis was performed using Kruskal-Wallis Test. 
***p<0.001. V, versus; Hpse, heparanase.
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Figure 6.11 Detection of active heparanase and inactive proheparanase 
protein in isolated islets, islet isografts and allografts by western blotting
Representative data for Western blotting analyses shows that a 48-fold increase 
of active heparanase was detected in rejecting islet allografts at 7 days post-
transplant compared to corresponding islet isografts. Conversely, active 
heparanase was absent in C57BL/6 and CBA isolated islets (Upper panel) . 
Inactive proheparanase protein was detected in isolated islets, islet isografts and 
islet allografts. Densitometry analyses demonstrated 6-18-fold higher levels of 
proheparanase in islet isografts and allografts, compared to isolated islets 
(Lower panel). n=2 independent experiments. For each experiment, C57BL/6 
and CBA isolated islets were each pooled from 2 separate islet preparations (5 
donors/preparation); Islet isografts and allografts were each pooled from 2 
individual day 7 transplants. Anti-heparanase HP130mAb was used to detect 
active heparanase and anti-heparanase 1453 pAb was used to detect inactive 
heparanase.
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Figure 6.12 Expression of cathepsin L and CD45R transcripts in isolated islets, 
islet isografts and allografts
Quantitative real-time RT-PCR analyses revealed a 2-fold increase in cathepsin L 
mRNA expression in day 3 C57BL/6 islet isografts relative to C57BL/6 isolated 
islets and the level of transcript expression showed only minor fluctuations at 4-7 
days post-transplant. In allografts, there was an initial 3-fold increase in cathepsin L 
mRNA expression at 3 days post-transplant to C57BL/6 recipient mice, compared 
with donor CBA isolated islets. Thereafter, cathepsin L mRNA expression 
decreased progressively with time, compared to corresponding isografts. In contrast, 
CD45R mRNA expression was 7.2-11.6-fold higher in islet allografts at 5-7 days, 
compared to corresponding islet isografts. The expression of cathepsin L mRNA 
therefore correlated inversely with the expression of CD45R in islet allografts. 
Normal C57BL/6 mouse kidney was included as a reference control for comparative 
CT analyses. Data represents mean±SEM. n=4 independent experiments *p<0.05; 
***p<0.001. (K) kidney. Statistical analysis was performed using one-way 
ANOVA.
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immunohistochemical and Western blotting analyses showed that the expression of 
active cathepsin L in islet allografts was localised mainly in the donor islet tissue (Figs. 
6.13, 6.15). Therefore the decreased expression of cathepsin L mRNA in allografts 
corresponded to the decline in islet cell mass during the course of rejection (Fig. 3.1). 
Immunohistochemical analyses showed that intense intra-islet staining for cathepsin L 
was localised in isolated islets and islet allografts at 3 and 5 days post-transplant (Day 3 
allografts, mean % Ctsl+ve islet area=37.82±6.88%; mean staining intensity=0.51±0.04 
A.U; Day 5 allografts, mean% Ctsl+ve islet area=24.50±6.54%; mean staining 
intensity=0.39±0.06 A.U) (Figs. 6.13C, E, 6.14). By 7-10 days post-transplant (Day 7 
allografts, mean % Ctsl+ve islet area=35.90±5.63%; mean staining intensity=0.44±0.04 
A.U; Day 10 allografts, mean % Ctsl+ve islet area=27.47±5.28%; mean staining 
intensity=0.60±0.05 A.U) (Figs. 6.13G, I, 6.14), rejecting allografts showed disrupted 
intra-islet cathepsin L staining in damaged islet tissue but little localisation was 
associated with the cellular infiltrate. This suggests that the endogenous cathepsin L 
may be released from islets upon tissue destruction. Consistent with this, Western 
blotting analyses revealed a 1.7-fold increase in active cathepsin L protein level in day 7 
allografts relative to corresponding isografts (Fig. 6.15).
6.1.3 The contribution of heparanase to the acute rejection of islet allografts 
6.1.3.1 Effect of in vivo treatment with heparanase inhibitors or anti-heparanase 
serum on islet allograft rejection
The capacity for in vivo heparanase inhibition to prolong CBA islet allograft survival 
and function was evaluated by treating diabetic C57BL/6 recipient mice with 
chemically modified heparins, BT-382 and BT-206 (Chapter 2, Section 2.5.1) at 80 
mg/kg/day i.p. from dO. Both treatments (BT-382, mean survival time (MST) of 7.0+0 
days; BT-206, MST of 6.3+0.3 days; n=3/groups) did not differ significantly to saline 
controls (MST=7.3±0.5 days, n=4/group) (Fig. 6.16A). To address the likely problem of 
the heparanase inhibitors having a short half-life in the circulation (Norrby, 2006, 
Shafat et al., 201 la), the frequency of drug administration was increased to 3 times/day. 
Likewise, treatment with BT-382 (mean survival time of 10.3+1.7 days, n=4) and BT- 
206 (mean survival time of 9.8+0.5 days, n=4), administered 3 times per day at 
40mg/kg/dose i.p, every 6-8 hours failed to enhance graft survival when compared with 
saline controls (mean survival time of 8.0+0.9 days, n=6) (Fig. 6.16B). Similarly, 
treatment of allograft recipient mice with polyclonal rabbit anti-human heparanase 
serum (2.5 mg/ml i.p at days 0, 3, 6 and 9 post-transplant) failed to improve allograft
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Figure 6.13 Localisation of cathepsin L in mouse islets in situ in host 
pancreas, isolated islets and islet allografts by immunohistochemistry 
using anti-cathepsin L mAh
Strong intra-islet staining for cathepsin L was observed in (A) CBA islets in 
situ, (B) isolated islets and (C, E, G, I) CBA donor islet tissue in islet allografts 
at days 3, 5, 7 and 10 post-transplant. Notably, (G, I) patchy staining for 
cathepsin L was observed in damaged islet tissue in rejecting islet allografts at 
7-10 days post-transplant. Arrows show cathepsin L localised in donor islet 
tissue and not infiltrating MNCs. (A, B, C, E, G, I) anti-cathepsin L mAb. (D, 
F, H, J) Haematoxylin and eosin. I, islets; DI, damaged islets; IR, islet 
remnants; MNCs, mononuclear cells; K, kidney parenchyma. Scale 
bars=100pM.
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Figure 6.14 Quantitative analysis of Ctsl+ve islet area in mouse pancreata, 
isolated islets and islet transplants
The levels of cathepsin L staining remained consistently high after islet 
isolation. In general, allografts (Day 3 allografts, mean % Ctsl+ve islet 
area=37.82±6.88%; mean staining intensity=0.51±0.04 A.U; Day 5 allografts, 
mean % Ctsl+ve islet area=24.50±6.54%; mean staining intensity=0.39±0.06 
A.U; Day 7 allografts, mean % Ctsl+ve islet area=35.90±5.63%; mean staining 
intensity=0.44±0.04 A.U; Day 10 allografts, mean % Ctsl+ve islet 
area=27.47±5.28%; mean staining intensity=0.60±0.05 A.U) displayed 
decreased levels of intra-islet cathepsin L compared to isolated islets (Isolated 
CBA islets, mean % Ctsl+ve islet area=58.84±1.50%; mean staining 
intensity=0.66±0.01 A.U). The data shows the mean % islet area stained with 
cathepsin L±SEM (A,B) and mean intensity of cathepsin L±SEM (C,D). The 
total number of islets examined/group, were as follows: n=21 CBA islets in 
situ\ n=93 isolated CBA islets; n= 12 islets at day 3 post-transplant; n= 17 
islets at day 5 post-transplant; n= 19 islets at day 7 post-transplant; n= 7 islets 
at day 10 post-transplant. Data were analysed from 3 independent specimens, 
n=l-39 islet(s) /sample. Statistical analysis was performed using Kruskal- 
WallisTest. *p<0.05; **p<0.01; ***p<0.001. V, versus; Ctsl, cathepsin L.
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Figure 6.15 Detection of active and inactive cathepsin L protein in in 
isolated islets, islet isografts and allografts by Western blotting
Western blotting analysis demonstrated that cathepsin L protein in C57BL/6 
and CBA isolated islets was predominantly in the non-catalytic or inactive 
form. In contrast, C57BL/6 islet isografts at 7 days post-transplant exhibited 
similar levels of active and inactive cathepsin L and corresponding CBA 
islet allografts in C57BL/6 recipient mice expressed mainly active cathepsin 
L. A 2-fold increase of active cathepsin L protein levels was observed in day 
7 allografts compared to the corresponding isografts. Islets isolated from 
cathepsin L knockout mice served as a negative control. No background 
staining was observed using isotype control, normal goat IgG. n=2 
independent experiments. For each experiment, C57BL/6 and CBA isolated 
islets were each pooled from 2 separate islet preparations (5 
donors/preparation); Islet isografts and allografts were each pooled from 2 
individual day 7 transplants.
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Figure 6.16 In vivo treatment with heparanase inhibitors fails to prolong 
islet allograft survival
Based on the Kaplan-Meier survival curves, treatment of alloxan diabetic 
C57BL/6 (H-2b) mice carrying allografts of CBA (H-2k) islets with the 
heparanase inhibitors, 382 (chemically modified low molecular weight 
heparin) or 206 (chemically modified 12 kDa heparin) administered as (A) a 
single daily dose (80 mg/kg/day i.p) from day 0 or (B) 3 daily doses of 40 
mg/kg i.p from day 0, did not prolong the survival and function of islet 
allografts. (C) Treatment with anti-heparanase serum (2.5 mg/day) i.p at days 
0, 3, 6 and 9 did not prolong islet allograft survival compared to saline-treated 
controls. Statistical analysis was performed using the log-rank test, showed no 
statistical significant differences between the groups.
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survival and function (mean survival time of 10.3+1.3 days, n=4) relative to islet 
allografts in saline-treated control mice (mean survival time of 10±1.2 days, n=4) (Fig. 
6.16C). These findings demonstrated that neither treatment of recipient mice with 
modified heparins as heparanase inhibitors (modified heparins BT-382 and BT-206) nor 
with anti-heparanase serum prolonged the survival of islet allografts.
6.1.3.2 Histological assessment of islet allografts in heparanase knockout recipient 
mice
To further examine the role of heparanase in the rejection of islet allografts and to avoid 
the potential issue of the short half-life of heparin derivatives/heparanase inhibitors in 
the circulation, CBA islets were transplanted into normal wild-type C57BL/6 and 
heparanase knockout (B6.Hpse-KO) recipient mice. The grafts were retrieved 7 days 
post-transplant for histological assessment. Allografts obtained from both wild-type 
(mean % islet+ve graft area=12.95±1.70%) (Fig. 6.17A, C) and B6.Hpse-KO (mean % 
islet+ve graft area=T 4.17+2.62%) (Fig. 6.17B, C) recipient mice were rejected. 
Damaged islet tissue accompanied by an intense infiltration of MNCs was observed at 
the graft site. While the removal of catalytically active heparanase from the host 
immune response by genetic engineering failed to prevent the rejection of islet 
allografts, it is possible that other HS-degradative processes compensate in host mice 
have developed under physiological conditions of heparanase deficiency.
6.1.3.3 Histological assessment of islet allografts in cathepsin L knockout (B6.Ctsl- 
KO) recipient mice
Since cathepsin L is required to activate propheparanase and islets represent a rich 
source of cathepsin L, the contribution of cathepsin L to allograft rejection was 
investigated as an alternative to heparanase inhibition or depletion. Compared to CBA 
(H-2k) islet allografts derived from B6.Hpse-KO (H-2b) (mean % islet+ve graft 
area= 14.17+2.62%) (Fig. 6.17B) and wild-type C57BL/6 recipient mice (mean % 
islet+ve graft area=12.95±1.70%) (Figs. 6.17A, 6.18A), islet allografts B6.Ctsl-KO 
recipient mice at 7 days post-transplant exhibited well-vascularised, intact islets with 
little, if any, cellular infiltration at the graft site (mean % islet+ve graft 
area=44.44±4.69%) (Fig. 6.18B, D). Conversely, allografts retrieved from B6.Ctsl-KO 
recipient mice at 14 days post-transplant exhibited extensively damaged islet 
morphology with intense MNC infiltration (mean % islet+ve graft area=6.37±1.67%)
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Figure 6.17 Histological assessment of islet allografts in wild-type and 
heparanase knock-out C57BL/6 recipient mice
Islet allografts in (A) C57BL/6 wild type and (B) B6.Hpse-KO recipient mice 
at day 7 post-transplant showed damaged islets and intense mononuclear cell 
infiltration at the graft site. (C) Quantitative assessment of islet tissue at the 
graft site revealed that donor islet tissue survival was not improved by the 
absence of active heparanase in host mice (WT, mean % islet+ve graft 
area=12.95±1.70%; B6.Hpse-KO, mean % islet+ve graft area=14.17±2.62%). 
(C) The data shows the mean islet+ve graft area±SEM, n=3/group. Statistical 
analysis was performed using unpaired Student’s t Test. (A and B) 
Haematoxylin and eosin. DI, Damaged islets; *, mononuclear cells; K, 
Kidney parenchyma. Scale bars=200pM.
304
---------!----------------- ------------------w n f M f
WT Hpse-KO
alio d7 alio d7
305
Figure 6.18 Histological assessment of CBA islet allografts in wild-type and 
cathepsin L knock-out C57BL/6 recipient mice
(A) Histological examination of CBA (H-2k) islet allografts in wildtype C57BL/6 
recipient mice showed an acute rejection response at 7 days post-transplant with an 
intense MNC infiltrate and only damaged islet remnant remaining at the graft site 
(mean % islet+ve graft area=12.95±1.70%) . In contrast, CBA islets transplanted 
to cathepsin L knockout (Ctsl-KO) mice were intact and well vascularised at (B) 7 
days post-transplant (mean % islet+ve graft area=44.44±4.69%) but were 
completely rejected by (C) 14 days, (mean % islet+ve graft area=6.37±1.67%) (D) 
Morphometric analysis demonstrated a significant 4-fold increase in the % 
allogeneic islet tissue remained at the graft site in Ctsl-KO recipient mice at 7 days 
post-transplant, compared to allografts in corresponding wild-type (WT) mice. 
Data shows mean islet+ve graft area±SEM, n=3/group. Statistical analysis was 
performed using Kruskal-Wallis Test. (A, B, C) Haematoxylin and eosin. I, Islets; 
DI, Damaged islets; *, mononuclear cells; K, Kidney parenchyma. Scale 
bars=100-200pM.
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(Fig. 6.18C, D). Collectively, these data demonstrated that the rejection of islet 
allografts was delayed in cathepsin L-deficient hosts.
6.1.4 The role of heparanase in the rejection of established islet allografts
Studies in Chapter 3 (Section 3.1.6) and Chapter 4 (Section 4.1.5) revealed that the islet 
BM (including islet BM HS) and intra-islet HS are lost after islet isolation and that a 
latent period exists early after transplantation during which both the islet BM and intra-
islet HS recover. In the following series of experiments, we evaluated whether the 
contribution of heparanase to the rejection of islet allografts is influenced by the HS 
status of the engrafted islets and is relevant for engrafted islets in which islet-associated 
HS (intra-islet HS+BM HS) has been restored. Two transplant models were used for 
these studies: delayed allograft rejection in immunocompetent mice and induced 
allograft rejection in immunoincompetent mice. The rationale was to allow complete 
islet engraftment and recovery of islet-associated HS before the grafts were subjected to 
the generation of a delayed anti-donor host immune response or the adoptive transfer of 
in vitro activated anti-donor T cells.
6.1.4.1 Effect of in vivo treatment with a heparanase inhibitor on the delayed 
rejection of rapamycin-established islet allografts
In the delayed rejection model, CBA islet allografts were established in recipient mice 
by short-term immunosuppression with rapamycin from 1-7 days post-transplant 
(Chapter 2, Section 2.5.3). In vivo administration of rapamycin at 0.3 mg/kg/day i.p 
from days 1-7 post-transplant significantly prolonged islet allograft survival by 1.7-fold 
(mean survival time of 16.0±0.4 days, n=4) compared to diluent-treated controls (mean 
survival time of 9.3±1.3 days, n=4) (p=0.0114) (Fig. 6.19A). The rapamycin-treated 
mice became hyperglycaemic due to rejection by 16-18 days post-transplant, i.e., 9-11 
days after terminating rapamycin treatmnet. This study confirmed that rapamycin 
treatment for 7 days significantly prolonged the survival of islet allografts beyond 12 
days. To determine whether the survival and function of islet allografts in rapamycin- 
treated mice could be extended beyond 14 days by supplementary inhibition of 
heparanase, the host mice were treated with polyclonal anti-heparanase serum (10 
mg/kg i.p, 250 pl/dose) intraperitoneally at days 12, 15, 18, and 21 post-transplant. The 
polyclonal rabbit anti-heparanase serum was administered at intervals of 3 days to avoid 
an anaphylactic response to the xenogeneic proteins. Control mice received saline at the 
same time points. Our results demonstrated that additional treatment with polyclonal
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Figure 6.19 Effect of in vivo treatment with rapamycin anti-heparanase 
serum on islet allograft survival in wildtype and heparanase knock-out 
recipient mice
(A) Kaplan-Meier survival curves show that the treatment of alloxan diabetic 
C57BL/6 mice with rapamycin (Rapa) (0.3 mg/kg i.p) for 7 days (days 1-7 
inclusive) post-transplantation of allogeneic CBA islets significantly prolonged 
islet allograft survival to MST=16.0±0.4 days, compared to diluent (2% 
Carboxymethyl-cellulose-Tween 80)-treated control recipient mice 
(MST=9.3±2.6 days. (B) Treatment of diabetic recipient C57BL/6 mice with 
Rapa (days 1-7 inclusive) followed by mouse anti-human heparanase serum (2.5 
mg/dose, days 12, 15, 18 and 21) (MST=14.3±2.1 days) failed to prolong islet 
allograft survival beyond controls (Rapa, days 1-7 + saline, days 12, 15, 18 and 
21). (C) Rapamycin treatment (days 1-7) of heparanase knockout mice did not 
prolong allograft survival beyond that of Rapa-treated wild type controls. 
Statistical analysis performed using the log-rank test did not show statistically 
significnat differences between the groups, except for rapamycin treatment 
versus diluent control (p=0.0014).
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anti-heparanase serum did not extend the survival of the islet allografts (mean survival 
time of 21.0+5.3 days, n=5) beyond that of saline-treated controls (mean survival time 
of 21.7±8.7 days, n=3) (Fig. 6.19B).
6.1.4.2 Effect of in vivo treatment with rapamycin on islet allograft survival in 
heparanase knockout recipient mice
Diabetic heparanase knockout recipient mice treated with rapamycin at 0.3 mg/kg/day 
i.p from days 1-7 post-transplant showed comparable survival of CBA islet allografts 
(mean survival time of 14.3+2.1 days, n=4) to rapamycin-treated diabetic wild-type 
recipient mice (mean survival time of 16.0+0.4 days, n=4) (Fig. 6.19C). Taken together, 
the studies in Sections 6.1.4.1 and 6.1.4.2 indicated that heparanase deficiency did not 
protect islet allografts against delayed rejection following the withdrawal of rapamycin 
immunosuppression,
To confirm our hypothesis that islet HS recovered in the delayed rejection model, we 
assessed the level of islet HS in the allografts immediately following rapamycin 
treatment. To our surprise, we found that the CBA islet allografts at 8 days post-
transplant following rapamycin treatment (days 1 -7) showed damaged islet morphology 
with intense MNC infiltration (Fig. 6.20B) despite a MST of 16.0+0.4 days was 
observed (Fig. 6.19A). In addition, the CBA islet allografts with rapamycin treatment 
exhibited immune damage and weak HS content (mean % HS+ve islet 
area=34.17+2.40%) (Fig. 6.20A, C), compared to CBA islets in situ (mean % HS+ve 
islet area=74.81±3.16%, pO.OOOl) (Fig. 6.20C). Taken together, we suggest that the 
findings in Sections 6.1.4.1 and 6.1.4.2 to examine the role of heparanase in the 
rejection of islet allografts by targeting islet HS were therefore inconclusive.
6.1.4.3 Adoptive transfer of alloreactive anti-donor activated wild-type or B6.Hpse- 
KO effector T cells to Ragl immunoincompetent mice carrying established CBA 
islet allografts
6.1.4.3 (a) In vitro activation and proliferation of anti-H-2k wild-type and 
heparanase knockout effector cells
Flow cytometry analyses of C57BL/6 (H-2b) anti-CBA(H-2k) mixed lymphocyte 
reactions (MLRs) (Chapter 2, Section 2.14) after 5 days of culture revealed that the total 
wild-type effector T cell population consisted of 30.9% CD4+ T cells and 40.1% CD8+
Figure 6.20 Heparan sulfate content of CBA islet allografts in C57BL/6 
recipient mice treated with rapamycin
CBA islet allografts in C57BL/6 recipient mice treated with rapamycin (0.3 
mg/kg i.p, days 1-7 post-transplant) showed (A) weak heparan sulfate staining, 
(B) damaged islet morphology and intense MNC infiltration by 8 days post-
transplant. (C) Quantitative analysis for the HS content of the engrafted islets 
showed that the levels of HS in the day 8 allografts with rapamycin treatment 
(mean % HS+ve islet area=34.17±2.40%) were 2-fold lower than that of CBA 
islets in situ (mean % HS+ve islet area=74.81±3.16%). The data shows the mean 
% HS+ve islet area±SEM (C). n=21 islets examined in CBA pancreas; n=28 
islets examined in Rapa-treated day 8 allografts. Data were analysed from 3-4 
independent specimens, n=4-7 islet(s) /sample Statistical analysis was performed 
using Mann-Whitney Test. (A) Alcian blue. (B) Haematoxylin and eosin. I, Islets; 
DI, Damaged islets; *, mononuclear cells; K, Kidney parenchyma. Scale 
bars=100pM.
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T cells (Fig. 6.21 A). The frequency of CD4 and CD8 T cell populations for anti-H-2k 
B6.Hpse-KO effector cells was 33.3% and 35.2%, respectively (Fig. 6.21 B). The 
absolute numbers of wild-type and B6.Hpse-KO CD4+ T cells were therefore not 
statistically different (Fig. 6.21 C). Likewise, the absolute numbers of wild-type and 
B6.Hpse-KO CD8+ T cells were also not statistically different (Fig. 6.21 C). Together, 
these data suggested comparable anti-H-2k wild-type and heparanase knockout effector 
cells were generated in the MLRs.
Furthermore, in vitro CFSE cell proliferation assay indicated that the majority of 
C57BL/6 (WT) (Fig. 6.22A) and B6.Hpse-KO (Fig. 6.22B) CD4+ and CD8+ T cells had 
divided after 5 days of culture. In addition, both anti-H-2k WT (Fig. 6.23A) and 
B6.Hpse-KO (Fig. 6.23B) effector T cells showed increased levels of the activation 
marker, CD44. Collectively, these data suggested that the activation and proliferation of 
B6.Hpse-KO T lymphocytes were not compromised in the absence of catalytically 
active heparanase and resembled the properties of C57BL/6 (WT) T cells.
6.1.4.3 (b) In vitro cytotoxicity profile of anti-H-2k C57BL/6(WT) and B6.Hpse-KO 
effector T cells
The capacity of anti-H-2k C57BL/6 (WT) and anti-FI-2k B6.FIpse-KO effector T cells to 
kill CBA target cells (H-2k) was examined using an in vitro cytotoxic T lymphocyte 
(CTL) killing assay, by labelling target cells with CFSE (Chapter 2, Section 2.14.5). 
Anti-H-2k WT and B6.Hpse-KO effector T cells displayed similar specific H-2k specific 
killing of 42.53±0.33-46.70±0.57% at effector to target ratios of 10:1 and 5:1 (WT, 
10:1 =46.70±0.57%; 5:1 =44.69±0.20%; B6.Hpse-KO, 10:1 =46.09± 1.19%;
5:1=42.53±0.33%). Specific killing decreased as the effector:target ratio decreased to 
1:1 (WT=28.32±1.04%; B6.Hpse-KO=25.20±0.27%) (Fig. 6.24). Whereas the absolute 
number of live CBA target cells (H-2k) inversely correlated with the effector:target ratio 
for both WT and B6.Hpse-KO effector T cells, the number of live isogeneic C57BL/6J 
target cells (H-2b) remained relatively consistent for all effector:target ratios, indicating 
lack of bystander killing of C57BL/6 targets (Fig. 6.25). Anti-H-2k C57BL/6 and anti- 
H-2k B6.Hpse-KO effector T cells therefore exhibited similar H-2k-specific cytotoxic 
activity.
The levels of LAMP1 + were 1.8-3.2-fold higher in the MLRs in the presence of 
CBA(H-2k) stimulator cells compared to effectors cultured alone or with naive C57BL/6
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Figure 6.21 Flow cytometry analysis of anti-H-2k wild-type and B6.Hpse-KO 
CD4+ and CD8 + T cells generated from allogeneic MLRs
Representative flow cytometry contour plots show that 5 day-cultured MLRs 
between irradiated CBA (H-2k) spleen cells and (A) C57BL/6 (H-2b) or (B) 
B6.Hpse-KO lymph node cells and spleen cells generated CD4+ and CD8+ T cells 
representing (A) 30.9% and 40.1% , respectively, and (B) 33.3% and 35.2% of the 
total lymphocyte population. Pooled data demonstrated that (C) the % T cell sub-
populations and (D) absolute number of CD4 + and CD8 + T cells of the 2 
responder populations were comparable (mean WT CD4 + cell count=27318; 
mean Hpse-KO CD4 + cell count=20153; mean WT CD8 + cell count=49093; 
mean Hpse-KO CD8 + cell count=30066). n= 6 experiments. Statistical analysis 
was performed using one-way ANOVA.
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Figure 6.22 Proliferation of activated anti-H-2k CD4 + and CD8 + T cells 
by CFSE labelling and flow cytometry
Representative flow cytometry analysis of CFSE labelling shows that in 5 
day-cultured MLRs, (A) 77.6% wildtype C57BL/6 anti-H-2k CD4 + T cells 
and 92.0% C57BL/6 anti-H-2k CD8 + T cells had proliferated, as shown by 
CFSE dilution. (B) Similarly, 69.7% B6.Hpse-KO anti-H-2k CD4 + T cells 
and 88.8% B6.Hpse-KO anti-H-2k CD8 + T cells had proliferated. This data is 
representative of 6 experiments.
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Figure 6.23 Activation status of in vitro activated anti-H-2k 
C57BL/6 (WT) and B6.Hpse-KO CD4+ and CD8+ T cells assessed 
by flow cytometry
Gated CD4+ and CD8+ T cells from (A) C57BL/6 (WT) and (B) 
B6.Hpse-KO effector populations from 5 day anti-CBA (H-2k) MLRs 
showed comparable levels of expression of the T cell activation marker 
CD44 for CD4+ T cells (56.0%; 61.3%) and CD8+ T cells (75.0%; 
84.3%), respectively. The data is representative of 6 experiments.
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Figure 6.24 Specific killing of CBA (H-2k) targets by C57BL/6 (WT) and 
B6.Hpse-KO anti-H-2k CD4 + and anti-H-2k CD8+ T cells
The cytotoxic T-lymphocyte killing (CTL) assay revealed that relative to the 
non-specific killing of bystander isogeneic targets, C57BL/6 anti-H-2k effector 
T cells showed 46.70±0.57%, 44.69±0.20% and 28.32± 1.04% specific killing 
of CBA (H-2k) target cells at effector Target ratio 10:1, 5:1 and 1:1, 
respectively. Similarly, B6.Hpse-KO anti-H-2k effector T cells showed 
46.09±1.19%, 42.5310.33% and 25.20+0.27% specific killing of CBA (H-2k) 
targets relative to isogeneic C57BL/6J (H-2b) targets. The data is representative 
of 6 experiments. Statistical analysis was performed using one-way ANOVA.
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Figure 6.25 Absolute number of live CBA and C57BL/6 target cells remaining 
in the in vitro cytotoxicity assay
The absolute number of live CFSE-labelled CBA (H-2k) target spleen cells 
decreased when cultured with anti-H-2k (A) C57BL/6J (WT) or (B) B6.Hpse-KO 
(H-2b) effectors at increasing effector to target ratios. The absolute number of 
bystander isogeneic C57BL/6 targets remained unchanged, confirming the 
specificity of killing for the H-2k allogeneic target cells. The data is representative 
of 6 experiments. Statistical analysis was performed using one-way ANOVA.
***p<0.001
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(Fig. 6.26A, B). These data indicated that the in vitro activated cytotoxic T cells 
degranulated upon encounter with CBA (H-2k) target cells. There was no significant 
difference in LAMP1 expression by cytotoxic C57BL/6 and B6.Hpse-KO T cells at 
various effector:target ratios.
6.1.4.3 (c) Adoptive transfer of in vitro stimulated anti-H-2kC57BL/6 and B6.Hpse- 
KO effector T cells to induce the rejection of established CBA islet allografts
Alcian blue histochemistry showed that intra-islet HS recovered substantially in 
engrafted CBA (H-2k) islets at 6 weeks post-transplant in immunoincompetent 
B6.Ragl-/- recipient mice (Fig. 6.27A). However, the level of HS in these grafts (mean 
% HS+ve islet area=58.3±3.1%) was lower than that of CBA islets in situ (mean % 
HS+ve islet area=74.8±3.2%) (Fig. 6.27C). Six individual experiments were set up to 
compare the kinetics of rejection of established islet allografts (>6 weeks post-
transplant) after the transfer of in vitro stimulated anti-H-2k C57BL/6 or B6.Hpse-KO 
effector T cells (Fig 6.28). Blood glucose levels were monitored to identify the onset of 
rejection. Five out of six experiments showed that recipient mice which received in 
vitro stimulated anti-H-2k C57BL/6 effector cells became hyperglycaemic more rapidly 
than transplant recipient mice receiving in vitro stimulated anti-H-2k B6.Hpse-KO 
effector cells (Fig. 6.28A, C-F). In one of six experiments, the tempo of rejection for 
both allografts was similar (Fig. 6.28B).
Histological examination revealed that allografts in B6.Ragl-/- hosts which received in 
vitro stimulated anti-H-2k C57BL/6 effector T cells consisted of damaged islets with an 
intense cell infiltrate at the graft site (% islet+ve graft area=l 1.50±2.64% ) (Fig. 6.29A, 
C). In contrast, adoptive transfer of in vitro stimulated anti-H-2k B6.Hpse-KO effector T 
cells resulted in better preserved engrafted islets with mainly peri-islet MNCs (% 
islet+ve graft area=40.06+3.92%, pO.OOOl ) (Fig. 6.29B, D, E).
Overall, this study showed that the adoptive transfer of C57BL/6 effector T cells 
rejected established islet allografts at a faster tempo than the transfer of B6.Hpse-KO 
effector T cells that lacked catalytically active heparanase. The contribution of 
heparanase to the induced rejection of established islet allografts is consistent with the 
re-established intra-islet and BM HS in the engrafted islets, acting as a substrate for 
degradation. Significantly, the prior restoration of the peri-islet BMs would be expected
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Figure 6.26 LAMP-1 expression by in vitro activated anti-H-2k 
C57BL/6 (WT) and B6.Hpse-KO CD4+ and CD8+ T cells assessed by 
flow cytometry
Flow cytometry analysis showed that in vitro stimulated anti-H-2k (A) 
C57BL/6J (WT) and (B) B6.Hpse-KO (H-2b) effector T cells 
demonstrated upregulation of LAMP-1 expression, indicative of 
degranulating cytotoxic T cells, at effector:target ratios of 10:1, 5:1 and 
1:1 when compared to culture with effector T cells alone (1:0) or with 
naive C57BL/6 splenocytes. The data is representative of 6 experiments. 
Statistical analysis was performed using one-way ANOVA. *p<0.05;
**p<0.01; ***p<0.001
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Figure 6.27 Heparan sulfate content in CBA (H-2k) islet allografts in 
immunoincompetent B6.Ragl-/- (H-2b) recipient mice
CBA (H-2k) islet allografts in immunoincompetent B6.Ragl-/- recipient mice 
at 42 days post-transplant contained HS+ve islet tissue (A) without cellular 
infiltration at the graft site (B). (C) Quantitative analysis of Alcian blue 
staining of the islet allografts demonstrated that 58.30±3.12% engrafted islet 
area, indicating substantial intra-islet recovery but was significantly lower 
than 74.81 ±3.16% of the islet area being HS+ve in CBA islets in situ in the 
pancreas.. The data shows the mean % HS+ve islet area±SEM (C). Data were 
analysed from 3-4 independent specimens. n=21-30 islets/group Statistical 
analysis was performed using Mann-Whitney Test. I, Intact islets; K, Kidney 
parenchyma. Scale bars=100pM.
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Figure 6.28 Non-fasting blood glucose profile of alloxan-diabetic Bö.Ragl*7' 
recipient mice carrying established CBA islet allografts before and after 
adoptive transfer of anti-donor activated wild-type C57BL/6 or B6.Hpse-KO 
effector T cells
Immunoincompetent alloxan diabetic Bö.Ragl'7“ (H-2b) mice promptly became 
normoglycaemic after transplantation of CBA (H-2k) islets beneath the kidney 
capsule, 400 islets/graft. Anti-donor activated C57BL/6 (WT) or B6.Hpse-KO T 
cells were adoptively transferred i.v at 42-55 days post-transplant. (A, C-F) In 5 
out of 6 experiments, B6.Ragl'/_ recipient mice receiving lx l07 anti-H-2k 
C57BL/6 (H-2b) effector T cells became hyperglycaemic more rapidly than 
recipient mice receiving lxlO7 anti-H-2k B6.Hpse-KO (H-2b) effector T cells. (B) 
In the remaining 1 of 6 experiments, the time taken for the adoptive transfer of 
anti-H-2k C57BL/6 and B6.Hpse-KO (H-2b) effector T cells to induce islet 
allgoraft rejection was similar. The normal blood glucose range (6.8-12.8 
mmol/L) for B6.Ragl'A mice is shown in each plot by a grey shaded region. The 
time at which the adoptive transfer of anti-donor activated C57BL/6 (WT) or 
B6.Hpse-KO T cells is performed was indicated by blue and red arrows, 
respectively.
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Figure 6.29 Histological asssessment of established CBA (H-2k) islet allografts 
in alloxan-diabetic B6.Ragl /_ (H-2b) recipient mice after transfer of lxlO7 anti- 
H-2k C57BL/6 (WT) or B6.Hpse-KO (H-2b) effector T cells
(A,C) Adoptive transfer of lxlO7 anti-H-2k C57BL/6J (H-2b) effector T cells to 
B6.Ragl7' mice rendered normoglycemic by a CBA(H-2k) islet allograft induced 
aggressive mononuclear cell infiltration at the graft site and substantial islet 
destruction, re-establishing diabetes. (B, D) In contrast, transfer of lxlO7 anti-H-2k 
B6.Hpse-KO (H-2b) effector T cells induced a mild, predominantly peri-islet cell 
infiltration and resulted in better preservation of the islet tissue. (C) Morphometric 
analysis revealed a 3.5-fold higher in islet+ve graft area in allografts receiving 
adoptive transfer of B6.Hpse-KO effector T cells (% islet+ve graft 
area=40.06±3.92% ) than the WT controls (% islet+ve graft area=l 1.50±2.64% ). 
The data shows the mean % islet+ve graft area±SEM (E). Data were analysed from 
6 independent specimens. Statistical analysis was performed using Mann-Whitney 
Test. (A-D) Haematoxylin and eosin. DI, Damaged islets; *, mononuclear cells; K, 
Kidney parenchyma. (A, B) Scale bars=200pM. (C, D) Scale bars=100pM.
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to act as physical barriers to MNC infiltration, requiring heparanase-mediated its 
degradation to facilitate leukocyte entry into the islet tissue.
6.2 Discussion
In this study, we detected an increase in heparanase mRNA expression in islets 
following isotransplantation (Fig. 6.1), which correlated with more pronounced cell 
surface staining for heparanase protein in the engrafted islet tissue (Figs. 6.2, 6.3). We 
postulate that heparanase expressed on the surface of islet cells, early post-transplant 
may facilitate revascularisation of the islet grafts and tissue remodelling upon 
engraftment. Islet beta cells produceVEGF (Brissova et al., 2006), an angiogenic factor 
which plays a pivotal role in the revascularisation of islet grafts by attracting endothelial 
cells (Nikolova et al., 2006). Transplant recipient mice with decreased expression of 
VEGF displayed reduced vascular density when compared with control wild-type 
recipient mice (Brissova et al., 2006). Conversely, enhanced VEGF expression has led 
to enhanced graft vascularity and survival (Olerud et al., 2008, Panakanti and Mahato, 
2009, Sigrist et al., 2003, Zhang et al., 2004). Since heparanase has been reported to 
induce the expression of VEGF in human embryonic kidney 293, MDA-MB-435 human 
breast carcinoma and rat C6 glioma cells (Zetser et al., 2006), heparanase expressed by 
beta cells may therefore aid the revascularisation of engrafted islets.
Heparanase-induced VEGF expression may also lead to the recruitment of pro- 
angiogenic leukocytes, i.e., CD1 lb+/Gr-l+/CXCR4hl neutrophils to islets transplanted 
under the kidney capsule, as recently reported for VEGF-supplemented islet isografts at 
intra-muscular sites (Christoffersson et al., 2012). In our study, we found low levels of 
CD45R (common leukocyte marker) positive transcripts and the accumulation of 
macrophages within islet isografts. It is possible that these macrophages are 
proangiogeneic (Mayer et al., 2010) and are involved in islet revascularisation. 
Heparanase induces VEGF expression independently of its enzymatic active HS- 
degrading activity. It has been shown that enhanced heparanase expression in human 
embryonic kidney 293, MDA-MB-435 human breast carcinoma, and rat C6 glioma cells 
promotes the phosphorylation of the tyrosine kinase, Src. This may result from 
signalling induced by heparanase bound to an unidentified cell surface receptor, thereby 
enhancing VEGF gene transcription (Zetser et al., 2006). Consistent with this notion, 
heparanase expressed by islet isografts was found in our study to be predominantly
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catalytically inactive. Our study also showed a decrease in heparanase protein levels by 
10 days post-isotransplantation (Fig. 6.3), coinciding with the near completion of 
revascularisation in the islet grafts (Chapter 3, Section 3.1.4).
The contribution of proheparanase to successful islet engraftment and revascularisation 
is speculative. Investigation of the kinetics of expression of inactive heparanase by 
Western blotting analyses of islet isografts early and late after transplantation, together 
with examination of the local expression of VEGF may provide supporting evidence for 
these roles. Based on our Western blotting studies of heparanase (Fig. 6.11) and 
cathepsin L (Fig. 6.15), the strong expression of cathepsin L protein in islets pre- and 
post-isotransplantation (Figs. 6.4-6.6) and the increase in expression of active cathepsin 
L in 7 days islet isografts (Fig. 6.15) does not appear to activate islet-derived 
heparanase. Instead, the activation of endogenous cathepsin L from the pool of latent 
cathepsin L, may be required for the degradation of empty insulin granule membrane 
proteins and/or other homeostatic functions in islet beta cells (Docherty et al., 1982, 
Ishidoh et al., 1998, Steiner et al., 1996).
In the case of islet allografts, a significant 1.7-4.2-fold up-regulation of intra-graft 
heparanase transcripts (Fig. 6.8) and a 48-fold increase in catalytically active 
heparanase was observed (Fig. 6.11), relative to corresponding isografts. This finding 
correlated with a 1.3-11.6-fold increase in intra-graft CD45 mRNA, relative to 
corresponding isografts (Fig. 6.8), and histological evidence of MNC infiltration, 
identifying the MNCs as the primary source of intra-graft heparanase (Fig. 6.9). The 
pathological role of heparanase is well-established for several disease models including 
cancer metastasis, cell invasion, inflammation, nephropathy and autoimmune diseases 
(Edovitsky et al., 2006, Nakajima et al., 1984, Parish, 2006, Parish et al., 2001, Patel et 
al., 2007, Vlodavsky and Friedmann, 2001, Vlodavsky et al., 1983, Ziolkowski et al., 
2012). Recently, heparanase was found to play a critical role in the onset of autoimmune 
Type 1 diabetes in the NOD/Lt mice (Ziolkowski et al., 2012). In the context of disease, 
heparanase activity is generally related to its HS-degrading function. We propose that 
heparanase is likely to contribute to several key processes during the course of the 
rejection of islet allografts. First, heparanase produced by the infiltrating MNCs would 
be crucial in the migration of leukocytes to the graft site, degrading HS in the 
subendothelial basement membrane (BM) and extracellular matrix. Activated 
endothelial cells in the inflammatory microenvironment may also secrete heparanase to
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facilitate the breakdown of BM HS (Parish et al., 1998). We further speculate that upon 
arrival at the graft site, production of catalytically active heparanase by the infiltrating 
MNCs would be needed to traverse the perlecan (HS) +ve stroma at the graft site 
(Chapter 3, Section 3.1.6) and the BM of those engrafted islets with complete BM 
recovery, culminating in the degradation of intra-islet HS and beta cell death. The 
cleavage of HS chains HSPGs would also be expected to release important HS-bound 
pro-inflammatory mediators such as chemokines, cytokines, growth factors, cell 
adhesion molecules and proteases that could facilitate cell invasion (Parish, 2006, 
Vlodavsky and Friedmann, 2001) and modulate the alloimmune response.
Most importantly, our study highlights yet another important heparanase-mediated 
effector mechanism in islet allograft rejection by degrading the intra-islet HS. Recent 
studies have pointed to a vital role of HS in the survival (Ziolkowski et al., 2012) and 
function of islet beta cells (Takahashi et al., 2009). During islet allograft rejection, we 
propose that the local production of heparanase by intra-graft alloreactive leukocytes 
represents a destructive effector mechanism that degrades intra-islet HS, potentiating 
beta cell death and islet allograft rejection.
The activation of heparanase that is required for HS degrading activity is mediated by 
cathepsin L. Leukocytes such as macrophages and T cells have been reported to produce 
cathepsin L for heparanase activation (Gocheva et al., 2010, Lemer et al., 2011). 
Interestingly, our study has identified that cathepsin L could be derived from the 
engrafted islets themselves during allograft rejection. Immunohistochemical analyses 
revealed patchy staining for cathepsin L, predominantly in islet tissue rather than 
infiltrating MNCs, and was most prominent during the peak of rejection at 7 days post-
transplant (Fig. 6.13). Western blotting analysis indicated high levels of active cathepsin 
L present in rejecting day 7 allografts (Fig. 6.15). It is therefore possible that the large 
reservoir of intra-islet cathepsin L is released and activated during islet destruction. 
Indeed, islet-derived cathepsin L may serve as the primary source for the activation of 
leukocyte-tethered heparanase at the graft site, thereby playing a permissive role in HS 
degradation. The production of heparanase and cathepsin L by different cell sources is 
not uncommon. In fact, during ulcerative colitis, the secretion of heparanase by colon 
epithelial and cathepsin L by local macrophages can convert the disease to colon cancer 
(Lemer et al., 2011).
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Although the real-time RT-PCR (Fig. 6.8), immunohistochemical (Figs. 6.9, 6.10) and 
Western blotting analyses (Fig. 6.11) showed a significant increase in heparanase 
expression during the acute rejection of islet allografts, our studies of allograft survival 
and function in the absence of heparanase argued against a major role for heparanase as 
an effector mechanism in acute allograft rejection (Figs. 6.16, 6.17). However, there are 
caveats to this interpretation.
Our histological studies demonstrated that allogeneic islets transplanted to B6.Hpse-KO 
recipient mice were rejected and resembled the acute allograft rejection observed in 
wild-type control mice (Fig. 6.17). However, it has recently been reported that B6.Hpse- 
KO mice exhibit upregulation of the degradative enzymes, MMPs, and the expression 
of the chemokine, CCR7, properties which could compensate for heparanase deficiency 
(Benhamron et al., 2012, Zcharia et al., 2009). In particular, increased levels of MMP-2 
and MMP-14 were noted in heparanase knock-out kidneys, the transplant site for islet 
allografts in our studies (Zcharia et al., 2009). Membrane-bound MMP-14 (also known 
as membrane type-1-matrix metalloprotease (MT1-MMP)) also demonstrated broad 
substrate specificity, including the HSPG perlecan and syndecan-1 (d'Ortho et al., 1997, 
Endo et al., 2003, Su et al., 2008). MT1-MMP was shown to cleave the core protein of 
perlecan at multiple sites (d'Ortho et al., 1997), which could indirectly result in HS 
degradation via HPSGF turnover in endosomes. The subsequent release of bioactive 
fragments could furthermore amplify the inflammatory responses, such as allograft 
rejection.
In addition, dendritic cells (DCs), which play a vital role in antigen presentation, 
increased the expression of chemokine, CCR7 in heparanase knockout mice 
(Benhamron et al., 2012). CCR7 is a major chemotactic factor for DC homing and 
transmigration (Forster et al., 2008, Forster et al., 1999, Yanagihara et al., 1998). 
Enhanced CCR7 expression may therefore circumvent the lack of HS-degrading activity 
by inducing the expression of co-stimulatory molecules (e.g., CD86, CD80 and CD40) 
and by producing proinflammatory mediators (TNF-a, IL-lß and IL-12) that could 
exacerbate a non-specific inflammatory response (Marsland et al., 2005). Collectively, 
compensatory increased levels of MMPs may replace heparanase-mediated HS 
degradation by targeting the core proteins of HSPGs. Additionally, increased levels of 
the MMPs and CCR7 may promote the release of proinflammatory mediators that 
augment, in particular the non-specific inflammatory component of allograft rejection
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response. The likely outcome of such compensatory processes would be allograft 
failure.
In vivo treatment with heparanase inhibitors failed to prolong the survival of islet 
allografts (Fig. 6.16). This initial failure could have been due to the short half-life of the 
heparanase inhibitors/HS mimetics (1-6 hours) (Norrby, 2006, Shafat et al., 2011a). 
Nevertheless, increasing the frequency of administration to transplant recipients did not 
improve the survival of islet allografts. Previous reports have demonstrated the 
prolonged survival of skin and heart allografts using low doses of LMWH (Cahalon et 
al., 1997, Gorski et al., 1994, Shapira et al., 1999). A bell curve for dosage-dependent 
efficacy of treatment was revealed, with high doses failing to be graft-protective. This 
phenomenon was attributed to the desensitisation of the receptors when high doses of 
LMWH were administered, a process which could contribute to the failure to prolong 
islet allograft survival in our studies (Cahalon et al., 1997, Shapira et al., 1999). Our 
attempts to block heparanase activity in vivo with anti-heparanase serum were restricted 
by the need to avoid anaphylactic shock (Hansel et al., 2010). Hence, the limited 
number of doses may have resulted in insufficient heparanase inhibition, culminating in 
allograft rejection.
Islet allografts in cathepsin L knockout mice showed prolonged survival at lweek but 
were rejected by 2 weeks post-transplant (Fig. 6.18). The contribution of heparanase to 
this delayed rejection response, however, is unclear. Cathepsin L also functions in the 
proteolytic cleavage of MHC class Il-associated invariant chain peptide (CLIP) and 
possibly the generation of the peptide repertoire for the positive selection of CD4+ T 
cells in the thymus (Honey et al., 2002, Hsieh et al., 2002, Nakagawa et al., 1998), 
impacting on the repertoire of the thymic and peripheral T cell population. Reduced 
levels of thymic CD4+ T cells and the down-regulation of effector CD4+ T cells 
correlated with an increased regulatory T cell population, which promotes immune 
tolerance (Maehr et al., 2005). Likewise, enhanced levels of Tregs may have occurred in 
the Ctsl-KO recipient mice in our studies, providing a transient protective effect against 
graft rejection. Secondly, since CD4+ T cells aid CD8+ T cell activation, the decreased 
CD4+ T cell population in the periphery could negatively impact on the activation of 
alloreactive T cells, which constitute the major effector cells mediating the rejection of 
islet allografts (Bueno and Pestana, 2002, Gill, 1998, Simeonovic et al., 1996). 
Alternatively, cathepsin L has been shown to impair CD8+ T cell cytotoxicity.
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Cathepsin L activates dipeptidyl peptidase I (DPPI), a granule protease required for the 
processing and activation of granzymes, the cytotoxic T-lymphocyte (CTL) granule 
serine proteases. In the absence of cathepsin L, the levels of granzyme B were 
significantly reduced, which in turn, led to decreased CD8+ T cell cytolytic activity 
(Yamada et al., 2010). The promotion of immune tolerance through the increased Treg, 
decreased CD4+ T cell help for CD8+ activation and/or defective cytotoxic effector 
functions of CD8+ T cells could have contributed to the delayed rejection of islet 
allografts in Ctsl-KO mice. Extensive destruction of allogeneic islets in cathepsin L 
knockout transplant recipient mice was found at the later time point of 2 weeks post-
transplant. This finding indicated that alternative effector mechanisms compensate for 
the defects arising from cathepsin L deficiency and ultimately contribute to the rejection 
of islet allografts.
We propose that the difficulties associated with evaluating the role of heparanase in the 
acute rejection of islet allografts (Figs. 6.16, 6.17) were probably due, at least in part, to 
incomplete recovery of the intra-islet HS and the peri-islet basement membrane (BM) of 
engrafted islets prior to MNC invasion. To circumvent these issues, we investigated the 
role of heparanase in the rejection of established islet allografts. These models offered 
the advantage of the complete recovery of intra-islet HS and the peri-islet BM before 
graft rejection was induced. In the “delayed rejection” model, the immunosuppressant 
rapamycin was administered from 1-7 days post-transplant, to temporarily suppress the 
rejection response, thereby allowing the recovery of islet-associated HS and the peri- 
islet BM HS. Wild-type recipient mice which received rapamycin treatment for 7 days 
post-allotransplantation and were treated with anti-heparanase serum did not exhibit 
prolonged allograft survival (Fig. 6.19). Similarly, B6.Hpse-KO allograft recipient mice 
treated with rapamycin for 7 days also rejected their allografts similar to wild-type 
counterparts (Fig. 6.19). However, damaged islet morphology with an intense MNC 
infiltrate was observed in the CBA islet allografts following rapamycin treatment (Fig. 
6.20), suggesting that the immunosuppression was insufficient halt the rejection process 
and to allow the recovery of islet HS. This issue confounded the evaluation of the role 
of heparanase in rejection using anti-heparanase serum or B6.Hpse-KO mice. We 
therefore conclude that the data obtained in the “delayed rejection” model using 
rapamycin treatment, are inconclusive.
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An alternative model of established islet allografts in immunoincompetent B6.Ragl-/- 
recipient mice was therefore set up, in which in vitro activated wild-type or Bö.Hpse- 
KO anti-donor activated effector T cells were adoptively transferred to induce rejection. 
This induced rejection model showed that allograft rejection was delayed when 
B6.Hpse-KO effector T cells were transferred, compared to wild-type C57BL/6 effector 
T cells (Figs. 6.28, 6.29). This finding suggests that heparanase could contribute to the 
chronic rejection of islet allografts. The transfer of heparanase-deficient anti-donor 
activated T cells appeared to circumvent the possible compensatory destructive 
mechanisms elicited in the B6.Hpse-KO hosts. However, it should be noted that 
heparanase could potentially be derived from the B6.Ragl-/- host or from the donor 
islets. We suggest that future experiments with the complete abolishment of heparanase 
in the graft models should be performed using heparanase knockout RIP-OVAhi islets 
transplanted to conditional heparanase knockout OT-I transplant recipients, where the 
impact of compensatory mechanisms would be mitigated.
Comparative in vitro studies between wild-type and B6.Hpse-KO effector T cells 
suggest both activated anti-CBA (H-2k) effector population exhibited comparable 
proliferative and activation profiles (Figs. 6.21-6.23). In addition, both activated cell 
populations displayed similar efficiency for killing donor-specific targets (Figs. 6.24- 
6.26). Therefore, the delayed rejection of CBA islet allografts following the transfer of 
B6.Hpse-KO anti-donor T cells suggests that heparanase can contribute to the rejection 
of islet allografts. We propose that heparanase is required to degrade HS in the 
subendothelial BM, navigate through the perlecan+ve graft site and solubilise the islet 
BM HS. The HS fragments could further release proinflammatory mediators (e.g., 
cytokines, chemokines, tissue remodelling factors, cell adhesion molecules, lipases and 
proteases) could further amplify the inflammatory milieu.
The local intra-islet production of heparanase would be expected to degrade intra-islet 
HS which is critical for the survival of islet beta cells. The loss of intra-islet HS would 
result in beta cell death and allograft failure. The interaction of heparanase at the level 
of the islet BM and intra-islet HS would be contingent on the recovery of the BM and 
intra-islet HS prior to MNC infiltration. Our pioneering study provides evidence for an 
important role for heparanase in the rejection of islet allografts by degrading HS in the 
islet BM and within the islet beta cells, as well as by degrading ECM HS to facilitate 
leukocyte migration and recruitment to the graft.
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While heparanse is the only mammalian endoglycosidase responsible for the efficient 
degradation of HS, HS may also be susceptible to destruction via alternative pathways. 
As mentioned in Chapter 5 (Section 5.1.4), HS can be depolymerised by free radicals. 
Raat et al. demonstrated that renal glomerular HS was depolymerised by hydroxyl 
radicals in vitro (Raats et al., 1997). In addition, it has been reported that peroxynitrite 
induces the fragmentation of HS (Kennett et al., 2010) and myeloperoxidase-derived 
hypochlorous acid (HOC1) and hypobroumous acid (HOBr) selectively disrupt the core 
protein of BM HSPG, perlecan (Rees et al., 2010).
Free radicals are common mediators during inflammation. The generation of hydroxyl 
radicals or reactive oxygen species has been reported in autoimmune type 1 diabetes, 
the rejection of cardiac and lung allografts as well as various types of tissue injury (de 
Groot, 1994, Delmastro and Piganelli, 2011, Eizirik and Mandrup-Poulsen, 2001, Pieper 
et al., 2008, Shiraishi et al., 1997). Additionally, peroxynitrite and myeloperoxidase are 
associated with the development of atherosclerosis, ischemic heart disease, cancer and 
diabetes (Kennett et al., 2010, Loria et al., 2008, Pacher et al., 2007, Rees et al., 2010). 
Antioxidant treatment using a salen-manganese compound, EUK-8, which expressed 
superoxide dismutase-, peroxidase- and catalase-like activity was reported to prolong 
the survival of islet allografts by 10-50 days in diabetic NOD recipient mice, compared 
to saline-treated controls, which rejected their allografts in 7-10 days post-transplant 
(Olcott et al., 2004). The administration of desferrioxamine, an inhibitor of the 
formation of hydroxyl radicals, and nicotinamide (a poly(ADP-ribose) synthase 
inhibitor has also been shown to prevent streptozotocin-induced islet beta cell toxicity 
in mice), and to delay the rejection of Balb/cJ islet allografts in C57BL/6 recipient mice 
(Mendola et al., 1989).
Despite our finding that free radicals contribute to the loss of islet HS during islet 
isolation (Chapter 5, Section 5.1.4), this study highlights a role for heparanase in 
degrading HS in vivo in the context of islet allograft rejection. We detected the 
production of extraordinarily high levels of active heparanase by the infiltrating MNCs 
at the graft site. In view of this, there is a need to develop potent heparanase inhibitors 
as an adjunct rejection therapy for combating the vigorous alloimmune response. 
Ideally, heparanase inhibitors to be used in the context of allograft rejection, should be 
devoid of anti-coagulant properties in order to prevent undesired haemorrhage and lack
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anti-angiogenic activity, as this may impede revascularisation of the islet grafts. More 
importantly, a versatile heparanase inhibitor that targets both enzymatic and non- 
enzymatic activities of heparanase and that offers a long half-life will be required to 
achieve profound and durable inhibition of heparanase activity in the context of 
pathologies such as the rejection of islet allografts.
Due to the expression of heparanase during the course of rejection, we suggest that 
heparanase may be used as a biomarker for islet allograft rejection. To date, the lack of 
reliable early detection markers for the rejection of islet transplants poses a challenge 
for long-term clinical monitoring of graft survival and function and for identifying when 
early anti-rejection interventions should be implemented. The current clinical methods 
for detecting islet graft rejection rely on monitoring of several metabolic parameters 
including blood glucose, insulin and C-peptide levels. However, these parameters might 
not be compromised sufficiently to sensitively detect early stages of rejection (Merani 
and Shapiro, 2006). Indeed, heparanase is probably deployed early in the rejection 
response to assist the migration of leukocytes to the graft site. Since upregulation of 
heparanase expression is restricted to pathological conditions, heparanase may therefore 
be useful as an early diagnostic marker for islet graft rejection. In fact, plasma or urine 
heparanase levels have been a useful diagnostic marker for assessing disease 
progression or intervention efficacy in several disease settings including sarcomas, 
carcinomas, ovarian cancers, type 2 diabetes and diabetes-associated nephropathy (Katz 
et al., 2002, Shafat et al., 2007, Shafat et ah, 2011b, Zhang et ah, 2011). The 
development of an ELISA method for detecting low levels of heparanase in tissue 
extracts, plasma and urine samples has become a powerful tool for disease diagnosis 
and prognosis (Shafat et ah, 2006). In clinical islet transplantation where islets are 
infused via the hepatic portal vein, plasma heparanase levels in the transplant recipients 
could potentially be monitored as an early indicator of rejection, signalling the need for 
early anti-graft rejection intervention to preserve the integrity of the engrafted islets.
In summary, this study has identified heparanase as a potential novel effector 
mechanism during islet allograft rejection. We postulated that heparanase is employed 
by the infiltrating mononuclear cells to degrade the subendothelial BM HS and possibly 
the islet BM HS during the process of leukocyte migration. We further identified islet 
HS as a bona fide target for heparanase-mediated immune destruction of islet 
transplants. Heparanase inhibitors could therefore represent a potential adjunct anti-
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rejection therapy for preventing the chronic rejection of islet allografts and we further 
speculate that plasma heparanase levels could potentially represent an early indicator of 
rejection.
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CHAPTER 7 : General discussion
7.0 Introduction
Islet transplantation is a promising treatment for type 1 diabetes to circumvent the need 
for long-term insulin therapy. In recent years, islet transplantation has benefited from a 
better understanding of the non-immune mediated attrition of islet transplants as well as 
immunological aspects of allograft rejection. This has led to considerable refinement of 
the protocols for islet isolation and immunosuppression. As a consequence, the islet 
transplant procedure now offers a graft survival rate that matches pancreas 
transplantation, with greater than 50% insulin independence at 5 years post-transplant 
(Shapiro, 2011). Nevertheless, the shortage of donor organs, the heavy use of 
immunosuppression and the need to achieve long-term insulin independence remain 
unmet goals. Assessment of the status of islet HS, a critical molecule for islet beta cell 
survival, has been central to this study of islet transplantation. Islets lose HS from beta 
cells during islet isolation, resulting in beta cell death (Ziolkowski et al., 2012).
In this study, we sought to investigate the mechanisms contributing to the loss of HS 
during islet isolation and to assess whether the levels of islet HS alters following 
transplantation. Additionally, we examined whether the HS-degrading heparanase 
contributes to the rejection of islet allografts by targeting islet HS. It is envisaged that a 
better understanding of the molecular status of islet HS in islet transplantation and the 
potential role of heparanase in islet allograft rejection could have important implications 
for developing strategies to improve the quality of isolated islets for transplantation as 
well as transplant outcome.
7.1 Heparan sulfate and heparanase in islet physiology
Heparan sulfate proteoglycans (HSPGs) are ubiquitously expressed in extracellular 
matrices (ECMs), basement membranes (BMs) and on cell surfaces. HSPGs consist of a 
core protein to which several linear heparan sulfate (HS) chains are attached (Parish, 
2006, Vreys and David, 2007). Compelling evidence has confirmed the presence of a 
continuous BM around mouse islets, separating the endocrine islets from the 
surrounding exocrine acinar tissue (Irving-Rodgers et al., 2008, Korpos et al., 2013).
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This peri-islet BM consists of laminin chains a2, ßl and yl, collagen type IV al and a2, 
nidogen-1 and -2. Irving-Rodgers et al. also reported the presence of a BM matrix 
component, the HSPG perlecan in the mouse islet BM (Irving-Rodgers et al., 2008). 
Perlecan, a large molecule (470 kDa) with linear HS chains (approximately 70-100 
kDa/chain) acts as a formidable barrier against cell invasion (Parish et al., 2001, 
Pillarisetti et al., 1997, Vlodavsky et al., 1992). In addition, the versatile HS binds and 
sequesters a wide range of molecules including cytokines, growth factors, proteases, 
lipases and cell adhesion molecules (Parish, 2006). Since HS acts as a storage depot for 
these bioactive molecules in ECMs, it plays a key regulatory role in modulating a series 
of physiological processes such as development, cell proliferation, cell differentiation, 
migration, angiogenesis and wound healing (Ali et al., 2003, Bishop et al., 2007, Parish, 
2006).
In addition to its presence in the peri-islet BM, HS is expressed at extraordinarily high 
levels in the islet cell mass, notably in beta cells (Ziolkowski et al., 2012). This 
intracellular localisation of HS is unique as HS is more commonly localised at the 
extracellular sites, i.e, in ECMs and BMs, and on the surface of cells. Ziolkowski et al. 
identified intra-islet HS as a critical constituent for islet beta cell survival. The authors 
reported that culture of isolated islet beta cells with highly sulfated HS mimetics such as 
heparin, HSh' or Pl-88 significantly protected the islet beta cells from both culture- 
induced death and from death induced by reactive oxygen species (ROS). The ability of 
the HS replacement to protect the beta cells from oxidative damage unveiled a novel 
role for intra-islet HS as an antioxidant or free radical sink (Ziolkowski et al., 2012). 
Indeed, intracellular HS represents a constitutive mechanism for protecting beta cells 
against oxidative damage, compensating for the low levels of free radical scavenging 
enzymes in the islets (Rabinovitch and Suarez-Pinzon, 1998).
It is speculated that the capture of free radicals by HS could potentially represent an 
effective defence mechanism against ROS in islet beta cells. In contrast, excessive 
levels of free radicals could depolymerise HS, leading to HS depletion (Raats et al., 
1997, Tsiapali et al., 2001, Ziolkowski et al., 2012). Moreover, intra-islet HS is pivotal 
for postnatal islet maturation and insulin function. A decreased beta cell mass was 
observed in mice with beta cell-targeted knockout of the exostosin-like 3 gene 
(ßExtBKO) and defective biosynthesis of HS, when compared with the heterozygous 
controls. The loss of HS in the ßExtBKO mice also resulted in impaired glucose-
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stimulated insulin secretion (Takahashi et al., 2009). The extent to which this 
impairment was due to beta cell death is unclear from these studies.
HS cannot be synthesised without the availability of the core proteins of HSPGs. Our 
study revealed the panel of HPSGs that are responsible for the abundance of HS within 
mouse islets. We detected the intra-islet localisation of high levels of type XVIII 
collagen, syndecan-1 and CD44 in mouse islets in situ providing an explanation, for the 
high levels of intra-islet HS. The expression of other forms of HSPGs including 
syndecans 2-4, glypicans -1 and -4, agrin have also been reported in mouse islets by 
independent studies (Cheng et al., 2012, Takahashi et al., 2009). Discrepancies in the 
detection of various HSPGs between different studies, could be due to the use of 
different antibodies and detection techniques. Although a role for HS in beta cell 
viability has been established, whether there exist other roles for HSPGs in beta cells is 
unclear. Future experiments to identify the subcellular localisation of HSPGs in islet 
beta cells with the aid of confocal or electron microscopy will be useful in elucidating 
any additional functions of HSPGs in normal islet biology.
Immunohistochemical analyses detected a low level of heparanase expressed at the 
surface of individual islet cells. Intracellular expression of heparanase was reported 
previously in isolated islet beta cells (Ziolkowski et al., 2012). Together, these findings 
suggest that the low levels of endogenous islet heparanase are required for the turnover 
of intracellular HS in beta cells. Although the exact mechanism of heparanase-mediated 
turnover of HS in beta cells is yet to be defined, evidence form other models suggest 
that latent heparanase is secreted and binds to cell surface HSPGs (Ben-Zaken et al., 
2008, Gingis-Velitski et al., 2004, Vreys et al., 2005). Upon internalisation via 
endocytosis, heparanase becomes localised in late endosomes and lysosomes, where 
storage of cathepsin L, the heparanase-activating protease is present in high levels. This 
is consistent with reports that HS chains are also degraded in endosomal and lysosomal 
compartments (Abboud-Jarrous et al., 2008, Cohen et al., 2005, Gingis-Velitski et al., 
2004). The relatively longer half-life of heparanase (approximately 30 hrs) and the 
shorter half-life of HS (2-6 hrs for transmembrane HSPGs and 25 mins for 
glycosylphosphatidylinositol (GPI)-anchored HSPGs), together with the intracellular 
co-localisation, are consistent with this proposed mechanism for heparanase-mediated 
HS turnover (Fux et al., 2009, Gingis-Velitski et al., 2004, Yanagishita and Hascall, 
1992).
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In support of this regulatory role for heparanase, we detected extraordinarily high levels 
of intra-islet expression for cathepsin L, which may account for the intracellular 
activation of heparanase needed for the turnover of islet HS. It is envisaged that the 
activation of heparanase would need to be tightly regulated under physiological 
conditions to avoid undesired degradation of beta cell HS. We postulate that intra-islet 
cathepsin L is predominantly expressed in the inactive form within the native islets in 
the pancreas. We further suggest that the inactive cathepsin L undergoes auto-cleavage 
upon exposure to the acidic pH in the islet lysosomes, where it exerts its enzymatically 
active function to activate heparanase. To further explore this notion, laser capture 
microdissection, a technique that allows isolation of islet beta cells without altering or 
damaging the morphometry of the islets, could be used to examine the activation status 
of cathepsin L and heparanase in native islets by Western blotting (Ahn et al., 2007, 
Fend and Raffeld, 2000, Koob et al., 2012, Negi et al., 2012). Additionally, cathepsin L 
has been documented to play a role in normal protein maturation and proenzyme 
activation (e.g., neuropeptide Y and enkephalin) (Funkelstein et al., 2008, Nakagawa et 
al., 1998, Reiser et al., 2010, Yasothomsrikul et al., 2003). It is possible that cathepsin L 
plays a role in the processing and secretion of insulin. Alternatively, cathepsin L may 
act as a “house-keeping” enzyme that degrades the vesicular membrane proteins once 
insulin is secreted. This notion remains to be elucidated.
Critical roles for HS in islet biology, have been identified particularly in beta cell 
survival and protection from free radical damage (Ziolkowski et al., 2012), beta cell 
proliferation and impaired glucose-stimulated insulin secretion (Takahashi et al., 2009). 
In contrast, the impact of impaired levels of HPSG core proteins, heparanase and 
cathepsin L in islet biology is unknown. Knock-out models of individual HSPG core 
proteins, e.g., type XVIII collagen and syndecan-1, have not exhibited abnormalities in 
the pancreas. This may be due to functional redundancy, with other HSPG core proteins 
substituting for the deleted HSPG and acting as a “backbone” for the synthesis of islet 
HS (Cheng et al., 2012, Sarrazin et al., 2011). Likewise, heparanase gene knock-out 
mice and cathepsin L gene knock-out mice have no apparent defects in the pancreas 
(Potts et al., 2004, Zcharia et al., 2009), as demonstrated in this project, display high 
levels of intra-islet HS. HS chains in heparanase knock-out mice were found to be 
longer and more homogeneous, suggesting that heparanase is likely to be a major 
mechanism for regulating the molecular properties of HS (Zcharia et al., 2009). We
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suggest that the role of the HS, HSPG core proteins (e.g., type XVIII collagen and 
syndecan-1) and heparanase in islet biology can be studied using conditional knockout 
mice. The gene of the enzymes for the biosynthesis of HS (e.g., exostoxin) (Takahashi 
et al., 2009), HSPG core proteins or heparanase can be deleted specifically in beta cells 
by crossing the mice that expressed the genes of interest flanked by loxP sites, with 
transgenic mice expressing RIP (rat insulin promoter)-cre. The beta-cell specific 
deficiency of the gene of interest may minimise the undesired compensatory 
mechanisms or embryonic lethality observed in a full knockout model.
7.2 Islets lose their basement membrane and heparan sulfate following isolation
Purification of islets for transplantation requires a collagenase-mediated isolation 
process to separate the islets from the surrounding pancreatic acinar tissue (Kin et al., 
2007). Our findings agree with other reports, demonstrating that islets became detached 
from their peri-islet BM/ECM (Rosenberg et al., 1999, Thomas et al., 1999, Wang and 
Rosenberg, 1999, Wang et al., 1999) and lose their HS (Ziolkowski et al., 2012) 
following isolation. In addition, our study has provided further evidence that while islet 
HS is lost, the core proteins of HSPG remain intact after islet isolation. Our findings 
further indicate that it is the HS component of HSPG and not the core proteins that is 
critical for the survival of islet beta cells. Despite the routine practice of short-term islet 
culture prior to clinical islet transplantation, our studies suggest that islets do not re-
establish their BM after 4 days of culture, and, similarly, regain only marginal levels of 
intra-islet HS.
Previous studies demonstrated the loss of islet-associated ECM during islet isolation 
(Rosenberg et al., 1999, Thomas et al., 1999, Wang and Rosenberg, 1999, Wang et al., 
1999). In this study, we provide a comprehensive analysis of the individual BM matrix 
components, showing that collagen type IV, laminin, perlecan and nidogen-2 that are 
normally present as a continuous peri-islet BM, are completely lost following islet 
isolation. Prior to transplantation, isolated islets therefore lack the BM barrier that 
protects them from cell invasion in situ, which in turn, renders them vulnerable to 
immune and non-immune mechanisms that impact on islet viability. The islet BM 
interacts with various critical trophic factors to maintain islet integrity and function 
(Cheng et al., 2011, Kaido et al., 2004, Kragl and Lammert, 2010, Wang and 
Rosenberg, 1999). Hence, the loss of the islet BM would deplete the islets from survival 
signals and expose islet beta cells to matrix detachment-induced cell death (anoikis).
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Consistent with this notion, the pro-apoptotic signal p38 and c-jun N-terminal kinase 
(JNK) activity were enhanced relative to pro-survival extracellular signal-related protein 
kinase (ERK) signal in the isolated canine islets (Rosenberg et al., 1999). Caspase-6, 
one of the effector caspases involved in apoptotic signalling was also upregulated in 
islets isolated from rhesus monkeys (Thomas et ah, 2001). Matrix detachment can also 
lead to the generation of reactive oxygen species (ROS) (Li et ah, 1999), which are 
detrimental to the viability of islet beta cells.
The integrity of isolated islets is further confounded by the loss of intra-islet HS that is 
essential for the survival of islet beta cells. In view of the proposed novel role of HS as 
an antioxidant in islet beta cells, it is likely that loss of islet HS renders the islets more 
susceptible to isolation-induced insults, particularly oxidative stress. The loss of HS 
from islet HSPG core proteins during islet isolation suggests a degradative process that 
is HS-specific. Despite the upregulation of heparanase expression in isolated islets, as 
shown in our immunohistochemical studies, our Western blotting analyses 
demonstrated that heparanase is mainly in its inactive latent form. Moreover, both 
isolated wild-type and heparanase-knockout mouse islets lost substantial levels of intra-
islet HS. Together, these findings suggest that heparanase activity is not the primary 
factor responsible for the loss of intra-islet HS during islet isolation. Instead, excessive 
levels of ROS, which can depolymerise HS chains (Raats et al., 1997), is likely to 
contribute to the depletion of HS during islet isolation. In contrast, under physiological 
conditions, intra-islet HS appears to act as a free radical sink to neutralise the damaging 
effect of ROS generated intracellularly during normal cell metabolism. Therefore, we 
speculate that high levels of free radicals are generated during the stress-prone islet 
isolation process and that the damaging effects of excessive ROS override the protective 
function of islet HS, resulting in fragmentation of islet HS. In our studies, we have 
identified a promising strategy for preserving beta cell HS in isolated islets. In vivo and 
in vitro antioxidant treatment using butylated hydroxyanisole (BHA) and 
dimethylthiourea (DMTU), respectively significantly preserved HS in isolated mouse 
islets, compared to non-treated islets. Additionally, inclusion of 4,4'-diisothiocyano- 
stilbene-2,2'-disulfonic acid (DIDS), an anion channel blocker with anti-oxidative and 
anti-apoptotic properties (Anazawa et al., 2011, Mizoguchi et al., 2002, Qi et al., 2009, 
Wang et al., 2005) in the isolation medium, significantly improved the HS content of 
isolated islets. Given these findings, it is envisaged that preservation of the islet HS
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would protect the islets against oxidative damage, enhance beta cell viability and hence 
improve the quality of the islets for transplantation.
The loss of intra-islet vasculature during islet isolation creates a hypoxic environment 
that promotes the generation of ROS (Itoh et al., 2012). Additionally, detachment of the 
islet BM may lead to anoikis-induced production of excessive levels of ROS (Li et al., 
1999), which subsequently deplete HS in the islet beta cells. Thus, we propose that 
reconstitution of an islet BM by embedding islets in BM matrix proteins, e.g., collagen, 
laminin and fibronectin (Wang and Rosenberg, 1999, Weber and Anseth, 2008) or 
facilitating the revascularisation of transplanted islets by supplementing isolated islets 
with endothelial cells and/or mesenchymal stem cells (Pan et al., 2011, Park et al., 
2010) may reduce the intra-islet levels of ROS. Previously, studies have demonstrated 
improved survival and function of islets treated with antioxidants such as vitamins 
(tocopherol, ascorbic acid), metabolites (glutamine, bilirubin) and enzyme mimetics 
(SOD mimetics) in vitro during isolation or in vivo during the peri-transplant period 
(Avila et al., 2005, Bottino et al., 2002, Brown et al., 2005, Tajiri and Grill, 1999). It is 
possible that these treatments exert their beneficial effects by protecting intra-islet HS 
against ROS-induced damage.
In addition to ROS, other molecules could also contribute to the degradation of HS 
during islet isolation. Like ROS, reactive nitrogen species (RNS), in particular 
peroxynitrite, a secondary oxidant formed by superoxide and nitric oxide (NO) has been 
shown to degrade HS (Kennett and Davies, 2007, Kennett et al., 2010). Significantly, 
enhanced NO levels have been reported in freshly isolated islets (Corbett et al., 1992, 
Pavlovic et al., 1999). Islet beta cells are also able to produce NO upon cytokine 
induction. The activation of islet intrinsic NF-kB, which has been demonstrated during 
islet isolation, promotes the expression of inducible nitric oxide synthase (iNOS), 
resulting in the intracellular production of NO in beta cells (Cowley et al., 2012, Negi et 
al., 2012). NO can also be produced by other cell types within islets, including ductal 
cells, endocrine cells and macrophages (Thomas et al., 2002). Hence, it is plausible that 
RNS may also contribute to the loss of islet HS during the process of islet isolation.
In view of the critical roles for the islet BM and intra-islet HS in islet cell survival, we 
suggest that islet BM and islet HS represent important biomarkers for islet integrity. 
Evaluation of the status of islet BM and islet HS could therefore be incorporated in the
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routine assessment of the quality of isolated islets for transplantation, and as a measure 
for developing optimal enzyme preparations for islet isolation procedures. We further 
suggest that the loss of the islet BM and intra-islet HS during the isolation procedure 
renders islets more susceptible to the beta cell damage, and may provide a feasible 
explanation for the high death rate observed in the isolated islets after 48 hrs (Thomas et 
al., 2001). Therefore, replacement or preservation of islet BM and HS could compensate 
for the shortage of donor organs, reduce the numbers of islets needed to restore 
normoglycaemia post-transplant, and overall, optimise the approach of islet 
transplantation as a treatment for established Type 1 diabetes.
7.3 Islet basement membrane and intra-islet heparan sulfate are recovered in 
isografts
Our studies demonstrated the progressive recovery of islet BMs after isotransplantation. 
The deposition of BM matrix proteins at the periphery of engrafted islets commenced as 
early as 3 days post-transplant. A continuous peri-islet BM was evident in day 5 
isografts and was followed by invagination of the BM matrix proteins into the islets to 
form the intra-islet subendothelial BMs by day 7 post-transplant. Essentially, peri-islet 
BMs and subendothelial BMs surrounding intra-islet capillaries, were re-established by 
10 days post-transplant. Our novel findings also shed light on the mechanism by which 
islet BMs are restored post-transplant. Our studies suggest that endothelial cells play a 
key role in producing the matrix proteins used for the assembly and reconstitution of the 
islet BM. Our immunofluorescence studies revealed colocalisation of endothelial cells 
and BM matrix proteins at the periphery of islets particularly by 5 days post-transplant. 
It is known that endothelial cells are capable of producing and secreting BM matrix 
proteins. Studies by Nikolova et al. showed that endothelial cells are recruited by beta 
cell-derived VEGF-A to form the vascular BMs that underlies the dense capillary 
network within islets (Nikolova et al., 2006). Endothelial cells lay down BM matrix 
proteins from the tip of vascular sprouts during their migration to form new blood 
vessels (Jin et al., 2005). We observed that the endothelial cells retracted from the 
periphery of the islets by day 7 post-transplant, leaving the islet BM as a stand-alone 
structure. Additionally, the formation of intra-islet capillaries by 7 days post-transplant 
coincided with the formation of intra-islet subendothelial BMs. These findings 
suggested that endothelial cells migrate from the periphery of the islets after the 
recovery of peri-islet BM is complete, and continue to deposit matrix proteins to form 
the intra-islet subendothelial BMs that underlie newly formed intra-islet capillaries. We
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therefore suggest that endothelial cells play pivotal roles not only for revascularisation 
of the islets after transplantation, but also in repair of islet architecture.
Similar to isolated islets, islet isografts at early post-transplant display low levels of 
intra-islet HS and only recover their HS by 10 days after isotransplantation. Thus, the 
deficiency of islet HS, which acts as a potent antioxidant, may render the avascular 
islets more susceptible to oxidative damage during the early post-transplant period. It is 
also possible that the sulfation status of intra-islet HS in islet transplants differs to 
native islets, a property which could influence the intensity of histochemical staining of 
HS with Alcian blue. Altered sulfation of HS has been reported during tissue 
remodelling, development, aging, injury and diseases (Brickman et al., 1998, 
Challacombe and Elam, 1995, David et al., 1992, Jayson et al., 1998, Lindahl et al., 
1998, Winterbourne and Mora, 1981). Highly sulfated, but not under-sulfated HS 
mimetics significantly protect islet beta cells from culture- and oxidant-induced cell 
death (Ziolkowski et al., 2012). These findings suggest that changes to the islet HS, 
particularly under-sulfation, may impact on the long-term function and survival of islet 
transplants. To address this notion, comparative analyses of the sulfation profile of islet 
HS in native islets in situ and in islet transplants could be performed using ion exchange 
high performance liquid chromatography (HPLC), which separates digested HS 
fragments based on the differences in the negative charge of the sulfated moieties 
(Brickman et al., 1998, Challacombe and Elam, 1995).
Taken together, the recovery of both the islet BM and intra-islet HS takes 
approximately 10 days following islet isotransplantation. This recovery period creates a 
window of vulnerability for islet transplants challenged with accumulating oxidative 
stress in the presence of low levels of beta cell HS. In addition, lack of islet BMs would 
decrease the trophic support. As a result, islet transplants are prone to early graft failure 
and consequently, excessive numbers of islets are transplanted to ensure engraftment of 
sufficient mass of islet tissue for restoring normoglycaemia. Hence, we propose that 
EC/MSC-supplemented (Johansson et al., 2008, Pan et al., 2011) or ECM-embedded 
(Jalili et al., 2011, Salvay et al., 2008, Weber and Anseth, 2008) islet transplants 
together with antioxidant treatment during islet isolation and in early peri-transplant 
period may improve the quality of islet transplants and hence substantially reduce the 
number of islets required for the re-establishment of normoglycaemia.
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Similar to isolated islets, islet isografts exhibited increased intra-islet cell surface 
heparanase expression, compared to islets in situ. However, our Western blotting 
analyses indicated that the heparanase expressed on islet cells was mainly inactive. We 
speculate that the up-regulation of cell surface proheparanase maybe due to its function 
in inducing VEGF, which is important for the revascularisation of islet transplants. 
Zetser et al. reported that secreted heparanase is able to stimulate VEGF expression, 
independently of its enzymatic activity. The authors proposed that following secretion, 
latent heparanase binds to heparanase-binding proteins at the cell surface, thereby 
activating p38 and Src signalling pathways, which are responsible for the upregulation 
of VEGF (Zetser et al., 2006). Although this in vitro study was performed using HEK 
293, B16 melanoma and MDA-MB-435 breast cancer cell lines, it is conceivable that a 
similar process of heparanase-induced VEGF occurs during the revascularisation of islet 
grafts. The cell surface expression of heparanase observed on islet cells of islet isografts 
could therefore represent heparanase bound to unidentified heparanase-binding proteins. 
Similar to the studies by Zetser et al., islet cell-bound heparanase could culminate in the 
upregulation of VEGF in the islets. The role of heparanase in revascularisation could 
potentially be investigated by assessing the revascularisation status of heparanase- 
overexpressing islet isografts compared to wild-type isografts.
Active cathepsin L was detected in the islet isografts, albeit to a lesser extent than that 
of the corresponding allografts. However, heparanase remained mainly inactive in the 
isografts. These findings suggest that intra-islet cathepsin L may be activated during 
tissue remodelling in the isografts but was remained in separate compartments to 
heparanase. The activation of cathepsin L may be associated with the increased insulin 
secretion during the peri-transplant period (Faradji et al., 2005). A confocal microscopy 
maybe used to examine the subcellular localisation of cathepsin L in the isografts and to 
investigate a possible function of cathepsin L in the regulation of insulin processing and 
secretion.
7.4 Heparanase contributes to the rejection of islet allografts by degrading HS in 
the peri-islet BM, graft stroma and islet beta cells
We found that the islet BM showed early signs of recovery in both islet isografts and 
allografts. However, enlarged peri-islet blood vessels were observed in islet allografts 
from day 5 post-transplant. The accumulation of mononuclear cells in the lumen 
suggested that these vessels acted as a conduit for MNCs migrating to the graft site. In
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addition, the graft stroma in allografts showed deposition of BM matrix proteins. In 
contrast to islet isografts, in which a continuous peri-islet BM was established by 5 days 
post-transplant, the complete recovery of peri-islet BMs in allografts was subject to the 
tempo of rejection. While CBA islet allografts in C57BL/6 recipient mice were devoid 
of fully restored peri-islet BMs and showed evidence of islet damage by 5 days post-
transplant, islet allografts in the reverse mouse combination, were rejected more slowly 
and continuous peri-islet BMs were sometimes established by 5 days post-transplant. 
Nonetheless, the presence of MNC-containing peri-islet vasculature, intra-graft 
distribution of BM matrix proteins, as well as the lack of intra-islet capillaries was 
consistent in both allograft mouse strain combinations. Taken together, our findings 
suggest that during acute rejection, the cue for the reconstruction of islet BM was 
diverted to form peri-islet vasculature that served as a migration portal for leukocytes to 
the graft site.
Despite the prevalent use of the subrenal capsular site for islet transplants in rodents, the 
route of leukocyte migration in this model has remained obscure. It is generally 
understood that alloreactive T cells are primed in the draining lymph node or spleen by 
mature alloantigen-loaded APCs that have migrated from the graft site (Le Moine et al., 
2002). Tatsuya et al. proposed that the revascularisation of islets transplanted under the 
rat kidney capsule originated from both renal artery and renal capsular veins, providing 
a possible route for leukocyte migration to the graft site from the draining lymph nodes 
(Kin et al., 2004). Investigation of possible interactions between the enlarged peri-islet 
blood vessels that we have observed in islet allografts and the renal vasculature could be 
done by adoptively transferring fluorescent-labelled in vitro stimulated anti-donor 
effector T cells to immunoincompetent recipients carrying islet allografts. The dynamics 
of leukocyte migration to the graft site could then be visualised using intra-vital 
microscopy.
The recovery of intra-islet HS was indicated by increased HS staining in islet allografts 
up to 5 days post-transplant. Thereafter, the intra-islet HS levels diminished before 
complete destruction of islet tissue due to graft rejection. Collectively, these findings 
suggest that islet HS may act as a target for destruction during islet allograft rejection. 
The presence of BM matrix proteins including the HSPG perlecan in the graft stroma 
together with the progressive loss of islet HS during rejection suggests that degradative 
enzymes are likely to be required for leukocytes to navigate through the graft site and to
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target intra-islet HS during the course of rejection. Consistent with this notion, our 
study identified the HS-degrading heparanase as a key endoglycosidase expressed by 
infiltrating mononuclear cells (MNCs) during islet allograft rejection. Our Western 
blotting analyses revealed that the heparanase in the allografts is mainly in its active 
form. Heparanase is involved in various pathological settings such as delayed type 
hypersensitivity, experimental autoimmune encephalomyelitis (EAE), glomerular 
diseases, inflammatory bowel diseases, rheumatoid arthritis, atherosclerosis, tumour 
growth and invasion (Bartlett et al., 1995, Hershkoviz et al., 1995, Nakajima et al., 
1984, Parish, 2006, Parish et al., 2001, Patel et al., 2007, Vlodavsky and Friedmann, 
2001, Vlodavsky et al., 1983, Ziolkowski et al., 2012). Recently, Ziolkowski 
demonstrated the onset of autoimmune T1D in the NOD mice correlates with the 
upregulation of heparanase by the insulitis MNCs and the loss of islet HS (Ziolkowski 
et al., 2012).
In the context of the rejection of islet allografts, we propose that the contribution of 
heparanase is determined by the tempo of rejection. Heparanase produced by infiltrating 
MNCs may be involved at multiple levels in the rejection response. Firstly, catalytically 
active heparanase produced by the MNCs could solubilise the subendothelial BM HS, 
aiding leukocyte migration from the blood into the graft site. Thereafter, the MNCs 
could produce heparanase to break down the BM HS (perlecan) in the graft stroma to 
migrate through the graft site. The need for heparanase to degrade HS in the islet BM 
will be determined by whether a continuous peri-islet BM is laid down before MNCs 
infiltrate the islet tissue. Irrespective of this, once leukocytes invade the islet cell mass, 
the local production of heparanase would degrade intra-islet HS, which is essential for 
the survival of islet beta cells. The loss of intra-islet HS would therefore contribute to 
the demise of islet allografts (Fig. 7.1).
We postulate that infiltrating MNCs represent the main source of heparanase during the 
rejection of islet allografts. However, it is possible that endothelial cells, which are 
known to produce heparanase may help solubilise the subendothelial BM HS (Bartlett et 
al., 1995, Naparstek et al., 1984, Sewell et al., 1989, Vlodavsky et al., 1992). In 
addition, islets could also play a supplementary role in facilitating leukocyte migration 
and in heparanase-mediated damage of islet transplants. In particular, we have 
demonstrated that islets act as a reservoir for cathepsin L, the lysosomal proteases 
responsible for the activation of proheparanase. Consistent with this, analyses from real-
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Figure 7.1 Proposed mechanism for heparanase-mediated destruction of islet 
transplants during allograft rejection
Leukocyte-derived Hpse may be involved in multiple stages of the rejection of islet 
allografts. First, leukocytes can produce catalytic active heparanase (red symbol) to 
degrade HS (blue symbol) in the subendothelial BM to aid leukocyte extravasation 
into the graft site. Thereafter, MNCs produce heparanase to solubilise the islet- 
associated HS. Once the MNCs invade the islet cell mass, the local production of 
heparanase could target intra-islet HS, with its depletion promoting beta cell death. 
Where the recovery of the islet BMs (broken peri-islet boundary) occurs before the 
peri-islet accumulation of host MNCs, heparanase produced by those leukocytes could 
then damage HS of HSPGs in the islet BMs, facilitating intra-islet entry of the MNCs. 
In the absence of continuous islet BMs, intra-islet invasion by the MNCs would be 
expected to be unimpeded. In addition to MNCs, endothelial may express heparanase 
(green symbol) to promote T cell adherence to the luminal side of the endothelium in 
the early stage of leukocyte migration and degrade the subendothelial BM HS. 
Additionally, islets represent another potential source of heparanase (dark blue 
symbol). The release of islet-derived cathepsin L (brown symbol) from the damaged 
islets may sustain the activation of leuckoute-derived heparanase and induce the 
activation of islet heparanase. The critical need for high levels of islet HS for the 
survival of islet beta cells and the rich reservoir of intra-islet cathepsin L render the 
islets highly vulnerable to heparanase-mediated immune destruction in the process of 
allograft rejection. EC, endothelial cell; BM, basement membrane.
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time RT-PCR studies, immunohistochemistry and Western blotting for cathepsin L 
revealed that in the rejecting islet allografts, the intra-islet cathepsin L is predominantly 
in its active form, possibly due to the autocleavage process of cathepsin L upon 
exposure to the acidic environment during the inflammatory response of graft rejection. 
It is possible that cathepsin L is released from the damaged islets during islet allograft 
rejection and could activate host leukocyte-bound heparanase and donor islet-derived 
heparanase.
In addition to its HS-degrading activity, it is possible that heparanase exerts non- 
catalytic functions during the course of islet graft rejection. Prior to extravasation, 
heparanase expressed by the vascular endothelial cells has been shown to promote T 
cell adherence to the endothelium. This in turn, activates betal-integrins on the 
leukocytes, allowing stable adherence to the endothelium via interaction with adhesion 
molecules such as VCAM-1, a prerequisite for leukocyte transmigration across the 
endothelium (Sotnikov et al., 2004). In addition, accumulating data have provided 
evidence for a role for non-catalytic heparanase in regulating gene transcription 
including inflammatory genes in the nuclei. Heparanase can translocate to the nucleus 
and regulate cell differentiation by degrading intra-nuclear HS (Chen and Sanderson, 
2009, Kobayashi et al., 2006, Nobuhisa et al., 2007). Heparanase can alter histone 
phosphorylation and modulate HS-mediated inhibition of histone acetyltransferases, 
which regulate the gene expression of VEGF, genes associated with glucose metabolism 
and inflammation (He et al., 2012, Purushothaman et al., 2011, Wang et al., 2012). 
However, these functions of heparanase in the context of islet allograft rejection remain 
to be elucidated.
The activation of heparanase provided by the MNCs could occur at the intracellular or 
extracellular level. Following secretion, the latent heparanase binds to cell surface 
receptors such as mannose 6-phophate receptor (MPR), low density lipoprotein-receptor 
related protein (LRP) and HSPG. Bound heparanase can then be internalised and 
activated in intracellular lysosomal compartments (Gingis-Velitski et al., 2004, Shafat et 
al., 2006, Vreys et al., 2005). Alternatively, heparanase could be activated 
extracellularly at the cell surface. Heparanase and cathepsin L can be produced by 
different types of cells, as demonstrated in a mouse model of ulcerative colitis, whereby 
heparanase is expressed by colon epithelial cells, and cathepsin L is secreted by local 
macrophages. Together, the cooperative activity of the two distinct cell types, the
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activation of heparanase plays an important role in generating a vigorous inflammatory 
response resulting in colitis-induced tumorigenesis (Lemer et al., 2011). Similarly, in 
the setting of islet allograft rejection, it is possible that leukocyte-bound heparanase is 
activated extracellularly by islet-derived cathepsin L, liberated in its active form during 
graft rejection. Endogenous islet heparanase could be activated by cathepsin L either 
intracellularly or at the cell surface of islet beta cells, to degrade intracellular HS and 
potentially aid leukocyte invasion into the islet cell mass.
Taken together, the extraordinarily high levels of intra-islet HS and cathepsin L within 
islets render islets highly susceptible to the heparanase-mediated destruction. We 
therefore propose that heparanase inhibition may represent a promising adjunct anti-
rejection strategy for clinical islet transplantation.
The upregulation of heparanase, which is largely restricted to pathological conditions 
and its involvement in the early stage of leukocyte migration suggest that heparanase 
may be used as an early anti-rejection marker for early intervention to be implemented 
to prevent graft rejection. The development of an ELISA method, which allows the 
detection of low levels of heparanase in tissue extracts, plasma and urine sample 
(Shafat, Zcharia et al. 2006) has generated a sensitive and reliable diagnostic and 
prognostic tool for several diseases, e.g., sarcomas, carcinomas, ovarian cancers, type 2 
diabetes and diabetes-associated nephropathy (Katz et al., 2002, Shafat et al., 2007, 
Shafat et al., 2011, Zhang et al., 2011). In the context of clinical islet transplantation, 
where islets are infused through the hepatic portal, the notion that plasma levels of 
heparanase may be used as an early biomarker for graft rejection remains to be 
explored.
In addition to heparanase, it is known that other possible mechanisms could degrade HS 
during allograft rejection. During islet isolation, we have found that loss of islet HS is 
not heparanase-dependent and that HS depletion can occur due to oxidative damage. 
Likewise, free radicals generated in the microenvironment of rejection-associated 
inflammation could depolymerise HS during graft rejection. The chemical structure of 
HS can also be modified by sulfatases such as endo-6-sulfatase, potentially impacting 
on the function and integrity of HS (Uchimura et al., 2006, Wang et al., 2004). The 
extent to which different mechanisms damage HS in inflammation is unknown. Such 
issues highlight a need for the development of HS mimetics that are resistant to all
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forms of degradation, or indeed for combined anti-HS degradative strategies, 
particularly in the context of islet inflammation and transplant rejection.
We suggest that the maximum contribution of heparanase to the rejection of islet 
allografts is likely to be observed during chronic rejection, where the islet BM and intra-
islet HS are established prior to immune injury. This is of paramount importance to the 
clinical islet transplantation, where islet transplants succumb to graft rejection despite 
long-term immunosuppression. It is envisaged that islet BM and intra-islet HS are 
restored in the presence of chronic immunosuppression and therefore, heparanase may 
exert its maximum graft-destructive function by targeting islet BM HS and intra-islet 
HS. Hence, it is necessary to incorporate heparanase-inhibiting strategy to efficiently 
prevent the graft-destructive activity.
Our study has identified yet another critical effector mechanism contributes to the 
rejection of islet allografts via heparanase-mediated degradation of islet HS. 
Previously, it has been reported that perforin and granzyme B, Fas-FasL signalling, 
IFN-y, upregulation of NF-kB and the generation of free radicals are involved in the 
rejection of islet allografts (Diamond and Gill, 2000, Porras et al., 2012, Sleater et al., 
2007). It is conceivable that the destruction of islet allografts particularly during the 
acute graft rejection is due to the combined effect of multiple effector mechanisms. 
Hence, effort should be explored to prevent graft rejection by using combined therapy 
that targets different pathways. For example, heparanase inhibitor can be used in 
parallel with the small molecule inhibitors for perforin, which show promising 
inhibitory activity against in vitro perforin-dependent cytotoxic T lymphocyte- and NK 
cell-mediated cell lysis (Spicer et al., 2012, Thomas et al., 2010) or caspase inhibitors 
that has recently been shown to significantly prolong the survival of islet allografts 
when used together with CTLA4-Ig, a novel inhibitor of costimulation (Emamaullee et 
al., 2010).
7.5 Future directions
In the future, studies to dissect the mechanism(s) contributing to the loss of HS during 
islet isolation should be pursued. A time course study to examine the status of islet HS 
(using Alcian blue histochemistry) at different stages of islet isolation, e.g., after 
intraductal injection of collagenase solution, incubation at 37°C, subsequent mechanical 
breakdown of pancreatic acinar tissue (agitation) and hand-picking of the islets. In
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addition, liquid chromatography/mass spectroscopy (HPLC/MS) could be used to 
identify the panel of oxidants generated in isolated islets by treating the donor mice with 
fluorescent probes such as hydroethidine. Identification of the fluorescent products 
would indirectly establish the identity of the oxidants produced during the isolation 
process (Maghzal and Stocker, 2007). It is envisaged that the identification of the free 
radicals would help identify the most appropriate antioxidants for use in the islet 
isolation to prevent the degradation of islet HS. In this context, combined BHA, DMTU 
and DIDS could also be explored to assess potential synergistic effects on preserving 
the HS content of isolated islets and improving the islet viability and function of 
marginal mass islet transplantation.
To further elucidate the role of endothelial cells in the recovery of islet BMs in islet 
transplants, the tempo of recovery of the islet BM in VEGF-overexpressing transgenic 
islet isografts could be examined in comparison to wild-type transplants. Islet beta cells 
are known to secrete VEGF-A to attract endothelial cells to the graft site during graft 
revascularisation (Brissova et al., 2006). Hence, this model could serve as a valid 
approach for ascertaining the contribution of endothelial cells to the recovery of the islet 
BM. Such studies may support the cotransplantation of islets with endothelial cells or 
their precursors (e.g., mesenchymal stem cells) to precipitate islet BM recovery. In vitro 
reconstitution of the donor islet BMs could also be investigated using BM matrix 
components, e.g., Matrigel (Bharat et al., 2005, Golocheikine et al., 2010), but this 
approach is likely to encounter practical problems at the level of islet infusion, 
restricting the surgical route for implantation.
Our studies have revealed that islet-associated HS (in islet beta cells and in the islet 
BM) represents a potential target for heparanase-mediated destruction during the 
rejection of islet allografts. It is postulated that heparanase is likely to provide a 
maximum contribution to the destruction of engrafted islets during a delayed rejection 
response or the chronic rejection of established allografts, after the complete recovery of 
the islet HS has been established. The role of heparanase in the chronic rejection of islet 
allografts could be clarified using minor histoincompatible islet allografts in mice, or 
after short-term immunosuppression which prevents an early inflammatory response to 
the engrafted islet tissue.
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Efforts should also be made to evaluate heparanase inhibitors that are not only devoid of 
anti-coagulant and anti-angiogenic properties, but display a longer serum half-life in 
vivo. The effect of heparanase inhibition in combination with peri-transplant antioxidant 
treatment and chronic low dose immunosuppression on the survival of islet allografts 
should be explored.
7.6 Conclusion
In conclusion, this study has identified a potential strategy for improving the quality of 
isolated islets for transplantation by preserving the intra-islet HS during islet isolation 
with the aid of antioxidants. In addition, we have revealed a potential role for 
heparanase in mediating the rejection of islet allografts. We propose that heparanase 
could impact at multiple stages during the course of rejection. We suggest that 
heparanase produced by the MNCs solubilises the subendothelial BM HS and intra- 
graft HS to navigate to the engrafted islets. For islets surrounded by a newly repaired 
islet BM, heparanase produced by peri-islet MNCs could damage the islet BM, thereby 
facilitating MNC entry into the islet cell mass. In contrast, islets devoid of their islet 
BM would be expected to be highly vulnerable to MNC invasion. Once intra-islet 
invasion is achieved, the local production of heparanase would further degrade intra-
islet HS, removing an essential requirement for the survival of islet beta cells. 
Heparanase inhibition may therefore serve as a promising adjunct anti-rejection therapy 
for islet transplantation. These important findings may help to establish clinical islet 
transplantation as a more routine therapy for patients with established Type 1 diabetes. 
Ultimately islet transplantation has the potential to restore the physiological delivery of 
insulin, optimise glucose metabolism and prevent the development of serious secondary 
vascular complications of Type 1 diabetes, which develop due to the imperfect control 
of glycaemia by insulin therapy.
358
Bibliography
Abboud-Jarrous, G., Atzmon, R., Peretz, T., Palermo, C., Gadea, B. B., Joyce, J. A. & 
Vlodavsky, I. 2008. Cathepsin L is responsible for processing and activation of 
proheparanase through multiple cleavages of a linker segment. The Journal of 
biological chemistry, 283, 18167-76.
Abdelli, S., Ansite, J., Roduit, R., Borsello, T., Matsumoto, I., Sawada, T., Allaman- 
Pillet, N., Henry, H., Beckmann, J. S., Hering, B. J. & Bonny, C. 2004. 
Intracellular Stress Signaling Pathways Activated During Human Islet 
Preparation and Following Acute Cytokine Exposure. Diabetes, 53, 2815-2823.
Abdi, R., Means, T. K. & Luster, A. D. 2003. Chemokines in islet allograft rejection. 
Diabetes-Metabolism Research and Reviews, 19, 186-190.
Adair-Kirk, T. L. & Senior, R. M. 2008. Fragments of extracellular matrix as mediators 
of inflammation. The International Journal o f Biochemistry & Cell Biology, 40, 
1101- 1110.
Adams, A. B., Shirasugi, N., Durham, M. M., Strobert, E., Anderson, D., Rees, P., 
Cowan, S., Xu, H., Blinder, Y., Cheung, M., Hollenbaugh, D., Kenyon, N. S., 
Pearson, T. C. & Larsen, C. P. 2002. Calcineurin Inhibitor-Free CD28 
Blockade-Based Protocol Protects Allogeneic Islets in Nonhuman Primates. 
Diabetes, 51,265-270.
Adams, A. B., Shirasugi, N., Jones, T. R., Durham, M. M., Strobert, E. A., Cowan, S., 
Rees, P., Hendrix, R., Price, K., Kenyon, N. S., Hagerty, D., Townsend, R., 
Hollenbaugh, D., Pearson, T. C. & Larsen, C. P. 2005. Development of a 
chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to 
prolong islet allograft survival. J  Immunol, 174, 542-50.
Ahn, Y. B., Xu, G., Marselli, L., Toschi, E., Sharma, A., Bonner-Weir, S., Sgroi, D. C. 
& Weir, G. C. 2007. Changes in gene expression in beta cells after islet isolation 
and transplantation using laser-capture microdissection. Diabetologia, 50, 334- 
42.
Ähren, B., Wierup, N. & Sundler, F. 2006. Neuropeptides and the Regulation of Islet 
Function. Diabetes, 55, S98-S107.
Aikawa, R., Nagai, T., Kudoh, S., Zou, Y., Tanaka, M., Tamura, M., Akazawa, H., 
Takano, H., Nagai, R. & Komuro, I. 2002. Integrins Play a Critical Role in 
Mechanical Stress,Äilnduced p38 MAPK Activation. Hypertension, 39, 233- 
238.
Ali, S., Fritchley, S. J., Chaffey, B. T. & Kirby, J. A. 2002. Contribution of the putative 
heparan sulfate,Äibinding motif BBXB of RANTES to transendothelial 
migration. Glycobiology, 12, 535-543.
Ali, S., Hardy, L. A. & Kirby, J. A. 2003. Transplant immunobiology: a crucial role for 
heparan sulfate glycosaminoglycans? Transplantation, 75, 1773-1782.
Alves, F., Vogel, W., Mossie, K., Millauer, B., Hofier, H. & Ullrich, A. 1995. Distinct 
structural characteristics of discoidin I subfamily receptor tyrosine kinases and 
complementary expression in human cancer. Oncogene, 10, 609-18.
Anazawa, T., Sato, Y., Saito, T., Tsuchiya, T., Kenjo, A., Kimura, T., Haga, J., Miyake, 
M., Waguri, S., Hazama, A. & Gotoh, M. 2011. Improved Islet Yield and 
Function by Use of a Chloride Channel Blocker During Collagenase Digestion. 
Transplantation, 92, 871-877 10.1097/TP.0b013e31822e6eb4.
Andersson, A., Korsgren, O. & Jansson, L. 1989. Intraportally transplanted pancreatic 
islets revascularized from hepatic arterial system. Diabetes, 38 Suppl 1, 192-5.
Auchincloss, H. & Winn, H. J. 2004. Clarence Cook Little (1888-1971): The Genetic 
Basis of Transplant Immunology. American Journal o f Transplantation, 4, 155- 
159.
359
Avila, J., Barbara, B., Gangemi, A., Romagnoli, T., Kuechle, J., Hansen, M , Shapiro,
J. , Testa, G., Sankary, H., Benedetti, E., Lakey, J. & Oberholzer, J. 2005. Intra-
ductal glutamine administration reduces oxidative injury during human 
pancreatic islet isolation. Am J  Transplant, 5, 2830-7.
Ayala Garcia, M. A., Gonzalez Yebra, B., Lopez Flores, A. L. & Guani Guerra, E. 
2012. The Major Histocompatibility Complex in Transplantation. Journal of 
Transplantation, 2012.
Azzi, J., Geara, A. S., El-Sayegh, S. & Abdi, R. 2010. Immunological aspects of 
pancreatic islet cell transplantation. Expert Rev Clin Immunol, 6, 111-24.
Bach, F. H. & Voynow, N. K. 1966. One-way stimulation in mixed leukocyte cultures. 
Science, 153,545-7.
Badell, I. R., Russell, M. C., Thompson, P. W., Turner, A. P., Weaver, T. A., 
Robertson, J. M., Avila, J. G., Cano, J. A., Johnson, B. E., Song, M., Leopardi, 
F. V., Swygert, S., Strobert, E. A., Ford, M. L., Kirk, A. D. & Larsen, C. P. 
2010. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. 
The Journal o f Clinical Investigation, 120, 4520-4531.
Bain, B., Vas, M. R. & Lowenstein, L. 1964. The Development of Large Immature 
Mononuclear Cells in Mixed Leukocyte Cultures. Blood, 23, 108-116. 
Balamurugan, A. N., Loganathan, G., Beilin, M. D., Wilhelm, J. J., Harmon, J., 
Anazawa, T., Soltani, S. M., Radosevich, D. M., Yuasa, T., Tiwari, M., Papas,
K. K., McCarthy, R., Sutherland, D. E. & Hering, B. J. 2012. A new enzyme 
mixture to increase the yield and transplant rate of autologous and allogeneic 
human islet products. Transplantation, 93, 693-702.
Banting, F. G., Best, C. H., Collip, J. B., Campbell, W. R. & Fletcher, A. A. 1922. 
Pancreatic Extracts in the Treatment of Diabetes Mellitus. Can Med Assoc J, 12, 
141-6.
Bar-Ner, M., Eldor, A., Wasserman, L., Matzner, Y., Cohen, I. R., Fuks, Z. & 
Vlodavsky, I. 1987. Inhibition of heparanase-mediated degradation of 
extracellular matrix heparan sulfate by non-anticoagulant heparin species. 
Blood, 70,551-7.
Baraz, L., Haupt, Y., Elkin, M., Peretz, T. & Vlodavsky, I. 2006. Tumor suppressor p53 
regulates heparanase gene expression. Oncogene, 25, 3939-47.
Barro, C., Zaoui, P., Morel, F. & Benhamou, P. Y. 1998. Matrix metalloproteinase 
expression in rat pancreatic islets. Pancreas, 17, 378-82.
Barry, M. & Bleackley, R. C. 2002. Cytotoxic T lymphocytes: all roads lead to death. 
Nature Reviews Immunology, 2, 401-409.
Barshes, N. R., Wyllie, S. & Goss, J. A. 2005. Inflammation-mediated dysfunction and 
apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. 
Journal o f Leukocyte Biology, 77, 587-597.
Bartholomaus, I., Kawakami, N., Odoardi, F., Schlager, C., Miljkovic, D., Ellwart, J. 
W., Klinkert, W. E., Flugel-Koch, C., Issekutz, T. B., Wekerle, H. & Flügel, A. 
2009. Effector T cell interactions with meningeal vascular structures in nascent 
autoimmune CNS lesions. Nature, 462, 94-8.
Bartlett, M. R., Underwood, P. A. & Parish, C. R. 1995. Comparative analysis of the 
ability of leucocytes, endothelial cells and platelets to degrade the subendothelial 
basement membrane: Evidence for cytokine dependence and detection of a 
novel sulfatase. Immunol Cell Biol, 73, 113-124.
Batchelor, J. R., Welsh, K. I. & Burgos, H. 1978. Transplantation antigens per se are 
poor immunogens within a species. Nature, 273, 54-56.
Belting, M. 2003. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends 
in biochemical sciences, 28, 145-151.
360
Ben-Zaken, O., Shafat, I., Gingis-Velitski, S., Bangio, H., Kelson, I. K., Alergand, T., 
Amor, Y., Maya, R. B., Vlodavsky, I. & Ilan, N. 2008. Low and high affinity 
receptors mediate cellular uptake of heparanase. Int J  Biochem Cell Biol, 40, 
530-42.
Benhamron, S., Reiner, I., Zcharia, E., Atallah, M., Grau, A., Vlodavsky, I. & 
Mevorach, D. 2012. Dissociation between Mature Phenotype and Impaired 
Transmigration in Dendritic Cells from Heparanase-Deficient Mice. PLoS One, 
7 ,e35602.
Bernard, D., Mehul, B., Delattre, C., Simonetti, L., Thomas-Collignon, A. & Schmidt, 
R. 2001. Purification and characterization of the endoglycosidase heparanase 1 
from human plantar stratum comeum: a key enzyme in epidermal physiology? 
Journal o f Investigative Dermatology, 117, 1266-73.
Bemfield, M., Gotte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J. & 
Zako, M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu 
Rev Biochem, 68, 729-77.
Bezakova, G. & Ruegg, M. A. 2003. New insights into the roles of agrin. Nat Rev Mol 
Cell Biol, 4, 295-308.
Bharat, A., Benshoff, N., Olack, B., Ramachandran, S., Desai, N. M. & Mohanakumar, 
T. 2005. Novel in vivo murine model to study islet potency: engraftment and 
function. Transplantation, 79, 1627-30.
Bhargava, S., Hotz, B., Hines, O. J., Reber, H. A., Buhr, H. J. & Hotz, H. G. 2007. 
Suramin inhibits not only tumor growth and metastasis but also angiogenesis in 
experimental pancreatic cancer. J Castrointest Surg, 11, 171-8.
Billingham, R., Brent, L. & Medawar, P. 1954. Quantitative studies on tissue 
transplantation immunity. II. The origin, strength and duration of actively and 
adoptively acquired immunity. Proceedings o f the Royal Society o f London. 
Series B-Biological Sciences, 143, 58-80.
Billingham, R. E., Brent, L. & Medawar, P. B. 1953. "Actively Acquired Tolerance" of 
Foreign Cells. Nature, 172,603-606.
Billingham, R. E., Brent, L. & Medawar, P. B. 1956. Quantitative studies on tissue 
transplantation immunity. III. Actively acquired tolerance. Philosophical 
Transactions o f the Royal Society o f London. Series B, Biological Sciences, 357- 
414.
Bishop, J. R., Passos-Bueno, M. R., Fong, L., Stanford, K. I., Gonzales, J. C., Yeh, E., 
Young, S. G., Bensadoun, A., Witztum, J. L., Esko, J. D. & Moulton, K. S. 
2010. Deletion of the basement membrane heparan sulfate proteoglycan type 
XVIII collagen causes hypertriglyceridemia in mice and humans. PLoS One, 5, 
el3919.
Bishop, J. R., Schuksz, M. & Esko, J. D. 2007. Heparan sulphate proteoglycans fine- 
tune mammalian physiology. Nature, 446, 1030-1037.
Bitan, M., Polliack, A., Zecchina, G., Nagler, A., Friedmann, Y., Nadav, L., Deutsch, 
V., Pecker, I., Eldor, A., Vlodavsky, I. & Katz, B. Z. 2002. Heparanase 
expression in human leukemias is restricted to acute myeloid leukemias. Exp 
Hematol, 30, 34-41.
Bliss, M. 1982. The discovery of insulin. Toronto: McClelland and Stewart Limited.
Bonner-Weir, S. & Orci, L. 1982. New perspectives on the microvasculature of the 
islets of Langerhans in the rat. Diabetes, 31, 883-9.
Bottino, R., Balamurugan, A. N., Bertera, S., Pietropaolo, M., Trucco, M. & Piganelli, 
J. D. 2002. Preservation of human islet cell functional mass by anti-oxidative 
action of a novel SOD mimic compound. Diabetes, 51, 2561-7.
Bottino, R., Balamurugan, A. N., Tse, H., Thirunavukkarasu, C., Ge, X., Profozich, J., 
Milton, M., Ziegenfuss, A., Trucco, M. & Piganelli, J. D. 2004. Response of
361
Human Islets to Isolation Stress and the Effect of Antioxidant Treatment. 
Diabetes, 53, 2559-2568.
Bowen, K. M., Andrus, L. & Lafferty, K. J. 1980. Successful allotransplantation of 
mouse pancreatic islets to nonimmunosuppressed recipients. Diabetes, 29 Suppl 
1,98-104.
Bowen, K. M. & Lafferty, K. J. 1980. Reversal of diabetes by allogenic islet 
transplantation without immunosuppression. AustJ Exp Biol Med Sei, 58, 441-7.
Brandhorst, H., Raemsch-Guenther, N., Raemsch, C., Friedrich, O., Huettler, S., 
Kurfuerst, M., Korsgren, O. & Brandhorst, D. 2008. The ratio between 
collagenase class I and class II influences the efficient islet release from the rat 
pancreas. Transplantation, 85,456-61.
Bretscher, P. & Cohn, M. 1970. A theory of self-nonself discrimination. Science (New 
York, NY), 169, 1042.
Brickman, Y. G., Ford, M. D., Gallagher, J. T., Nurcombe, V., Bartlett, P. F. & 
Turnbull, J. E. 1998. Structural modification of fibroblast growth factor-binding 
heparan sulfate at a determinative stage of neural development. J Biol Chem, 
273, 4350-9.
Brissova, M., Fowler, M., Wiebe, P., Shostak, A., Shiota, M., Radhika, A., Lin, P. C., 
Gannon, M. & Powers, A. C. 2004. Intraislet endothelial cells contribute to 
revascularization of transplanted pancreatic islets. Diabetes, 53, 1318-25.
Brissova, M., Fowler, M. J., Nicholson, W. E., Chu, A., Hirshberg, B., Harlan, D. M. & 
Powers, A. C. 2005. Assessment of Human Pancreatic Islet Architecture and 
Composition by Laser Scanning Confocal Microscopy. Journal o f 
Histochemistry & Cytochemistry, 53, 1087-1097.
Brissova, M., Shostak, A., Shiota, M., Wiebe, P. O., Poffenberger, G., Kantz, J., Chen, 
Z., Carr, C., Jerome, W. G., Chen, J., Baldwin, H. S., Nicholson, W., Bader, D. 
M., Jetton, T., Gannon, M. & Powers, A. C. 2006. Pancreatic islet production of 
vascular endothelial growth factor—a is essential for islet vascularization, 
revascularization, and function. Diabetes, 55, 2974-85.
Brix, K., Dunkhorst, A., Mayer, K. & Jordans, S. 2008. Cysteine cathepsins: cellular 
roadmap to different functions. Biochimie, 90, 194-207.
Brown, M. L., Braun, M., Cicalese, L. & Rastellini, C. 2005. Effect of perioperative 
antioxidant therapy on suboptimal islet transplantation in rats. Transplant Proc, 
37,217-9.
Brule, S., Chamaux, N., Sutton, A., Ledoux, D., Chaigneau, T., Saffar, L. & Gattegno, 
L. 2006. The shedding of syndecan-4 and syndecan-1 from HeLa cells and 
human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by 
the matrix metalloproteinase-9. Glycobiology, 16, 488-501.
Brunner, K. T., Mauel, J., Cerottini, J. C. & Chapuis, B. 1968. Quantitative assay of the 
lytic action of immune lymphoid cells on 51 -Cr-labelled allogeneic target cells 
in vitro; inhibition by isoantibody and by drugs. Immunology, 14, 181-96.
Bueno, V. & Pestana, J. O. 2002. The role of CD8+ T cells during allograft rejection. 
Braz J  Med Biol Res, 35, 1247-58.
Burnet, S. F. M. & Fenner, F. 1949. The production o f antibodies, Macmillan.
Cabrera-Vasquez, S., Navarro-Tableros, V., Sanchez-Soto, C., Gutierrez-Ospina, G. & 
Hiriart, M. 2009. Remodelling sympathetic innervation in rat pancreatic islets 
ontogeny. BMC Dev Biol, 9, 34.
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P. O. & Caicedo, A. 
2006. The unique cytoarchitecture of human pancreatic islets has implications 
for islet cell function. Proc Natl Acad Sei USA,  103, 2334-9.
Cahalon, L., Lider, O., Schor, H., Avron, A., Gilat, D., Hershkoviz, R., Margalit, R., 
Eshel, A., Shoseyev, O. & Cohen, I. R. 1997. Heparin disaccharides inhibit
362
tumor necrosis factor-alpha production by macrophages and arrest immune 
inflammation in rodents. Int Immunol, 9, 1517-22.
Cantor, H. & Boyse, E. A. 1975. Functional subclasses of T-lymphocytes bearing 
different Ly antigens. I. The generation of functionally distinct T-cell subclasses 
is a differentiative process independent of antigen. The Journal o f experimental 
medicine, 141, 1376-1389.
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, 
E., Frisch, S. & Reed, J. C. 1998. Regulation of cell death protease caspase-9 by 
phosphorylation. Science, 282, 1318-21.
Carlsson, P.-O., Palm, F., Andersson, A. & Liss, P. 2001. Markedly Decreased Oxygen 
Tension in Transplanted Rat Pancreatic Islets Irrespective of the Implantation 
Site. Diabetes, 50, 489-495.
Carlsson, P.-O., Palm, F. & Mattsson, G. R. 2002. Low Revascularization of 
Experimentally Transplanted Human Pancreatic Islets. Journal o f Clinical 
Endocrinology & Metabolism, 87, 5418-5423.
Carlsson, P. O. 2011. Influence of microenvironment on engraftment of transplanted 
beta-cells. Ups J  Med Sei, 116, 1-7.
Carlsson, P. O., Liss, P., Andersson, A. & Jansson, L. 1998. Measurements of oxygen 
tension in native and transplanted rat pancreatic islets. Diabetes, 47, 1027-32.
Carlsson, P. O., Nordin, A. & Palm, F. 2003. pH is decreased in transplanted rat 
pancreatic islets. Am J Physiol Endocrinol Metab, 284, E499-504.
Casu, B. & Naggi, A. 2003. Antiangiogenic heparin-derived heparan sulfate mimics. 
Pure and Applied Chemistry’, 75, 157-166.
Cejvan, K., Coy, D. H. & Efendic, S. 2003. Intra-islet somatostatin regulates glucagon 
release via type 2 somatostatin receptors in rats. Diabetes, 52, 1176-81.
Celie, J. W., Beelen, R. H. & Van Den Bom, J. 2009. Heparan sulfate proteoglycans in 
extravasation: assisting leukocyte guidance. Frontiers in Bioscience-Landmark, 
14, 4932-49.
Challacombe, J. F. & Elam, J. S. 1995. Structural analysis of glycosaminoglycans 
derived from axonally transported proteoglycans in regenerating goldfish optic 
nerve. Neurochem Res, 20, 253-9.
Chatenoud, L. 2008. Chemical immunosuppression in islet transplantation—friend or 
foe? N Engl J  Med, 358, 1192-3.
Chatenoud, L., Thervet, E., Primo, J. & Bach, J. F. 1994. Anti-CD3 antibody induces 
long-term remission of overt autoimmunity in nonobese diabetic mice. 
Proceedings o f the National Academy o f Sciences, 91, 123-127.
Chauhan, S. S., Goldstein, L. J. & Gottesman, M. M. 1991. Expression of Cathepsin L 
in Human Tumors. Cancer research, 51, 1478-1481.
Chen, G., Wang, D., Vikramadithyan, R., Yagyu, H., Saxena, U., Pillarisetti, S. & 
Goldberg, I. J. 2004. Inflammatory cytokines and fatty acids regulate endothelial 
cell heparanase expression. Biochemistry, 43, 4971-7.
Chen, L. & Sanderson, R. D. 2009. Heparanase regulates levels of syndecan-1 in the 
nucleus. PLoS One, 4.
Chen, M., Xiao, X., Demirci, G. & Li, X. C. 2008. 0X40 controls islet allograft 
tolerance in CD 154 deficient mice by regulating FOXP3+ Tregs. 
Transplantation, 85, 1659-62.
Chen, P., Abacherli, L. E., Nadler, S. T., Wang, Y., Li, Q. & Parks, W. C. 2009. MMP7 
shedding of syndecan-1 facilitates re-epithelialization by affecting 
alpha(2)beta( 1) integrin activation. PLoS One, 4, e6565.
Cheng, J. Y., Raghunath, M., Whitelock, J. & Poole-Warren, L. 2011. Matrix 
components and scaffolds for sustained islet function. Tissue Eng Part B Rev, 
17, 235-47.
363
Cheng, J. Y., Whitelock, J. & Poole-Warren, L. 2012. Syndecan-4 is associated with 
beta-cells in the pancreas and the MIN6 beta-cell line. Histochem Cell Biol.
Chhabra, P. & Brayman, K. L. 2011. Current status of immunomodulatory and cellular 
therapies in preclinical and clinical islet transplantation. J Transplant, 2011, 
637692.
Christoffersson, G., Vagesjo, E., Vandooren, J., Liden, M., Massena, S., Reinert, R. B., 
Brissova, M., Powers, A. C., Opdenakker, G. & Phillipson, M. 2012. VEGF-A 
recruits a proangiogenic MMP-9-delivering neutrophil subset that induces 
angiogenesis in transplanted hypoxic tissue. Blood, 120, 4653-62.
Cohen, E., Atzmon, R., Vlodavsky, I. & Ilan, N. 2005. Heparanase processing by 
lysosomal/endosomal protein preparation. FEBS Lett, 579, 2334-8.
Corbett, J. A., Wang, J. L., Sweetland, M. A., Lancaster, J. R. & Mcdaniel, M. L. 1992. 
Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified 
from rodent islets of Langerhans. Evidence for the beta-cell as a source and site 
of action of nitric oxide. The Journal o f Clinical Investigation, 90, 2384-2391.
Correa-Giannella, M. L. & Raposo Do Amaral, A. S. 2009. Pancreatic islet 
transplantation. Diabetol Metab Syndr, 1, 9.
Coulombe, M., Yang, H., Guerder, S., Flavell, R., Lafferty, K. & Gill, R. 1996. Tissue 
immunogenicity: the role of MHC antigen and the lymphocyte costimulator B7- 
1. The Journal o f Immunology, 157, 4790-4795.
Cowden, W. B., Lewis-Hughes, P. H. & Clark, I. A. 1985. Protection against alloxan- 
induced diabetes in mice by the free radical scavenger butylated hydroxyanisole. 
Biochem Pharmacol, 34, 3601-3.
Cowley, M. J., Weinberg, A., Zammit, N. W., Walters, S. N., Hawthorne, W. J., 
Loudovaris, T., Thomas, H., Kay, T., Gunton, J. E., Alexander, S. I., Kaplan, 
W., Chapman, J., O'connell, P. J. & Grey, S. T. 2012. Human islets express a 
marked proinflammatory molecular signature prior to transplantation. Cell 
Transplant, 21,2063-78.
Cresswell, P. 2005. Antigen processing and presentation. Immunological Reviews, 207, 
5-7.
D'ortho, M. P., Will, H., Atkinson, S., Butler, G., Messent, A., Gavrilovic, J., Smith, B., 
Timpl, R., Zardi, L. & Murphy, G. 1997. Membrane-type matrix 
metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities 
comparable to many matrix metalloproteinases. Eur JBiochem, 250, 751-7.
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. & Greenberg, M. E. 
1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic 
death machinery. Cell, 91, 231-41.
Davalli, A. M., Scaglia, L., Zangen, D. H., Hollister, J., Bonner-Weir, S. & Weir, G. C. 
1996. Vulnerability of islets in the immediate posttransplantation period. 
Dynamic changes in structure and function. Diabetes, 45, 1161-7.
David, G., Bai, X. M., Van Der Schueren, B., Cassiman, J. J. & Van Den Berghe, H. 
1992. Developmental changes in heparan sulfate expression: in situ detection 
with mAbs. J  Cell Biol, 119, 961-75.
Davidson, B., Shafat, I., Risberg, B., Ilan, N., Trope, C. G., Vlodavsky, I. & Reich, R. 
2007. Heparanase expression correlates with poor survival in metastatic ovarian 
carcinoma. Gynecol Oncol, 104, 311-9.
De Freitas, R. C., Diller, K. R., Lachenbruch, C. A. & Merchant, F. A. 1998. Network 
thermodynamic model of coupled transport in a multicellular tissue—the islet of 
Langerhans. Ann N Y Acad Sei, 858, 191-204.
De Groot, H. 1994. Reactive oxygen species in tissue injury. Hepatogastroenterology, 
41,328-32.
364
Decherchi, P., Cochard, P. & Gauthier, P. 1997. Dual staining assessment of Schwann 
cell viability within whole peripheral nerves using calcein-AM and ethidium 
homodimer. Journal o f neuroscience methods, 71, 205-213.
Deijnen, J. H. M., Hulstaert, C. E., Wolters, G. H. J. & Schilfgaarde, R. 1992. 
Significance of the peri-insular extracellular matrix for islet isolation from the 
pancreas of rat, dog, pig, and man. Cell and Tissue Research, 267, 139-146.
Delmastro, M. M. & Piganelli, J. D. 2011. Oxidative stress and redox modulation 
potential in type 1 diabetes. Clin Dev Immunol, 2011, 593863.
Dempsey, L. A., Brunn, G. J. & Platt, J. L. 2000. Heparanase, a potential regulator of 
cell-matrix interactions. Trends in biochemical sciences, 25, 349-51.
Diamond, A. S. & Gill, R. G. 2000. An essential contribution by IFN-gamma to CD8+ 
T cell-mediated rejection of pancreatic islet allografts. J  Immunol, 165, 247-55.
Dinarello, C. A. 2007. Historical insights into cytokines. Eur J  Immunol, 37 Suppl 1, 
S34-45.
Docherty, K., Carroll, R. J. & Steiner, D. F. 1982. Conversion of proinsulin to insulin: 
involvement of a 31,500 molecular weight thiol protease. Proceedings o f the 
National Academy o f Sciences, 79, 4613-4617.
Doweck, I., Kaplan-Cohen, V., Naroditsky, I., Sabo, E., Ilan, N. & Vlodavsky, I. 2006. 
Heparanase localization and expression by head and neck cancer: correlation 
with tumor progression and patient survival. Neoplasia, 8, 1055-61.
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., 
Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., Dassopoulos, T., 
Bitton, A., Yang, H., Targan, S., Datta, L. W., Kistner, E. O., Schümm, L. P., 
Lee, A. T., Gregersen, P. K., Barmada, M. M., Rotter, J. I., Nicolae, D. L. & 
Cho, J. H. 2006. A genome-wide association study identifies IL23R as an 
inflammatory bowel disease gene. Science, 314, 1461-3.
Dupraz, P., Rinsch, C., Pralong, W. F., Rolland, E., Zufferey, R., Trono, D. & Thorens, 
B. 1999. Lentivirus-mediated Bcl-2 expression in betaTC-tet cells improves 
resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro 
and in vivo control of insulin secretion. Gene Ther, 6, 1160-9.
Easom, R. A. 2000. Beta-granule transport and exocytosis. Semin Cell Dev Biol, 11, 
253-66.
Ebling, F. J. G. 1980. Homage to Paul Langerhans. JInvestig Dermatol, 75, 3-5.
Edovitsky, E., Lemer, I., Zcharia, E., Peretz, T., Vlodavsky, I. & Elkin, M. 2006. Role 
of endothelial heparanase in delayed-type hypersensitivity. Blood, 107, 3609-16.
Eich, T., Eriksson, O. & Lundgren, T. R. 2007. Visualization of Early Engraftment in 
Clinical Islet Transplantation by Positron-Emission Tomography. New England 
Journal o f Medicine, 356, 2754-2755.
Eizirik, D. L. & Mandrup-Poulsen, T. 2001. A choice of death—the signal-transduction 
of immune-mediated beta-cell apoptosis. Diabetologia, 44, 2115-33.
Elbakri, A., Nelson, P. N. & Abu Odeh, R. O. 2010. The state of antibody therapy. 
Human Immunology, 71, 1243-1250.
Elkin, M., Ilan, N., Ishai-Michaeli, R., Friedmann, Y., Papo, O., Pecker, I. & 
Vlodavsky, I. 2001. Heparanase as mediator of angiogenesis: mode of action. 
FASEBJ, 15, 1661-3.
Elkins, W. L. & Guttmann, R. D. 1968. Pathogenesis of a local graft versus host 
reaction: immunogenicity of circulating host leukocytes. Science (New York, 
NY), 159, 1250.
Elliott, T. J. & Eisen, H. N. 1990. Cytotoxic T lymphocytes recognize a reconstituted 
class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule. 
Proc Natl Acad Sei USA,  87, 5213-7.
365
Emamaullee, J. A., Davis, J., Pawlick, R., Toso, C., Merani, S., Cai, S. X., Tseng, B. & 
Shapiro, A. M. 2010. Caspase inhibitor therapy synergizes with costimulation 
blockade to promote indefinite islet allograft survival. Diabetes, 59, 1469-77.
Emamaullee, J. A., Rajotte, R. V., Liston, P., Korneluk, R. G., Lakey, J. R., Shapiro, A. 
M. & Elliott, J. F. 2005. XIAP overexpression in human islets prevents early 
posttransplant apoptosis and reduces the islet mass needed to treat diabetes. 
Diabetes, 54, 2541-8.
Endo, K., Maejara, U., Baba, H., Tokunaga, E., Koga, T., Ikeda, Y., Toh, Y., Kohnoe, 
S., Okamura, T., Nakajima, M. & Sugimachi, K. 2001. Heparanase gene 
expression and metastatic potential in human gastric cancer. Anticancer Res, 21, 
3365-9.
Endo, K., Takino, T., Miyamori, H., Kinsen, H., Yoshizaki, T., Furukawa, M. & Sato, 
H. 2003. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 
stimulates cell migration. J  Biol Chem, 278, 40764-70.
Erickson, A. C. & Couchman, J. R. 2000. Still More Complexity in Mammalian 
Basement Membranes. Journal o f Histochemistry & Cytochemistry, 48, 1291- 
1306.
Eriksson, O., Eich, T., Sundin, A., Tibell, A., Tufveson, G., Andersson, H., Felldin, M., 
Foss, A., Kyllönen, L., Langstrom, B., Nilsson, B., Korsgren, O. & Lundgren, T. 
2009. Positron Emission Tomography in Clinical Islet Transplantation. 
American Journal o f Transplantation, 9, 2816-2824.
Fabian, M. C., Lakey, J. R., Rajotte, R. V. & Kneteman, N. M. 1993. The efficacy and 
toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies. 
Transplantation, 56, 1137-42.
Fairbanks, M. B., Mildner, A. M., Leone, J. W., Cavey, G. S., Mathews, W. R., Drong, 
R. F., Slightom, J. L., Bienkowski, M. J., Smith, C. W., Bannow, C. A. & 
Heinrikson, R. L. 1999. Processing of the human heparanase precursor and 
evidence that the active enzyme is a heterodimer. J  Biol Chem, 274, 29587-90.
Faradji, R. N., Monroy, K., Cure, P., Froud, T., Baidal, D., Pileggi, A., Messinger, S., 
Ricordi, C. & Alejandro, R. 2005. C-peptide and glucose values in the 
peritransplant period after intraportal islet infusions in type 1 diabetes. 
Transplant Proc, 37, 3433-4.
Faustman, D., Hauptfeld, V., Lacy, P. & Davie, J. 1981. Prolongation of murine islet 
allograft survival by pretreatment of islets with antibody directed to la 
determinants. Proc Natl Acad Sei USA,  78, 5156-9.
Faustman, D. L., Steinman, R. M., Gebel, H. M., Hauptfeld, V., Davie, J. M. & Lacy, P. 
E. 1984. Prevention of rejection of murine islet allografts by pretreatment with 
anti-dendritic cell antibody. Proc Natl Acad Sei USA,  81, 3864-8.
Feldmann, M. 2008. Many cytokines are very useful therapeutic targets in disease. The 
Journal o f Clinical Investigation, 118, 3533-3536.
Fend, F. & Raffeld, M. 2000. Laser capture microdissection in pathology. Journal o f 
Clinical Pathology, 53, 666-672.
Ferletta, M. & Ekblom, P. 1999. Identification of laminin-10/11 as a strong cell 
adhesive complex for a normal and a malignant human epithelial cell line. J  Cell 
Sei, 112 ( Pt 1), 1-10.
Ferro, V., Hammond, E. & Fairweather, J. K. 2004. The development of inhibitors of 
heparanase, a key enzyme involved in tumour metastasis, angiogenesis and 
inflammation. Mini Rev Med Chem, 4, 693-702.
Forsberg, E., Lindblom, A., Paulsson, M. & Johansson, S. 1994. Laminin Isoforms 
Promote Attachment of Hepatocytes via Different Integrins. Experimental Cell 
Research, 215, 33-39.
366
Forster, R., Davalos-Misslitz, A. C. & Rot, A. 2008. CCR7 and its ligands: balancing 
immunity and tolerance. Nat Rev Immunol, 8, 362-71.
Forster, R., Schubel, A., Breitfeld, D., Kremmer, E., Renner-Müller, I., Wolf, E. & 
Lipp, M. 1999. CCR7 coordinates the primary immune response by establishing 
functional microenvironments in secondary lymphoid organs. Cell, 99, 23-33.
Freeman, C. & Parish, C. R. 1997. A rapid quantitative assay for the detection of 
mammalian heparanase activity. BiochemJ, 325 ( Pt 1), 229-37.
Freeman, C. & Parish, C. R. 1998. Human platelet heparanase: purification, 
characterization and catalytic activity. Biochem J, 330 ( Pt 3), 1341-50.
Frisch, S. M. & Francis, H. 1994. Disruption of epithelial cell-matrix interactions 
induces apoptosis. J  Cell Biol, 124, 619-26.
Froud, T., Baidal, D. A., Faradji, R., Cure, P., Mineo, D., Selvaggi, G., Kenyon, N. S., 
Ricordi, C. & Alejandro, R. 2008. Islet Transplantation with Alemtuzumab 
Induction and Calcineurin-Free Maintenance Immunosuppression Results in 
Improved Short- and Long-Term Outcomes. Transplantation, 86, 1695-1701 
10.1097/TP.ObO 13e31819025e5.
Froud, T., Ricordi, C., Baidal, D. A., Hafiz, M. M., Ponte, G., Cure, P., Pileggi, A., 
Poggioli, R., Ichii, H., Khan, A., Ferreira, J. V., Pugliese, A., Esquenazi, V. V., 
Kenyon, N. S. & Alejandro, R. 2005. Islet Transplantation in Type 1 Diabetes 
Mellitus Using Cultured Islets and Steroid-Free Immunosuppression: Miami 
Experience. American Journal o f Transplantation, 5, 2037-2046.
Funkelstein, L., Toneff, T., Hwang, S.-R., Reinheckel, T., Peters, C. & Hook, V. 2008. 
Cathepsin L participates in the production of neuropeptide Y in secretory 
vesicles, demonstrated by protease gene knockout and expression. Journal o f 
Neurochemistry, 106,384-391.
Fux, L., Ilan, N., Sanderson, R. D. & Vlodavsky, I. 2009. Heparanase: busy at the cell 
surface. Trends in biochemical sciences, 34, 511-9.
Gibson, T. & Medawar, P. B. 1943. The fate of skin homografts in man. J  Anat, 77, 
299-310 4.
Gilat, D., Hershkoviz, R., Goldkom, I., Cahalon, L., Komer, G., Vlodavsky, I. & Lider, 
O. 1995. Molecular behavior adapts to context: heparanase functions as an 
extracellular matrix-degrading enzyme or as a T cell adhesion molecule, 
depending on the local pH. J  Exp Med, 181, 1929-34.
Gill, R. G. 1998. Direct and indirect pathways of immunity to pancreatic islet 
transplants. Transplantation reviews (Orlando, Fla.), 12, 85-95.
Gilmore, A. P. 2000. Anoikis. Cell Death Differ, 12, 1473-1477.
Ginath, S., Menczer, J., Friedmann, Y., Aingom, H., Aviv, A., Tajima, K., Dantes, A., 
Glezerman, M., Vlodavsky, I. & Amsterdam, A. 2001. Expression of 
heparanase, Mdm2, and erbB2 in ovarian cancer. Int J  Oncol, 18, 1133-44.
Gingis-Velitski, S., Ishai-Michaeli, R., Vlodavsky, I. & Ilan, N. 2007. Anti-heparanase 
monoclonal antibody enhances heparanase enzymatic activity and facilitates 
wound healing. FASEB journal : official publication o f the Federation o f 
American Societies for Experimental Biology, 21, 3986-93.
Gingis-Velitski, S., Zetser, A., Kaplan, V., Ben-Zaken, O., Cohen, E., Levy-Adam, F., 
Bashenko, Y., Flugelman, M. Y., Vlodavsky, I. & Ilan, N. 2004. Heparanase 
Uptake Is Mediated by Cell Membrane Heparan Sulfate Proteoglycans. Journal 
o f Biological Chemistry, 279, 44084-44092.
Giuliani, M., Moritz, W., Bodmer, E., Dindo, D., Kugelmeier, P., Lehmann, R., 
Gassmann, M., Groscurth, P. & Weber, M. 2005. Central necrosis in isolated 
hypoxic human pancreatic islets: evidence for postisolation ischemia. Cell 
transplantation, 14, 67-76.
367
Gocheva, V., Wang, H. W., Gadea, B. B., Shree, T., Hunter, K. E., Garfall, A. L., 
Berman, T. & Joyce, J. A. 2010. IL-4 induces cathepsin protease activity in 
tumor-associated macrophages to promote cancer growth and invasion. Genes 
Dev, 24, 241-55.
Goldshmidt, O., Nadav, L., Aingom, H., Irit, C., Feinstein, N., Ilan, N., Zamir, E., 
Geiger, B., Vlodavsky, I. & Katz, B. Z. 2002. Human heparanase is localized 
within lysosomes in a stable form. Exp Cell Res, 281, 50-62.
Goldshmidt, O., Zcharia, E., Cohen, M., Aingom, H., Cohen, I., Nadav, L., Katz, B. Z., 
Geiger, B. & Vlodavsky, I. 2003. Heparanase mediates cell adhesion 
independent of its enzymatic activity. FASEB J, 17, 1015-25.
Golocheikine, A., Tiriveedhi, V., Angaswamy, N., Benshoff, N., Sabarinathan, R. & 
Mohanakumar, T. 2010. Cooperative signaling for angiogenesis and 
neovascularization by VEGF and HGF following islet transplantation. 
Transplantation, 90, 725-31.
Gonzalez, A. D., Kaya, M., Shi, W., Song, H., Testa, J. R., Penn, L. Z. & Filmus, J. 
1998. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the 
Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line- 
specific manner. J Cell Biol, 141, 1407-14.
Goodison, S., Urquidi, V. & Tarin, D. 1999. CD44 cell adhesion molecules. Mol 
Pathol, 52, 189-96.
Görden, D. L., Mandriota, S. J., Montesano, R., Orci, L. & Pepper, M. S. 1997. 
Vascular endothelial growth factor is increased in devascularized rat islets of 
Langerhans in vitro. Transplantation, 63, 436-443.
Gorski, A., Makula, J., Morzycka-Michalik, M., Lao, M. & Gradowska, L. 1994. Low- 
dose heparin: a novel approach in immunosuppression. Transpl Int, 7 Suppl 1, 
S567-9.
Goss, J. A., Goodpastor, S. E., Brunicardi, F. C., Barth, M. H., Soltes, G. D., Garber, A. 
J., Hamilton, D. J., Alejandro, R. & Ricordi, C. 2004. Development of a human 
pancreatic islet-transplant program through a collaborative relationship with a 
remote islet-isolation center. Transplantation, 77, 462-6.
Govaerts, A. 1960. Cellular antibodies in kidney homotransplantation. J  Immunol, 85, 
516-22.
Gowans, J. 1959. The recirculation of lymphocytes from blood to lymph in the rat. The 
Journal o f physiology, 146, 54-69.
Gowans, J., Mcgregor, D., Cowen, D. M. & Ford, C. 1962. Initiation of immune 
responses by small lymphocytes. Nature, 196.
Gray, D. W., Sutton, R., Mcshane, P., Peters, M. & Morris, P. J. 1988. Exocrine 
contamination impairs implantation of pancreatic islets transplanted beneath the 
kidney capsule. J  Surg Res, 45, 432-42.
Gray, D. W., Wamock, G. L., Sutton, R., Peters, M., Mcshane, P. & Morris, P. J. 1986. 
Successful autotransplantation of isolated islets of Langerhans in the 
cynomolgus monkey. Br J  Surg, 73, 850-3.
Greenbaum, C. J., Havel, P. J., Taborsky, G. J. & Klaff, L. J. 1991. Intra-islet insulin 
permits glucose to directly suppress pancreatic A cell function. The Journal of 
Clinical Investigation, 88, 767-773.
Groffen, A. J., Ruegg, M. A., Dijkman, H., Van De Velden, T. J., Buskens, C. A., Van 
Den Bom, J., Assmann, K. J., Monnens, L. A., Veerkamp, J. H. & Van Den 
Heuvel, L. P. 1998. Agrin is a major heparan sulfate proteoglycan in the human 
glomerular basement membrane. J  Histochem Cytochem, 46, 19-27.
Grossmann, J. 2002. Molecular mechanisms of "detachment-induced apoptosis— 
Anoikis". Apoptosis, 7, 247-60.
368
Hacker, U., Nybakken, K. & Perrimon, N. 2005. Heparan sulphate proteoglycans: the 
sweet side of development. Nat Rev Mol Cell Biol, 6, 530-541.
Haegel, H. & Ceredig, R. 1991. Transcripts encoding mouse CD44 (Pgp-1, Ly-24) 
antigen: strain variation and induction by mitogen. Eur JImmunol, 21, 1549-53.
Halin, C., Mora, J. R., Sumen, C. & Von Andrian, U. H. 2005. In vivo imaging of 
lymphocyte trafficking. Annu Rev Cell Dev Biol, 21, 581-603.
Hamalainen, H. K., Tubman, J. C., Vikman, S., Kyrola, T., Ylikoski, E., Warrington, J. 
A. & Lahesmaa, R. 2001. Identification and validation of endogenous reference 
genes for expression profiling of T helper cell differentiation by quantitative 
real-time RT-PCR. Anal Biochem, 299, 63-70.
Hanley, S., Liu, S., Lipsett, M., Castellarin, M., Rosenberg, L., Tchervenkov, J. & 
Paraskevas, S. 2006. Tumor necrosis factor-alpha production by human islets 
leads to postisolation cell death. Transplantation, 82, 813-8.
Hanley, S. C., Paraskevas, S. & Rosenberg, L. 2008. Donor and isolation variables 
predicting human islet isolation success. Transplantation, 85, 950-5.
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A. & George, A. J. T. 2010. The 
safety and side effects of monoclonal antibodies. Nat Rev Drug Discov, 9, 325- 
338.
Harlan, D. M., Kenyon, N. S., Korsgren, O. & Roep, B. O. 2009. Current advances and 
travails in islet transplantation. Diabetes, 58, 2175-84.
He, Y. Q., Sutcliffe, E. L., Bunting, K. L., Li, J., Goodall, K. J., Poon, I. K., Hulett, M. 
D., Freeman, C., Zafar, A., Mcinnes, R. L., Taya, T., Parish, C. R. & Rao, S. 
2012. The endoglycosidase heparanase enters the nucleus of T lymphocytes and 
modulates H3 methylation at actively transcribed genes via the interplay with 
key chromatin modifying enzymes. Transcription, 3, 130-45.
Henderson, J. R. & Moss, M. C. 1985. A morphometric study of the endocrine and 
exocrine capillaries of the pancreas. Q J Exp Physiol, 70, 347-56.
Hering, B. J., Kandaswamy, R., Harmon, J. V., Ansite, J. D., Clemmings, S. M., Sakai, 
T., Paraskevas, S., Eckman, P. M., Sageshima, J., Nakano, M., Sawada, T., 
Matsumoto, I., Zhang, H. J., Sutherland, D. E. R. & Bluestone, J. A. 2004. 
Transplantation of Cultured Islets from Two-Layer Preserved Pancreases in 
Type 1 Diabetes with Anti-CD3 Antibody. American Journal of 
Transplantation, 4, 390-401.
Hershkoviz, R., Mor, F., Miao, H. Q., Vlodavsky, I. & Lider, O. 1995. Differential 
effects of polysulfated polysaccharide on experimental encephalomyelitis, 
proliferation of autoimmune T cells, and inhibition of heparanase activity. 
Journal o f autoimmunity, 8, 741-50.
Heuser, M., Wolf, B., Vollmar, B. & Menger, M. D. 2000. Exocrine contamination of 
isolated islets of Langerhans deteriorates the process of revascularization after 
free transplantation. Transplantation, 69, 756-61.
Honey, K., Nakagawa, T., Peters, C. & Rudensky, A. 2002. Cathepsin L regulates 
CD4+ T cell selection independently of its effect on invariant chain: a role in the 
generation of positively selecting peptide ligands. J  Exp Med, 195, 1349-58.
Hoogewerf, A. J., Kuschert, G. S., Proudfoot, A. E., Borlat, F., Clark-Lewis, I., Power, 
C. A. & Wells, T. N. 1997. Glycosaminoglycans mediate cell surface 
oligomerization of chemokines. Biochemistry, 36, 13570-8.
Hsieh, C. S., Deroos, P., Honey, K., Beers, C. & Rudensky, A. Y. 2002. A role for 
cathepsin L and cathepsin S in peptide generation for MHC class II presentation. 
J  Immunol, 168,2618-25.
Hsu, B. R., Juang, J. H., Fu, S. H., Kuo, C. H. & Lu, W. T. 2001. Reduction in primary 
nonfunction of syngeneic islet transplants with nordihydroguaiaretic acid, a 
lipoxygenase inhibitor. Cell Transplant, 10, 255-62.
369
Hughes, A., Jessup, C., Drogemuller, C., Mohanasundaram, D., Milner, C., Rojas, D., 
Russ, G. R. & Coates, P. T. 2010. Gene therapy to improve pancreatic islet 
transplantation for Type 1 diabetes mellitus. Curr Diabetes Rev, 6, 274-84.
Hui, H., Dotta, F., Di Mario, U. & Perfetti, R. 2004. Role of caspases in the regulation 
of apoptotic pancreatic islet beta-cells death. J Cell Physiol, 200, 177-200.
Hulett, M. D., Freeman, C., Hamdorf, B. J., Baker, R. T., Harris, M. J. & Parish, C. R. 
1999. Cloning of mammalian heparanase, an important enzyme in tumor 
invasion and metastasis. Nat Med, 5, 803-9.
Ilan, N., Elkin, M. & Vlodavsky, I. 2006. Regulation, function and clinical significance 
of heparanase in cancer metastasis and angiogenesis. Int J  Biochem Cell Biol, 
38,2018-39.
Iozzo, R. V. 1998. Matrix proteoglycans: from molecular design to cellular function. 
Annu Rev Biochem, 67, 609-52.
Iozzo, R. V. 2005. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev 
Mol Cell Biol, 6, 646-56.
Irimura, T., Nakajima, M. & Nicolson, G. L. 1986. Chemically modified heparins as 
inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of 
metastatic melanoma cells. Biochemistry, 25, 5322-8.
Irving-Rodgers, H. F., Choong, F. J., Hummitzsch, K., Parish, C. R., Rodgers, R. J. & 
Simeonovic, C. J. 2012. Pancreatic islet basement membrane loss and 
remodeling after mosue islet isolation and transplantation: Impact for allograft 
rejection. Cell Transplant.
Irving-Rodgers, H. F., Ziolkowski, A. F., Parish, C. R., Sado, Y., Ninomiya, Y., 
Simeonovic, C. J. & Rodgers, R. J. 2008. Molecular composition of the peri- 
islet basement membrane in NOD mice: a barrier against destructive insulitis. 
Diabetologia, 51, 1680-8.
Ishida, K., Hirai, G., Murakami, K., Teruya, T., Simizu, S., Sodeoka, M. & Osada, H. 
2004. Structure-based design of a selective heparanase inhibitor as an 
antimetastatic agent. Mol Cancer Ther, 3, 1069-77.
Ishidoh, K., Saido, T. C., Kawashima, S., Hirose, M., Watanabe, S., Sato, N. & 
Kominami, E. 1998. Multiple processing of procathepsin L to cathepsin L in 
vivo. Biochem Biophys Res Commun, 252, 202-7.
Itoh, S., Nakae, S., Axteil, R. C., Velotta, J. B., Kimura, N., Kajiwara, N., Iwakura, Y., 
Saito, H., Adachi, H., Steinman, L., Robbins, R. C. & Fischbein, M. P. 2010. IL- 
17 contributes to the development of chronic rejection in a murine heart 
transplant model. J  Clin Immunol, 30, 235-40.
Itoh, T., Sugimoto, K., Takita, M., Shimoda, M., Chujo, D., Sorelle, J. A., Naziruddin, 
B., Levy, M. F. & Matsumoto, S. 2012. Low Temperature Condition Prevents 
Hypoxia Induced Islet Cell Damage and HMGB1 Release in a mouse model. 
Cell Transplant.
Jackson, D. G. 1997. Human leucocyte heparan sulphate proteoglycans and their roles 
in inflammation. Biochem Soc Trans, 25, 220-4.
Jalili, R. B., Moeen Rezakhanlou, A., Hosseini,Äetabatabaei, A., Ao, Z., Wamock, G. 
L. & Ghahary, A. 2011. Fibroblast populated collagen matrix promotes islet 
survival and reduces the number of islets required for diabetes reversal. Journal 
o f cellular physiology, 226, 1813-1819.
Jayson, G. C., Lyon, M., Paraskeva, C., Turnbull, J. E., Deakin, J. A. & Gallagher, J. T. 
1998. Heparan sulfate undergoes specific structural changes during the 
progression from human colon adenoma to carcinoma in vitro. J  Biol Chem, 
273,51-7.
Jensen, P. E. 2007. Recent advances in antigen processing and presentation. Nat 
Immunol, 8, 1041-1048.
370
Jiang, F.-X., Naselli, G. & Harrison, L. C. 2002a. Distinct Distribution of Laminin and 
Its Integrin Receptors in the Pancreas. Journal o f Histochemistry & 
Cytochemistry, 50, 1625-1632.
Jiang, P., Kumar, A., Parrillo, J. E., Dempsey, L. A., Platt, J. L., Prinz, R. A. & Xu, X. 
2002b. Cloning and characterization of the human heparanase-1 (HPR1) gene 
promoter: role of GA-binding protein and Spl in regulating HPR1 basal 
promoter activity. J Biol Chem, 277, 8989-98.
Jin, S.-W., Beis, D., Mitchell, T., Chen, J.-N. & Stainier, D. Y. R. 2005. Cellular and 
molecular analyses of vascular tube and lumen formation in zebrafish. 
Development, 132,5199-5209.
Johansson, U., Olsson, A., Gabrielsson, S., Nilsson, B. & Korsgren, O. 2003. 
Inflammatory mediators expressed in human islets of Langerhans: implications 
for islet transplantation. Biochem Biophys Res Commun, 308, 474-9.
Johansson, U., Rasmusson, I., Niclou, S. P., Forslund, N., Gustavsson, L., Nilsson, B., 
Korsgren, O. & Magnusson, P. U. 2008. Formation of Composite Endothelial 
Cell-Mesenchymal Stem Cell Islets A Novel Approach to Promote Islet 
Revascularization. Diabetes, 57, 2393-2401.
Johnson, P. R. V. & Jones, K. E. 2012. Pancreatic islet transplantation. Seminars in 
pediatric surgery, 21, 272-280.
Jones, E. Y. 1997. MHC class I and class II structures. Current opinion in immunology, 
9, 75-79.
Jones, M., Tussey, L., Athanasou, N. & Jackson, D. G. 2000. Heparan Sulfate 
Proteoglycan Isoforms of the CD44 Hyaluronan Receptor Induced in Human 
Inflammatory Macrophages Can Function as Paracrine Regulators of Fibroblast 
Growth Factor Action. Journal o f Biological Chemistry, 275, 7964-7974.
Kaido, T., Yebra, M., Cirulli, V. & Montgomery, A. M. 2004. Regulation of human 
beta-cell adhesion, motility, and insulin secretion by collagen IV and its receptor 
alpha 1 beta 1. J Biol Chem, 279, 53762-9.
Katz, A., Van-Dijk, D. J., Aingom, H., Erman, A., Davies, M., Darmon, D., Hurvitz, H. 
& Vlodavsky, I. 2002. Involvement of human heparanase in the pathogenesis of 
diabetic nephropathy. Isr Med Assoc J, 4, 996-1002.
Kelly, T., Miao, H. Q., Yang, Y., Navarro, E., Kussie, P., Huang, Y., Macleod, V., 
Casciano, J., Joseph, L., Zhan, F., Zangari, M., Barlogie, B., Shaughnessy, J. & 
Sanderson, R. D. 2003. High heparanase activity in multiple myeloma is 
associated with elevated microvessel density. Cancer research, 63, 8749-56.
Kemp, C. B., Knight, M. J., Scharp, D. W., Ballinger, W. F. & Lacy, P. E. 1973. Effect 
of transplantation site on the results of pancreatic islet isografts in diabetic rats. 
Diabetologia, 9,486-491.
Kenmochi, T., Miyamoto, M. & Mullen, Y. 1996. Protection of mouse islet isografts 
from nonspecific inflammatory damage by recipient treatment with nicotinamide 
and 15-deoxyspergualin. Cell Transplant, 5, 41-7.
Kennett, E. C. & Davies, M. J. 2007. Degradation of matrix glycosaminoglycans by 
peroxynitrite/peroxynitrous acid: Evidence for a hydroxyl-radical-like
mechanism. Free Radical Biology and Medicine, 42, 1278-1289.
Kennett, E. C., Rees, M. D., Malle, E., Hammer, A., Whitelock, J. M. & Davies, M. J. 
2010. Peroxynitrite modifies the structure and function of the extracellular 
matrix proteoglycan perlecan by reaction with both the protein core and the 
heparan sulfate chains. Free Radic Biol Med, 49, 282-93.
Kenyon, N. S., Fernandez, L. A., Lehmann, R., Masetti, M., Ranuncoli, A., 
Chatzipetrou, M., Iaria, G., Han, D., Wagner, J. L., Ruiz, P., Berho, M., 
Inverardi, L., Alejandro, R., Mintz, D. H., Kirk, A. D., Harlan, D. M., Burkly, L. 
C. & Ricordi, C. 1999. Long-term survival and function of intrahepatic islet
allografts in baboons treated with humanized anti-CD 154. Diabetes, 48, 1473- 
81.
Keymeulen, B., Gillard, P., Mathieu, C., Movahedi, B., Maleux, G., Delvaux, G., 
Ysebaert, D., Roep, B., Vandemeulebroucke, E., Marichal, M., In T  Veld, P., 
Bogdani, M , Hendrieckx, C., Gorus, F., Ling, Z., Van Rood, J. & Pipeleers, D. 
2006. Correlation between beta cell mass and glycemic control in type 1 diabetic 
recipients of islet cell graft. Proceedings o f the National Academy o f Sciences of 
the United States o f America, 103, 17444-17449.
Khwaja, A. 1999. Apoptosis: Akt is more than just a Bad kinase. Nature, 401,33-34.
Kikkawa, Y. & Miner, J. H. 2005. Review: Lutheran/B-CAM: a laminin receptor on red 
blood cells and in various tissues. Connect Tissue Res, 46, 193-9.
Kin, T., Johnson, P. R., Shapiro, A. M. & Lakey, J. R. 2007. Factors influencing the 
collagenase digestion phase of human islet isolation. Transplantation, 83, 7-12.
Kin, T., Rajotte, R. V. & Korbutt, G. S. 2004. Reassessment of the Vascularization of 
Renal Subcapsular Islet Grafts. Pancreas, 29, e59-e63.
Kin, T., Senior, P., O'gorman, D., Richer, B., Salam, A. & Shapiro, A. M. 2008. Risk 
factors for islet loss during culture prior to transplantation. Transpl lnt, 21, 
1029-35.
King, A., Lock, J., Xu, G., Bonner-Weir, S. & Weir, G. C. 2005. Islet transplantation 
outcomes in mice are better with fresh islets and exendin-4 treatment. 
Diabetologia, 48, 2074-2079.
Kizaki, K., Nakano, H., Takahashi, T., Imai, K. & Hashizume, K. 2001. Expression of 
heparanase mRNA in bovine placenta during gestation. Reproduction, 121, 573- 
80.
Kleeff, J., Ishiwata, T., Kumbasar, A., Friess, H., Buchler, M. W., Lander, A. D. & 
Kore, M. 1998. The cell-surface heparan sulfate proteoglycan glypican-1 
regulates growth factor action in pancreatic carcinoma cells and is 
overexpressed in human pancreatic cancer. J Clin Invest, 102, 1662-73.
Klein, J. 2001. George Snell's first foray into the unexplored territory of the major 
histocompatibility complex. Genetics, 159,435-9.
Klein, J. & Sato, A. 2000. The HLA System. New England Journal o f Medicine, 343, 
702-709.
Klerk, C. P., Smorenburg, S. M., Otten, H. M., Lensing, A. W., Prins, M. H., Piovella, 
F., Prandoni, P., Bos, M. M., Richel, D. J., Van Tienhoven, G. & Buller, H. R. 
2005. The effect of low molecular weight heparin on survival in patients with 
advanced malignancy. J  Clin Oncol, 23, 2130-5.
Kliment, C. R., Tobolewski, J. M., Manni, M. L., Tan, R. J., Enghild, J. & Oury, T. D. 
2008. Extracellular superoxide dismutase protects against matrix degradation of 
heparan sulfate in the lung. Antioxid Redox Signal, 10, 261-8.
Kobayashi, M., Naomoto, Y., Nobuhisa, T., Okawa, T., Takaoka, M., Shirakawa, Y., 
Yamatsuji, T., Matsuoka, J., Mizushima, T., Matsuura, H., Nakajima, M., 
Nakagawa, H., Rustgi, A. & Tanaka, N. 2006. Heparanase regulates esophageal 
keratinocyte differentiation through nuclear translocation and heparan sulfate 
cleavage. Differentiation, 74, 235-243.
Koliopanos, A., Friess, H., Kleeff, J., Shi, X., Liao, Q., Pecker, I., Vlodavsky, I., 
Zimmermann, A. & Buchler, M. W. 2001. Heparanase expression in primary 
and metastatic pancreatic cancer. Cancer research, 61, 4655-9.
Konstantinova, I. & Lammert, E. 2004. Microvascular development: learning from 
pancreatic islets. BioEssays, 26, 1069-75.
Koob, A. O., Bruns, L., Prassler, C., Masliah, E., Klopstock, T. & Bender, A. 2012. 
Protein analysis through Western blot of cells excised individually from human 
brain and muscle tissue. Analytical Biochemistry, 425, 120-124.
372
Kops, G. J. & Burgering, B. M. 2000. Forkhead transcription factors are targets of 
signalling by the proto-oncogene PKB (C-AKT). J  Anat, 197 Pt 4, 571-4.
Korpos, E., Kadri, N., Kappelhoff, R., Wegner, J., Overall, C. M., Weber, E., 
Holmberg, D., Cardell, S. & Sorokin, L. 2013. The peri-islet basement 
membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and 
human. Diabetes, 62, 531-42.
Kragl, M. & Lammert, E. 2010. Basement membrane in pancreatic islet function. Adv 
Exp Med Biol, 654, 217-34.
Krishan, A. 1975. Rapid flow cytofluorometric analysis of mammalian cell cycle by 
propidium iodide staining. The Journal o f cell biology, 66, 188-193.
Kumar, S., Farmer, R., Turnbull, A. P., Tripathy, N. K. & Manjasetty, B. A. 2012. 
Structural and functional conservation profiles of novel cathepsin L-like proteins 
identified in the Drosophila melanogaster genome. JBiomol Struct Dyn.
Kussie, P. H., Hulmes, J. D., Ludwig, D. L., Patel, S., Navarro, E. C., Seddon, A. P., 
Giorgio, N. A. & Bohlen, P. 1999. Cloning and functional expression of a 
human heparanase gene. Biochem Biophys Res Commun, 261, 183-7.
La Rosa, F. 1988. Abrogation of Mouse Pancreatic Islet Allograft Rejection By A Four- 
Day Culture. Transplantation, 46, 330-333.
Lacy, P. E., Davie, J. M. & Finke, E. H. 1979. Prolongation of islet allograft survival 
following in vitro culture (24 degrees C) and a single injection of ALS. Science, 
204,312-3.
Lacy, P. E. & Kostianovsky, M. 1967. Method for the isolation of intact islets of 
Langerhans from the rat pancreas. Diabetes, 16, 35-9.
Lafferty, K. J., Bootes, A., Dart, G. & Talmage, D. W. 1976. Effect of organ culture on 
the survival of thyroid allografts in mice. Transplantation, 22, 138-49.
Lafferty, K. J. & Cunningham, A. 1975. A new analysis of allogeneic interactions. 
Immunology and Cell Biology, 53, 27-42.
Lafferty, K. J. & Jones, M. 1969. Reactions of the graft versus host (GVH) type. 
Immunology and Cell Biology, 47, 17-54.
Lafferty, K. J., Prowse, S. J., Simeonovic, C. J. & Warren, H. S. 1983. Immunobiology 
of tissue transplantation: a return to the passenger leukocyte concept. Annu Rev 
Immunol, 1, 143-73.
Lambaerts, K., Wilcox-Adelman, S. A. & Zimmermann, P. 2009. The signaling 
mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol, 
21,662-9.
Lardon, J., De Breuck, S., Rooman, I., Van Lommel, L., Kruhoffer, M., Omtoft, T., 
Schuit, F. & Bouwens, L. 2004. Plasticity in the adult rat pancreas: 
Transdifferentiation of exocrine to hepatocyte-like cells in primary culture. 
Hepatology, 39, 1499-1507.
Lau, H., Reemtsma, K. & Hardy, M. 1984. Prolongation of rat islet allograft survival by 
direct ultraviolet irradiation of the graft. Science, 223, 607-609.
Laurila, P. & Leivo, I. 1993. Basement membrane and interstitial matrix components 
form separate matrices in heterokaryons of PYS-2 cells and fibroblasts. J  Cell 
Sei, 104 (Pt 1), 59-68.
Le Moine, A., Goldman, M. & Abramowicz, D. 2002. Multiple pathways to allograft 
rejection. Transplantation, 73, 1373-81.
Lebleu, V. S., Macdonald, B. & Kalluri, R. 2007. Structure and Function of Basement 
Membranes. Experimental Biology and Medicine, 232, 1121-1129.
Lemasters, J. J. & Holmuhamedov, E. 2006. Voltage-dependent anion channel (VDAC) 
as mitochondrial govemator—thinking outside the box. Biochimica et biophysica 
acta, 1762, 181-90.
373
Lenzen, S. 2008. The mechanisms of alloxan- and streptozotocin-induced diabetes. 
Diabetologia, 51,216-226.
Leonard, W. J. & Lin, J. X. 2000. Cytokine receptor signaling pathways. J  Allergy Clin 
Immunol, 105, 877-88.
Lemer, L, Hermano, E., Zcharia, E., Rodkin, D., Bulvik, R., Doviner, V., Rubinstein, A. 
M., Ishai-Michaeli, R., Atzmon, R., Sherman, Y., Meirovitz, A., Peretz, T., 
Vlodavsky, I. & Elkin, M. 2011. Heparanase powers a chronic inflammatory 
circuit that promotes colitis-associated tumorigenesis in mice. J  Clin Invest, 121, 
1709-21.
Levidiotis, V., Freeman, C., Tikellis, C., Cooper, M. E. & Power, D. A. 2004. 
Heparanase is involved in the pathogenesis of proteinuria as a result of 
glomerulonephritis. J  Am Soc Nephrol, 15, 68-78.
Levisetti, M., Padrid, P., Szot, G., Mittal, N., Meehan, S., Wardrip, C., Gray, G., Bruce, 
D., Thistlethwaite, J. & Bluestone, J. 1997. Immunosuppressive effects of 
human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet 
transplantation. The Journal o f Immunology, 159, 5187-5191.
Levy-Adam, F., Miao, H. Q., Heinrikson, R. L., Vlodavsky, I. & Ilan, N. 2003. 
Heterodimer formation is essential for heparanase enzymatic activity. Biochem 
Biophys Res Commun, 308, 885-91.
Lewis, E. C., Shapiro, L., Bowers, O. J. & Dinarello, C. A. 2005. al-Antitrypsin 
monotherapy prolongs islet allograft survival in mice. Proceedings o f the 
National Academy of Sciences o f the United States o f America, 102, 12153- 
12158.
Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. 2007. Getting to the site of 
inflammation: the leukocyte adhesion cascade updated. Nature reviews. 
Immunology, 7, 678-89.
Li, A. E., Ito, H., Rovira, I. I., Kim, K.-S., Takeda, K., Yu, Z.-Y., Ferrans, V. J. & 
Finkei, T. 1999. A Role for Reactive Oxygen Species in Endothelial Cell 
Anoikis. Circulation Research, 85, 304-310.
Li, J. & Yuan, J. 2008. Caspases in apoptosis and beyond. Oncogene, 27, 6194-206.
Li, J. P. & Vlodavsky, I. 2009. Heparin, heparan sulfate and heparanase in 
inflammatory reactions. Thromb Haemost, 102, 823-8.
Li, Q., Park, P. W., Wilson, C. L. & Parks, W. C. 2002. Matrilysin shedding of 
syndecan-1 regulates chemokine mobilization and transepithelial efflux of 
neutrophils in acute lung injury. Cell, 111, 635-46.
Lindahl, U., Kusche-Gullberg, M. & KjellV©N, L. 1998. Regulated Diversity of 
Heparan Sulfate. Journal o f Biological Chemistry, 273, 24979-24982.
Lindall, A., Steffes, M. & Sorenson, R. 1969. Immunoassayable insulin content of 
subcellular fractions of rat islets. Endocrinology, 85, 218-23.
Linhardt, R. J. & Gunay, N. S. 1999. Production and chemical processing of low 
molecular weight heparins. Semin Thromb Hemost, 25 Suppl 3, 5-16.
Linsley, P. 1994. Immunosuppression and the CD28 receptor. Perspectives in Drug 
Discovery and Design, 2, 221 -231.
Little, C. C. 1914. A possible Mendelian explanation for a type of inheritance 
apparently non-Mendelian in nature. Science, 40, 904-6.
Liu, J. & Pedersen, L. C. 2007. Anticoagulant heparan sulfate: structural specificity and 
biosynthesis. Appl Microbiol Biotechnol, 74, 263-72.
Liu, Z. & Perlin, A. S. 1994. Evidence of a selective free radical degradation of heparin, 
mediated by cupric ion. Carbohydr Res, 255, 183-91.
Loria, V., Dato, I., Graziani, F. & Biasucci, L. M. 2008. Myeloperoxidase: a new 
biomarker of inflammation in ischemic heart disease and acute coronary 
syndromes. Mediators Inflamm, 2008, 135625.
374
Lou, J., Triponez, F., Oberholzer, J., Wang, H., Yu, D., Buhler, L., Cretin, N., Mentha, 
G., Wollheim, C. B. & Morel, P. 1999. Expression of alpha-1 proteinase 
inhibitor in human islet microvascular endothelial cells. Diabetes, 48, 1773-8.
Lu, W. C., Liu, Y. N., Kang, B. B. & Chen, J. H. 2003. Trans-activation of heparanase 
promoter by ETS transcription factors. Oncogene, 22, 919-23.
Lukes, A., Mun-Bryce, S., Lukes, M. & Rosenberg, G. 1999. Extracellular matrix 
degradation by metalloproteinases and central nervous system diseases. 
Molecular Neurobiology, 19, 267-284.
Luo, B., Nanji, S. A., Schur, C. D., Pawlick, R. L., Anderson, C. C. & James Shapiro, 
A. M. 2005. Robust Tolerance to Fully Allogeneic Islet Transplants Achieved 
by Chimerism with Minimal Conditioning. Transplantation, 80, 370-377.
Lynch, F. & Ceredig, R. 1989. Mouse strain variation in Ly-24 (Pgp-1) expression by 
peripheral T cells and thymocytes: implications for T cell differentiation. Eur J  
Immunol, 19,223-9.
Maehr, R., Mintem, J. D., Herman, A. E., Lennon-Dumenil, A. M., Mathis, D., Benoist, 
C. & Ploegh, H. L. 2005. Cathepsin L is essential for onset of autoimmune 
diabetes in NOD mice. J  Clin Invest, 115, 2934-43.
Maghzal, G. J. & Stocker, R. 2007. Improved analysis of hydroethidine and 2- 
hydroxyethidium by HPLC and electrochemical detection. Free Radio Biol Med, 
43, 1095-6.
Makhlouf, L., Yamada, A., Ito, T., Abdi, R., Ansari, M. J., Khuong, C. Q., Winn, H. J., 
Auchincloss, H., Jr. & Sayegh, M. H. 2003. Allorecognition and effector 
pathways of islet allograft rejection in normal versus nonobese diabetic mice. J  
Am Soc Nephrol, 14, 2168-75.
Maikov, D., Wang, H. Z., Dinh, S. & Gomez-Orellana, I. 2002. Pathway of oral 
absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate. 
Pharmaceutical research, 19, 1180-4.
Manon-Jensen, T., Itoh, Y. & Couchman, J. R. 2010. Proteoglycans in health and 
disease: the multiple roles of syndecan shedding. FEBSJ, 277, 3876-89.
Marchesi, V. T. & Florey, H. W. 1960. Electron micrographic observations on the 
emigration of leucocytes. Q J  Exp Physiol Cogn Med Sei, 45, 343-8.
Marchetti, D., Li, J. & Shen, R. 2000. Astrocytes Contribute to the Brain-metastatic 
Specificity of Melanoma Cells by Producing Heparanase. Cancer research, 60, 
4767-4770.
Marchetti, D. & Nicolson, G. L. 2001. Human heparanase: a molecular determinant of 
brain metastasis. Adv Enzyme Regul, 41, 343-59.
Marchetti, D., Reiland, J., Erwin, B. & Roy, M. 2003. Inhibition of heparanase activity 
and heparanase-induced angiogenesis by suramin analogues. Int J  Cancer, 104, 
167-74.
Markmann, J. F., Bassiri, H., Desai, N. M., Odorico, J. S., Kim, J. I., Koller, B. H., 
Smithies, O. & Barker, C. F. 1992. Indefinite survival of MHC class I-deficient 
murine pancreatic islet allografts. Transplantation, 54, 1085-9.
Markmann, J. F., Deng, S., Huang, X., Desai, N. M., Velidedeoglu, E. H., Lui, C., 
Frank, A., Markmann, E., Palanjian, M., Brayman, K., Wolf, B., Bell, E., 
Vitamaniuk, M., Doliba, N., Matschinsky, F., Barker, C. F. & Naji, A. 2003. 
Insulin independence following isolated islet transplantation and single islet 
infusions. Ann Surg, 237, 741-9; discussion 749-50.
Marsland, B. J., Battig, P., Bauer, M., Ruedl, C., Lassing, U., Beerli, R. R., Dietmeier, 
K., Ivanova, L., Pfister, T., Vogt, L., Nakano, H., Nembrini, C., Saudan, P., 
Kopf, M. & Bachmann, M. F. 2005. CCL19 and CCL21 induce a potent 
proinflammatory differentiation program in licensed dendritic cells. Immunity, 
22, 493-505.
375
Mattsson, G. 2005. The endothelial cells in islets of langerhans. Ups J Med Sei, 110, 1- 
15.
Mattsson, G. R., Jansson, L. & Carlsson, P.-O. 2002. Decreased Vascular Density in 
Mouse Pancreatic Islets After Transplantation. Diabetes, 51, 1362-1366.
Matzner, Y., Bar-Ner, M., Yahalom, J., Ishai-Michaeli, R., Fuks, Z. & Vlodavsky, I. 
1985. Degradation of heparan sulfate in the subendothelial extracellular matrix 
by a readily released heparanase from human neutrophils. Possible role in 
invasion through basement membranes. J  Clin Invest, 76, 1306-13.
Mayer, A., Lee, S., Jung, F., Grutz, G., Lendlein, A. & Hiebl, B. 2010. CD 14+ CD 163+ 
IL-10+ monocytes/macrophages: Pro-angiogenic and non pro-inflammatory 
isolation, enrichment and long-term secretion profile. Clin Hemorheol 
Microcirc, 46, 217-23.
Mcalister, V. C., Gao, Z., Peltekian, K., Domingues, J., Mahalati, K. & Macdonald, A. 
S. 2000. Sirolimus-tacrolimus combination immunosuppression. The Lancet, 
355, 376-377.
Mckenzie, E. A. 2007. Heparanase: a target for drug discovery in cancer and 
inflammation. Br J  Pharmacol, 151, 1-14.
Medawar, P. 1958. The Croonian Lecture: the homograft reaction. Proceedings o f the 
Royal Society o f London. Series B, Biological Sciences, 145-166.
Medawar, P. B. 1944. The behaviour and fate of skin autografts and skin homografts in 
rabbits: A report to the War Wounds Committee of the Medical Research 
Council. J  Anat, 78, 176-99.
Medawar, P. B. 1945. A second study of the behaviour and fate of skin homografts in 
rabbits: A Report to the War Wounds Committee of the Medical Research 
Council. J  Anat, 79, 157-176 4.
Melvold, R. W. 2001. Major Histocompatibility Complex (MHC): Mouse. eLS. John 
Wiley & Sons, Ltd.
Mendola, J., Wright, J. R. & Lacy, P. E. 1989. Oxygen Free-Radical Scavengers and 
Immune Destruction of Murine Islets in Allograft Rejection and Multiple Low- 
Dose Streptozocin-Induced Insulitis. Diabetes, 38, 379-385.
Menger, M. D., Jaeger, S., Walter, P., Feifel, G., Hammersen, F. & Messmer, K. 1989. 
Angiogenesis and hemodynamics of microvasculature of transplanted islets of 
Langerhans. Diabetes, 38 Suppl 1, 199-201.
Menger, M. D., Wolf, B., Hobel, R., Schorlemmer, H. U. & Messmer, K. 1991. 
Micro vascular phenomena during pancreatic islet graft rejection. Langenbecks 
Arch Chir, 376, 214-21.
Merani, S. & Shapiro, A. M. 2006. Current status of pancreatic islet transplantation. 
Clin Sei (Lond), 110, 611-25.
Meredith, J. E., Jr., Fazeli, B. & Schwartz, M. A. 1993. The extracellular matrix as a 
cell survival factor. Mol Biol Cell, 4, 953-61.
Metcalfe, D. D., Thompson, H. L., Klebanoff, S. J. & Henderson, W. R., Jr. 1990. 
Oxidative degradation of rat mast-cell heparin proteoglycan. Biochem J, 272, 
51-7.
Middleton, J., Neil, S., Wintle, J., Clark-Lewis, L, Moore, H., Lam, C., Auer, M., Hub, 
E. & Rot, A. 1997. Transcytosis and surface presentation of IL-8 by venular 
endothelial cells. Cell, 91, 385-95.
Middleton, J., Patterson, A. M., Gardner, L., Schmutz, C. & Ashton, B. A. 2002. 
Leukocyte extravasation: chemokine transport and presentation by the 
endothelium. Blood, 100,3853-60.
Miller, J. F. A. P. 1962. ROLE OF THE THYMUS IN TRANSPLANTATION 
IMMUNITY*. Annals o f the New York Academy o f Sciences, 99, 340-354.
376
Mineo, D., Ricordi, C., Xu, X., Pileggi, A., Garcia-Morales, R., Khan, A., Baidal, D. A., 
Han, D., Monroy, K., Miller, J., Pugliese, A., Froud, T., Inverardi, L., Kenyon, 
N. S. & Alejandro, R. 2008. Combined Islet and Hematopoietic Stem Cell 
Allotransplantation: A Clinical Pilot Trial to Induce Chimerism and Graft 
Tolerance. American Journal o f Transplantation, 8, 1262-1274.
Miner, J. H. & Yurchenco, P. D. 2004. Laminin functions in tissue morphogenesis. 
Annu Rev Cell Dev Biol, 20, 255-84.
Minkowski, O. 1892. Weitere Mitteilungen über den Diabetes mellitus nach Extirpation 
des Pankreas. BerlKlin Wochenschr 29, 90-93.
Mitchison, N. A. 1954. Passive Transfer of Transplantation Immunity. Proceedings of 
the Royal Society o f London. Series B - Biological Sciences, 142, 72-87.
Mizoguchi, K., Maeta, H., Yamamoto, A., Oe, M. & Kosaka, H. 2002. Amelioration of 
myocardial global ischemia/reperfusion injury with volume-regulatory chloride 
channel inhibitors in vivo. Transplantation, 73, 1185-93.
Molano, R. D., Bemey, T., Li, H., Cattan, P., Pileggi, A., Vizzardelli, C., Kenyon, N. S., 
Ricordi, C., Burkly, L. C. & Inverardi, L. 2001. Prolonged Islet Graft Survival in 
NOD Mice by Blockade of the CD40-CD154 Pathway of T-Cell Costimulation. 
Diabetes, 50, 270-276.
Morini, S., Brown, M. L., Cicalese, L., Elias, G., Carotti, S., Gaudio, E. & Rastellini, C. 
2007. Revascularization and remodelling of pancreatic islets grafted under the 
kidney capsule. J  Anat, 210, 565-77.
Moseley, R., Waddington, R., Evans, P., Halliwell, B. & Embery, G. 1995. The 
chemical modification of glycosaminoglycan structure by oxygen-derived 
species in vitro. Biochimica et biophysica acta, 1244, 245-52.
Moskalewski, S. 1965. Isolation and culture of the islets of Langerhans of the guinea 
pig. General and Comparative Endocrinology, 5, 342-353.
Myler, H. A., Lipke, E. A., Rice, E. E. & West, J. L. 2006. Novel heparanase-inhibiting 
antibody reduces neointima formation. J  Biochem, 139, 339-45.
Nadav, L., Eldor, A., Yacoby-Zeevi, O., Zamir, E., Pecker, L, Ilan, N., Geiger, B., 
Vlodavsky, I. & Katz, B. Z. 2002. Activation, processing and trafficking of 
extracellular heparanase by primary human fibroblasts. J  Cell Sei, 115, 2179-87.
Nadir, Y., Brenner, B., Zetser, A., Ilan, N., Shafat, L, Zcharia, E., Goldshmidt, O. & 
Vlodavsky, I. 2006. Heparanase induces tissue factor expression in vascular 
endothelial and cancer cells. Journal o f Thrombosis and Haemostasis, 4, 2443- 
2451.
Nagasawa, K., Uchiyama, H., Sato, N. & Hatano, A. 1992. Chemical change involved 
in the oxidative-reductive depolymerization of heparin. Carbohydr Res, 236, 
165-80.
Naggi, A., Casu, B., Perez, M., Torri, G., Cassinelli, G., Penco, S., Pisano, C., Giannini, 
G., Ishai-Michaeli, R. & Vlodavsky, I. 2005. Modulation of the Heparanase- 
inhibiting Activity of Heparin through Selective Desulfation, Graded N- 
Acetylation, and Glycol Splitting. Journal o f Biological Chemistry, 280, 12103- 
12113.
Nakagawa, T., Roth, W., Wong, P., Nelson, A., Farr, A., Deussing, J., Villadangos, J. 
A., Ploegh, H., Peters, C. & Rudensky, A. Y. 1998. Cathepsin L: critical role in 
Ii degradation and CD4 T cell selection in the thymus. Science, 280, 450-3.
Nakagiri, T., Inoue, M., Morii, E., Minami, M., Sawabata, N., Utsumi, T., Kadota, Y., 
Ideguchi, K., Tokunaga, T. & Okumura, M. 2010. Local IL-17 production and a 
decrease in peripheral blood regulatory T cells in an animal model of 
bronchiolitis obliterans. Transplantation, 89, 1312-9.
Nakajima, M., Dechavigny, A., Johnson, C. E., Hamada, J., Stein, C. A. & Nicolson, G. 
L. 1991. Suramin. A potent inhibitor of melanoma heparanase and invasion. J  
Biol Chem, 266, 9661-6.
Nakajima, M., Irimura, T., Di Ferrante, D., Di Ferrante, N. & Nicolson, G. L. 1983. 
Heparan sulfate degradation: relation to tumor invasive and metastatic properties 
of mouse B16 melanoma sublines. Science, 220, 611-3.
Nakajima, M., Irimura, T., Di Ferrante, N. & Nicolson, G. L. 1984. Metastatic 
melanoma cell heparanase. Characterization of heparan sulfate degradation 
fragments produced by B16 melanoma endoglucuronidase. J Biol Chem, 259, 
2283-90.
Naparstek, Y., Cohen, I. R., Fuks, Z. & Vlodavsky, I. 1984. Activated T lymphocytes 
produce a matrix-degrading heparan sulphate endoglycosidase. Nature, 310, 
241-4.
Nasser, N. J. 2008. Heparanase involvement in physiology and disease. Cell Mol Life 
Sei, 65, 1706-15.
Negi, S., Jetha, A., Aikin, R., Hasilo, C., Sladek, R. & Paraskevas, S. 2012. Analysis of 
beta-cell gene expression reveals inflammatory signaling and evidence of 
dedifferentiation following human islet isolation and culture. PLoS One, 7, 
e30415.
Nelson, P. J. & Krensky, A. M. 2001. Chemokines, chemokine receptors, and allograft 
rejection. Immunity, 14, 377-386.
Newsholme, P., Haber, E. P., Hirabara, S. M., Rebelato, E. L., Procopio, J., Morgan, D., 
Oiiveira-Emiiio, H. C., Carpinelli, A. R. & Cun, R. 2007. Diabetes associated 
cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS 
production and activity. J  Physiol, 583, 9-24.
Nicolls, M. R., Coulombe, M. & Gill, R. G. 2001. The basis of immunogenicity of 
endocrine allografts. Critical reviews in immunology, 21, 87.
Nicolls, M. R. & Gill, R. G. 2006. LFA-1 (CDlla) as a Therapeutic Target. American 
Journal o f Transplantation, 6, 27-36.
Nikolova, G., Jabs, N., Konstantinova, I., Domogatskaya, A., Tryggvason, K., Sorokin, 
L., Fassler, R., Gu, G., Gerber, H. P., Ferrara, N., Melton, D. A. & Lammert, E. 
2006. The vascular basement membrane: a niche for insulin gene expression and 
Beta cell proliferation. Dev Cell, 10, 397-405.
Nikolova, G., Strilic, B. & Lammert, E. 2007. The vascular niche and its basement 
membrane. Trends Cell Biol, 17, 19-25.
Nir, T., Melton, D. & Dor, Y. 2007. Recovery from diabetes in mice by beta cell 
regeneration.
Nobuhisa, T., Naomoto, Y., Okawa, T., Takaoka, M., Gunduz, M., Motoki, T., 
Nagatsuka, H., Tsujigiwa, H., Shirakawa, Y., Yamatsuji, T., Haisa, M., 
Matsuoka, J., Kurebayashi, J., Nakajima, M., Taniguchi, S., Sagara, J., Dong, J. 
& Tanaka, N. 2007. Translocation of heparanase into nucleus results in cell 
differentiation. Cancer Sei, 98, 535-40.
Noguchi, H., Matsumoto, S., Matsushita, M., Kobayashi, N., Tanaka, K., Matsui, H. & 
Tanaka, N. 2006. Immunosuppression for islet transplantation. Acta Med 
Okayama, 60, 71-6.
Noguchi, H., Naziruddin, B., Shimoda, M., Fujita, Y., Chujo, D., Takita, M., Peng, H., 
Sugimoto, K., Itoh, T., Tamura, Y., Olsen, G. S., Kobayashi, N., Onaca, N., 
Levy, M. F. & Matsumoto, S. 2010. Comparison of fresh and cultured islets 
from human and porcine pancreata. Transplant Proc, 42, 2084-6.
Noguchi, H., Yamada, Y., Okitsu, T., Iwanaga, Y., Nagata, H., Kobayashi, N., Hayashi, 
S. & Matsumoto, S. 2008. Secretory unit of islet in transplantation (SUIT) and
378
engrafted islet rate (EIR) indexes are useful for evaluating single islet 
transplantation. Cell Transplantation, 17, 121-128.
Norrby, K. 2006. Low-molecular-weight heparins and angiogenesis. APMIS, 114, 79- 
102.
Nyqvist, D., Kohler, M., Wahlstedt, H. & Berggren, P. O. 2005. Donor islet endothelial 
cells participate in formation of functional vessels within pancreatic islet grafts. 
Diabetes, 54, 2287-93.
Nyqvist, D., Speier, S., Rodriguez-Diaz, R., Molano, R. D., Lipovsek, S., Rupnik, M., 
Dicker, A., Ilegems, E., Zahr-Akrawi, E., Molina, J., Lopez-Cabeza, M., Villate, 
S., Abdulreda, M. H., Ricordi, C., Caicedo, A., Pileggi, A. & Berggren, P. O. 
2011. Donor islet endothelial cells in pancreatic islet revascularization. 
Diabetes, 60, 2571-7.
Obermajer, N., Jevnikar, Z., Doljak, B. & Kos, J. 2008. Role of cysteine cathepsins in 
matrix degradation and cell signalling. Connect Tissue Res, 49, 193-6.
Ogishima, T., Shiina, H., Breault, J. E., Tabatabai, L., Bassett, W. W., Enokida, H., Li,
L. C., Kawakami, T., Urakami, S., Ribeiro-Filho, L. A., Terashima, M., Fujime,
M. , Igawa, M. & Dahiya, R. 2005a. Increased heparanase expression is caused 
by promoter hypomethylation and up-regulation of transcriptional factor early 
growth response-1 in human prostate cancer. Clin Cancer Res, 11, 1028-36.
Ogishima, T., Shiina, H., Breault, J. E., Terashima, M., Honda, S., Enokida, H., 
Urakami, S., Tokizane, T., Kawakami, T., Ribeiro-Filho, L. A., Fujime, M., 
Kane, C. J., Carroll, P. R., Igawa, M. & Dahiya, R. 2005b. Promoter CpG 
hypomethylation and transcription factor EGR1 hyperactivate heparanase 
expression in bladder cancer. Oncogene, 24, 6765-72.
Ogren, S. & Lindahl, U. 1975. Cleavage of macromolecular heparin by an enzyme from 
mouse mastocytoma. Journal o f Biological Chemistry, 250, 2690-2697.
Ohlen, C., Bastin, J., Ljunggren, H. G., Foster, L., Wolpert, E., Klein, G., Townsend, A. 
R. & Karre, K. 1990. Resistance to H-2-restricted but not to allo-H2-specific 
graft and cytotoxic T lymphocyte responses in lymphoma mutant. J  Immunol, 
145,52-8.
Olcott, A. P., Tocco, G., Tian, J., Zekzer, D., Fukuto, J., Ignarro, L. & Kaufman, D. L. 
2004. A salen-manganese catalytic free radical scavenger inhibits type 1 
diabetes and islet allograft rejection. Diabetes, 53, 2574-80.
Olerud, J., Johansson, M., Lawler, J., Welsh, N. & Carlsson, P. O. 2008. Improved 
vascular engraftment and graft function after inhibition of the angiostatic factor 
thrombospondin-1 in mouse pancreatic islets. Diabetes, 57, 1870-7.
Olsson, R. & Carlsson, P. O. 2006. The pancreatic islet endothelial cell: emerging roles 
in islet function and disease. The international journal o f biochemistry & cell 
biology, 38, 492-7.
Oppenheim, J. J. 2001. Cytokines: past, present, and future. Int JHematol, 74, 3-8.
Osorio, R. W., Ascher, N. L., Jaenisch, R., Freise, C. E., Roberts, J. P. & Stock, P. G. 
1993. Major Histocompatibility Complex Class I Deficiency Prolongs Islet 
Allograft Survival. Diabetes, 42, 1520-1527.
Pacher, P. L., Beckman, J. S. & Liaudet, L. 2007. Nitric Oxide and Peroxynitrite in 
Health and Disease. Physiological Reviews, 87, 315-424.
Page-Mccaw, A., Ewald, A. J. & Werb, Z. 2007. Matrix metalloproteinases and the 
regulation of tissue remodelling. Nat Rev Mol Cell Biol, 8, 221-33.
Pan, X., Xue, W., Li, Y., Feng, X., Tian, X. & Ding, C. 2011. Islet graft survival and 
function: concomitant culture and transplantation with vascular endothelial cells 
in diabetic rats. Transplantation, 92, 1208-14.
Panakanti, R. & Mahato, R. I. 2009. Bipartite adenoviral vector encoding hHGF and 
hIL-IRa for improved human islet transplantation. Pharm Res, 26, 587-96.
379
Pappan, K. L., Pan, Z., Kwon, G., Marshall, C. A., Coleman, T., Goldberg, I. J., 
Mcdaniel, M. L. & Semenkovich, C. F. 2005. Pancreatic ß-Cell Lipoprotein 
Lipase Independently Regulates Islet Glucose Metabolism and Normal Insulin 
Secretion. Journal o f Biological Chemistry, 280, 9023-9029.
Parish, C. R. 2006. The role of heparan sulphate in inflammation. Nat Rev Immunol, 6, 
633-643.
Parish, C. R., Coombe, D. R., Jakobsen, K. B., Bennett, F. A. & Underwood, P. A. 
1987. Evidence that sulphated polysaccharides inhibit tumour metastasis by 
blocking tumour-cell-derived heparanases. International Journal o f Cancer, 40, 
511-518.
Parish, C. R., Freeman, C., Brown, K. J., Francis, D. J. & Cowden, W. B. 1999. 
Identification of sulfated oligosaccharide-based inhibitors of tumor growth and 
metastasis using novel in vitro assays for angiogenesis and heparanase activity. 
Cancer research, 59, 3433-41.
Parish, C. R., Freeman, C. & Hulett, M. D. 2001. Heparanase: a key enzyme involved in 
cell invasion. Biochimica et biophysica acta, 1471, M99-108.
Parish, C. R., Glidden, M. H., Quah, B. J. & Warren, H. S. 2009. Use of the intracellular 
fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr 
Protoc Immunol, Chapter 4, Unit4 9.
Parish, C. R., Hindmarsh, E. J., Bartlett, M. R., Staykova, M. A., Cowden, W. B. & 
Willenborg, D. O. 1998. Treatment of central nervous system inflammation with 
inhibitors of basement membrane degradation. Immunol Cell Biol, 76, 104-13.
Park, C., Kim, J.-R., Shim, J.-K., Kang, B.-S., Park, Y.-Ü., Nam, K.-S., Lee, Y.-C. & 
Kim, C.-H. 1999. Inhibitory Effects of Streptozotocin, Tumor Necrosis Factor-a, 
and Interleukin-1 ß on Glucokinase Activity in Pancreatic Islets and Gene 
Expression of GLUT2 and Glucokinase. Archives o f Biochemistry and 
Biophysics, 362,217-224.
Park, K. S., Kim, Y. S., Kim, J. H., Choi, B., Kim, S. H., Tan, A. H., Lee, M. S., Lee, 
M. K., Kwon, C. H., Joh, J. W., Kim, S. J. & Kim, K. W. 2010. Trophic 
molecules derived from human mesenchymal stem cells enhance survival, 
function, and angiogenesis of isolated islets after transplantation. 
Transplantation, 89, 509-17.
Patel, V. N., Knox, S. M., Likar, K. M., Lathrop, C. A., Hossain, R., Eftekhari, S., 
Whitelock, J. M., Elkin, M., Vlodavsky, I. & Hoffman, M. P. 2007. Heparanase 
cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo 
submandibular gland branching morphogenesis. Development, 134, 4177-86.
Pavin, E. J., Pinto, G. A., Zöllner, R. L. & Vassallo, J. 2003. Immunohistochemical 
study of the pancreatic basement membrane in non obese diabetic mice (NOD) 
with spontaneous autoimmune insulitis. J  Submicrosc Cytol Pathol, 35, 25-7.
Pavlovic, D., Chen, M. C., Bouwens, L., Eizirik, D. L. & Pipeleers, D. 1999. 
Contribution of ductal cells to cytokine responses by human pancreatic islets. 
Diabetes, 48, 29-33.
Pease, L., Horton, R., Pullen, J. & Cai, Z. 1991. Structure and diversity of class I 
antigen presenting molecules in the mouse. Crit. Rev. Immunol, 11.
Persad, S., Attwell, S., Gray, V., Mawji, N., Deng, J. T., Leung, D., Yan, J., Sanghera, 
J., Walsh, M. P. & Dedhar, S. 2001. Regulation of protein kinase B/Akt-serine 
473 phosphorylation by integrin-linked kinase: critical roles for kinase activity 
and amino acids arginine 211 and serine 343. J  Biol Chem, 276, 27462-9.
Persson-Sjögren, S., Forsgren, S. & Täljedal, I.-B. 2000. Peptides and other neuronal 
markers in transplanted pancreatic islets. Peptides, 21, 741-752.
380
Piemonti, L., Guidotti, L. G. & Battaglia, M. 2010. Modulation of Early Inflammatory 
Reactions to Promote Engraftment and Function of Transplanted Pancreatic 
Islets in Autoimmune Diabetes
The Islets of Langerhans. In: ISLAM, M. S. (ed.). Springer Netherlands.
Piemonti, L., Leone, B. E., Nano, R., Saccani, A., Monti, P., Maffi, P., Bianchi, G., 
Sica, A., Peri, G., Melzi, R., Aldrighetti, L., Secchi, A., Di Carlo, V., Allavena, 
P. & Bertuzzi, F. 2002. Human pancreatic islets produce and secrete MCP- 
1/CCL2: relevance in human islet transplantation. Diabetes, 51, 55-65.
Pieper, G. M., Nilakantan, V., Nguyen, T. K., Hilton, G., Roza, A. M. & Johnson, C. P. 
2008. Reactive oxygen and reactive nitrogen as signaling molecules for caspase 
3 activation in acute cardiac transplant rejection. Antioxid Redox Signal, 10, 
1031-40.
Pikas, D. S., Li, J. P., Vlodavsky, I. & Lindahl, U. 1998. Substrate specificity of 
heparanases from human hepatoma and platelets. J  Biol Chem, 273, 18770-7.
Pileggi, A., Molano, R. D., Bemey, T., Cattan, P., Vizzardelli, C., Oliver, R., Fraker, C., 
Ricordi, C., Pastori, R. L., Bach, F. H. & Inverardi, L. 2001. Heme Oxygenase-1 
Induction in Islet Cells Results in Protection From Apoptosis and Improved In 
Vivo Function After Transplantation. Diabetes, 50, 1983-1991.
Pileggi, A., Molano, R. D., Bemey, T., Ichii, H., San Jose, S., Zahr, E., Poggioli, R., 
Linetsky, E., Ricordi, C. & Inverardi, L. 2005. Prolonged allogeneic islet graft 
survival by protoporphyrins. Cell Transplant, 14, 85-96.
Pileggi, A., Molano, R. D., Song, S., Zahr, E., Sanjose, S., Villate, S., Wasserfall, C., 
Ricordi, C., Atkinson, M. A. & Inverardi, L. 2008. Alpha-1 Antitrypsin 
Treatment of Spontaneously Diabetic Nonobese Diabetic Mice Receiving Islet 
Allografts. Transplantation Proceedings, 40, 457-458.
Pillarisetti, S., Paka, L., Obunike, J. C., Berglund, L. & Goldberg, I. J. 1997. 
Subendothelial retention of lipoprotein (a). Evidence that reduced heparan 
sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest, 100, 
867-74.
Pin, C. L., Rukstalis, J. M., Johnson, C. & Konieczny, S. F. 2001. The bHLH 
transcription factor Misti is required to maintain exocrine pancreas cell 
organization and acinar cell identity. J  Cell Biol, 155, 519-30.
Pober, J. S. & Cotran, R. S. 1990. The role of endothelial cells in inflammation. 
Transplantation, 50, 537-44.
Ponta, H., Sherman, L. & Herrlich, P. A. 2003. CD44: from adhesion molecules to 
signalling regulators. Nat Rev Mol Cell Biol, 4, 33-45.
Popp, S. K., Mann, D. A., Milbum, P. J., Gibbs, A. J., Mccullagh, P. J., Wilson, J. D., 
Tonjes, R. R. & Simeonovic, C. J. 2007. Transient transmission of porcine 
endogenous retrovirus to fetal lambs after pig islet tissue xenotransplantation. 
Immunol Cell Biol, 85, 238-48.
Porras, D. L., Wang, Y., Zhou, P., Molinero, L. L. & Alegre, M. L. 2012. Role of T- 
Cell-Specific Nuclear Factor kappaB in Islet Allograft Rejection. 
Transplantation, 93, 976-82.
Posselt, A. M., Beilin, M. D., Tavakol, M., Szot, G. L., Frassetto, L. A., Masharani, U., 
Kerlan, R. K., Fong, L., Vincenti, F. G., Hering, B. J., Bluestone, J. A. & Stock, 
P. G. 2010. Islet transplantation in type 1 diabetics using an immunosuppressive 
protocol based on the anti-LFA-1 antibody efalizumab. Am J  Transplant, 10, 
1870-80.
Potts, W., Bowyer, J., Jones, H., Tucker, D., Freemont, A. J., Millest, A., Martin, C., 
Vernon, W., Neerunjun, D., Slynn, G., Harper, F. & Maciewicz, R. 2004. 
Cathepsin L-deficient mice exhibit abnormal skin and bone development and
381
show increased resistance to osteoporosis following ovariectomy. Int J  Exp 
Pathol, 85, 85-96.
Probst, O. C., Ton, P., Svoboda, B., Gannon, A., Schuhmann, W., Wieser, J., Pohlmann, 
R. & Mach, L. 2006. The 46-kDa mannose 6-phosphate receptor does not 
depend on endosomal acidification for delivery of hydrolases to lysosomes. 
Journal o f Cell Science, 119, 4935-4943.
Proudfoot, A. E., Handel, T. M., Johnson, Z., Lau, E. K., Liwang, P., Clark-Lewis, L, 
Borlat, F., Wells, T. N. & Kosco-Vilbois, M. H. 2003. Glycosaminoglycan 
binding and oligomerization are essential for the in vivo activity of certain 
chemokines. Proc Natl Acad Sei USA,  100, 1885-90.
Pruessmeyer, J., Martin, C., Hess, F. M., Schwarz, N., Schmidt, S., Kogel, T., 
Hoettecke, N., Schmidt, B., Sechi, A., Uhlig, S. & Ludwig, A. 2010. A 
Disintegrin and Metalloproteinase 17 (ADAM 17) Mediates Inflammation- 
induced Shedding of Syndecan-1 and -4 by Lung Epithelial Cells. Journal of 
Biological Chemistry, 285, 555-564.
Pure, E. & Cuff, C. A. 2001. A crucial role for CD44 in inflammation. Trends in 
Molecular Medicine, 7, 213-221.
Purushothaman, A., Hurst, D. R., Pisano, C., Mizumoto, S., Sugahara, K. & Sanderson, 
R. D. 2011. Heparanase-mediated loss of nuclear syndecan-1 enhances Histone 
Acetyltransferase (HAT) activity to promote expression of genes that drive an 
aggressive tumor phenotype. Journal o f Biological Chemistry, 286, 30377- 
30383.
Pybus, F. 1924. Notes on syprarenal and pancreatic grafting. Lancet, 550.
Qi, S., Den Hartog, G. J. & Bast, A. 2009. Superoxide radicals increase transforming 
growth factor-beta 1 and collagen release from human lung fibroblasts via 
cellular influx through chloride channels. Toxicol Appl Pharmacol, 237, 111-8.
Quah, B. J., Warren, H. S. & Parish, C. R. 2007. Monitoring lymphocyte proliferation 
in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein 
diacetate succinimidyl ester. Nat Protoc, 2, 2049-56.
Raats, C. J., Bakker, M. A., Van Den Bom, J. & Berden, J. H. 1997. Hydroxyl radicals 
depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic 
syndrome. J  Biol Chem, 272, 26734-41.
Rabenstein, D. L. 2002. Heparin and heparan sulfate: structure and function. Natural 
Product Reports, 19,312-331.
Rabinovitch, A. & Suarez-Pinzon, W. L. 1998. Cytokines and their roles in pancreatic 
islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem 
Pharmacol, 55, 1139-49.
Rapraeger, A. C., Krufka, A. & Olwin, B. B. 1991. Requirement of heparan sulfate for 
bFGF-mediated fibroblast growth and myoblast differentiation. Science, 252, 
1705-8.
Reckard, C. R., Ziegler, M. M. & Barker, C. F. 1973. Physiological and immunological 
consequences of transplanting isolated pancreatic islets. Surgery, 74, 91-9.
Rees, M. D., Whitelock, J. M., Malle, E., Chuang, C. Y., Iozzo, R. V., Nilasaroya, A. & 
Davies, M. J. 2010. Myeloperoxidase-derived oxidants selectively disrupt the 
protein core of the heparan sulfate proteoglycan perlecan. Matrix Biol, 29, 63- 
73.
Reid, R. 2011. A Comparative Analysis of Biomaterials Currently Used in Pelvic 
Reconstructive Surgery. In: THEOBALD, P., ZIMMERMAN, C. W. & 
DAVILA, G. W. (eds.) New Techniques in Genital Prolapse Surgery. Springer 
London.
Reiland, J., Sanderson, R. D., Waguespack, M., Barker, S. A., Long, R., Carson, D. D. 
& Marchetti, D. 2004. Heparanase Degrades Syndecan-1 and Perlecan Heparan
382
Sulfate: FUNCTIONAL IMPLICATIONS FOR TUMOR CELL INVASION. 
Journal o f Biological Chemistry, 279, 8047-8055.
Reiser, J., Adair, B. & Reinheckel, T. 2010. Specialized roles for cysteine cathepsins in 
health and disease. The Journal o f Clinical Investigation, 120, 3421 -3431.
Rickies, F. R. 2006. If heparanase is the answer, what is the question? Journal of 
Thrombosis and Haemostasis, 4, 557-559.
Ricordi, C., Alejandro, R., Rilo, H. H., Carroll, P. B., Tzakis, A. G., Starzl, T. E. & 
Mintz, D. H. 1995. Long-term in vivo function of human mantled islets obtained 
by incomplete pancreatic dissociation and purification. Transplant Proc, 27, 
3382.
Ricordi, C., Finke, E. H. & Lacy, P. E. 1986. A method for the mass isolation of islets 
from the adult pig pancreas. Diabetes, 35, 649-53.
Ricordi, C. & Strom, T. B. 2004. Clinical islet transplantation: advances and 
immunological challenges. Nat Rev Immunol, 4, 259-68.
Riemer, J., Bulleid, N. & Herrmann, J. M. 2009. Disulfide formation in the ER and 
mitochondria: two solutions to a common process. Science, 324, 1284-7.
Rizza, R., Go, V., Cryer, P., Verdonk, C. & Gerich, J. 1982. Stimulation of human 
pancreatic polypeptide secretion by hypoglycemia is independent of adrenergic 
mechanisms. J  Clin Endocrinol Metab, 55, 1234-6.
Rocha, P. N., Plumb, T. J., Crowley, S. D. & Coffman, T. M. 2003. Effector 
mechanisms in transplant rejection. Immunol Rev, 196, 51-64.
Romashkova, J. A. & Makarov, S. S. 1999. NF-kappaB is a target of AKT in anti- 
apoptotic PDGF signalling. Nature, 401, 86-90.
Rosenau, W. & Moon, H. D. 1961. Lysis of homologous cells by sensitized 
lymphocytes in tissue culture. J  Natl Cancer Inst, 27, 471-83.
Rosenberg, L., Wang, R., Paraskevas, S. & Maysinger, D. 1999. Structural and 
functional changes resulting from islet isolation lead to islet cell death. Surgery, 
126,393-8.
Rot, A. 2010. Chemokine patterning by glycosaminoglycans and interceptors. Frontiers 
in Bioscience-Landmark, 15, 645-60.
Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., 
Lakey, J. R. & Shapiro, A. M. 2005. Five-year follow-up after clinical islet 
transplantation. Diabetes, 54, 2060-9.
Saleem, S., Li, J., Yee, S. P., Fellows, G. F., Goodyer, C. G. & Wang, R. 2009. betal 
integrin/FAK/ERK signalling pathway is essential for human fetal islet cell 
differentiation and survival. J  Pathol, 219, 182-92.
Salvay, D. M., Rives, C. B., Zhang, X., Chen, F., Kaufman, D. B., Lowe Jr, W. L. & 
Shea, L. D. 2008. Extracellular matrix protein-coated scaffolds promote the 
reversal of diabetes after extrahepatic islet transplantation. Transplantation, 85, 
1456.
Sarrazin, S., Lamanna, W. C. & Esko, J. D. 2011. Heparan sulfate proteoglycans. Cold 
Spring Harbor perspectives in biology, 3.
Satoh, M., Yasunami, Y., Matsuoka, N., Nakano, M., Itoh, T., Nitta, T., Anzai, K., Ono, 
J., Taniguchi, M. & Ikeda, S. 2007. Successful islet transplantation to two 
recipients from a single donor by targeting proinflammatory cytokines in mice. 
Transplantation, 83, 1085-92.
Sayegh, M. H., Watschinger, B. & Carpenter, C. B. 1994. MECHANISMS OF T CELL 
RECOGNITION OF ALLOANTIGEN: The Role of Peptides. Transplantation, 
57, 1295-1302.
Scharp, D. W., Kemp, C. B., Knight, M. J., Ballinger, W. F. & Lacy, P. E. 1973. The 
use of ficoll in the preparation of viable islets of langerhans from the rat 
pancreas. Transplantation, 16,686-9.
383
Scharp, D. W., Lacy, P. E., Santiago, J. V., Mccullough, C. S., Weide, L. G., Falqui, L., 
Marchetti, P., Gingerich, R. L., Jaffe, A. S., Cryer, P. E. & Et Al. 1990. Insulin 
independence after islet transplantation into type I diabetic patient. Diabetes, 39, 
515-8.
Schumann, K., L%oMmermann, T., Bruckner, M., Legier, D. F., Polleux, J., Spatz, J. P., 
Schuler, G., F'Rster, R., Lutz, M. B., Sorokin, L. & Sixt, M. 2010. Immobilized 
Chemokine Fields and Soluble Chemokine Gradients Cooperatively Shape 
Migration Patterns of Dendritic Cells. Immunity, 32, 703-713.
Seals, D. F. & Courtneidge, S. A. 2003. The ADAMs family of metalloproteases: 
multidomain proteins with multiple functions. Genes Dev, 17, 7-30.
Sewell, R. F., Brenchley, P. E. & Mallick, N. P. 1989. Human mononuclear cells 
contain an endoglycosidase specific for heparan sulphate glycosaminoglycan 
demonstrable with the use of a specific solid-phase metabolically radiolabelled 
substrate. Biochem J, 264, 777-83.
Shafat, L, Barak, A. B., Postovsky, S., Elhasid, R., Ilan, N., Vlodavsky, I. & Arush, M. 
W. 2007. Heparanase levels are elevated in the plasma of pediatric cancer 
patients and correlate with response to anticancer treatment. Neoplasia, 9, 909- 
lb.
Shafat, L, Ben-Arush, M. W., Issakov, J., Meller, L, Naroditsky, L, Tortoreto, M., 
Cassinelli, G., Lanzi, C., Pisano, C., Ilan, N., Vlodavsky, I. & Zunino, F. 2011a. 
Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. Journal 
o f cellular and molecular medicine, 15, 1857-1864.
Shafat, L, Ilan, N., Zoabi, S., Vlodavsky, I. & Nakhoul, F. 2011b. Heparanase Levels 
Are Elevated in the Urine and Plasma of Type 2 Diabetes Patients and Associate 
with Blood Glucose Levels. PLoS One, 6, e l7312.
Shafat, L, Vlodavsky, I. & Ilan, N. 2006a. Characterization of mechanisms involved in 
secretion of active heparanase. J Biol Chem, 281,23804-11.
Shafat, L, Zcharia, E., Nisman, B., Nadir, Y., Nakhoul, F., Vlodavsky, I. & Ilan, N. 
2006b. An ELISA method for the detection and quantification of human 
heparanase. Biochem Biophys Res Commun, 341, 958-63.
Shapira, O. M., Rene, H., Lider, O., Pfeffermann, R. A., Shemin, R. J. & Cohen, I. R. 
1999. Prolongation of rat skin and cardiac allograft survival by low molecular 
weight heparin. J  Surg Res, 85, 83-7.
Shapiro, A. M. 2011. State of the art of clinical islet transplantation and novel protocols 
of immunosuppression. Curr Diab Rep, 11, 345-54.
Shapiro, A. M., Suarez-Pinzon, W. L., Power, R. & Rabinovitch, A. 2002. Combination 
therapy with low dose sirolimus and tacrolimus is synergistic in preventing 
spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. 
Diabetologia, 45, 224-30.
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Wamock, G. L., 
Kneteman, N. M. & Rajotte, R. V. 2000. Islet Transplantation in Seven Patients 
with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive 
Regimen. New England Journal o f Medicine, 343, 230-238.
Sharmeen, S., Skrtic, M., Sukhai, M. A., Hurren, R., Gronda, M., Wang, X., Fonseca, S. 
B., Sun, H., Wood, T. E., Ward, R., Minden, M. D., Batey, R. A., Datti, A., 
Wrana, J., Kelley, S. O. & Schimmer, A. D. 2010. The antiparasitic agent 
ivermectin induces chloride-dependent membrane hyperpolarization and cell 
death in leukemia cells. Blood, 116, 3593-603.
Sherman, L. A. & Chattopadhyay, S. 1993. The Molecular Basis of Allorecognition. 
Annual Review o f Immunology, 11, 385-402.
Shiraishi, T., Kuroiwa, A., Shirakusa, T., Kawahara, K., Yoneda, S., Kitano, K., 
Okabayashi, K. & Iwasaki, A. 1997. Free radical-mediated tissue injury in acute
384
lung allograft rejection and the effect of superoxide dismutase. Ann Thorac 
Surg, 64, 821-5.
Shore, G. C. 2009. Apoptosis: it's BAK to VDAC. EMBO Rep, 10, 1311-3.
Shteper, P. J., Zcharia, E., Ashhab, Y., Peretz, T., Vlodavsky, I. & Ben-Yehuda, D. 
2003. Role of promoter methylation in regulation of the mammalian heparanase 
gene. Oncogene, 22, 7737-7749.
Sies, H. 1997. Oxidative stress: oxidants and antioxidants. Experimental Physiology, 82, 
291-295.
Sigrist, S., Mechine-Neuville, A., Mandes, K., Calenda, V., Braun, S., Legeay, G., 
Bellocq, J. P., Pinget, M. & Kessler, L. 2003. Influence of VEGF on the 
viability of encapsulated pancreatic rat islets after transplantation in diabetic 
mice. Cell Transplant, 12, 627-35.
Simeonovic, C. J., Bowen, K. M., Kotlarski, I. & Lafferty, K. J. 1980. Modulation of 
tissue immunogenicity by organ culture. Comparison of adult islets and fetal 
pancreas. Transplantation, 30, 174-9.
Simeonovic, C. J., Brown, D. J., Townsend, M. J. & Wilson, J. D. 1996. Differences in 
the contribution of CD4+ T cells to proislet and islet allograft rejection correlate 
with constitutive class II MHC alloantigen expression. Cell Transplant, 5, 525- 
41.
Simeonovic, C. J., Prowse, S. J. & Lafferty, K. J. 1986. Reversal of diabetes in outbred 
mice by islet allotransplantation. Diabetes, 35, 1345-9.
Simeonovic, C. J., Zarb, J. C., Gazda, L. S., Lafferty, K. J. & Wilson, J. D. 1998. 
Pancreatic Islet and Proislet Transplantation in the Mouse Model. In: 
TIMMERMANN, W., GASSEL, H.-J., ULRICHS, K., ZHONG, R. & THIEDE, 
A. (eds.) Organtransplantation in Rats and Mice. Springer Berlin Heidelberg.
Simonsen, M. 1962. Graft Versus Host Reactions. Their Natural History, and 
Applicability as Tools o f Research (Part 1 o f 3), Karger Publishers.
Singh, L., Bakshi, D., Vasishta, R., Arora, S., Majumdar, S. & Wig, J. 2008. Primary 
Culture of Pancreatic (Human) Acinar Cells. Digestive Diseases and Sciences, 
53, 2569-2575.
Slack, J. M. 1995. Developmental biology of the pancreas. Development, 121, 1569-80.
Sleater, M., Diamond, A. S. & Gill, R. G. 2007. Islet allograft rejection by contact- 
dependent CD8+ T cells: perforin and FasL play alternate but obligatory roles. 
Am J  Transplant, 7, 1927-33.
Snell, G. 1957. The homograft reaction. Annual Reviews in Microbiology, 11, 439-458.
Sorokin, L. 2010. The impact of the extracellular matrix on inflammation. Nat Rev 
Immunol, 10,712-723.
Sotnikov, I., Hershkoviz, R., Grabovsky, V., Ilan, N., Cahalon, L., Vlodavsky, I., Alon, 
R. & Lider, O. 2004. Enzymatically quiescent heparanase augments T cell 
interactions with VCAM-1 and extracellular matrix components under versatile 
dynamic contexts. J  Immunol, 172, 5185-93.
Spicer, J. A., Huttunen, K. M., Miller, C. K., Denny, W. A., Ciccone, A., Browne, K. A. 
& Trapani, J. A. 2012. Inhibition of the pore-forming protein perforin by a series 
of aryl-substituted isobenzofuran-l(3H)-ones. Bioorganic & Medicinal 
Chemistry, 20, 1319-1336.
Stanley, S., Wynne, K., Mcgowan, B. & Bloom, S. 2005. Hormonal Regulation of Food 
Intake. Physiological Reviews, 85, 1131-1158.
Steiner, D. F., Rouille, Y., Gong, Q., Martin, S., Carroll, R. & Chan, S. J. 1996. The 
role of prohormone convertases in insulin biosynthesis: evidence for inherited 
defects in their action in man and experimental animals. Diabetes Metab, 22, 94- 
104.
385
Steiner, L., Kroncke, K. D., Fehsei, K. & Kolbbachofen, V. 1997. Endothelial cells as 
cytotoxic effector cells: Cytokine-activated rat islet endothelial cells lyse 
syngeneic islet cells via nitric oxide. Diabetologia, 40, 150-155.
Stringer, S. E. & Gallagher, J. T. 1997. Heparan sulphate. The International Journal of 
Biochemistry & Cell Biology, 29, 709-714.
Su, G., Blaine, S. A., Qiao, D. & Friedl, A. 2008. Membrane type 1 matrix 
metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast 
carcinoma cell proliferation. Cancer research, 68, 9558-65.
Sutton, R., Gray, D. W., Mcshane, P., Dallman, M. J. & Morris, P. J. 1989. The 
specificity of rejection and the absence of susceptibility of pancreatic islet beta 
cells to nonspecific immune destruction in mixed strain islets grafted beneath the 
renal capsule in the rat. J  Exp Med, 170, 751-62.
Tait, S. W. G. & Green, D. R. 2010. Mitochondria and cell death: outer membrane 
permeabilization and beyond. Nat Rev Mol Cell Biol, 11, 621-632.
Tajiri, Y. & Grill, V. E. 1999. Interactions between vitamin E and glucose on B-cell 
functions in the rat: an in vivo and in vitro study. Pancreas, 18, 274-81.
Takahashi, I., Noguchi, N., Nata, K., Yamada, S., Kaneiwa, T., Mizumoto, S., Ikeda, T., 
Sugihara, K., Asano, M., Yoshikawa, T., Yamauchi, A., Shervani, N. J., Uruno, 
A., Kato, I., Unno, M., Sugahara, K., Takasawa, S., Okamoto, H. & Sugawara, 
A. 2009. Important role of heparan sulfate in postnatal islet growth and insulin 
secretion. Biochem Biophys Res Commun, 383, 113-8.
Tamsma, J. T., Bom, J., Bruijn, J. A., Assmann, K. J. M., Weening, J. J., Berden, J. H. 
M., Wieslander, J., Schrama, E., Hermans, J., Veerkamp, J. H., Lemkes, H. H. P. 
J. & Woude, F. J. 1994. Expression of glomerular extracellular matrix 
components in human diabetic nephropathy: decrease of heparan sulphate in the 
glomerular basement membrane. Diabetologia, 37, 313-320.
Telek, G., Regoly-Merei, J., Kovacs, G. C., Simon, L., Nagy, Z., Hamar, J. & Jakab, F. 
2001. The first histological demonstration of pancreatic oxidative stress in 
human acute pancreatitis. Hepatogastroenterology, 48, 1252-8.
Teti, A. 1992. Regulation of cellular functions by extracellular matrix. J  Am Soc 
Nephrol, 2, S83-7.
Thomas, F., Wu, J., Contreras, J. L., Smyth, C., Bilbao, G., He, J. & Thomas, J. 2001. A 
tripartite anoikis-like mechanism causes early isolated islet apoptosis. Surgery>, 
130,333-338.
Thomas, F. T., Contreras, J. L., Bilbao, G., Ricordi, C., Curiel, D. & Thomas, J. M. 
1999. Anoikis, extracellular matrix, and apoptosis factors in isolated cell 
transplantation. Surgery, 126, 299-304.
Thomas, H. E., Darwiche, R., Corbett, J. A. & Kay, T. W. 2002. Interleukin-1 plus 
gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-
cell nitric oxide production. Diabetes, 51,311-6.
Thomas, H. E., Trapani, J. A. & Kay, T. W. H. 2010. The role of perforin and 
granzymes in diabetes. Cell Death Differ, 17, 577-585.
Tillmar, L. & Welsh, N. 2004. In vitro cultured rat islets express genes that both prevent 
and promote angiogenesis. JOP : Journal o f the pancreas, 5, 81-91.
Timpl, R. & Brown, J. C. 1996. Supramolecular assembly of basement membranes. 
BioEssays, 18, 123-132.
Toso, C., Mccall, M., Emamaullee, J., Merani, S., Davis, J., Edgar, R., Pawlick, R., Kin, 
T., Knudsen, L. B. & Shapiro, A. M. 2010. Liraglutide, a long-acting human 
glucagon-like peptide 1 analogue, improves human islet survival in culture. 
Transplant international : official journal o f the European Society for Organ 
Transplantation, 23, 259-65.
386
Toyoshima, M. & Nakajima, M. 1999. Human heparanase. Purification, 
characterization, cloning, and expression. J Biol Chem, 274, 24153-60.
Tsiapali, E., Whaley, S., Kalbfleisch, J., Ensley, H. E., Browder, I. W. & Williams, D. 
L. 2001. Glucans exhibit weak antioxidant activity, but stimulate macrophage 
free radical activity. Free Radio Biol Med, 30, 393-402.
Tuhkanen, A. L., Tammi, M. & Tammi, R. 1997. CD44 substituted with heparan sulfate 
and endo-beta-galactosidase-sensitive oligosaccharides: a major proteoglycan in 
adult human epidermis. Journal o f Investigative Dermatology, 109, 213-8.
Tzakis, A. G., Zeng, Y., Fung, J. J., Todo, S., Demetris, A. J., Starzl, T. E., Mintz, D. 
H., Alejandro, R. & Ricordi, C. 1990. Pancreatic islet transplantation after upper 
abdominal exeriteration and liver replacement. The Lancet, 336, 402-405.
Uchimura, K., Morimoto-Tomita, M., Bistrup, A., Li, J., Lyon, M., Gallagher, J., Werb, 
Z. & Rosen, S. D. 2006. HSulf-2, an extracellular endoglucosamine-6-sulfatase, 
selectively mobilizes heparin-bound growth factors and chemokines: effects on 
VEGF, FGF-1, and SDF-1. BMC Biochem, 7, 2.
Unsworth, D. J., Scott, D. L., Almond, T. J., Beard, H. K., Holborow, E. J. & Walton, 
K. W. 1982. Studies on reticulin. I: Serological and immunohistological 
investigations of the occurrence of collagen type III, fibronectin and the non- 
collagenous glycoprotein of Pras and Glynn in reticulin. Br J  Exp Pathol, 63, 
154-66.
Vaday, G. G., Franitza, S., Schor, H., Hecht, L, Brill, A., Cahalon, L., Hershkoviz, R. & 
Lider, O. 2001. Combinatorial signals by inflammatory cytokines and 
chemokines mediate leukocyte interactions with extracellular matrix. Journal of 
Leukocyte Biology, 69, 885-892.
Vajkoczy, P., Olofsson, A. M., Lehr, H. A., Leiderer, R., Hammersen, F., Arfors, K. E. 
& Menger, M. D. 1995. Histogenesis and ultrastructure of pancreatic islet graft 
microvasculature. Evidence for graft revascularization by endothelial cells of 
host origin. Am J Pathol, 146, 1397-405.
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M. & Telser, J. 2007. Free 
radicals and antioxidants in normal physiological functions and human disease. 
Int J  Biochem Cell Biol, 39, 44-84.
Van Brüggen, M. C., Kramers, K., Hylkema, M. N., Van Den Bom, J., Bakker, M. A., 
Assmann, K. J., Smeenk, R. J. & Berden, J. H. 1995. Decrease of heparan 
sulfate staining in the glomerular basement membrane in murine lupus nephritis. 
Am J  Pathol, 146,753-63.
Varani, J., Bendelow, M., Sealey, D., Kunkel, S., Gannon, D., Ryan, U. & Ward, P. 
1988. Tumor necrosis factor enhances susceptibility of vascular endothelial cells 
to neutrophil-mediated killing. Laboratory investigation; a journal o f technical 
methods and pathology, 59, 292.
Vasir, B., Aiello, L. P., Yoon, K. H., Quickel, R. R., Bonner-Weir, S. & Weir, G. C. 
1998. Hypoxia induces vascular endothelial growth factor gene and protein 
expression in cultured rat islet cells. Diabetes, 47, 1894-903.
Velleman, S. & Caini, L. 2005. Structure and Function o f Cell Associated and 
Pericellular Heparan Sulfate Proteoglycans, Chemistry and Biology of Heparin 
and Heparan Sulfate.
Vergani, A., D'addio, F., Jurewicz, M., Petrelli, A., Watanabe, T., Liu, K., Law, K., 
Schuetz, C., Carvello, M., Orsenigo, E., Deng, S., Rodig, S. J., Ansari, J. M., 
Staudacher, C., Abdi, R., Williams, J., Markmann, J., Atkinson, M., Sayegh, M. 
H. & Fiorina, P. 2006. A Novel Clinically Relevant Strategy to Abrogate 
Autoimmunity and Regulate Alloimmunity in NOD Mice. Diabetes, 59, 2253- 
2264.
387
Viigek, J. & Feldmann, M. 2004. Historical review: Cytokines as therapeutics and 
targets of therapeutics. Trends in Pharmacological Sciences, 25, 201-209.
Virtanen, L, Banerjee, M., Palgi, J., Korsgren, O., Lukinius, A., Thomell, L. E., 
Kikkawa, Y., Sekiguchi, K., Hukkanen, M., Konttinen, Y. T. & Otonkoski, T. 
2008. Blood vessels of human islets of Langerhans are surrounded by a double 
basement membrane. Diabetologia, 51, 1181-91.
Vivot, K., Jeandidier, N., Dollinger, C., Bietiger, W., Pinget, M., Sigrist, S. & Langlois,
A. 2011. Role of islet culture on angiogenic and inflammatory mechanisms. 
Transplant Proc, 43, 3201-4.
Vlodavsky, I., Eldor, A., Haimovitz-Friedman, A., Matzner, Y., Ishai-Michaeli, R., 
Lider, O., Naparstek, Y., Cohen, I. R. & Fuks, Z. 1992. Expression of 
heparanase by platelets and circulating cells of the immune system: possible 
involvement in diapedesis and extravasation. Invasion Metastasis, 12, 112-27.
Vlodavsky, I. & Friedmann, Y. 2001. Molecular properties and involvement of 
heparanase in cancer metastasis and angiogenesis. The Journal o f Clinical 
Investigation, 108, 341-7.
Vlodavsky, I., Friedmann, Y., Elkin, M., Aingom, H., Atzmon, R., Ishai-Michaeli, R., 
Bitan, M., Pappo, O., Peretz, T., Michal, I., Spector, L. & Pecker, I. 1999. 
Mammalian heparanase: gene cloning, expression and function in tumor 
progression and metastasis. Nat Med, 5, 793-802.
Vlodavsky, I., Fuks, Z., Bar-Ner, M., Ariav, Y. & Schirrmacher, V. 1983. Lymphoma 
cell-mediated degradation of sulfated proteoglycans in the subendothelial 
extracellular matrix: relationship to tumor cell metastasis. Cancer research, 43, 
2704-11.
Vlodavsky, I., Goldshmidt, O., Zcharia, E., Atzmon, R., Rangini-Guatta, Z., Elkin, M., 
Peretz, T. & Friedmann, Y. 2002. Mammalian heparanase: involvement in 
cancer metastasis, angiogenesis and normal development. Seminars in cancer 
biology, 12, 121-9.
Vlodavsky, I., Ilan, N., Nadir, Y., Brenner, B., Katz, B. Z., Naggi, A., Torri, G., Casu,
B. & Sasisekharan, R. 2007. Heparanase, heparin and the coagulation system in 
cancer progression. Thromb Res, 120 Suppl 2, SI 12-20.
Volpi, N., Mascellani, G. & Bianchini, P. 1992. Low molecular weight heparins (5 kDa) 
and oligoheparins (2 kDa) produced by gel permeation enrichment or radical 
process: comparison of structures and physicochemical and biological 
properties. Anal Biochem, 200, 100-7.
Vreys, V. & David, G. 2007. Mammalian heparanase: what is the message? Journal of 
cellular and molecular medicine, 11, 427-52.
Vreys, V., Delande, N., Zhang, Z., Coomans, C., Roebroek, A., DV°Rr, J. & David, G. 
2005. Cellular Uptake of Mammalian Heparanase Precursor Involves Low 
Density Lipoprotein Receptor-related Proteins, Mannose 6-Phosphate Receptors, 
and Heparan Sulfate Proteoglycans. Journal o f Biological Chemistry, 280, 
33141-33148.
Walter, A. & Gutknecht, J. 1986. Permeability of small nonelectrolytes through lipid 
bilayer membranes. The Journal o f Membrane Biology, 90, 207-217.
Wang, F., Wang, Y., Zhang, D., Puthanveetil, P., Johnson, J. D. & Rodrigues, B. 2012. 
Fatty Acid-Induced Nuclear Translocation of Heparanase Uncouples Glucose 
Metabolism in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular 
Biology, 32, 406-414.
Wang, F. H., Yip, Y. C., Zhang, M., Vong, H. T., Chan, K. I., Wai, K. C. & Wen, J. M. 
2010. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver 
needle biopsy. J  Clin Pathol, 63, 599-603.
388
Wang, L., Fuster, M., Sriramarao, P. & Esko, J. D. 2005a. Endothelial heparan sulfate 
deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking 
during inflammatory responses. Nat Immunol, 6, 902-10.
Wang, R. & Rosenberg, L. 1999. Maintenance of beta-cell function and survival 
following islet isolation requires re-establishment of the islet-matrix 
relationship. Journal o f Endocrinology, 163, 181-190.
Wang, R. N., Paraskevas, S. & Rosenberg, L. 1999. Characterization of Integrin 
Expression in Islets Isolated from Hamster, Canine, Porcine, and Human 
Pancreas. Journal o f Histochemistry & Cytochemistry, 47, 499-506.
Wang, S., Ai, X., Freeman, S. D., Pownall, M. E., Lu, Q., Kessler, D. S. & Emerson, C. 
P., Jr. 2004. QSulfl, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast 
growth factor signaling in mesoderm induction and angiogenesis. Proc Natl 
Acad Sei US A, 101,4833-8.
Wang, X., Takahashi, N., Uramoto, H. & Okada, Y. 2005b. Chloride channel inhibition 
prevents ROS-dependent apoptosis induced by ischemia-reperfusion in mouse 
cardiomyocytes. Cell Physiol Biochem, 16, 147-54.
Wamock, G. L., Meloche, R. M., Thompson, D., Shapiro, R. J., Fung, M., Ao, Z., Ho, 
S., He, Z., Dai, L. J., Young, L., Blackburn, L., Kozak, S., Kim, P. T., Al-Adra, 
D., Johnson, J. D., Liao, Y. H., Elliott, T. & Verchere, C. B. 2005. Improved 
human pancreatic islet isolation for a prospective cohort study of islet 
transplantation vs best medical therapy in type 1 diabetes mellitus. Arch Surg, 
140,735-44.
Watanabe, H., Hattori, S., Katsuda, S., Nakanishi, I. & Nagai, Y. 1990. Human 
neutrophil elastase: degradation of basement membrane components and 
immunolocalization in the tissue. J  Biochem, 108, 753-9.
Watts, T. H. 2005. TNF/TNFR family members in costimulation of T cell responses. 
Annu Rev Immunol, 23, 23-68.
Weber, G. & Menko, S. 2003. JNK Regulation of Bcl-2 Association with FAK and 
Paxillin in Differentiating Lens Fiber Cells. Invest. Ophthalmol. Vis. Sei., 44, 
952-.
Weber, L. M. & Anseth, K. S. 2008. Hydrogel encapsulation environments 
functionalized with extracellular matrix interactions increase islet insulin 
secretion. Matrix Biol, 27, 667-73.
Welsh, N., Eizirik, D. L., Bendtzen, K. & Sandler, S. 1991. Interleukin-1-Beta-Induced 
Nitric-Oxide Production in Isolated Rat Pancreatic-Islets Requires Gene- 
Transcription and May Lead to Inhibition of the Krebs Cycle Enzyme 
Aconitase. Endocrinology, 129, 3167-3173.
Wiegand, F., Kroncke, K. D. & Kolbbachofen, V. 1993. Macrophage-Generated Nitric- 
Oxide as Cytotoxic Factor in Destruction of Alginate-Encapsulated Islets - 
Protection of Arginine Analogs and/or Coencapsulated Erythrocytes. 
Transplantation, 56, 1206-1212.
Williams, P. 1894. Notes on diabetes treated with extract and by grafts of sheep's 
pancreas. Br Med J, 2, 1303-4.
Winterbourne, D. J. & Mora, P. T. 1981. Cells selected for high tumorigenicity or 
transformed by simian virus 40 synthesize heparan sulfate with reduced degree 
of sulfation. Journal o f Biological Chemistry, 256, 4310-4320.
Wong, C. K., Lit, L. C., Tam, L. S., Li, E. K., Wong, P. T. & Lam, C. W. 2008. 
Hyperproduction of IL-23 and IL-17 in patients with systemic lupus 
erythematosus: implications for Thl7-mediated inflammation in auto-immunity. 
Clin Immunol, 127, 385-93.
Wood, K. J. & Goto, R. 2012. Mechanisms of rejection: current perspectives. 
Transplantation, 93, 1-10.
389
Woodle, E. S., Xu, D., Zivin, R. A., Auger, J., Charette, J., O'laughlin, R., Peace, D., 
Jolliffe, L. K., Haverty, T., Bluestone, J. A. & Thistlethwaite, J. R. J. 1999. 
Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, 
huOKT3gammal(Ala-Ala) in the treatment of acute renal allograft rejection. 
Transplantation, 68, 608-616.
Xia, H., Nho, R. S., Kahm, J., Kleidon, J. & Henke, C. A. 2004. Focal adhesion kinase 
is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival 
in response to contraction of type I collagen matrices via a beta 1 integrin 
viability signaling pathway. J Biol Chem, 279, 33024-34.
Xia, J., Chen, J., Shao, W., Lan, T., Wang, Y., Xie, B., Thorlacius, H., Tian, F., Huang, 
R. & Qi, Z. 2010. Suppressing memory T cell activation induces islet allograft 
tolerance in alloantigen-primed mice. Transplant International, 23, 1154-1163.
Yamada, A., Ishimaru, N., Arakaki, R., Katunuma, N. & Hayashi, Y. 2010. Cathepsin L 
inhibition prevents murine autoimmune diabetes via suppression of CD8(+) T 
cell activity. PLoS One, 5, e l2894.
Yanagihara, S., Komura, E., Nagafune, J., Watarai, H. & Yamaguchi, Y. 1998. 
EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up- 
regulated upon maturation. J  Immunol, 161, 3096-102.
Yanagishita, M. & Hascall, V. C. 1992. Cell surface heparan sulfate proteoglycans. J  
Biol Chem, 267, 9451-4.
Yang, M., Zhang, Y., Pan, J., Sun, J., Liu, J., Libby, P., Sukhova, G. K., Doria, A., 
Katunuma, N., Peroni, O. D., Guerre-Millo, M., Kahn, B. B., Clement, K. & Shi, 
G. P. 2007. Cathepsin L activity controls adipogenesis and glucose tolerance. 
Nat Cell Biol, 9, 970-7.
Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y. H., 
Schluns, K. S., Broaddus, R. R., Zhu, Z. & Dong, C. 2008. Regulation of 
inflammatory responses by IL-17F. J  Exp Med, 205, 1063-75.
Yasothomsrikul, S., Greenbaum, D., Medzihradszky, K. F., Toneff, T., Bundey, R., 
Miller, R., Schilling, B., Petermann, I., Dehnert, J., Logvinova, A., Goldsmith, 
P., Neveu, J. M., Lane, W. S., Gibson, B., Reinheckel, T., Peters, C., Bogyo, M. 
& Hook, V. 2003. Cathepsin L in secretory vesicles functions as a prohormone-
processing enzyme for production of the enkephalin peptide neurotransmitter. 
Proceedings o f the National Academy o f Sciences, 100, 9590-9595.
Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P. & Omitz, D. M. 1991. Cell surface, 
heparin-like molecules are required for binding of basic fibroblast growth factor 
to its high affinity receptor. Cell, 64, 841-8.
Younoszai, R., Sorensen, R. & Lindall, A. 1970. Homotransplantation of isolated 
pancreatic islets. Diabetes, 19 (suppl 1), 406.
Yu, Q. & Stamenkovic, I. 2000. Cell surface-localized matrix metalloproteinase-9 
proteolytically activates TGF-beta and promotes tumor invasion and 
angiogenesis. Genes Dev, 14, 163-76.
Yu, W. H., Woessner, J. F., Jr., Mcneish, J. D. & Stamenkovic, I. 2002. CD44 anchors 
the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth 
factor precursor and ErbB4 and regulates female reproductive organ remodeling. 
Genes Dev, 16, 307-23.
Yuan, D. H., Xie, H. H., Wang, Y., Meng, C. Y., Yang, L. P., Feng, Y. C., Song, J. G., 
Zou, X., Wu, K. C. & Liu, J. 2008. Expression and significance of glypican-3 in 
colorectal cancer. Zhonghua Yi Xue Za Zhi, 88, 1540-2.
Yuan, Y., Wang, Z. H. & Tang, J. G. 1999. Intra-A chain disulphide bond forms first 
during insulin precursor folding. Biochem J, 343 Pt 1, 139-44.
390
Zcharia, E., Jia, J., Zhang, X., Baraz, L., Lindahl, U., Peretz, T., Vlodavsky, I. & Li, J.- 
P. 2009. Newly Generated Heparanase Knock-Out Mice Unravel Co-Regulation 
of Heparanase and Matrix Metalloproteinases. PLoS One, 4, e5181.
Zetser, A., Bashenko, Y., Edovitsky, E., Levy-Adam, F., Vlodavsky, L & Ilan, N. 2006. 
Heparanase Induces Vascular Endothelial Growth Factor Expression: 
Correlation with p38 Phosphorylation Levels and Src Activation. Cancer 
research, 66, 1455-1463.
Zetser, A., Bashenko, Y., Miao, H.-Q., Vlodavsky, I. & Ilan, N. 2003. Heparanase 
Affects Adhesive and Tumorigenic Potential of Human Glioma Cells. Cancer 
research, 63, 7733-7741.
Zetser, A., Levy-Adam, F., Kaplan, V., Gingis-Velitski, S., Bashenko, Y., Schubert, S., 
Flugelman, M. Y., Vlodavsky, I. & Ilan, N. 2004. Processing and activation of 
latent heparanase occurs in lysosomes. J  Cell Sei, 117, 2249-58.
Zhang, N., Richter, A., Suriawinata, J., Harbaran, S., Altomonte, J., Cong, L., Zhang, 
H., Song, K., Meseck, M., Bromberg, J. & Dong, H. 2004. Elevated vascular 
endothelial growth factor production in islets improves islet graft 
vascularization. Diabetes, 53, 963-70.
Zhang, W., Yang, H. C., Wang, Q., Yang, Z. J., Chen, H., Wang, S. M., Pan, Z. M., 
Tang, B. J., Li, Q. Q. & Li, L. 2011. Clinical value of combined detection of 
serum matrix metalloproteinase-9, heparanase, and cathepsin for determining 
ovarian cancer invasion and metastasis. Anticancer Res, 31, 3423-8.
Zheng, X. X., Sanchez-Fueyo, A., Sho, M., Domenig, C., Sayegh, M. H. & Strom, T. B. 
2003. Favorably tipping the balance between cytopathic and regulatory T cells 
to create transplantation tolerance. Immunity, 19, 503-14.
Zhu, H., Wang, J., Jiang, H., Ma, Y., Pan, S., Reddy, S. & Sun, X. 2010. Bilirubin 
protects grafts against nonspecific inflammation-induced injury in syngeneic 
intraportal islet transplantation. Exp Mol Med, 42, 739-48.
Zhu, J. & Paul, W. E. 2008. CD4 T cells: fates, functions, and faults. Blood, 112, 1557- 
1569.
Zimmermann, P. & David, G. 1999. The syndecans, tuners of transmembrane signaling. 
FASEBJ, 13 Suppl, S91-S100.
Ziolkowski, A. F., Popp, S. K., Freeman, C., Parish, C. R. & Simeonovic, C. J. 2012. 
Heparan sulfate and heparanase play key roles in mouse ß cell survival and 
autoimmune diabetes. The Journal o f Clinical Investigation, 122, 132-141.
391
Appendix
1. General solution
Solution Components
Avertin 70 mM 2, 2, 2, Tribomoethanol (Cat. No.: 
T48402, Sigma- Aldrich, St. 
Louis, MO, USA)
2%(v/v) 2-methyl-2-2butanol (Fluka
Chemie AG, Buch, Switzerland) 
Made in warm tap water and sterile filtered
20 mM HEPES-buffered Hanks 
Balanced Salt
500 ml Hanks balanced salt solution 
10 ml 1MHEPES
2. Islet isolation
Solution Components
1MHEPES, pH 7.4 25 g HEPES (Cat. No.: 11344-041,
GIBCO®, Life Technologies, 
Carlsbad, CA, USA)
100 ml Hanks balanced salt solution 
Adjust to pH 7.4 with sodium hydroxide 
solution
Bovine serum albumin (BSA) 15 g BSA Fraction V IgG Free (Cat.
No. :30063-481, GIBCO®, Life 
Technologies, Carlsbad, CA, 
USA)
100 ml Hanks balanced salt solution 
sterile filtered
Wash medium A 300 ml Hanks balanced salt solution
6 ml 1M HEPES
3 ml Bovine serum albumin
0.6 ml PSN (Penicillin-Streptomycin-
Neomycin)
3 mg DNase (Cat. No.: D5025, Sigma-
Aldrich, St. Louis, MO, USA)
Wash medium B 45 ml Hanks balanced salt solution
1m l 1M HEPES
5 ml heat-inactivated fetal calf serum
(Serana, Bunbury, WA, Australia) 
0.1m l PSN
Collagenase P (5ml/mouse) at 2.5 
mg/ml
12.5 mg Collagenase P 
5 ml Wash medium A
Islet culture medium 20 ml RPMI-1640 (Invitrogen,
Carlsbad, CA, USA)
2 ml heat-inactivated fetal calf serum
400 pi L-glutamine
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40 j l i I  PSN
20 pi Gentamicin (Cat. No.: 15750-060,
GIBCO®, Life Technologies, 
Carlsbad, CA, USA)
3. Treatment with heparin-derived heparanase inhibitors
Dosage 382/206 stock 
concentration (mg/ml)
Volume (pl/dose)
single dose 15 mg/ml Mouse weight = w (g)
80 mg/kg/day (3 mg in 200 pi 0.9%
saline) Volume of heparanase 
inhibitors
= w x 0.08 mg/g/day x 200 
pi/ 3mg 
= 5.33w pl/day
eg. If 24.5g mouse = 5.33 x 
24.5 pg/day
= 130 pi
triple dose 15 mg/ml Mouse weight = w (g)
3x(40 mg/kg/dose) (4 mg in 267 pi 0.9%
saline) Volume of heparanase 
inhibitors
= w x 0.04 mg/g/day x 200 
pi/ 3 mg 
= 2.67w pl/day
eg. If 24.5 g mouse = 2.67 x 
24.5 pg/day
= 70 pi
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4. Rapamycin treatment
Solution Components
0.2% (w/v)
Carboxymethyl cellulose 
0.25% (v/v) Tween80
0.2 g Carboxymethylcellulose Sodium,
low viscosity (Cat. No.: CA193, 
Spectrum®, New Brunswick, NJ, 
USA)
250 pi Tween 80 (Cat. No.: P I754, Sigma- 
Aldrich, St. Louis, MO, USA)
100 ml dH20
Dosage Rapamycin stock 
concentration (mg/ml)
Volume (pl/dose)
0.3 mg/kg/day 0.5 mg/0.1 ml 
(0.5 mg in 100 pi
Mouse weight = w (g)
carboxymethyl cellulose- Volume of rapamycin
Tween80) = w x 0.0003 mg/g/day x 
200 pi/ 0.01 mg
diluted 1:100 from stock 
concentration with dH20
= 6w pl/day
(final concentration = 0.01 eg. If 25 g mouse = 6 x 2 5
mg/200 pi) by adding 10 pi pg/day
stock rapamycin into 990 pi 
dH20
= 150 pi
5. Real-time RT-PCR
Solution Components
GIT lysis buffer 23.7 g Guanidine (iso)thiocyanate in 25 ml 
DEPC- treated H20  (Cat. No.: 0380, 
Amresco, Solon, OH, USA)
0.418 ml 3M Sodium acetate (pH 6.0)
Made up to 50 ml with DEPC-treated H20
1 % (v/v) ß-mercaptoethanol
(Cat. No.: 4196, Eastman Organic Chemicals,
Rochester, NY, USA)
5.7M CsCl 48 g Caesium chloride (Cat. No.: 0887,
Amresco, Solon, OH, USA)
0.418 ml 3M Sodium acetate (pH6.0)
Made up to 50 ml with DEPC-treated H20
3M sodium acetate (pH6.0) 81.65 g Sodium acetate (Cat. No.: 679,
UNIVAR, Auburn, NSW, Australia) 
200 ml DEPC-treated H20
DEPC
(Diethylpyrocarbonate)- 
treated H20
500 pi DEPC (Cat. No.: D5758, Sigma- 
Aldrich,St. Louis, MO, USA) 
500 ml MiliQ grade water
TaqMan Universal Master 
Mix
TaqMan buffer
AmpliTaq Gold DNA Polymerase
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AmpErase UNG, dNTPs with dUTP 
Passive reference
FAM dye-labelled TaqMan® 
MGB probe
Heparanase - Mm00461768_ml Hpse 
Cathepsin L - Mm00515597 m l Cstl 
CD45R - Mm00448463 mlPtprC
UBC - Mm00461037_gl ube2dl
6. Histology
Alcian blue histochemistry
Solution Components
lM M gC l2 20.33 gm MgCl2 
100 ml dH20
1M Acetate buffer 1M Acetic acid (6ml glacial acetic acid in 
100 ml dH20 )
1M Sodium acetate trihydrate
(68 g in 500 ml dH20 )
Adjust to pH 5.8 with a few drops of 
glacial acetic acid
MgCl2 buffer 10 ml 1M Acetate buffer
6.5 ml lM M gC l2
Made up to 100 ml with dH20
Alcian Blue working solution 10 ml 1M Acetate buffer
6.5 ml IM M gCl
1 ml Alcian Blue solution
Made up to 100 ml with dH20
7. Immunohistochemistry 
General solution
Solution Components
3% H20 2 to block endogenous 
peroxidise activity
25 ml 10% H2O2(Cat. No.:
HA 154, Chem-Supply, Pty. 
Ltd, Gillman, SA, Australia) 
225 ml methanol (EMSURE®, Merck,
Darmstadt, Germany)
0.1N acetic acid 2.9 ml glacial acetic acid (Cat. No.:
UN2789, VWR International 
Ltd., Lutterworth, 
Leicestershire, UK)
500 ml dH20
0.1M sodium acetate 0.68 g anhydrous CH2C00N a.3.dH 20
(Cat. No.: 10235, BDH, Poole, 
Dorset, UK)
500 ml dH20
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0.1M Acetate buffer 10.5 ml 0.1N acetic acid
39.5 ml 0.1M sodium acetate
AEC (3-Amino-9- 
ethylcarbazole) stock solution
40 mg AEC (Cat. No.: A5754, Sigma-
Aldrich,St. Louis, MO, USA)
5 ml N-N-dimethyl formamide (Cat.
No.: D158550, Sigma- 
Aldrich,St. Louis, MO, USA)
AEC working solution 4.75 ml Acetate buffer
0.25 ml AEC stock solution
25 pi 3% H2O2 (prepared in dlUO)
Sterile filtered using a 0.2 pm CR filter
ammonium water 100 pi concentrated ammonium
250 ml dH20
8. Immunohistochemistry for the core protein of HSPG, type XVIII collagen
Solution Components
Pronase 2.5 g pronase
5 ml dH20
M.O.M Ig Blocking Reagent 2.5 ml PBS
2 drops of M.O.M Ig Blocking Reagent
Animal Free Blocker 0.5 ml AFB 5X
2 ml dH20
M.O.M Diluent 2.5 ml PBS
200 pi M.O.M protein concentrate
Antibody preparation
Antibody/isotype control, stock 
concentration
Dilution
anti-type XVIII collagen, 0.2 mg/ml 1:25
purified mouse IgG2bK, 0.5 mg/ml 1:62.5
antibody prepared in M.O.M Diluent
HRP-conjugated polyclonal rabbit 1:50
anti-mouse Ig antibody prepared in M.O.M Diluent
9. Immunohistochemistry for the core protein of HSPG, syndecan-1 and CD44
Solution Components
Citrate buffer 1.05 g citric acid
500 ml dH20
Adjust to pH 6.0 using sodium hydroxide 
solution
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Animal Free Blocker 0.5 ml AFB 5X
2 ml dH20
M.O.M Diluent 2.5 ml PBS
200 pi M.O.M protein concentrate
Antibody preparation
Antibody/isotype control, stock 
concentration
Dilution
Purified Rat anti-mouse CD 138 
(Syndecan-1) mAb, 0.5 mg/ml
1:10
purified rat IgG2a, 0.5 mg/ml 1:10
Purified NA/LE rat anti-mouse 
CD44, 1 mg/ml
1:25
Rat IgG2bic, 1 mg/ml 1:25
antibody prepared in M.O.M Diluent
HRP-conjugated polyclonal rabbit 
anti-rat Ig
1:50 for Syndecan-1 and 1:25 for CD44 
antibody prepared in M.O.M Diluent
10. Immimohistochemistry for heparanase
Solution Components
Citrate buffer 1.05 g citric acid
500 ml dH20
Adjust to pH 6.0 using sodium 
hydroxide solution
M.O.M Ig Blocking Reagent 2.5 ml PBS
2 drops of M.O.M Ig Blocking Reagent
Animal Free Blocker 0.5 ml AFB 5X
2 ml dH20
M.O.M Diluent 2.5 ml PBS
200 pi M.O.M protein concentrate
M.O.M VECTASTAIN ABC Reagent 2.5 ml PBS
2 drops of reagent A 
2 drops of reagent B
Antibody preparation
Antibody/isotype control, stock 
concentration
Dilution
HP 130 mAb, 1.7 mg/ml 1:10
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purified mouse IgGlic, 0.5 mg/ml 7:20
antibody prepared in M.O.M Diluent
11. Immunohistochemistry for cathepsin L
Solution Components
Citrate buffer 1.05 g citric acid
500 ml dH20
Adjust to pH 6.0 using sodium hydroxide solution
Animal Free Blocker 0.5 ml AFB 5X
2 ml dH20
10% Serum diluent 5.37 ml PBS
600 pi rabbit serum (Cat. No.: R9133,
Sigma-Aldrich, St. Louis, MO,
USA)
30 pi 18% sodium azide
Sterile filtered
25% Serum diluent 3.4 ml 10% serum diluent
600 pi rabbit serum
Sterile filtered
Antibody preparation
Antibody/isotype control, stock 
concentration
Dilution
anti-cathepsin L mAb, 0.5 mg/ml 1:40 for pancreas; 1:60 for isolated islets 
and transplants
purified rat IgG2a, 1 mg/ml
antibody prepared in 10% serum diluents
HRP-conjugated polyclonal rabbit 1:50
anti-rat Ig antibody prepared in 25% serum diluents
Immunohistochemistry for macrophages (F4/80)
Solution Components
5% diluent buffer 7.6 ml PBS
400 pi Normal mouse serum
40 pi 18% sodium azide
25% diluent buffer 2.4 ml 5% diluent buffer
600 pi Normal mouse serum
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12. Immunofluorescence staining
A n tig e n  ( s p e c ie s ) P r im a r y  A n t ib o d ie s S o u rc e D i lu t io n F ix a t io n
H o s t s p e c ie s C o d e
L a m in in  a 2  
(m o u s e )
R a b b i t 4 H 8 - 2 S ig m a  C h e m ic a l ,  
C a s t l e  H il l ,  N S W , 
A u s t r a l ia
1 :3 2 0 0 F o rm a lin
T y p e  IV  c o l la g e n  
(m o u s e )
R a b b i t T 4 0 2 6 3 R B io d e s ig n 1 :1 0 0 F o rm a lin
L a m in in  E H S  
(m o u s e )
R a b b i t L 9 3 9 3 S ig m a  C h e m ic a l 1 :1 0 0 1 0 0 %
E th a n o l
N id o g e n - 2
(m o u s e )
R a b b i t A M 4 5 1 3 A b e a m ,
C a m b r id g e ,  U K
1 :8 0 0 F o rm a lin
P e r le c a n  (m o u s e ) R a b b i t 9 0 6 D r  D z ia d e k 1 :8 0 0 1 0 0 %
E th a n o l
P E C  A M - 1 R a t 3 9 0 B D  P h a r m in g e n ,  
B D  B io s c ie n c e s ,  
N o r th  R y d e ,  
N S W , A u s t r a l ia
1 :5 0 0 1 0 0 %
E th a n o l
13. Flow cytometry for the detection of basement membrane matrix proteins
Solution Components
Culture medium for PFHR-9 cells 500 ml DMEM High Glucose (Cat. 
No.: 11995, GIBCO®, Life 
Technologies, Carlsbad, CA, 
USA)
10 ml L-Glutamine
50 ml heat-inactivated fetal calf
serum
0.5 ml Penicillin-Streptomycin- 
Neomycin (PSN)
Trypan blue solution 8 ml 0.5% Trypan blue (Fluka
Chemie AG, Buch, 
Switzerland)
12 ml Saline
Chelation buffer 100 ml Hanks balanced salt
solution
2 ml 1MHEPES
116 mg EDTA
1 mg DNase
sterile filtered
Dispersion buffer 10 mg dispase II (Cat. No.:
04942078001, Godo 
Shusei Co. Ltd, Tokyo, 
Japan)
10 ml Chelation buffer
sterile filtered
FACS wash buffer 500 ml PBS
25 ml Fetal Calf Serum
10 ml 10% Sodium azide (final
0.2%)
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Primary antibodies and isotype controls
A ntigen Prim ary A ntibodies Source D ilu tion Stock
(species) H ost C ode concentra tion
species
L am inin  EH S R abbit L9393 S igm a C hem ical 1/25 0.5 m g/m l
(m ouse)
T ype IV 
collagen 
(m ouse)
R abbit 2150-1470 A bD  Serotec 1/25 1 m g/m l
Perlecan
(m ouse)
R abbit 906 D r D ziadek 1/800 64.48 m g/m l
N idogen-1 R abbit A M 4511 A beam , 1/200 18.36 m g/m l
(m ouse) C am bridge, U K
N idogen-2
(m ouse)
R abbit A b l4 5 1 3 A beam ,
C am bridge, U K
1/200 25.06 m g/m l
R abb it IgG 0111 Southern  B io tech 1/62
1/54
5 m g/m l
1/40
1/125
T ype X V III M ouse sc-32720 S anta  C ruz 1/25 0.2 m g/m l
co llagen
(m ouse)
M ouse IgG 2bK B D 557351 BD  P harm ingen 1/62.5 0.5 m g/m l
S y n d ecan -1 
(m ouse)
Rat B D 553712 BD  Pharm ingen 1/25 0.5 m g/m l
Rat IgG 2a B D 555841 BD  P harm ingen 1/25 0.5 m g/m l
C D 44 (m ouse) Rat B D 553130 BD  Pharm ingen 1/25 1 m g/m l
Rat IgG 2bK B D 555845 B D  P harm ingen 1/25 1 m g/m l
A grin M ouse M A B 5204 C hem icon 1/25 1 m g/m l
M ouse IgG | sc-3877 Santa C ruz 1/10 0.4 m g/m l
G lypican-2
(m ouse)
Rat M A B 2355 R & D  System s 1/25 0.25 m g/m l
R at IgG 2a M A B 006 R & D  System s 1/50 1 m g/m l
14. Western blotting
Solution Components
Special wash medium, pH 8.0 300 ml Hanks balanced salt
solution
6 ml 1MHEPES
3 mg DNase
5.85 g EDTA(Cat. No.: 180,
UNIVAR, Auburn, NSW, 
Australia)
300 gl E64
lx  Complete Protease Inhibitor Cocktail 
Tablet
Adjust to pH 8.0
lysis buffer (for heparanase 
detection)
1% CHAPS detergent in 0.5M NaCl
5 ml CHAPS
92.6 mg EDTA
5 mg perfabloc (Cat. No.:
11585916001, Roche, 
Mannheim, Germany)
5 pi E64
lx  Complete Protease Inhibitor Cocktail
Tablet
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R IP A  ly sis  b u f fe r  ( fo r  c a th e p s in  L 
d e te c tio n )
50  m M  T R IZ M A  B a se  (C a t.
N o .: T 1 5 0 3 , S ig m a - 
A ld r ic h ,S t.
L o u is , M O , U S A )
150 m M  N a C l
1%  T rito n -X  (C a t. N o .:
3 0 6 3 2 .6 P , B D H , P o o le , 
D o rse t, U K )
0 .2 5 %  N a -d e o x y c h o la te
(S ta n se n s ,
K in g sg ro v e , N S W , 
A u s tra lia )
1 m g /m l P e rfa b lo c
l x  C o m p le te  P ro te a se  In h ib ito r  C o c k ta il
T a b le t
20  m M  H E P E S -b u ffe re d  H a n k s  
B a la n c e d  S a lt so lu tio n  ( fo r  is le t 
tra n sp la n ts  h a rv e s te d  fo r  h e p a ra n a se  
d e te c tio n )
2 0  m M  H E P E S -b u ffe re d  H a n k s
B a la n c e d  S a lt S o lu tio n  
50  p M  E -6 4
l x  C o m p le te  P ro te a se  In h ib ito r  C o c k ta il 
T a b le t
0 .5 M  T ris -H C l, p H  6 .8 7 .5 7  g  T R IZ M A  B a se
125 m l 125 m l M illiQ  w a te r
S D S  sa m p le  re d u c in g  b u f fe r  s to ck  
2x
2 g  S D S
10 m l G ly c e ro l (C a t. N o .:
D 6 7 5 0 , M e rc k , 
D a rm s ta d t, G e rm a n y ) 
12.5 m l 0 .5 M  T r is -H C l, p H 6 .8
5 m l 0 .1 %  (w /v )
B ro m o p h e n o l 
b lu e  (C a t. N o .: B 5 5 2 5 , 
S ig m a -A ld ric h ,S t. L o u is , 
M O , U S A )
m a d e  u p  to  50  m l in  M illiQ  w a te r
S D S  sa m p le  b u f fe r  ( fo r  h e p a ra n a se  
d e te c tio n )
8 m g  D ith io th re ito l  (D T T )
5 0 0  p i S D S  sa m p le  re d u c in g
b u ffe r  s to c k  so lu tio n
S D S  ru n n in g  b u f f e r - 1 Ox s to ck 6 0 .5  g  T r is -H C l
119 g  H E P E S
5 g  S D S
M a d e  u p  to  5 0 0  m l in  M illiQ  w a te r
S D S  ru n n in g  b u f fe r 100 m l S D S  ru n n in g  b u f f e r - 1 Ox
s to c k
9 0 0  m l M illiQ  w a te r
W e s te rn  b lo t tra n s fe r  b u f fe r 3 0 .3  g  (25  m M ) T r iz m a  B ase  
144 g  (1 9 2  m M ) G ly c in e  (C a t. N o .:
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G8898, Sigma- Aldrich, 
St. Louis, MO, USA) 
Made up to 2L in 20% methanol (v/v) in 
dH20
5% Skim milk block 2 g Skim milk powder
40 ml PBS
0.05% PBST (0.05% (v/v) Tween 20 1 ml Tween 20 (Cat. No.:
P1379,
Sigma-Aldrich, St. Louis, 
MO, USA)
2L PBS
3% (w/v) BSA in PBS 1.5 g BSA (Cat. No.: A-7030,
Sigma-Aldrich, St. Louis, 
MO, USA)
50 ml PBS
Antibody preparation
Antibody/isotype control, stock concentration Dilution
HP 130 anti-heparanase mAb, 0.2 mg/ml 1:100
purified mouse IgGlic, 0.5 mg/ml 1:250
anti-proheparanase polyclonal Ab 1453 1:300
rabbit IgG, 5 mg/ml 1:6000
anti-cathepsin L mAb, 0.1 mg/ml 1:100
normal goat IgG, 1 mg/ml 1:1000
prepared using 3% (w/v) 
BSA in PBS
HRP-conjugated polyclonal rabbit anti-mouse Ig 1:100
HRP-conjugated polyclonal swine anti-rabbit Ig 1:300
HRP-conjugated affinity purified donkey anti-
goat IgG
1:500
prepared using 3% (w/v) 
BSA in PBS
15. HS culture
Solution Components
Islet culture medium 20 ml RPMI-1640
2 ml heat-inactivated fetal calf
serum
400 pi L-glutamine
40 j l i I  PSN
Chelation buffer 100 ml Hanks balanced salt
solution
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2 ml 1MHEPES
116 mg EDTA
1 mg DNase
sterile filtered
Dispersion buffer with 
collagenase P at 1.25 mg/ml
8 mg dispase II (Cat. No.:
04942078001, Godo Shusei 
Co. Ltd, Tokyo, Japan)
8 ml Chelation buffer
10 mg collagenase P
sterile filtered
16. ln vitro treatment of free radical scavengers
Solution Components
BHA at 30 mg/ml 30 mg BHA
1 ml of olive oil
dissolved in tube submerged in a beaker 
with warm water (approx 50°C)
17. Allogeneic mixed lymphocyte reaction
Solution Components
Red blood cell lysis buffer 8.34 g Ammonium chloride
0.037 g EDTA
1.0 g NaHC03 (Cat. No.: 10247, 
BDH Chemicals, VIC, 
Australia)
1L dH20
adjust to pH 7.3
MLC medium 500 ml MLC
100 mM MEM sodium pyruvate solution 
(Cat. No.: 11360, GIBCO®, 
Life Technologies, Carlsbad, 
CA, USA)
1M EPES buffer solution (Cat. No.: 
15630, GIBCO®, Life 
Technologies, Carlsbad, CA, 
USA)
100 mM L-glutamine
10% heat-inactivated fetal calf serum
ß-mercaptoethanol (Cat. No.: 4196, Eastman 
Organic Chemicals, Rochester, NY, USA)
0.5 ml Penicillin-Streptomycin- 
Neomycin (PSN)
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Primary antibodies, isotype controls and fluorescent dyes
A n tig en
(sp e c ie s )
F lu o r o c h r o m e P r im a r y  A n tib o d ie s S o u r c e D ilu tio n S to ck
c o n c e n tr a t io nH o st
sp e c ie s
C o d e
C D 4
(m ouse)
Pe-Cy7 rat 552775 BD
B iosciences
1:300 0.2 m g/m l
CD 8
(m ouse)
P e rC P -C y 'M5.5 rat 551162 BD
P harm ingen
1:100 0.2 m g/m l
H oechst
33258
H 1398 Invitrogen 1:1000 1 m g/m l
H -2K b
(m ouse)
PE m ouse 553570 BD
P harm ingen
1:25 0.2 m g/m l
C D 44
(m ouse)
A PC rat 559250 BD
B iosciences
1:200 0.2 m g/m l
B 220/C D 45 
R (m ouse)
Pacific B lue rat 558108 BD
B iosciences
1:100 0.2 m g/m l
LAM P-1 
107 A
PE 121071-81 eB iosciences 1:300 0.2 m g/m l
Cytotoxic T Lymphocyte (CTL) assay using CFSE labelling 
CFSE concentration
5000 nM 1 ml 5% FCS medium cells
(for CBA target 54.5 pi PBS
splenocytes) 55.5 pi 100 pM CFSE
300 nM 1 ml 5% FCS medium cells
(for B6 target 106.7 pi PBS
splenocytes) 3.3 pi 100 pM CFSE
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Appendix 18 - HS mimetics
HS
m im etics
M o le c u la r
w e ig h t
(kD a)
Description Chem ical s tructure
B T -3 8 2
M H (gc)
3 k D a
3 •  p e r io d a te  m o d i f ie d  
h e p a r in  (g ly c o l 
s p lit t in g  t o  e n h a n c e  
c h a in  f le x ib i l i ty )
•  s ize  r e d u c t io n
R
r  cx,oso, >
^  nms  oso, J
= so3-
n
CMjQSO,- COO
B T -2 0 6
(gc)
1 2 •  p e r io d a te  m o d if ie d  
h e p a r in  (g ly c o l 
s p lit t in g  t o  e n h a n c e  
c h a in  f le x ib i l i t y
•  N d e s u l f a t e d /N  
a c e ty la te d  (N S /N A c )  
(le ss  s u lfa te d ) R
r  C M ,oso,
-€ ^ -C r
>» mm« ( p i j )  >
=  A c e ty l (A c )
n
r  CMjOSO, COO- ''j
O  Blue circle - Glycol splitting (gc)
O  Red circle - N-desulfated
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Appendix 19 - FITC-conjugated HS mimetics
FITC-HS
mimetics
Molecular
weight
(kDa)
Description Chemical structure
Heparin negatively charged 
FITC labelling along 
the chain
" CHjOSOy ^  C  CH.OSO,' COO ^
^  hmso, oso .- Jn v  nhac oh  JV- MHSO OSO, 
n»>m
BT-443
MH(gc)
12kDa
periodate modified 
heparin (glycol 
splitting to enhance 
chain flexibility)
FITC labelling along 
the chain
CHjOSO,
V. NH« OSO, -//n V  NMAc \0 H  O * \ J
R= SO,'
CHjOSO,- coo-
BT-446
MH(gc)
3kDa
periodate modified 
heparin (glycol 
splitting to enhance 
chain flexibility) 
size reduction 
FITC labelling along 
the chain
<xoso, ^  ^  cnpso, coo- ^
^  NHR OSO, V  NHAc \0 H  0*1/
R= SO,-
BT-426
MH(gc)
3kDa
periodate modified 
heparin (glycol 
splitting to enhance 
chain flexibility 
size reduction 
End terminal labelling 
of FITC
r  CHjOSO, coo-
BT-487
(BT-487
representing
FITC-labelled
206(gc))
periodate modified 
heparin (glycol 
splitting to enhance 
chain flexibility 
N desulfated/N 
acetylated (NS/NAc) 
(less sulfated)
FITC labelling along 
the chain
R= Acetyl (Ac)
O Blue circle 
O Red circle
Glycol splitting (gc) 
N-desulfated
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FITC-HS
m im etics
M o le cu la r
w e ig h t
(kD a)
Description Chem ical structure
PI-88 2-2.5 •  Phosphom anno- 
pentaose
•  FITC labelling 
along th e  chain
0 P 0 3N a2
n R
/ ,RoR
<O R o r
R = OSO^ aorH R(£ S 5 ^ L , OR
BT-447
HShi
12-15 •  h igh ly su lfated
•  FITC labelling 
along th e  chain C  CHPSO,- V f  cupso,- COP ^
Leugv j 0 ^ £ V i
^  NMSO,- OSO,- >n V *hAc OH J m
n « m
BT-463
M H -
b u ty la ted
•  add ition  o f alkyl 
chains (m ore 
lipoph ilic )
•  FITC labelling 
along th e  chain
co, * 4 AcHN m ,<">£
OR X*OjSO
R H or acyl to varied degrees of substitution
Butyl: R = CO-(CH2)2CH3
BT-464
M H -
hexy lated
•  add ition  o f alkyl 
chains (m ore 
lipoph ilic )
•  FITC labelling 
along the  chain
OR X* CSSO
R - H or acyl to varied degrees of substitution
Hexyl: R = CO-(CH2)4CH3
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FITC-HS
m im etics
M o lecu la r
w e ig h t
(kD a)
Description Chem ical s tructure
BT-454
M H -p ro ta m in e
•  charge 
neu tra lisa tion
•  FITC labelling at 
along the  chain
heparin
k : o o "  J  c  h I o s o , ) t  o o n
ö ö  © 0
j ,  0
7 -----------'  h \  '  II |
protam ine f N - c — c j -
BT-459
M H -chitosan
•  charge 
neu tra lisa tion
•  FITC labelling  at 
along th e  chain
chitosan
CHjOH CH,OH
- n I & v Ö -
T o o ’ J  c h U>s o ,  J c o o h  c w s o J
O O  O Ü
heparin
BT-461
MH-CPC
•  charge 
neu tra lisa tion
•  FITC labe lling  at 
along the  chain
CPC (cetylpyridinium chloride)
j C i  JO
©  ©  ©  ©  
heparin
SNAC-BT-487 •  Enhanced 
adsorp tion  via 
unknow n 
physicochem ical 
in te rac tion
•  FITC labelling at 
a long th e  chain
OH O
SNAC (sodium N-[8-(2- 
hydroxybenzoyl)am ino]caprylate)
O Purple circle - Negative charge 
O Green circle - Positive charge
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